FACTORS AFFECTING SKELETAL MUSCLE PROTEIN SYNTHESIS IN THE HORSE by Wagner, Ashley Leigh
University of Kentucky 
UKnowledge 
Theses and Dissertations--Animal and Food 
Sciences Animal and Food Sciences 
2011 
FACTORS AFFECTING SKELETAL MUSCLE PROTEIN SYNTHESIS 
IN THE HORSE 
Ashley Leigh Wagner 
University of Kentucky, ashleylwagner@uky.edu 
Right click to open a feedback form in a new tab to let us know how this document benefits you. 
Recommended Citation 
Wagner, Ashley Leigh, "FACTORS AFFECTING SKELETAL MUSCLE PROTEIN SYNTHESIS IN THE HORSE" 
(2011). Theses and Dissertations--Animal and Food Sciences. 1. 
https://uknowledge.uky.edu/animalsci_etds/1 
This Doctoral Dissertation is brought to you for free and open access by the Animal and Food Sciences at 
UKnowledge. It has been accepted for inclusion in Theses and Dissertations--Animal and Food Sciences by an 
authorized administrator of UKnowledge. For more information, please contact UKnowledge@lsv.uky.edu. 
STUDENT AGREEMENT: 
I represent that my thesis or dissertation and abstract are my original work. Proper attribution 
has been given to all outside sources. I understand that I am solely responsible for obtaining 
any needed copyright permissions. I have obtained and attached hereto needed written 
permission statements(s) from the owner(s) of each third-party copyrighted matter to be 
included in my work, allowing electronic distribution (if such use is not permitted by the fair use 
doctrine). 
I hereby grant to The University of Kentucky and its agents the non-exclusive license to archive 
and make accessible my work in whole or in part in all forms of media, now or hereafter known. 
I agree that the document mentioned above may be made available immediately for worldwide 
access unless a preapproved embargo applies. 
I retain all other ownership rights to the copyright of my work. I also retain the right to use in 
future works (such as articles or books) all or part of my work. I understand that I am free to 
register the copyright to my work. 
REVIEW, APPROVAL AND ACCEPTANCE 
The document mentioned above has been reviewed and accepted by the student’s advisor, on 
behalf of the advisory committee, and by the Director of Graduate Studies (DGS), on behalf of 
the program; we verify that this is the final, approved version of the student’s dissertation 
including all changes required by the advisory committee. The undersigned agree to abide by 
the statements above. 
Ashley Leigh Wagner, Student 
Dr. Kristine L. Urschel, Major Professor 
David Harmon, Ph.D., Director of Graduate Studies 
  
 
 
FACTORS AFFECTING SKELETAL MUSCLE PROTEIN SYNTHESIS IN THE 
HORSE 
 
 
DISSERTATION 
A dissertation submitted in partial fulfillment of the requirements for the degree of 
Doctor of Philosophy in the College of Agriculture at the University of Kentucky 
 
By 
Ashley Leigh Wagner 
 
Lexington, Kentucky 
Director: Dr. Kristine L. Urschel, Assistant Professor of Animal and Food Sciences 
Lexington, Kentucky 
2011 
 
 
Copyright © Ashley L. Wagner 2011 
  
 
 
ABSTRACT OF DISSERTATION 
 
FACTORS AFFECTING SKELETAL MUSCLE PROTEIN SYNTHESIS IN THE 
HORSE 
Skeletal muscle protein synthesis is regulated by the mammalian target of 
rapamycin (mTOR) signaling pathway.  The first objective was to optimize the 
methodological procedures for assessing mTOR signaling in horses.  The response of 
mTOR signaling (P-Akt Ser473, P-S6K1 Thr389, P-rpS6 Ser235/26 & 240/244, and P-4EBP1 
Thr37/46 by Western blotting techniques) to meal consumption was determined at three 
gluteal muscle biopsy depths (6, 8, and 10 cm), and the repeatability of the contralateral 
side at 8 cm during 5 days of repeated biopsies.  There was no effect (P > 0.05) of 
sampling side or biopsy depth on mTOR signaling in mature horses.  During repeated 
biopsies there was an increase (P < 0.05) in downstream (P-S6K1 Thr389, P-rpS6 Ser235/236 
& 240/244 and P-4EBP1 Thr389) mTOR signaling in response to feeding.  The second 
objective was to characterize alterations in mTOR signaling throughout the equid 
lifespan.  Adolescent horses (yearlings and two year olds) studied in the postprandial had 
a lowered (P < 0.05) activation of downstream mTOR signaling with aging.  There was a 
lower (P < 0.05) abundance of P-S6K1 Thr389 in aged horses (23.5 years old) than in 
mature horses (11 years old) during the post-absorptive state.  The final objective was to 
assess mTOR signaling during acute and chronic inflammation.  Acute inflammation 
occurred during 5 days of repeated biopsies, and chronic inflammation is characteristic of 
the aged.  During acute inflammation, characterized by increased muscle mRNA 
expression of inflammatory cytokines, there was an increase (P < 0.05) in downstream 
mTOR signaling.  Chronic inflammation resulted in a decrease (P < 0.05) in the 
abundance of P-S6K1 Thr389.  Phenylbutazone was administered to reduce (P < 0.05) 
acute and chronic inflammation in muscle.  Phenylbutazone administration during acute 
inflammation reduced (P < 0.05) the activation of downstream mTOR signaling and 
trended to increase (P = 0.09) P-S6K1 Thr389 abundance during chronic inflammation. 
Whole-body protein synthesis determined using isotope infusion techniques increased (P 
< 0.05) when chronic inflammation was reduced due to phenylbutazone administration.  
This research provides new standards for muscle biopsy collection when examining 
 mTOR signaling, and insight into management and feeding practices for adolescent and 
aging horses. 
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CHAPTER I. 
The literature review 
1.1.  INTRODUCTION 
 The horse is a highly athletic animal that excels in a wide variety of sports that 
require targeted training of specific muscle groups with the intent of muscle accretion.  
Skeletal muscle is a unique tissue with a high degree of plasticity in its ability to increase 
and decrease in size, which is dictated by protein content, and in the horse comprises 
50% of body mass (1).  However, the horse has received little research attention with 
regards to protein metabolism and accretion.  Rather, the research in the horse has 
focused on N balance studies, and assessment of ADG during development in order to 
determine protein and lysine requirements, and characterization of skeletal muscle 
physiology, specifically fiber types, during exercise and development. 
 The molecular signaling pathway that regulates protein synthesis has been 
extensively studied in cell culture, rodents, neonatal piglets, and humans.  The 
mammalian target of rapamycin signaling (mTOR) pathway regulates protein synthesis 
and has been examined in a single study in the mature horse, where it was demonstrated 
that the anabolic stimulus of meal consumption increases mTOR signaling (2).  These 
results were in agreement with the numerous studies examining mTOR signaling in 
response to meal consumption in other mammalian species.  The end point of the mTOR 
signaling pathway is protein synthesis and has been examined in the mature horse 
following the anabolic stimuli of exercise using isotope techniques, where it was 
demonstrated that muscle protein synthesis increased to the greatest extent when an 
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amino acid-glucose mixture was infused in the jugular vein during the recovery period 
(3).  Although the studies examining mTOR signaling and muscle protein fractional 
synthesis rates have examined the response to anabolic stimuli in various ages of animals, 
including neonates, adults, and the aged, there has not been a single study in any 
mammalian species to examine mTOR signaling in response to anabolic stimuli during 
adolescent development. 
 The focus of this review is to examine the literature pertaining to the current 
knowledge of the mTOR signaling pathway, the pathways involved in protein 
breakdown, whole-body and muscle protein synthesis, acute and chronic inflammation, 
and to provide a review of the relevant equine literature.  Specifically, the upstream and 
downstream factors involved in the mTOR signaling pathway, and a review of the 
literature examining the effects of anabolic stimuli throughout the lifespan will be 
discussed.  The methodologies used to examine whole-body and muscle protein synthesis 
and the literature regarding whole-body and muscle protein synthesis in response to 
anabolic stimuli throughout the lifespan will also be discussed.  Next, there will be a brief 
discussion of inflammatory signaling, followed by a description of the inflammatory 
response to both acute and chronic stimuli.  The literature review will end with an 
overview of the equine literature, including an overview of the research pertaining to 
protein nutrition (digestion and absorption, digestibility, and requirements), 
characterization of how muscle physiology, specifically fiber typing, changes with 
development and exercise, and the inflammatory response to acute and chronic 
inflammation. 
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1.2.  THE MAMMALIAN TARGET OF RAPAMYCIN SIGNALING PATHWAY 
 The mTOR signaling pathway was initially discovered in yeast in 1991 by 
Heitman and colleagues (4).  In yeast, mTOR is referred to simply as TOR and received 
its name because it was demonstrated that the protein was inhibited by rapamycin (4).  In 
mammals the mTOR signaling pathway proteins are ubiquitous (5), but the focus of this 
literature review will focus on mTOR signaling in skeletal muscle (Figure 1.1). 
Protein synthesis is limited by both the abundance and efficiency of ribosomes to 
translate mRNA into protein and the availability of amino acids to form a protein.  The 
efficiency of ribosomes to translate mRNA into a protein is modulated by a series of 
intracellular signaling cascades that are associated with the mTOR pathway. 
1.2.1.  The mammalian target of rapamycin complexes 
mTOR and the complexes it forms are predominately localized to the cytoplasm 
during inactivated states, but shuttling to the nucleus and lysosomes occurs during 
various activated states (6), which will be discussed further below.  mTOR behaves as the 
catalytic subunit in 2 complexes: the mTOR complex 1 and 2 (mTORC1 and mTORC2).  
mTORC1 (Figure 1.2A) consists of 5 proteins: mTOR, mammalian lethal with SEC13 
protein 8 (mLST8; also known as GβL), DEP domain-containing mTOR-interacting 
protein (DEPTOR), regulatory-associated protein of mTOR (RAPTOR), and 40 kDa pro-
rich Akt substrate (PRAS40; also known as AKT1S1).  GβL acts as a stabilizer for the 
mTOR-RAPTOR association, and RAPTOR serves to recruit mTOR substrates (7).  GβL 
is also thought to act as a positive regulator for mTORC1 function (8), whereas DEPTOR 
(9) and PRAS40 (10) may have an inhibitory role; all of which will be further described 
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below (Section 1.2.2).  mTORC2 (Figure 1.2B) is comprised of six proteins, three of 
which are also found in mTORC1: mTOR, GβL, and DEPTOR.  The three remaining 
proteins that are unique to mTORC2 are rapamycin-insensitive companion of mTOR 
(RICTOR), mammalian stress-activated map kinase-interacting protein 1 (mSIN1; also 
known as MAPKAP1), and protein observed with RICTOR (PROTOR).  RICTOR and 
PROTOR aid in the assembly of the mTORC2 complex (11).  mSIN1 appears to function 
in the relocalization of the mTORC2 complex towards the cell membrane where it can 
interact with Akt, a signaling factor within the mTOR signaling pathway (12, 13).  The 
two complexes of mTOR have varied functions and contributions to the mTOR signaling 
pathway which will be discussed further below (Section 1.2.2).  Regardless of complex, 
the activated form of mTOR is phosphorylated at sites Ser2448 and Ser2481 (14, 15).  From 
this point on mTOR signaling will refer to mTORC1 signaling. 
1.2.2.  Upstream inputs of the mTOR signaling pathway 
 Upstream input into the mTOR signaling pathway comes from a variety of 
sources including: metabolites, hormones, mechanical stimulation, and physiological 
states.  This section of the literature review will be subdivided by these inputs. 
1.2.2.1.  Insulin and Insulin like growth factor 
The insulin and mTOR signaling pathways are joined through protein kinase B 
(PKB; also known as Akt).  Insulin and insulin like growth factor (IGF) bind with their 
respective receptors, resulting in the autophosphorylation of tyrosine residues.  The 
activation of this insulin receptor tyrosine kinase complex results in the phosphorylation 
of the insulin receptor substrates (IRS-1, IRS-2, and IRS-3) (16).  The IRS act as docking 
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units for the regulatory subunit of phosphoinositide 3-kinase (PI3K) (16, 17), and 
together the activated subunit phosphorylates PtdIns(3,4)P2 / PtdIns(3,4,5)P3-dependent 
kinase 1 (PDK1) on the serine residues.  PDK1 then phosphorylates Akt at Thr308 (18).  
An additional phosphorylation site (Ser473) must also be phosphorylated for Akt to be 
activated (18).  Akt is phosphorylated at Ser473 by the mTORC2 (19, 20).  Although the 
upstream substrates resulting in mTORC2 activation have not been fully elucidated, Akt 
is phosphorylated at Ser473 in response to insulin and IGF-1(18).  Researchers currently 
theorize that phosphorylation of Ser473 primes Akt for further phosphorylation at Thr308 
(21); however, additional research is necessary to confirm this.  In summary, insulin and 
IGF act through the insulin signaling pathway to activate Akt, linking the insulin and 
mTOR signaling pathways. 
There are also several negative effectors that can inhibit activation in the insulin 
signaling pathway which include protein tyrosine phosphatase-1β (PTP1β), phosphatase 
and tensin homolog deleted on chromosome 10 (PTEN), and protein phosphatase 
2A(PP2A) (22-24).  PTP1β dephosphorylates both the insulin receptor and IRS, and thus, 
deactivating the insulin receptor and IRS, which inhibits signaling through the pathway 
(22, 24).  PTEN prevents PI3K from phosphorylating PDK1, inhibiting further signaling 
in the insulin pathway (22, 24).  PP2A dephosphorylates the upstream effector Akt, and 
the downstream effector, 70 kDa S6 Kinase 1 (S6K1) (22, 24), which will be discussed in 
detail below (Section 1.2.3.1).  Ultimately, for Akt activation to occur through the insulin 
signaling pathway the activity of these negative effectors must be suppressed. 
Akt activation leads to mTOR activation through the inhibition of PRAS40 and 
tuberous sclerosis 2 (TSC2).  PRAS40 interacts with RAPTOR as a component of 
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mTORC1 and behaves as a negative regulator, inhibiting mTORC1 activity (25).  Akt 
phoshphorylation of PRAS40 at Thr246 inhibits PRAS40 activity (10), allowing mTORC1 
activation which results in the activation of PRAS40 at Ser183 and Ser221 and subsequent 
disassociation from mTOR (26, 27).  Disassociated PRAS40 then binds to the scaffolding 
protein 14-3-3 (27).  Activated Akt phosphorylates TSC2 at four residues (Ser939, 
Ser1086/1088, Thr1462, and Thr1422) (28, 29).  TSC2 is a component of the TSC1/2 complex, 
which acts as a GTPase activating protein (GAP) for the G protein, Ras homologue 
enriched in brain (RHEB) (30, 31).  Because GDP loaded RHEB cannot activate mTOR, 
the TSC1/2 complex acts as an upstream inhibitor of mTOR.  Akt inhibition of TSC2 
inhibits the TSC1/2 complex resulting in the inhibition of GAP activity.  This keeps 
RHEB bound to GTP, allowing for the activation of mTOR.  PRAS40 and TSC1/2 
complex are inactivated by Akt through phosphorylation and mediate the activity of the 
mTORC1 complex. 
Akt influences other cell mediators not involved in the mTOR signaling pathway.  
Although a detailed description of this is beyond the scope of this literature review, a 
discussion of Akt would not be complete without it.  Activation of Akt results in the 
translocation of glucose transporter 4 (GLUT4) to the cell membrane (16), and 
phosphorylates the transcription factors, forkhead box protein O1 (FoxO1) and O3 
(FoxO3) (32).  The translocation of the 12-transmembrane domain protein, GLUT4, 
results in the transport of glucose into the cell (33, 34).  Alternatively, the FoxO proteins 
are involved in the molecular signaling pathway regulating protein breakdown (Section 
1.3) (35), and in activating the expression of genes regulating apoptosis (36).  Thus, Akt 
influences protein synthesis, protein breakdown, glucose metabolism, and the cell cycle. 
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1.2.2.2. Glucose 
 Although glucose does not directly influence mTOR signaling, cellular energy, 
which is partly derived from glucose, mediates mTOR signaling.  Glucose is transported 
into the cell by GLUT4, which is translocated to the cell membrane by Akt (16).  Briefly, 
ATP is produced from glucose through glycolysis in the cytoplasm, and the Krebs cycle 
and electron chain transport in the mitochondria.  The ratio of AMP to ATP, an indicator 
of cellular energy status, is allosterically monitored by AMPK.  AMPK activity is 
inhibited when there are elevated levels of ATP because the AMP/ATP ratio is reduced.  
During times of low energy status, AMP/ATP ratio is increased, activating AMPK.  
Therefore, any physiological state altering ATP status can affect mTOR signaling, 
because activated AMPK phosphorylates TSC2 at Thr1227 and Ser1345, causing activation 
of TSC2 and forms the TSC1/2 complex (37).  As previously mentioned, the TSC1/2 
complex acts as a GAP for RHEB (30, 31).  Activation of the TSC1/2 complex stimulates 
GAP activity toward RHEB inhibiting mTOR.  AMPK can also inhibit mTORC1 through 
phosphorylating RAPTOR at Ser722 and Ser792 inducing the association of RAPTOR and 
scaffold protein 14-3-3 (38).  Any physiological state affecting AMPK status, such as 
stress and DNA damage, will alter mTOR signaling.  DNA damage upregulates AMPK 
in a p53 dependent manner (39), resulting in inhibition of mTOR signaling.  Because 
AMPK can directly and indirectly inhibit mTORC1, any physiological state affecting 
ATP status can alter mTOR signaling; therefore, in a glucose rich environment, for 
example following a meal, AMPK is reduced allowing mTOR signaling. 
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1.2.2.3  Amino Acids 
 Intracellular amino acids stimulate mTOR signaling (40), and this stimulation 
requires a system of amino acid transporters in order to transport extracellular amino 
acids from blood into the muscle.  Although there is not a full understanding of how 
amino acids stimulate mTORC1 activation, potential mediators have been recognized 
including mitogen-activated protein 4 kinase kinase kinase kinase (MAP4K3) (41, 42) 
and PI3K catalytic subunit type 3 (VPS34) (43).  MAP4K3 is stimulated by amino acids 
independent of insulin and is not suppressed by rapamycin, and results in the activation 
of S6K1, a downstream signaling factor in the mTOR signaling pathway, which will be 
discussed in detail below (Section 1.2.3.1) (42).  Therefore, it is thought that amino acid 
stimulation of MAP4K3 activates S6K1 independent of mTOR, but this requires further 
elucidation.  Although the mechanistic action of VPS34 on downstream mTOR signaling 
factors is not fully understood, VPS34 may be the primary modulator of mTOR signaling 
in response to amino acids (44), and it has been suggested that VPS34 is required for 
leucine stimulation of S6K1 (45).  Another potential mediator is the Rag family of 
GTPases (46).  In the absence of amino acids, the Rag GTPases maintain an inactive 
conformation, but in the presence of amino acids the Rag GTPases become activated and 
interact with RAPTOR resulting in mTORC1 relocalization onto the surface of 
endosomes and lysosomes.  This may enable mTORC1 interaction with RHEB and 
mTORC1 activation (46); however, this requires further elucidation.  Even though a 
mixture of amino acids stimulate mTOR signaling, arginine and leucine have been shown 
to directly stimulate mTOR signaling.  Although the mechanism requires further 
elucidation, arginine stimulated mTOR signaling in a nitric oxide independent manner 
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(47).  Leucine has been identified as a key amino acid in mTORC1 activation (48-50).  
The stimulation of the mTOR signaling pathway by amino acids is pivitol area of 
research and may provide insight to more effective diet formulation. 
1.2.2.4.  Growth factors 
 Growth factors, such as IGF, epidermal growth factor (EGF), platelet derived 
growth factor (PDGF), and vascular endothelial growth factor (VEGF) can also stimulate 
mTOR through Akt-independent mechanism (51-53).  Stimulation of the extracellular 
regulated kinase (MEK/ERK) axis through growth factor activation of a small GTPase in 
the RAt Sarcoma protein subfamily (Ras) and subsequently mitogen activated protein 
kinase kinase kinase (MAP3K) stimulates MEK and then ERK1/2 to inactivate TSC2 
through phosphoryaltion at Ser664 (52).  Additionally, Wingless-Type MMTV Integration 
site family (Wnt) inhibits glycogen synthase kinase 3β (GSK3β) through the β-catenin 
pathway, allowing mTOR activation; however, β-catenin, itself, does not affect mTOR 
activation (51).  The activated form of GSK3β phosphorylates TSC2 at Thr1329, Ser1333, 
Ser1337, and Ser1341 resulting in mTOR inhibition (51).  Growth factors, specifically IGF, 
can also stimulate mTOR signaling in an Akt-dependent manner, which was previously 
discussed above (Section 1.2.2.1). 
1.2.2.5.  Other physiological states 
 Regulated in development and DNA damage response 1 (REDD1; also known as 
RTP801/DDIT4) is a hypoxia induced gene, and can alter mTOR signaling through 
several mechanisms including stress (54-56), glucocorticoid treatment (57), and exercise 
(58).  Hypoxia induces REDD1 expression causing TSC2 to dissociate from scaffolding 
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protein 14-3-3, and allowing TSC1/2 complex activation (55, 56).  Energy stress can also 
act through AMPK dependent and independent mechanisms similar to what is seen 
during hypoxia, with induced expression REDD1 and subsequent TSC1/2 complex 
activation (54).  Additionally, REDD1 expression is induced following glucocorticoid 
treatment with dexamethasone leading to mTOR inhibition through TSC1/2 complex 
activation (59).  Immediately following endurance exercise REDD1 expression is 
elevated (58) and may be responsible for the inhibition of mTOR during exercise; 
however, these mechanisms have not been fully elucidated. 
Another hypoxia induced gene, REDD2 (also known as RTP801L/DDIT4L), also 
acts as an mTOR signaling inhibitor; however, much less is known about REDD2.  
Similar to REDD1, REDD2 does not inhibit mTOR signaling through TSC2 activation 
directly, but through interactions with the scaffolding protein 14-3-3, which results in 
activation of the TSC1/2 complex.  REDD2 expression is stimulated by leucine and 
mechanical stretch (60), demonstrating that positive and negative signaling components 
influence the activation of mTOR simultaneously.  As a result, in order for mTOR 
activation to occur, the positive signaling must be greater than the negative signaling. 
1.2.2.6.  Summary of the upstream activators of mTOR 
 In conclusion, physiological states such as stress, hypoxia, and exercise, growth 
factors, and metabolites are all upstream effectors of the mTOR signaling pathway.  With 
the exception of amino acids, all other effectors work through either activating (negative 
effectors: low energy status, DNA damage, hypoxia) or inhibiting (positive effectors: 
high energy status, insulin, amino acids, and growth factors) the TSC1/2 complex which 
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allows for the inhibition or activation of the mTORC1, respectively.  Upstream of 
mTORC1 the insulin and mTOR signaling pathways converge at Akt (Figure 1.3).  
Additionally, the MEK/ERK axis feeds into the mTOR signaling pathway through the 
TSC1/2 complex.  This series of events leads to the activation of mTORC1. 
1.2.3.  Downstream effectors of the mTOR signaling pathway 
Following mTORC1 activation by RHEB, a series of cell signaling events occurs 
leading to the formation of the ribosome and the initiation of the translation of mRNA 
into a protein.  Activated mTORC1 causes the phosphorylation of S6K1 at Thr389, Thr229, 
Ser404, and Thr412 and eukaryotic initiation factor (eIF) 4E-binding protein 1 (4EBP1) at 
Thr 36/47 Ser65, and Thr70 through RAPTOR recruitment (61).  The function of RAPTOR 
in mTORC1 is to recruit substrates in order for these substrates to be in close enough 
proximity for the catalytic activity of mTOR to phosphorylate the substrates (7).  This 
section of the literature review will be subdivided by the downstream effectors. 
1.2.3.1. S6K1 
The activation of S6K1 through phosphorylation is required for RNA processing 
and mRNA translation initiation.  S6K1 mediates several downstream proteins including: 
the transcription factor CREMτ (62), the 80 kDa RNA splicing export factor nuclear cap-
binding protein (CBP80; also known as NCBP1) (63), Aly/REF-like target (SKAR; also 
known as POLDIP3) (64), ribosomal protein S6 (rpS6) (65, 66), and eIF4B (67, 68).  Of 
the targets of S6K1, only SKAR, rpS6, and eIF4B have been extensively studied.  SKAR 
is a scaffolding protein that recruits S6K1 to newly synthesized mRNAs and interacts 
with the exon junction complex that is involved in splicing pre-mRNA (64).  S6K1 
12 
 
influence on both CBP80 and SKAR demonstrates the contribution of S6K1 in enhancing 
translational efficiency gained from splicing of pre-mRNA (63, 64).  Translation 
efficiency is the effectiveness of the ribosome to form a protein from the mRNA and 
depends on the availability of amino acids.  rpS6 is activated through phosphorylation at 
Ser235, Ser236, Ser240, Ser244, and Ser247 by S6K1, and was once suggested to increase 
translational efficiency of 5’terminal oligopyrimidine (TOP) mRNAs, which encode 
components of the translation machinery, through ribosomal recruitment (65, 66); 
however, this theory has been disproven (69).  rpS6 activation is necessary for increased 
protein synthesis, but the mechanism is still unclear (69).  rpS6 is also involved in cell 
proliferation (70) and determining cell growth (69).  rpS6 knockout mouse embryo 
fibroblasts have accelerated cell division due to a shortened G1 phase (70).  rpS6 aids in 
the determination of cell growth through controlling protein synthesis and cell division 
(69).  S6K1 activates the RNA-binding protein, eIF4B, through phosphorylation at Ser422, 
and is required for ribosomal recruitment to mRNA (68).  Activated eIF4B stimulates the 
ATPase and helicase activities of eIF4A (67), which enhances the translation of mRNAs 
with some secondary structure because the helicase function can unwind the mRNA 
secondary structure (71).  Overall, S6K1 is thought to increase translational capacity of 
the cell through translation component enhancement (also known as ribosome biogenesis) 
(72), and through ribosomal recruitment to mRNA. 
1.2.3.2.  4EBP1 
mTORC1 activation leads to the phosphorylation of 4EBP1at Thr37and Thr46, 
which is thought to prime 4EBP1 for the subsequent phosphorylation at Ser65 and Thr70 
(73).  4EBP1 acts as a regulator for the formation of the eIF4F complex that is required in 
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the initiation of cap-dependent mRNA translation.  The phosphorylation of 4EBP1 causes 
its dissociation from eIF4E, which allows eIF4E and eIF4G to associate.  eIF4E is the 
rate-limiting translation initiation factor that initiates cap-dependent translation through 
binding to the Cap structure (m7GpppN) at the 5’ end of mRNA transcripts (74); 
therefore, the phosphorylation of 4EBP1 and subsequent dissociation from eIF4E is a key 
step in translation initiation.  The eIF4E/G complex behaves as a scaffolding protein and 
recruits eIF4A and eIF3; together forming the eIF4F complex (75) that is bound to 
m7GpppN.  This complex acts as a mediator of mRNA binding to the 40S ribosomal 
subunit.  Next, eIF4B associates with the eIF4F complex, facilitating mRNA and 
ribosome association (76).  Prior to mRNA recruitment to the 40S subunit, GTP loaded 
eIF2 bound to Met-tRNAi is recruited to the 40S subunit (77).  This entire complex is 
referred to as the 43S pre-initiation complex.  At this point, the 43S complex scans the 
mRNA, once the AUG start codon is reached, the GTPase, eIF5, binds to the complex 
and hydrolyzes eIF2 loaded with GTP to GDP allowing eIF5B to bind to the complex.  
This series of events causes displacement of the eIF2 and recruitment of the 60S 
ribosomal subunit, and relocalizes the 60S ribosomal subunit to the 43S complex (77, 
78).  
1.2.3.3.  Elongation of the polypeptide chain 
The initiation complex then begins elongating the peptide chain with the 
association of eukaryotic elongation factor (eEF) 2 (79).  eEF2 mediates the translocation 
step from the “P” to the “A” site of the peptidyl-tRNA, facilitating ribosome movement 
along the mRNA (53).  The “P” and “A” sites are named because they are the sites where 
the peptidyl-tRNA and the aminoacyl-tRNA bind, respectively.  eEF1A bound to GTP 
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delivers the next aminoacyl-tRNA to the ribosome at the “A” site (80).  A second GTP is 
then needed to remove eEF1A following correct codon, anti-codon recognition (80).  
Finally, eEF1B assists in the regeneration of eEF1A to its active form, where it can 
collect another aminoacyl-tRNA (80).  This process requires metabolic energy in the 
form of GTP, where two molecules of GTP are cleaved for every amino acid added to the 
polypeptide chain. 
1.2.3.4.  Termination of the elongation of the polypeptide chain 
The last step in translation is termination which occurs when the ribosome reaches 
the stop codon.  The eukaryotic releasing factor 1 (eRF1) is activated by eRF3 in a GTP-
dependent manner, which results in eRF1 binding to the ribosome and cleaving the bond 
between the peptide chain and the tRNA (80).  This also requires the hydrolysis of GTP 
(80).  The net result is an increase in protein synthesis. 
1.2.3.5.  Summary of the downstream effectors of mTOR 
 In conclusion, the activation of mTORC1 results in the downstream activation of 
S6K1 and 4EBP1 (Figure 1.3).  Each of these proteins are key players in forming the 
initiation complex.  S6K1 activates rpS6 and eIF4B.  The phosphorylation of 4EBP1 
causes it to dissociate from eIF4E, allowing for the association of eIF4E and eIF4G.  This 
series of events initiates the formation of the initiation complex along the mRNA.  
Initiation is followed by elongation and, once the polypeptide chain is formed, 
termination.  The net result is protein synthesis. 
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1.2.4.  Feedback mechanisms within the mTOR signaling pathway 
 The interaction of the insulin and mTOR signaling pathways has been previously 
discussed in regards to activation through these pathways toward translation initiation.  
These pathways also interact in a negative feedback manner.  Hyperactivation of 
mTORC1 triggers activated S6K1 to inhibit IRS1, resulting in decreased Akt activation 
and subsequently mTORC1 (81).  This negative feedback loop also has consequences for 
insulin signaling, such as reduced insulin sensitivity and glucose uptake, which may have 
implications for horses with metabolic syndrome. 
1.2.5.  Effects of anabolic stimuli on mTOR signaling in mature mammals 
  Anabolic stimuli such as meal consumption (82-84), amino acid administration 
(85, 86), insulin (85, 86), or exercise (87-91) increases the activation of translation 
initiation factors in the mTOR signaling pathway and increases muscle protein fractional 
synthesis rates.  In mature sedentary animals, skeletal muscle protein turnover occurs at a 
fairly slow rate with slight variations occurring during fasting and feeding, where the net 
breakdown and synthesis are greater at these times, respectively (92).  Fasting has a 
greater effect of reducing mTOR signaling in muscles primarily composed of fast twitch 
fibers compared to slow twitch fibers (93).  Specifically, during times of short term 
fasting (18-24 hours) and long term (2-3 days), phosphorylation of Akt and mTOR, 
respectively, are greater in muscle primarily composed of slow twitch fibers than fast 
twitch fibers (93).  The absence of insulin, glucose, and amino acids during fasting 
activates AMPK which subsequently activates the TSC1/2 complex which inhibits 
mTOR activation (Section 1.2.2.2), ultimately suppressing protein synthesis (37, 56, 94).  
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The difference in mTOR signaling during short and long term fasting where there is an 
increase in the phosphorylation of Akt and mTOR, respectively, is due to the pro-survival 
role of autophagy.  Upregulation of autophagy in liver, white adipose tissue, and muscle 
recycles protein, glycogen and lipid stores and releases them as amino acids, glucose, and 
free fatty acids into the blood stream.  These metabolites can then be used by skeletal 
muscle to cause partial reactivation of mTOR signaling (95), which suppresses autophagy 
during long term fasting (96). A recent study showed that Gadd34, a protein that is 
traditionally upregulated during growth arrest and DNA damage, binds to and 
dephosphorylates TSC2 at Thr1462 during fasting, leading to mTOR suppression (97). 
Meal consumption results in the stimulation of the mTOR signaling pathway (82-
84).  Following meal consumption, there is an elevation in amino acids, free fatty acids, 
glucose, and insulin concentrations in the blood stream.  As mentioned above (Section 
1.2.2), amino acids and insulin stimulate mTOR signaling.  Therefore, many studies have 
been performed using clamps to stimulate a fed state (98) which have demonstrated 
increased mTOR signaling.  Intravenous clamps maintain circulating levels of a desired 
metabolite or hormone at a set state.  Regardless of nutrient content, ingestion of any type 
of meal will increase circulating insulin.  Therefore, in order to determine if both amino 
acids and insulin are required to stimulate mTOR leading to protein synthesis, reduced 
amino acid hyperglycemic hyperinsulinemic hyperlipidemic clamp studies were 
performed, which demonstrated that insulin alone does not sufficiently stimulate mTOR 
to lead to increased protein synthesis (85, 86), but Akt is activated (86).  This 
phenomenon may be explained due to a lack of available amino acids to form a protein or 
due to insufficient translation initiation.  Additionally, insulin stimulates vasodilation 
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which promotes protein synthesis through increasing the flow of available nutrients, such 
as amino acids, to the muscle (99).  This mechanism has not been fully elucidated, but 
does not appear to require Akt activation (99). 
 Amino acids alone can stimulate the mTOR signaling pathway and subsequently 
protein synthesis.  The increase in protein synthesis due to amino acids is not affected by 
the method of delivery of amino acids (oral or infusion) (100).  Because leucine has been 
demonstrated as the key amino acid in regulating mTOR signaling, many studies have 
focused on supplementing leucine.  Even though elevating leucine ingestion past 
0.14g/kg in mature rodents resulted in a near maximal stimulation of protein synthesis, 
the activation of mTOR signaling factors appears to be dose dependent (101).  
Additionally, the ingestion of carbohydrate and amino acid mixture enriched in leucine 
seems to stimulate mTOR signaling through AMPK-TSC1/2 complex axis, likely from 
the carbohydrate portion of the mixture (102), and S6K1 and 4EBP1 due to the amino 
acid and leucine component in resting humans (103).  This study also demonstrated that 
this leucine enriched mixture decreased the phosphorylation of eEF2 which promotes 
elongation and stimulated muscle protein fractional synthesis rates (103).  Regardless of 
delivery method, amino acids stimulate protein synthesis at the molecular points of 
translation and elongation. 
 During exercise, skeletal muscle contractile activity, which can also be thought of 
as mechanical stimulation, increases.  Mechanical stimulation of skeletal muscle fiber 
(104) can occur through the stimulation of muscle fibers in the laboratory, or subjects 
performing aerobic or resistance exercise, the result is still some form of mechanical 
stimulation.  Mechanical stimulation increases the activity of the mTOR signaling 
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pathway.  Elevated protein synthesis through activation of the mTOR signaling pathway 
can lead to an enlargement in muscle fibers (105).  Following acute resistance exercise in 
rodents, there is almost an immediate (5-10 min post exercise bout) increase in mTOR 
signaling factors: phosphorylation of Akt, 4EBP1, and rpS6 and the association of eIF4E 
to eIF4G (87).  The activation of mTOR itself has had mixed reports in response to 
mechanical stimulation, where there are reports of no affect on the phosphorylation of 
mTOR at Ser2481 (88, 89), an increase in the phosphorylation of mTOR at Ser2448 (91), or 
no affect on the phosphorylation of mTOR at Ser2448 (87).  However, the downstream 
effectors have been shown to increase in phosphorylation (61, 65, 67), and these proteins 
are associated with an increase in the rate of muscle protein synthesis (81).  Although the 
mechanism still requires elucidation, it is currently accepted that there is an increase in 
the downstream effectors (90, 106, 107) and subsequent protein synthesis (108) following 
the mechanical stimulation of skeletal muscle.  It has been demonstrated that activation of 
the downstream effectors due to mechanical stimulation is independent of PI3K/Akt 
signaling (90).  However, it appears that mechanical stimulation activates the 
downstream effector, rpS6 through an mTORC1 independent mechanism.  Following 
mechanical stimulation there is an increase in MEK/ERK signaling (90), which activates 
p 90 ribosomal S6 kinases (RSK).  RSK activate rpS6 through phosphorylation of Ser235 
and Ser236 (90, 107).  Because mTORC1 inhibitor rapamycin can inhibit S6K1 
phosphorylation following mechanical stimulation, and not rpS6 phosphorylation, it 
appears that protein synthesis due to mechanical stimulation is regulated by both the 
MEK/ERK signaling pathway and the mTOR signaling pathway (90). 
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  The adaptation of skeletal muscle to hypertrophy following exercise has been 
shown to be fiber type dependent, where fast twitch fibers (Type II) are more susceptible 
to adaptation than slow twitch fibers (Type I) (109).  This can be partly explained by the 
fact that muscle groups containing greater proportion of Type II compared to Type I 
fibers have a greater phosphorylation of S6K1 in response to resistance exercise (110).  
Additionally, maximal lengthening contraction stimulates S6K1, rpS6, and MAP3K 
greater in Type II fibers compared to Type I, which not only further demonstrates fiber 
type differences, but also indicates the role of MEK/ERK in contraction driven protein 
synthesis (111).  Another explanation may be that the majority of muscle groups that are 
predominately slow twitch fibers are mainly used in posture and this continuous 
mechanical stimulation is less effective than intermittent mechanical stimulation at 
activating the mTOR pathway (112, 113). 
Both aerobic (endurance) and resistance exercise increase mTOR pathway 
signaling and subsequent protein synthesis (106, 108).  However, following resistance 
exercise the phosphorylation of S6K1, rpS6, and myofibrillar muscle fraction synthesis 
rates were higher than following endurance exercise in untrained humans (108).  Humans 
who have been trained for resistance exercise have elevated phosphorylation of Akt and 
eIF4E, and increased myofibrillar protein fractional synthesis rates following a bout of 
resistance exercise compared to following a bout of endurance exercise in endurance-
trained individuals (108).  Additionally, mitochondrial protein fractional synthesis rates 
in the muscle are elevated to the same extent following a bout of endurance or resistance 
exercise in untrained individuals; however, in trained individuals muscle mitochondrial 
protein fractional synthesis rates are greater following endurance exercise (108).  The 
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mechanistic differences in which endurance and resistance exercise stimulate the mTOR 
signaling pathway may explain the differences demonstrated by Wilkinson and 
colleagues (108).  Endurance exercise results in AMPK inhibition of TSC2, while 
resistance exercise elevates phosphorylation of Akt and subsequent TSC2 
phosphorylation (114).  A recent study in untrained subjects, following a bout of aerobic 
exercise the phosphorylated forms of Akt, TSC2, and 4EBP1 were greater in the skeletal 
muscle of these subjects than in those subjects performing the resistance exercise (106).  
However, a few studies (115, 116) in humans have indicated an additional upstream 
mechanism (MEK/ERK) that results in the stimulation of mTOR during resistance 
exercise, but this has yet to be demonstrated under endurance exercise conditions. 
The combination of consuming a high protein meal either before (117) or after 
(118) an endurance exercise bout has been demonstrated to have greater activation of 
mTOR signaling than either stimulus alone.  However, the effect of resistance exercise on 
the activation of mTOR signaling appears to be benefitted from the ingestion of a high 
protein meal following exercise, but not prior to exercise (82, 119, 120).  In addition to 
activating mTOR signaling, elevated MAPK signaling occurs when a high protein meal is 
consumed following resistance exercise (82).  Thus, combining anabolic stimuli (exercise 
and feeding) results in a further increase in mTOR signaling. 
Both amino acid supplementation and exercise have been demonstrated to 
increase the mRNA expression of several amino acid transporters in skeletal muscle 
(121-123).  One hour following ingestion of essential amino acids, mRNA expressions of 
the amino acid transporters LAT1/SLC7A5, CD98/SLC3A2, SNAT2/SLC38A2, and 
PAT1/SLC36A1 were elevated (121).  This led to increased protein abundance of 
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LAT1/SLC7A5 and SNAT2/SLC38A2 3 hours following the ingestion of essential amino 
acids (121).  Resistance exercise had similar effects on amino acid transporters, but the 
time course was delayed.  The mRNA expression of the amino acid transporters 
CD98/SLC3A2, PAT1/SLC36A1, and CAT1/SLC7A1 increased 6 hours following 
resistance exercise (122), and the mRNA expression of LAT1/SLC7A5 increased 3 hours 
following resistance exercise (122).  This led to increased protein abundance of 
LAT1/SLC7A5 and CD98/SLC3A2 at 6 and 24 hours post-resistance exercise, 
respectively (122).  These studies (121-123) also examined VPS34, mTOR, S6K1, rpS6, 
and eIF4G markers of mTOR signaling, which were elevated following the respective 
anabolic stimulus used in each study indicating that the elevated expression of amino acid 
transporters may be dependent on mTOR signaling; however, this requires further 
elucidation. 
1.2.6.  mTOR signaling response to anabolic stimuli throughout the life span 
As previously mentioned (Section 1.2.2.4), growth factors affect the activation of 
translation initiation, and thus, during the life stage where there are increased (neonatal 
and development) or decreased (aging) circulating growth factors (124), there are 
alterations in the response of mTOR signaling and subsequently protein synthesis to 
anabolic stimuli.  The neonatal period is characterized by the highest growth rate during 
the lifespan with skeletal muscle showing the largest increase in mass (125).  Elevated 
growth rate in the neonate is a result of protein synthesis rates being higher than protein 
degradation rates. However, with post-natal maturation, protein synthesis rates gradually 
decrease (125-127) until both synthesis and degradation are equal in non-growing adult 
muscle (128). 
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The activation of translation initiation factors (129-131) and protein synthesis 
(132, 133) in skeletal muscle are more responsive to feeding during early postnatal life 
and declines with development.  Insulin infusion can stimulate muscle protein synthesis 
and whole-body protein synthesis during a period of fasting in weaned rats (134) and 
fetal sheep (135), respectively.  However, insulin alone does not stimulate protein 
synthesis in adult animals or humans (85, 86, 136), which indicates that muscle protein 
synthesis response may be developmentally regulated.  This was further demonstrated by 
examining the insulin signaling pathway activation in response to feeding where the 
activation of insulin receptor, IRS-1, IRS-2, PI3K (137) and Akt (23) are greater in the 7 
day old neonatal pig compared to the 26 day old.  Additionally, increasing insulin 
elevates protein synthesis and the activation of insulin and mTOR signaling factors in a 
dose-dependent manner, even when amino acid concentrations are low (138-140). 
Elevated rates of protein synthesis during the neonatal period are a result of an 
increased efficiency of dietary amino acids used for protein accretion (141).  Activated 
mTOR signaling and protein synthesis due to amino acid supplementation decreases with 
development, similar to the response of insulin and feeding (138, 142).  Of all of the 
essential amino acids, leucine, has received the most attention, because leucine alone has 
been shown to stimulate mTOR signaling (143), while the other branched chain amino 
acids cannot stimulate mTOR signaling alone (49).  Leucine, individually, does not elicit 
the same increase in mTOR signaling activation as when it is given with a balanced 
amino acid mixture (48), which may be partly attributed to the fact that the ability of 
leucine or any other anabolic stimuli to stimulate protein synthesis is dependent on the 
availability of amino acids needed for synthesis of a protein (50). 
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The negative regulators of insulin and mTOR signaling, PTP1B, PTEN, PP2A, 
and TSC2, are less active in the skeletal muscle of neonates, but the activity of these 
negative regulators increases with age (23, 144).  However, the inhibition of mTOR 
signaling due to AMPK did not appear to be developmentally regulated when the 
stimulation was feeding (23).  Feeding also inhibits TSC2 activation in the skeletal 
muscle of neonates, and this is attenuated with age (23).  
Not only are the positive factors of the insulin and mTOR signaling pathways 
more active during neonatal development, but there is also a greater total abundance of 
these factors in skeletal muscle.  The abundance of the insulin receptor, PDK-1, and Akt 
in skeletal muscle decreases with development (131, 137).  The abundance of mTOR and 
RAPTOR also decreases with postnatal development, which results in a decreased 
association of the two proteins (23, 129, 145)  However, the abundance of downstream 
signaling factors such as S6K1, rpS6, and 4EBP1 do not change with development (146).  
In addition to the highly responsive mTOR signaling pathway, skeletal muscle of 
neonates has been reported to have a higher concentration of ribosomes which decreases 
with age (127, 147), and may also contribute to the elevated protein synthetic rates 
because of a higher efficiency to synthesize proteins.  Overall, the skeletal muscle of the 
rapidly growing neonate is physiologically adept to synthesize protein efficiently and 
thus accrete muscle mass. 
Aging is characterized by the involuntary loss of muscle mass and strength which 
is referred to as sarcopenia.  Sarcopenia has been partially attributed to a multitude of 
factors which include a decline in physical activity and a less than optimal diet in the 
aging human population (148-150).  Sarcopenia is a result of an imbalance of protein 
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synthesis and breakdown.  The increase in muscle protein fractional synthesis rates in 
response to anabolic stimuli such as exercise (149, 151, 152), amino acids (149, 153), 
insulin (154), or meal consumption (152, 153) is decreased in the aged compared to the 
younger adult, and may be due to dysregulation of signaling factors in the insulin and 
mTOR signaling pathways (155, 156).  Meal consumption in the aged does not increase 
protein synthesis or activate the mTOR signaling pathway to the same magnitude as in 
the young adult (155-157); however, when the meal is supplemented with leucine there is 
a restoration in the anabolic effect of feeding (158).  This may indicate that amino acid 
supplementation, specifically leucine, plays a larger role in stimulating protein synthesis 
than insulin in the aged.  Physiological hyperinsulinemia does not stimulate mTOR 
signaling in aging skeletal muscle as it does in young adult skeletal muscle (159, 160); 
however, at supraphysiological levels of hyperinsulinemia mTOR signaling in the aging 
skeletal muscle is restored (159).  This may indicate that insulin resistance with aging 
may at least partially be responsible for sarcopenia (161).  Additionally, aerobic exercise 
(162, 163), amino acid supplementation (164), and vaso-dilation (165) can improve the 
anabolic response of mTOR signaling to hyperinsulinemia.  Thus, activation of the 
mTOR signaling pathway in aging skeletal muscle appears to behave similar to young 
adult skeletal muscle when stimulated by multiple anabolic stimuli rather than just one.  
This also holds true for resistance exercise, which more effectively stimulates mTOR 
signaling in the elderly if amino acids are supplemented following the exercise bout 
(166).  However, amino acid supplementation prior to a bout of resistance exercise does 
not enhance muscle protein synthesis relative to resistance exercise alone (120).  Similar 
to the young adult, aging skeletal muscle has increased mRNA expression of several 
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amino acid transporters (LAT1/SLC7A5, CD98/SLC3A2, PAT1/SLC36A1, 
CAT1/SLC7A1) following resistance exercise; however, the expression of these amino 
acid transporters remain elevated for a longer period of time in the aged skeletal muscle 
(122).  This may mechanistically explain how adding amino acid supplementation to 
resistance exercise stimulates the activation of mTOR signaling pathway to the same 
extent as in the young adult skeletal muscle. 
 It has been stated that mTOR signaling and protein synthesis decrease with aging; 
however, the signaling factor that appears to be the most influenced by aging is S6K1.  
The activation of S6K1 in response to various anabolic stimuli such as meal consumption 
(129, 145, 156), amino acids (142, 155-157), insulin (142, 156, 162), and exercise (157, 
162) consistently decreases throughout development and into aging.  Additionally, the 
activation of S6K1 in the post-absorptive state declines during development (142, 145) 
and from mature to aging adults (155).  The influence on aging is also demonstrated in 
the time course response of S6K1 compared to the other mTOR signaling factors.  With 
aging, the activation of the mTOR signaling factors to exercise and amino acids is 
delayed except for the activation of S6K1, even though the abundance is still lowered in 
the aged (157).  It has also been demonstrated that the total abundance of S6K1 declines 
during aging (155).  The response of S6K1 to various anabolic stimuli during aging 
indicates that it may be the most influenced by aging. 
 Even though it is currently accepted that there is an overall decline with aging in 
the activation of mTOR signaling and protein synthesis in response to anabolic stimuli, 
the research that supports this only examines the neonatal phase and post-adulthood 
aging.  This leaves a hole in the literature for the peri-pubertal, and post-pubertal slow 
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growth phase occasionally referred to as adolescence.  In order to be sure that mTOR 
signaling and protein synthesis decline throughout the lifespan this life phase must not be 
ignored.  Unfortunately, due to the restrictions of common research models, this phase 
has been overlooked.  In the humans there are regulations making it difficult to collect 
muscle tissue from healthy children under the age of 18 years; whereas, the time of the 
adolescent phase is extremely brief in both rodents and pigs, making it difficult to 
implement experimental conditions.  As a result, this phase has received little to no 
research attention. 
1.3.  THE MOLECULAR MARKERS OF PROTEIN BREAKDOWN AND THE 
INTERACTION WITH mTOR SIGNALING 
A review of the literature pertaining to muscle mass accretion would not be 
complete without mentioning protein breakdown.  Although the focus of this dissertation 
has been on protein synthesis, muscle mass cannot be accreted without the rates of 
muscle protein synthesis being greater than the rates of muscle protein breakdown.  
Protein breakdown, similar to protein synthesis, has associated pathways that can be 
studied to improve our understanding of the process.  The main pathways involved in 
protein breakdown are the lysosome, ubiquitin-proteasome, and calcium dependent 
pathways, and apoptosis (167); however, skeletal muscle contains a limited number of 
lysosomes, and the contribution of lysosomal proteases and cathepsins to proteolysis or 
myofibrillar protein degradation is limited (168).  The lysosomal system is mainly 
responsible for the degradation of organelles and membrane proteins.  The ubiquitin-
proteasome pathway is responsible for the degradation of most of the skeletal muscle 
proteins (169), and requires muscle specific ubiquitin ligases, such as muscle-RING-
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finger protein 1(MuRF1) and atrogin-1/MAFbx (169-171).  There are three ubiquitin 
ligases involved in the addition of ubiquitin to a protein substrate: E1 ubiquitin-activating 
enzyme, E2 ubiquitin-conjugating enzyme and E3 ubiquitin –ligating enzyme (172).  The 
E3 ubiquitin ligases confer substrate specificity (172), and muscle has the specific 
ubiquitin ligases (169-171), mentioned earlier.  Many sarcomeric proteins are degraded 
through the calcium dependent pathway due to ubiquitous calpains 1 and 2, and muscle 
specific calpain 3 (168, 173).  Within skeletal muscle, satellite cells, which are muscle 
stem cells, are the most susceptible to apoptosis, which activates the caspases (174) and is 
regulated by the transcription factor, forkead box proteins (FoxO) (175).  Caspase-3 may 
be involved in the initiation of the degradation of actin (176).  FoxO also regulates the 
expression of atrogin-1 (177), which is a muscle specific E3 ubiquitin ligase (171).  The 
molecular components of these pathways such as MuRF1, atrogin-1, calpain 3, and FoxO 
can be studied as indicators of protein degradation. 
 Many of the mTOR signaling proteins interact with the main molecular 
components of protein degradation.  The active form of Akt inhibits FoxO through 
phosphorylation, which recruits 14-3-3 proteins preventing relocalization to the nucleus 
(175).  Additionally, FoxO is inhibited by the phosphorylation of serum- and 
glucocorticoid regulated kinase by mTORC2 and PDK1 (21).  Caspase 3 may also be 
inhibited by the activated form of Akt (177), but further elucidation is required.  Nuclear 
factor κ B (NF-κB) is stimulated by inflammatory cytokines, and may play a role in 
inactivating Akt and increasing the expression of MuRF-1 (177); however further 
research is warranted.  Additionally, activation of mTOR inhibits atrogin-1,  
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independently of FoxO (178); however this mechanism requires further elucidation.  
Therefore, Akt and mTOR play a pivotal role in both protein synthesis and degradation. 
Similar to protein synthesis, protein breakdown is altered during various 
physiological states such as aging (35, 179), and during postprandial and post-absorptive 
states (180).  During development, muscle protein metabolism is elevated, and rates of 
both muscle protein synthesis and breakdown are increased, with a net result of protein 
synthesis (181).  Research examining the molecular markers of protein degradation is 
limited; however, it has been determined that caspase-3 and caspase-9 are downregulated 
during development in the skeletal muscle of rodents (182).  This is an area that requires 
further elucidation during development; however, aging rodents have elevated 
proteasome content and activity and free ubiquitin and ubiquitylated protein 
concentrations in skeletal muscle compared to younger mature rodents (179).  The aged 
also have higher abundance of FoxO than the mature counterparts (35).  Additionally, 
ubiquitination rate is greater in the post-absorptive state than the postprandial state in the 
aged rodent whereas the mature rodents are not affected by physiological state (180).  
Overall, it appears that there is an increase in the molecular markers of protein 
degradation throughout the lifespan. 
Although there is much work still to be done examining these interactions 
between the molecular markers of protein synthesis and breakdown, it appears that 
protein breakdown and protein synthesis are both regulated by the activation of Akt (175, 
177) and mTOR (178).  Additionally, with aging there is an elevation in the molecular 
markers of protein degradation (179-181), which is pronounced during the post-
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absorptive state (180).  Ultimately, in order to study protein accretion effectively, both 
protein synthesis and degradation need to be examined. 
1.4.  WHOLE-BODY AND MUSCLE PROTEIN SYNTHESIS: 
METHODOLOGIES AND THE EFFECT OF ANABOLIC STIMULI 
1.4.1.   Isotope methodologies 
Up to this point the literature review has focused on the mTOR signaling pathway 
and how it results in protein synthesis.  Studying the mTOR signaling pathway provides 
insight to researchers as to whether or not a potential exists for an increase in the rate of 
muscle protein synthesis.  Isotopic measurements are used to quantify rates of protein 
synthesis.  Both whole-body and muscle protein synthesis rates are typically measured 
using the infusion of a stable amino acid isotope, for example [1-13C]phenylalanine.  By 
measuring phenylalanine flux and rates of phenylalanine oxidation to carbon dioxide 
(CO2) during [1-13C]phenylalanine infusion, researchers can estimate the rate of whole-
body protein synthesis using a stochastic approach (Figure 1.4).  This estimate of whole-
body protein synthesis is based on the principle that phenylalanine flux is equal to the 
rate that phenylalanine enters (from the diet and protein breakdown) and exits (through 
oxidation to CO2, use in protein synthesis and conversion to tyrosine) the free amino acid 
pool, and is calculated from the dilution of the isotope by unlabeled phenylalanine in the 
plasma (183).  The calculated difference of measured phenylalanine converted to CO2 
and flux results in non-oxidative disposal, which is an indirect measure of whole-body 
protein synthesis, because non-oxidative disposal includes the rate of phenylalanine used 
for protein synthesis and phenylalanine conversion to tyrosine.  If researchers supply both 
phenylalanine and tyrosine at equal levels to the different treatment groups, then it is 
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generally assumed that the phenylalanine conversion to tyrosine should also be equal 
among treatment groups; therefore, an increase in phenylalanine oxidation indicates a 
decrease in whole-body protein synthesis.  During these infusion procedures, the rate of 
muscle protein synthesis can also be measured, through the collection of muscle biopsies, 
during and at the end of the isotope infusion and measuring the rate of [1-
13C]phenylalanine incorporation into muscle protein (184).  Although phenylalanine was 
used during this explanation of isotope methodologies, researchers can use any stable 
indispensable amino acid isotope, as long as the carboxyl group is released as 13CO2 in 
the breath as the amino acids are catabolized. 
1.4.2.  Alterations in whole-body protein metabolism in response to anabolic stimuli 
 Whole-body protein synthesis is the sum of all of the individual tissue rates of 
protein synthesis and reflects the overall change in protein synthesis occurring during the 
physiological state that is being studied.  This makes it a useful tool to understand what is 
occurring on a large scale basis. 
 Whole-body protein metabolism is affected by anabolic stimuli such as meal 
consumption (185, 186) and exercise (187).  During the post-absorptive state, isotope 
tracer oxidation is less than following the consumption of a high protein meal (186), 
indicating that feeding increases the amino acid flux.  The additional amino acids that 
enter the free amino acid pool following meal consumption (dietary intake) that are not 
utilized for protein synthesis or conversion to other metabolites are oxidized; therefore, 
during the postprandial state amino acid isotope tracer oxidation is elevated because there 
is an excess of free amino acids in the plasma pool.  However, during the post-absorptive 
state the opposite is true, there is a reduction in free amino acids in the plasma pool 
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because amino acid entry is coming entirely from protein degradation rather than dietary 
intake, as is the case of the postprandial state.  Because there is a reduction in the free 
amino acid pool, there is not an excess of free amino acids, which results in a decrease in 
amino acid oxidation.  If flux is unchanged then, the increase in amino acid oxidation 
typically results in a decrease in protein synthesis; however, during the post-absorptive 
and postprandial periods, flux is not equal.  Non oxidative disposal can then be derived 
from the difference in flux and oxidation (Section 1.4.1).  In addition to a reduction in 
amino acid oxidation during the post-absorptive state, there is a reduction in protein 
synthesis in comparison to protein breakdown (186, 188, 189).  As a result, protein 
balance is in a negative state, where protein degradation is occurring at a higher rate than 
protein synthesis.  However, the opposite is true during the postprandial state, where non-
oxidative disposal is greater than release from protein breakdown (186, 188, 189), which 
results in a positive protein balance, because there is a greater rate of protein synthesis 
than protein degradation.  Overall, during the postprandial state there is a net increase in 
whole-body protein synthesis leading to protein accretion, and a net loss of whole-body 
protein during the post-absorptive period.  In a mature, sedentary, individual this cyclical 
balance of protein gain and loss during the postprandial and post-absorptive states 
throughout the day is equal, resulting in no accretion of protein. 
Whole-body protein metabolism is altered both during and following an exercise 
bout.  Because most exercise bouts last only a short period of time (minutes to hours), 
many researchers hypothesize that post-exercise changes in whole-body protein 
metabolism are of greater physiological relevance than changes occurring during the 
exercise state.  As a result, there is an abundance of literature examining the post-exercise 
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effects on whole-body protein metabolism, whereas studies of whole-body protein 
metabolism during exercise are limited and typically examine endurance or aerobic type 
exercise.  There are conflicting reports regarding changes in whole-body protein 
breakdown during aerobic exercise, where it has been demonstrated to be elevated (190-
192) or remain unchanged (193, 194).  However, all of these reports are in agreement that 
there is an increase in amino acid tracer oxidation (190, 192, 194), which may be derived 
from an increase in protein degradation.  The majority of these studies used leucine as the 
amino acid tracer, which is extensively catabolized in skeletal muscle.  Additionally, 
whole-body protein synthesis has been demonstrated to both decrease (190, 192) and 
remain unchanged (193) during aerobic exercise.  This provides supporting evidence for 
a negative protein balance during exercise, where there is an overall loss in whole-body 
protein.  The authors of these reports attribute two possible tissue systems for the increase 
in whole-body protein breakdown during aerobic exercise: the gastrointestinal tract (191), 
and skeletal muscle (190).  Reports on post-exercise alterations in whole-body protein 
metabolism are also conflicting; however, this may be primarily due to differences in the 
types of exercise.  Whole-body protein synthesis is elevated and unchanged following 
aerobic (190, 195) and resistance (196) type exercise, respectively.  Whole-body protein 
breakdown has been demonstrated to decrease (190) or remain unchanged (195) from 
pre-exercise resting rates following aerobic exercise.  Additionally, whole-body protein 
breakdown is unchanged from resting rates following resistance type exercise (196, 197).  
Thus, it appears that following resistance exercise there is no change in whole-body 
protein metabolism, whereas, following endurance exercise there appears to be an 
increase in protein accretion.  The majority of these studies, regardless of exercise type, 
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examine individuals exercising during the post-absorptive period, which may attribute to 
a negative protein balance and may not be physiologically relevant to the common 
practices of athletic humans or horses.  Therefore, additional research is warranted 
examining the effects of exercise on whole-body protein metabolism during the 
postprandial state. 
Skeletal muscle is responsible for 25% of whole-body protein synthesis (198, 
199), and fat free mass plays a key role in whole-body protein synthesis (187, 200, 201).  
Specifically, differences in the fat free mass of human subjects accounts for up to 87% of 
the variation seen in whole-body protein kinetics (187).  For this reason, some 
researchers theorize that the reduction in whole-body protein synthesis during the 
postprandial state seen in the aged may not be due to aging specifically, but rather due to 
a reduction in the fat free mass in this population (185).  Regardless of whether the 
reduction in whole-body protein synthesis in the aged population in response to the 
anabolic stimuli of meal consumption is actually due to aging or a product of the increase 
in fat mass, it is certain that there are differences in whole-body protein metabolism in the 
frail aged population and younger mature adults, which may suggest a higher protein 
requirement (202).  However, there is no effect of age on whole-body protein synthesis 
during the post-absorptive state (186).  Unfortunately, studies examining whole-body 
protein metabolism in children and adolescents are limited, due to the ethical constraints 
in studying this population (203), compared to healthy children of the same age.  It has 
been determined that children with diabetes have elevated whole-body protein 
degradation and amino acid oxidation (203).  Further research is warranted to examine 
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whole-body protein metabolism in a research model for healthy human children and 
adolescents. 
1.4.3.  Alterations in muscle protein fractional synthesis rates in response to anabolic 
stimuli 
Skeletal muscle comprises approximately 50% of body weight, but only 
contributes to 25% of whole-body protein synthesis (198, 199).  As a result, changes in 
muscle protein synthesis may only be detected at the whole-body level if they are 
dramatic.  Furthermore, if another tissue decreases its rate of protein synthesis and the 
muscle increases its rate of protein synthesis, then there would be no net effect measured 
at the whole-body level.  Because of this, it is useful to measure skeletal muscle protein 
synthesis directly.  In Section 1.2, the anabolic stimuli that increase muscle protein 
fractional synthesis rates were discussed.  There have been numerous studies (103, 204-
206) examining feeding-induced changes in muscle protein synthesis and breakdown, 
which highlight the more dramatic elevation in muscle protein synthesis compared to 
muscle protein breakdown (Section 1.3).  Because of the alterations in protein synthesis 
and breakdown in response to anabolic stimuli, it can be stated that within protein 
metabolism the overall limitation is within the regulation of protein synthesis.  Muscle 
protein synthesis increases following meal consumption in adult humans (103, 204-206) 
and neonatal pigs (133, 207), but eventually slows and returns to basal levels 
approximately 240 min post meal consumption, as demonstrated in the neonatal piglet 
(207).  Muscle protein synthesis is greatly affected by extracellular levels of amino acids 
following meal consumption; however, the effects of amino acids on muscle protein 
synthesis is graded until saturation (208).  Regardless of age, the muscle protein synthesis 
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response to graded intakes of amino acids has been demonstrated to be curvilinear, with a 
plateau at 0.13 g/kg body weight of indispensable amino acids in humans (155).  
However, it is important to note that the postprandial rates of muscle protein synthesis at 
any given concentration of amino acids for younger adults (~28 years old) was greater 
than for older humans (~70 years old) (155).  There are no age related differences 
between adults and aged humans in muscle protein synthesis during the post-absorptive 
state (155-157).  It was previously mentioned that whole-body protein synthesis is 
affected by fat free mass and this also holds true for muscle protein synthesis, where 
muscle protein fractional synthesis rates in lean young adult (20 years old) and aged lean 
men (75 years old) following the co-ingestion of a protein and leucine supplement are not 
different (209). 
Exercise may influence protein metabolism to a greater extent in muscle than in 
any other tissue in the body.  However, similar to whole-body protein metabolism, 
different types of exercise affect muscle protein fractional synthesis rates differently.  
Myofibrillar protein fractional synthesis rates are elevated and remain unchanged from 
pre-exercise resting rates following a bout of resistance and aerobic type exercise, 
respectively, in previously untrained muscle (108).  However, mitochondrial protein 
fractional synthesis rates were elevated from pre-exercise resting rates following a bout 
of exercise, regardless of exercise type, in previously untrained muscle (108).  Other 
reports (210, 211) examining mixed muscle protein fractional synthesis rates immediately 
following aerobic type exercise are conflicting with reports of no change (210) and 
increases (211) compared to pre-exercise rates.  Wilkinson and colleagues (108) suggest 
that these conflicts are due to differences in exercise intensity, increased AMPK (Section 
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1.2.2), time of sampling, and only examining mixed muscle rather than mitochondrial and 
myofibrillar fractional synthesis rates, which may have concealed the changes in 
mitochondrial fractional synthesis rates.  Additionally, the increased mitochondrial 
fractional synthesis rates following aerobic exercise (108) correspond to increased 
mitochondrial content with aerobic training (212, 213).   
In addition to the bout of exercise, the training status of an individual can alter 
both resting and post-exercise muscle protein fractional synthesis rates.  Resting 
myofibrillar fractional synthesis rates were elevated following 10 weeks of resistance 
training (108).  However, a single bout of resistance exercise increased myofibrillar 
fractional synthesis rates to the same extent in trained and untrained individuals (108).  
Resistance training did alter resting mitochondrial fractional synthesis rates, and the 
increase in mitochondrial fractional synthesis rates seen with a single bout of resistance 
exercise in untrained individuals was not present when trained individuals performed a 
single bout of resistance exercise (108).  Ten weeks of aerobic exercise training did not 
alter myofibrillar or mitochondrial fractional synthesis rates at rest or following a bout of 
aerobic exercise, compared to pre-training rates (108).  The authors hypothesized that the 
untrained individual may be in a heightened state of responsiveness to the anabolic 
stimuli of exercise (108). 
As with other anabolic stimuli, such as feeding, the response of muscle protein 
fractional synthesis rates to an exercise bout is altered with aging.  Reports have indicated 
a delayed response of mixed muscle protein fractional synthesis rates in aged subjects (3-
6 hours following an exercise bout) compared to adults (1-3 hours following an exercise 
bout) (157).  However, the use of resistance exercise to increase muscle mass and 
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strength is recommended in older individuals for the prevention or delay of sarcopenia 
(214-216).  Furthermore, combining anabolic stimuli, specifically consuming amino acids 
following a bout of resistance exercise increases mixed muscle protein fractional 
synthesis rates beyond the effects of amino acid supplementation or exercise alone (119, 
217, 218), and may prove to be useful in reducing sarcopenia in the aging population; 
however, further research is warranted. 
1.4.4.  Summary of the alterations in whole-body and muscle protein metabolism in 
response to anabolic stimuli 
 The use of isotope infusion protocols is a useful and commonly practiced 
technique in human research examining both whole-body and muscle protein synthesis.  
Both whole-body and muscle protein synthesis in response to anabolic stimuli such as 
meal consumption (103, 157, 202) and exercise (157, 211), declines with age.  However, 
aging does not alter whole-body and muscle protein synthesis during the post-absorptive 
state (122, 155, 186).  Additionally, at least a portion of the variation in both whole-body 
and muscle protein synthesis are attributed to differences in fat free mass of the subjects 
(187).  Overall, using isotope infusion protocols to study whole-body and muscle protein 
synthesis allows researchers to examine protein metabolism of the entire subject and at 
the tissue level.  When these techniques are used in addition to molecular tools to 
determine mTOR signaling, then information about the whole system can be studied from 
the cellular to the whole-body level. 
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1.5.  AN OVERVIEW OF THE LITERATURE ON INFLAMMATION 
RELATING TO THE RESEARCH IN THIS DISSERTATION: 
MECHANISMS OF INFLAMMATORY SIGNALING, THE EFFECTS OF 
ACUTE AND CHRONIC INFLAMMATION IN CIRCULATION AND 
SKELETAL MUSCLE, AND THE REDUCTION OF ACUTE AND CHRONIC 
INFLAMMATION THROUGH NON-STEROIDAL ANTI-INFLAMMATORY 
DRUGS 
1.5.1.  Inflammatory signaling 
 Inflammation is a physiological response to a variety of stimuli such as infection, 
tissue damage, exercise, and aging.  Inflammation can occur as an acute or chronic 
process depending on the stimulation.  For example, the inflammatory response to a 
disease or aging can be chronic, whereas the response to infection, exercise and tissue 
damage from a muscle biopsy is typically acute.  Both acute and chronic inflammation 
will be discussed below (Section1.5.3-1.5.4), but first, this review of inflammation will 
examine inflammatory cytokine production (Figure 1.5). 
 There are a number of inflammatory cytokines that play a pivotal role in the 
development of both chronic and acute inflammation.  A cytokine is a small (molecular 
weights range from 8 to 40,000 d) nonstructural signaling protein, and an inflammatory 
cytokine is a cytokine that mediates inflammation.  Examples of cytokines include the 
interleukins (-1,-6,-8, -10, -12,-18), tumor necrosis factor−α (TNF−α), and interferon γ 
(IFN−γ).  When tissue damage (which we will define as anything that elicits an 
inflammatory response such as exercise, infection or a muscle biopsy) occurs, mast cells 
that are located in the damaged tissue degranulate, resulting in the release of pro-
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inflammatory cytokines, histamine, and eicosanoids (219).  Histamine, eicosanoids, and 
the initial pro-inflammatory cytokines move from the damaged tissue into circulation, 
resulting in neutrophil migration from bone marrow to circulation.  Full infiltration of 
neutrophils into the damaged tissue occurs within 6 hours (219).  Neutrophil migration to 
the damaged tissue occurs as a result of mediators of acute inflammation from the 
vascular endothelial cell release of E- and P-selectin which are endothelial adhesion 
molecules (219, 220).  Once at the site of damage, neutrophils begin to tether to the 
vascular endothelium and release macrophage inflammatory proteins.  These macrophage 
inflammatory proteins attract and activate macrophages to the site of damage (219, 220).  
Macrophages arrive at the site of tissue damage 5-6 hours later.  Activated macrophages 
secrete IL-1, IL-6, and TNF−α (221, 222).  The effects of these inflammatory cytokines 
are similar: induction of localized fever, synthesis of acute phase inflammatory proteins 
in the liver, increased vascular permeability, and T and B cell activation (219, 221, 222).  
Both IL-1 and TNF−α also increase adhesion molecules on vascular epithelium, 
fibroblast proliferation, and induce IL-6 and IL-8 secretion, which are potent 
chemoattractors of neutrophils and can be produced by almost all cell types (219, 221, 
222).  The stimulation of platelet production and immunoglobin synthesis are unique 
effects of the interleukins and IL-6, respectively (219, 221, 222).  IFN−γ also activates 
macrophage and monocyte secretion of inflammatory cytokines, and is produced by 
activated CD4+, CD8+, and natural killer cells (223).  The overall response of 
inflammatory cytokines to tissue damage in circulation is to draw attention to the site of 
tissue damage, and stimulate macrophage migration into the damaged tissue. 
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Inflammatory cytokines and macrophages migrate into the damaged tissue, where 
activated macrophages secrete IL-1, IL-6 and TNF−α.  These inflammatory cytokines 
then activate IκB kinase complex (IκKB), which phosphorylates NF−κB (224).  Even 
though IL-1, IL-6, and TNF−α are secreted together in the body, cell culture work with 
C2C12 myocytes treated with TNF−α indicates that IκKB activation is very susceptible 
to TNF−α alone (225).  Although NF−κB is phosphorylated, activation does not occur 
until IκB is ubiquitinated and targeted to the proteasome for degradation (224).  
Activated NF−κB interferes with mTOR signaling and stimulates further production of 
inflammatory cytokines, as described in Section 1.3.  Overall this entire inflammatory 
response typically results in the involvement of the components of the adaptive immune 
response (T and B cells), although it can occur without it (as described above).  For the 
purposes of this literature review, where the focus of inflammation is due to exercise and 
aging, the involvement of the adaptive immune response is limited and therefore will not 
be discussed. 
 Until this point, the focus has been on the pro-inflammatory response; however, 
some of the pro-inflammatory cytokines also have anti-inflammatory properties.  
Additionally, there are many cytokines that function in suppressing the inflammatory 
response, and are appropriately referred to as anti-inflammatory cytokines.  The role of 
anti-inflammatory cytokines is to regulate the pro-inflammatory response so that healing 
can occur without resulting in further tissue damage.  The role of IFN−γ as a pro-
inflammatory cytokine was discussed above; however, IFN−γ suppresses the production 
of IL-1 in macrophages (226), and inhibits IL-1 activity through stimulating the 
production of IL-1 receptor antagonist (227) and type II IL-1 receptors (222, 228), which 
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binds the receptors of IL-1, inhibiting interaction of IL-1 and its receptor.  IFN−γ also 
inhibits IL-18 function through the stimulation of IL-18 binding protein gene induction 
(229, 230).  This may serve as a negative feedback loop because IL-18 induces IFN−γ 
production (231).  Additionally, IFN−γ disrupts the stimulation of IL-8 production by 
TNF−α (232) and IL-1 (233), and reduced IL-8 expression has been associated with 
impaired TNF−α induced NF−κB activation (234).  Because of the involvement of 
NF−κB in potentially reducing protein synthesis through interactions with mTOR 
signaling (Section 1.3), this may be a regulatory mechanism in the protection of protein 
loss; however, further research is necessary.  Other major anti-inflammatory cytokines 
include transforming growth factor−β (TGF−β) and IL-10.  TGF−β inhibits NF−κB 
activation through the decreased production of IL-8, IL-1 and TNF−α.  Additionally, 
TGF−β blocks differentiation of naive CD4+and CD8+ cells (235), which when activated 
secrete IFN−γ, a pro-inflammatory cytokine that stimulates the macrophage secretion of 
IL-1 and TNF−α.  IL-10 is secreted by anti-inflammatory macrophages, T, B, dendritic, 
and mast cells, and neutrophils and eosinophils (236) in response to IL-12 (237), IL-6 
(238), Il-27 (239), and TGF−β (240).  IL-10 acts in a negative feedback loop inhibiting 
the secretion of IFN−γ, TNF−α, IL-1 and IL-2 (241-243).  Therefore, following a pro-
inflammatory response, IL-10 secretion is induced and serves to mitigate inflammation, 
possibly inhibiting potentially harmful effects of inflammation (protein loss) on tissue. 
1.5.2.  Summary of inflammatory signaling 
 There are two types of inflammatory cytokines, pro-and anti-inflammatory 
cytokines, which stimulate and suppress inflammation, respectively.  Some of the main 
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pro-inflammatory cytokines include: IL-1, IL-2, IL-6, IL-8, IL-12, IL-18, TNF−α, and 
IFN−γ.  The major anti-inflammatory cytokines include: IL-10, TGF−β, and IFN−γ.  
IFN−γ is a unique cytokine with both pro- and anti-inflammatory properties.  When tissue 
is damaged, there is a rise in circulating pro-inflammatory cytokines which results in the 
migration of macrophages into the damaged tissue, resulting in the production of more 
pro-inflammatory cytokines.  In relation to protein metabolism, the increase in pro-
inflammatory cytokines in the damaged tissue activates NF−κB, which interacts with 
mTOR signaling and may reduce protein synthesis in the damaged tissue.  Anti-
inflammatory cytokines regulate this process and are secreted in response to elevated 
circulating pro-inflammatory cytokines.  The purpose of anti-inflammatory cytokines is 
to protect the tissue from potentially harmful effects that may be induced by prolonged 
inflammation. 
1.5.3.  Factors affecting acute inflammation 
 In addition to acute illness, acute inflammation can occur following muscle 
biopsy collection or a bout of exercise.  Acute inflammation is characterized by a local 
increase in inflammatory cytokines that persists for no longer than 24 hours (244, 245).  
There may also be an increase in systemic inflammatory cytokines which does persist 
longer than 24 hours (244, 245). 
 The effect of percutaneous muscle biopsy collection on muscle and circulating 
inflammatory cytokines has been examined.  From a methodological standpoint, the use 
of a single incision for the collection of repeated biopsies separated by 30 min is not 
advised because of alterations in the stress related ERK1/2 signaling pathway (246), 
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which is affected by inflammatory cytokines (247).  Unfortunately, research examining 
the effects of using of a single incision site for the collection of repeated biopsies on 
muscle inflammatory cytokines is limited, but previous work (246) demonstrating an 
increase in the activation of the ERK1/2 pathway, suggests that there may be an increase 
in muscle inflammatory cytokines, even though muscle inflammatory cytokines were not 
examined.  Thus, there is a need to study the effects of the collection of repeated biopsies 
from a single incision site on muscle inflammatory cytokines.  Further research is also 
necessary to determine if the use of single incision site for multiple biopsies induces a 
greater inflammatory response than the use of multiple incision sites for additional 
biopsies.  In humans, the collection of two percutaneous muscle biopsies from separate 
incision sites on the right leg immediately and 30 minutes following the collection of the 
first biopsy did not result in differences in IL-6 mRNA expression (248).  An additional 
biopsy was collected from the left leg 31 minutes following the incision on the right leg 
of the subjects in this study and again no differences in IL-6 mRNA expression were  
reported (248).  However, in a biopsy collected from the right leg 123 minutes after the 
initial biopsy, from a new incision site, there was a 1.8 fold increase in IL-6 mRNA 
expression (248).  The results from this study indicate that the collection of multiple 
biopsies from the separate incision sites can be performed within a 30 minute period 
without altering IL-6 expression.  Additionally, the collection of repeated biopsies using a 
new incision site for each consecutive biopsy in humans has demonstrated an increase in 
the percentage of neutrophils in circulation at 30 minutes and up to 24 hours following 
the initial biopsy from the percentage of circulating neutrophils at the time of the initial 
biopsy (245).  It was also determined that the expression of IL−1β was elevated in the 
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muscle 30 minutes after the collection of the initial muscle biopsy, and IL−1α expression 
in skeletal muscle was elevated at 30 minutes and up 6 hours following the initial biopsy 
(245).  However, in horses there was no change in muscle or circulating inflammatory 
cytokine mRNA expression (IFN−γ, IL-1, IL-6, and TNF−α) for 24 hours following the 
initial biopsy when a separate incision site was used for each biopsy (244).  This apparent 
disconnect between human and equine skeletal muscle requires further investigation to 
determine whether it is a result of different research protocols or due to different 
physiological mechanisms in the two species.  
The vast research examining the effects of aerobic exercise on inflammation 
varies in both tissue collection methods and in the inflammatory markers studied; 
however, it is clear that a bout of aerobic exercise elicits an acute inflammatory response.  
The percentage of neutrophils and monocytes in circulation were elevated at 6 hours and 
on the fourth day following a bout of aerobic exercise (245).  Circulating levels of IL-6 
are elevated for 24 hours following a plyometric exercise (249), which is aerobic exercise 
that involves rapid deceleration followed by rapid acceleration in the opposite direction, 
and for at least 4 hours (last sampling point) following an incremental aerobic exercise 
test (250).  Other pro-inflammatory cytokines, TNF−α and IL−1β, were also elevated in 
circulation for 3 hours and 30 minutes, respectively, following aerobic exercise (250).  In 
addition, the anti-inflammatory cytokine, IL-10, and the functional blocker of IL-1, IL-1 
receptor antagonist, are elevated in circulation following aerobic exercise for at least 4 
hours, which was the last sampling point in that study (250).  Unfortunately, the literature 
examining exercise induced skeletal muscle inflammation is limited; however, IL−1β has 
been demonstrated to increase in skeletal muscle 30 minutes following an aerobic 
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exercise bout (245).  Although the majority of this work has been performed in humans, 
performance of an incremental exercise test in horses increased IFN−γ, IL-6, and TNF−α 
in skeletal muscle 1 hour, 30 minutes, and immediately following exercise, respectively, 
whereas skeletal muscle IL-1 mRNA expression remained unchanged from pre-exercise 
values (244).  The authors of this study also examined circulating inflammatory cytokines 
and demonstrated an increase in IL-1, TNF−α, and IFN−γ from 2 to 6 hours, at 6 hours, 
and immediately following exercise, respectively; however, there was no change in the 
mRNA expression of circulating IL-6 following exercise (244).  Although species may 
play a role in the time course elevations of the respective inflammatory cytokines, which 
needs further investigation, it is certain that a bout of aerobic exercise induces an acute 
inflammatory response. 
The role of exercise induced inflammation is currently thought to be a result of 
muscle damage in the form of disrupted contractile structures (251, 252) and 
permeabilization of the sarcolemma (253, 254).  Thus, the body of literature has been 
focused on bouts of strenuous aerobic exercise with limited investigation of resistance 
exercise, which has been the focus of the majority of exercise studies on mTOR signaling 
and protein synthesis.  As a result of the interaction of downstream inflammatory 
signaling components (Section 1.5.1) and mTOR signaling factors (Section 1.2) needs to 
be studied in response to resistance exercise.  However, it has been determined that 3 
hours after a bout of resistance exercise, circulating mRNA expression of TNF−α, IL−1β, 
IL-6, and IL-8 were elevated from pre-exercise levels, despite no change in the mRNA 
expression in skeletal muscle of these inflammatory cytokines (255). 
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1.5.4.  Factors affecting low grade chronic inflammation 
Aging is characterized by chronic low grade inflammation which has been coined 
“inflamm-aging” (256).  Low grade chronic inflammation results from increased 
concentrations of circulating inflammatory cytokines (257-259) and a prolonged acute 
inflammatory response to infections and tissue damage in the aged, compared to their 
younger counterparts  (260-262).  Compared to the healthy, mature population, there is an 
elevated expression of pro-inflammatory cytokines, such as TNF−α (263−265) and IL-6 
(263, 266, 267), increased concentration of acute phase proteins, for example, C-reactive 
protein, which is associated with the acute inflammatory response (268), and high 
neutrophil count (269) in the circulation of the human aging population.  Additionally, 
there is an increase in anti-inflammatory cytokine, IL-10, and anti-inflammatory 
mediator, IL-1 receptor antagonist, in human aging circulation (270).  There is an overall 
increase in circulating inflammatory cytokines with aging. 
Low grade chronic inflammation has been associated with the loss of skeletal 
muscle mass, referred to as sarcopenia, in the aging population (271-273).   The mRNA 
expression of circulating TNF−α and the concentration of circulating soluble TNF−α 
receptor have been inversely correlated with hand grip (274) and muscular strength (275), 
respectively, in aged humans (older than 85 years of age).  Elevated serum IL-6 
concentrations have been correlated with decreased muscle strength in the aged (271).  
Additionally, reduced muscle strength that has been attributed to increased circulating IL-
6 and TNF−α has also been correlated with decreased muscle mass in the aged (273).  As 
a result, low grade chronic inflammation is thought to be a partial cause of reduced 
skeletal muscle mass in the elderly. 
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The alterations in skeletal muscle inflammatory cytokines and their relationship to 
sarcopenia have not been as well characterized as the elevations in the circulating 
inflammatory cytokines in the aged population.  Current research on the role of IL−1β 
and TNF−α mRNA expression in skeletal muscle in the aged is inconclusive (276-278), 
and there is no difference in skeletal muscle mRNA expression of IL-6 and TGF−β 
between young and aging humans (276, 278, 279).  However, the skeletal muscle mRNA 
expression of IL-6 receptor has been demonstrated to increase with aging (280), which 
may indicate that cells are more sensitive to IL-6.  TNF−α has been demonstrated to be a 
greater stimulus of satellite cell apoptosis in aged compared to young rodents (174, 281).  
Although the expression of muscle inflammatory cytokines in the aged varies, it appears 
that there may be an increased sensitivity to muscle inflammatory cytokines in aged 
skeletal muscle fibers and satellite cells. 
The association of skeletal muscle inflammatory cytokines with sarcopenia has 
primarily been studied using cell culture techniques.   C2C12 myotube cell culture studies 
have shown that IL−1β stimulates IL-6 mRNA expression, resulting in the activation of 
p38 MAPK, NF−κB, atrogen-1 and MuRF-1, leading to proteolysis (282, 283).  TNF−α 
reduces mTOR signaling in human myoblast (284) and C2C12 myoblasts (285-287).  
Although human studies in this area are limited, it has been demonstrated that increased 
TNF−α  mRNA expression in the skeletal muscle is inversely correlated with muscle 
protein synthesis following resistance exercise in the aged (288).  These studies indicate 
that sarcopenia may be a result of increased inflammatory cytokines interfering with the 
signaling pathways for muscle protein synthesis, while stimulating the pathways of 
muscle protein degradation. 
48 
 
In addition to the increase in pro-inflammatory cytokines with aging, there is also 
an increase in anti-inflammatory cytokines.  The skeletal muscle of aged men shows 
increased mRNA expression of both IL-10 and IL-1 receptor antagonist, compared to 
younger men.  These anti-inflammatory cytokines may be produced in the circulation and 
then migrate to skeletal muscle, because the number of anti-inflammatory macrophages 
in skeletal muscle is less in the aged compared to younger adult humans; however, 
further research is needed to determine this.  Alternatively, it is possible that the 
increased skeletal muscle anti-inflammatory cytokines in the aged are due to elevations in 
the activity of anti-inflammatory macrophages in skeletal muscle.  The elevated 
expression of anti-inflammatory cytokines in skeletal muscle is thought to be a 
physiological attempt to reduce pro-inflammatory cytokines in the aged. 
Low grade chronic inflammation in the aged is thought to contribute to delayed 
skeletal muscle regeneration following injury (289-291).  Skeletal muscle damage can 
occur after a bout of exercise (Section 1.5.3), and because the aged are in a state of 
chronic inflammation, it is possible that the capacity of the immune cells to respond to 
additional inflammatory stimuli is limited.  The reported changes in inflammation that 
occur following a bout of exercise in the aged are conflicting due to differences in the age 
and physical condition of the elderly subjects studied.  This results in differences in the 
extent of chronic inflammation, and differences in the mode and intensity of the aerobic 
exercise bout, which may lead to differences in the acute inflammatory response.  It has 
been demonstrated that 4-6 hours following a bout of aerobic exercise, there is a decrease 
in circulating neutrophils (292, 293) and IL-6 (294) concentration in aged humans 
compared to their mature counterparts.  In contrast, no difference in the post-aerobic 
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exercise (6 hour) circulating neutrophil count and an increase in IL-6 concentration were 
found when comparing aged and mature humans (295).  The conflicting results of these 
studies may be a result of the intensity of aerobic exercise.  Additionally, circulating IL-1 
receptor antagonist and TGF−β protein concentrations increased similarly in both age 
groups following a bout of aerobic exercise (294, 295), indicating that the anti-
inflammatory response to acute inflammatory stimuli is not altered with low grade 
chronic inflammation in the aged. 
 Another characteristic of low grade chronic inflammation in the aged is an 
increase in the time it takes for skeletal muscle regeneration to occur following tissue 
damage.  This prolongs the muscle damage associated with exercise in the aged 
compared to their younger counterparts.  Reduced macrophage infiltration of skeletal 
muscle in aged compared to younger mature men following exercise (276, 278) may play 
a pivitol role in inhibiting muscle regeneration.  Reports of the effects of aging on the 
muscle inflammatory cytokine response to acute inflammatory stimuli of exercise vary.  
Skeletal muscle TNF−α mRNA expression increases similarly in both mature and aged 
humans (276) or remains unchanged (296).  mRNA expression of IL-6 in aged skeletal 
muscle is increased (297), decreased (276), or is similar to mature counterparts (278), 
following exercise.  There is either a decrease (278, 298) or similar increase as seen in 
mature adult skeletal muscle (276) in the mRNA expression of IL−1β in aged skeletal 
muscle following exercise.  There has been less examination of aged skeletal muscle anti-
inflammatory cytokine response to exercise, but it has been determined that IL-1 receptor 
antagonist mRNA is unchanged following exercise regardless of age, and IL-10 is lower 
in skeletal muscle of aged compared to mature men following exercise (278).  In order to 
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improve our understanding of the response of aged skeletal muscle to acute inflammation 
cause by exercise, additional research is necessary which should attempt to standardize 
for the degree of pre-study low grade chronic inflammation in the aged subjects and 
standardize the experimental exercise tests. 
1.5.5.  Summary of acute and chronic Inflammation 
 Acute inflammation is a response to inflammatory stimuli such as an infection, 
tissue damage, or exercise and typically persists for a 24 hour period.  Chronic 
inflammation can be a result of a disease state or aging.  Following exercise, there is an 
increase in circulating and skeletal muscle inflammatory cytokines which is thought as a 
necessary step for satellite cell proliferation and regeneration of damaged skeletal muscle, 
and will be discussed in detail below (Section 1.5.6).  Inflamm-aging occurs in the 
elderly, where there are persisting increased levels of both circulating and skeletal muscle 
inflammatory cytokines.  This is thought to be at least partially responsible for 
sarcopenia, through the increased activation of NF−κΒ and the signaling pathways of 
protein degradation (Section 1.3) and reduction in the activation of the protein synthesis 
pathways.  Additionally, chronic inflammation alters the acute inflammatory response 
and affects the muscle’s ability to recover from acute tissue damage, such as exercise.  
This is thought to be a result of a decreased capacity of immune cells to increase 
inflammatory cytokines in both circulation and skeletal muscle in response to exercise; 
however, the results from these studies are extremely variable and require further 
research.  Ultimately, the interaction of inflammation and protein synthesis is 
complicated, where the effects of acute and chronic inflammation on protein synthesis 
appear beneficial and deleterious, respectively, and require further elucidation. 
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1.5.6.  Effect of acute and chronic inflammation on satellite cells 
 Satellite cells have been mentioned throughout this dissertation, but to this point 
have not been fully explained.  Satellite cells are undifferentiated myogenic stem cells 
that have the ability to re-enter the cell cycle, generating new muscle fibers or providing 
new myonuclei during postnatal growth (299, 300).  Additionally, satellite cells have the 
ability to generate daughter cells that can become new satellite cells (301).  Satellite cells 
are located outside of the sarcolemma, under the basal lamina of the muscle, laying 
parallel or obliquely to the long axis of the fiber (302).  A number of molecular markers 
have been proposed to identify satellite cells have been the topic of recent review (303), 
and are an alternate method to the more classical method of using toluidine blue staining 
and a light microscope to examine the high heterochromatin myonuclei (304).  Some of 
these molecular markers include: the membrane-bound neural cell adhesion molecule (N-
CAM/CD56/Leu-19), which is a cell-surface glycoprotein localized to satellite cells, the 
Ca++-dependent muscle specific cadherin (M-cadherin), the myocyte nuclear factor 
(MNF), the receptor for the hepatocyte growth factor (HGF), and the paired box protein 7 
(PAX7), a transcription factor that plays a role in embryonic patterning and 
organogenesis (303).  However, many of these molecular markers are expressed during 
both the quiescent and activated state and there is currently no consensus on the best 
marker to label activated versus quiescent satellite cells. 
Satellite cell content in humans varies between muscle groups (305-308), the 
amount of physical activity (305-307) and the age (307, 308) of the individual.  Satellite 
cells are activated (proliferated) following a single bout of exercise, regardless of 
exercise type, for up to 8 days (309).  Typically activated satellite cells will proliferate 
52 
 
following exercise, but terminal differentiation does not always occur (309).  Satellite 
cells are also altered following exercise training where, regardless of exercise type, 
training enhances the satellite cell content in the skeletal muscle of human athletes (306, 
307, 310, 311).  However, the satellite cell response to low intensity aerobic exercise 
training is greater than for high intensity resistance training (307).  Overall, a single bout 
of exercise increases satellite cell proliferation and exercise training increases satellite 
cell content in skeletal muscle. 
The alterations in satellite cell activity following exercise are thought to be a 
result of tissue damage, and the release of inflammatory cytokines and growth factors 
following exercise.  Section 1.5.3 discussed the changes in inflammatory cytokines 
following exercise as a result of exercise induced tissue damage.  It has been 
demonstrated that IL-6 and TNF−α are involved in the regulation of satellite cell 
proliferation in rodent skeletal muscle (312, 313).  Additionally, the administration of 
non-steroidal anti-inflammatory drugs (NSAID) to humans and animal models negatively 
affects satellite cell proliferation, differentiation and fusion (314-318).  Thus, the increase 
in inflammatory cytokines during acute inflammation is a beneficial process enhancing 
skeletal muscle repair, and in the case of exercise this process coincides with elevated 
mTOR signaling and subsequent protein synthesis. 
The alterations in circulating and muscle inflammatory cytokines during low 
grade chronic inflammation that is associated with aging have been discussed in detail in 
Section 1.5.4.  In that section, it was briefly mentioned that in aging rodents, the increase 
in TNF−α stimulates satellite cell apoptosis (174, 281).  As a result, the number of 
satellite cells is lowered in the elderly compared to the younger mature rodents (307, 
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319).  Additionally, in humans the proliferative capacity of the satellite cells of the aged 
is decreased compared to the mature counterparts (320).  Together these studies indicate 
that low grade chronic inflammation reduces the number and activity of satellite cells in 
the aging population.  Non-damaging exercise (aerobic and resistance) has been shown to 
increase satellite cell proliferation in the aged (305, 309, 311), and if a training regimen is 
implemented, the satellite cell pool can be replenished in this population (310). 
1.5.7.   Summary of the effects of acute and chronic inflammation on satellite cells 
Satellite cells are myogenic stem cells that are activated by inflammatory 
cytokines.  During an acute inflammatory response, there is an increase in satellite cell 
proliferation indicating a beneficial effect of inflammation.  However, during low grade 
chronic inflammation there is a reduction in both satellite cell content and activity, which 
can be combated by non-damaging exercise training. 
1.5.8.   Reducing inflammation with non-steroidal anti-inflammatory drugs 
1.5.8.1.  Mechanism of action of non-steroidal anti-inflammatory drugs 
NSAID include a range of drugs that inhibit prostaglandin formation, for example 
aspirin, ibuprofen, mefenamic acid, and phenylbutazone (321).  Although the entire 
mechanism in which NSAID reduce inflammatory cytokines has not been elucidated, it 
has been the topic of several reviews (321-323).  Briefly, NSAID reduce inflammation by 
blocking cyclo-oxygenase (COX) enzymatic activity.  As a result, the production of 
prostaglandin E2 (PGE2) from arachadonic acid is nearly ceased (321, 323).  Both COX-2 
and PGE2 regulate the activation of NF−κB (322, 323); however this mechanism is still 
unclear.  Because NF−κB is also a regulator of inflammatory cytokine release (Section 
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1.5.1) (322, 323), the reduction in COX activity is believed to be the mechanism whereby 
NSAID reduce inflammatory cytokines.  There are two different isoforms of the COX: 
COX-1 and COX-2.  Both forms of COX are expressed in the majority of tissues in the 
body, including skeletal and cardiac muscle, gastrointestinal tissue, kidney, brain and 
epithelial cells.  COX-2 expression in these tissues is minimal unless activated by 
inflammatory cytokines (324), whereas, COX-1 is highly expressed in gastrointestinal 
tissue.  As previously mentioned, both COX-1 and -2 are involved in the formation of 
PGE2 from arachadonic acid.  PGE2 has a physiological protective role in gastrointestinal 
tissue, behaves as a vaso-dilator, and contributes to erythema, and hyperalgesia (321, 
323).  Because of the role of PGE2 in gastrointestinal tissue, when PGE2 production is 
ceased in the presence of NSAID, gastric ulcer formation may occur. 
Prolonged NSAID administration has been implicated in the development of 
gastric ulcers in several species (323, 325), including horses (326).  In the stomach, the 
COX-1 enzyme is generally expressed at a higher level than the COX-2 enzyme, and the 
resulting PGE2 plays an important protective role.  PGE2 in the stomach suppresses 
TNF−α expression, neutrophil adherence, and epithelial cell apoptosis (323).  As a result 
the overall function of PGE2 in the stomach is to prevent the formation of gastric ulcers.  
However, when COX-1 is inhibited or in the presence of gastric ulcers, COX-2 becomes 
upregulated (327), due to an increase in inflammatory cytokines to the tissue.  The 
increase in COX-2 activity results in an increase in PGE2 formation, which is an attempt 
to suppress further tissue damage.  Unfortunately, most NSAID do not selectively inhibit 
the activity of COX-2 and as a result, both COX-1 and COX-2 in the stomach are 
inhibited (323), reducing  PGE2 production.  The COX enzymes also regulate the 
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formation of other prostaglandins from arachadonic acid.  These prostaglandin are 
involved in the regulation of bicarbonate, mucous, and acid secretion, and accelerate 
ulcer healing (323).  As a result, extended NSAID administration can result in gastric 
ulcers in many mammalian species. 
1.5.8.2.  Reducing acute inflammation with NSAID 
NSAID are commonly used to reduce the discomfort associated with muscle 
damage caused by strenuous exercise.  NSAID administration post-exercise has been 
extensively studied to characterize post-exercise physiology and as a mechanism to 
eliminate inflammatory effects on physiological responses to exercise. Following any 
type of exercise, skeletal muscle COX-2 mRNA expression and protein content are 
elevated (255, 328, 329) compared to at rest, and post-exercise NSAID administration 
reduced the elevated levels of COX-2 mRNA expression and protein content (329, 330).  
Oral administration of a NSAID during 12 weeks of resistance exercise training resulted 
in skeletal muscle COX-1 protein abundance that was lower than in an exercised group 
that received a placebo in place of NSAID (331).  Furthermore, oral administration of a 
herbal supplement (curcumin), with properties functionally similar to a NSAID, reduced 
muscle IL-1β, IL-6, and TNF-α mRNA expression in rodents following exercise (332).  
The local infusion of a NSAID post-exercise in humans reduced the skeletal muscle 
mRNA expression of TNF-α, but did not alter the skeletal muscle mRNA expression of 
TGF−β and IL−1β (333), nor was there an increase in macrophage or neutrophil 
infiltration (316).  Because the increase in inflammatory cytokines following exercise 
may be necessary for muscle repair post-exercise (334), and inflammatory cytokines play 
a regulatory role in satellite cell proliferation (312, 313), the administration of NSAID 
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with the goal of reducing inflammation may be preventing muscle recovery by reducing 
satellite cell proliferation (316).  Further research is required in this area to determine if 
the benefits of NSAID during an acute inflammatory response outweigh the possible 
consequences. 
1.5.8.3.  Reducing chronic inflammation with NSAID 
The study of the use of NSAID to reduce circulating and skeletal muscle 
inflammatory cytokines in the aged has been limited because of the long term harmful 
effects of NSAID use, such as gastric ulcers (323).  However, the use of NSAID 
administration as a tool to study the association behind aging related inflammatory 
cytokines and the development of sarcopenia has been investigated.  In aged rodents, 5 
months of oral NSAID administration (ibuprofen) reduced circulating levels of IL-6 and 
IL−1β, while increasing skeletal muscle mass and muscle protein fractional synthesis 
rates (335).  Therefore, future research is needed to fully elucidate these mechanisms and 
then develop strategies to reduce both circulating and skeletal muscle inflammatory 
cytokines in order to promote the maintenance of muscle mass with old age. 
1.5.8.4.  Summary of reducing inflammation with NSAID 
 NSAID reduce inflammatory cytokines through the inhibition of the enzymatic 
activity of COX, which suppresses the activation of NF−κB and inhibits the release of 
inflammatory cytokines.  Although the prostaglandins produced by COX mediate 
inflammatory cytokines through NF−κB, there are also many beneficial physiological 
effects of these prostaglandins throughout the body.  In the stomach, the prostaglandins 
produced by COX-1 play an important role in protecting the stomach from the 
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development of gastric ulcers.  However, because most NSAID do not inhibit a specific 
COX isoform, the beneficial effects of prostaglandins are also affected by NSAID 
administration and prolonged NSAID administration has been associated with the 
development of gastric ulcers (323).  The administration of NSAID during acute 
inflammation reduces circulating and muscle inflammatory cytokines, which coincides 
with a reduction in satellite cell proliferation.  The latter may impair the recovery of 
skeletal muscle during acute inflammation (Section 1.5.6).  The literature examining 
NSAID reduction of inflammatory cytokines during chronic inflammation is limited due 
to the side effects of extended NSAID use; however, NSAID administration has been 
demonstrated to reduce circulating inflammatory cytokines in the aged.  Ultimately, 
further research is warranted to determine whether there are other methods that can be 
used over a longer period to reduce chronic inflammation without causing side effects 
such as gastric ulcers.  
1.6.  AN OVERVIEW OF THE EQUINE LITERATURE RELATING TO THE 
RESEARCH IN THIS DISSERTATION: PROTEIN NUTRITION AND 
METABOLISM, AND MUSCLE PHYSIOLOGY THAT MAY ALTER 
PROTEIN METABOLISM 
 In comparison to cell culture models, rodents, neonatal piglets, and humans, there 
is only limited data regarding muscle protein metabolism in the horse.  However, there is 
considerable research in horses concerning protein digestibility and utilization, crude 
protein requirements, muscle biology and development, and inflammation and the review 
of the literature in horses will focus on these areas. 
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1.6.1.  Protein nutrition in the horse 
1.6.1.1.  Dietary indispensable and dispensable amino acids in the horse 
 Although the protein requirement as reported by the NRC (336) is written for 
crude protein (CP), the horse actually has requirements for individual amino acids, the 
building blocks of protein.  CP is a calculation of total nitrogen (N) in the feed, where CP 
is equal to N times 6.25 (336).  This calculation is derived from the fact that, by weight, 
protein is 16% N.  Horses, like other mammals, are believed to require 9 dietary 
indispensable amino acids (histidine, isoleucine, leucine, lysine, methionine, 
phenylalanine, threonine, tryptophan, and valine) and, under certain physiological states, 
an additional 6 conditionally indispensable amino acids (arginine, cysteine, glutamine, 
glycine, proline, and tyrosine) may be required.  Arginine is a conditionally indispensable 
amino acid because the rate of arginine synthesis in many growing mammals is 
insufficient to meet its needs, and is indispensable during illness or injury due to the role 
of arginine in immune function as a precursor to nitric oxide.  Cysteine and tyrosine can 
be synthesized from dietary methionine and phenylalanine, respectively, if supplied in 
sufficient quantities.  During times of illness or physiological stress, glutamine becomes 
indispensable, and glycine and proline are also indispensable during the growth period.  
The remaining amino acids are considered dietary dispensable amino acids because of 
their ability to be synthesized in sufficient enough quantities to meet the body’s needs 
(alanine, asparagine, aspartate, glutamate, and serine). 
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1.6.1.2.  Protein digestion in the horse 
For the most part, amino acids are consumed in the equine diet as part of whole 
proteins, which must be broken down to individual amino acids or small peptides for 
absorption.  In the horse, dietary protein is digested in the foregut, similar to other 
nonruminant species, and this process has been the topic of several chapters and entire 
books (337-339).  In short, prior to consumption of a meal, the vagal release of 
acetylcholine stimulates the upper gastro-intestinal tract, initiating saliva secretion in the 
mouth, and hydrochloric acid, pepsinogen, and sodium bicarbonate secretion from the 
stomach.  The equine stomach is unique in that it has a section referred to as the margo 
plicatus where the squamous epithelial mucosa lacks the mucous-sodium bicarbonate 
barrier to buffer the high acidity.  This is the area where gastric ulcers and erosion tends 
to occur (340), and gastric ulcers do occur at a higher rate in horses compared to other 
nonruminants.  The stomach has four main secretions, hydrochloric acid, pepsinogen, 
sodium bicarbonate, and mucus, which begin enzymatic digestion of proteins.  
Hydrochloric acid is secreted from the parietal cells resulting in an increase in the acidity 
of the stomach.  The reduced pH denatures dietary protein, unfolding it to a linear 
polypeptide chain, and at pH 4 causes pepsinogen, the zymogen (inactive enzyme) of 
pepsin, to become pepsin.  This mechanism protects the cells of the stomach from pepsin 
trying to break the peptide bonds involving aromatic amino acids (phenylalanine, 
tryptophan, and tyrosine) of proteins bound to cell membranes: pepsin is only in its active 
form when there is protein from feedstuffs available for enzymatic digestion.  Pepsinogen 
is secreted from chief cells, and once it is in the active form it begins cleaving the peptide 
bonds involving aromatic amino acids, resulting in some oligopeptides and short 
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polypeptide chains which will be further enzymatically digested in the small intestine.  
As previously mentioned, sodium bicarbonate is also secreted in the stomach from 
epithelial mucous cells and acts to buffer the stomach from the acidic pH. 
 During the initial digestion of dietary proteins in the stomach, the vagal release of 
cholecystokinin in the exocrine pancreas stimulates release of other zymogens.  Although 
this causes the release of a number of enzymes from the pancreas, the ones involved in 
protein digestion (trypsinogen, chymotrypsinogen, and procarboxypeptidase A and B) are 
secreted from the acinar cells.  These zymogens and sodium bicarbonate, produced by the 
duct cells, enter the duodenum, the first section of the small intestine, where 
enteropeptidase, secreted from the duodenal crypts of Lieberkühn, converts trypsinogen 
into the active form, trypsin.  Together enteropeptidase and trypsin convert 
chymotrypsinogen, and procarboxypeptidase A and B to chymotrypsin and 
carboxypeptidase A and B, respectively.  Trypsin is a serine protease that cleaves at the 
carboxyl side of lysine and arginine, except when followed by proline.  Chymotrypsin is 
an endopeptidase that cleaves peptide amide bonds where the carboxyl side of the bond is 
an aromatic amino acid.  Carboxypeptidase A and B are exopeptidases, cleaving peptide 
bonds at either the C- or N-terminus of the oligopeptides and short polypeptide chains 
that have entered the duodenum from the stomach.  As a result, oligopeptides, di- and tri- 
peptides, and free amino acids enter the jejunum, the second section of the small 
intestine. 
The di-, tri-peptides are absorbed via peptide transporter 1 (PepT1) located on the 
apical side of the enterocytes in the jejunum (341).  It is important to note that PepT1 
transporters are also located in the enterocytes of the ileum, resulting in some di-, tri-
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peptide absorption; however, the majority of PepT1 transporter expression is in the 
jejunum, and therefore, most di-, tri-peptide absorption occurs in the jejunum (341).  
Some of these di-, tri-peptides are broken down to free amino acids in the cytosol of the 
enterocyte cells, while others remain intact.  For the oligopeptides and di-, tri-peptides 
that do not get transported into the enterocytes by PepT1, further digestion occurs at the 
enterocytes brush border membrane, by aminopeptidases and endopeptidases.  Although 
these peptidases are located throughout the entire length of the small intestine, the 
jejunum and ileum posses the highest activities (342).  PepT1 has not yet been 
characterized in the equine gastrointestinal tract, but the mRNA expression of PepT1 was 
high in the small intestine, decreased in the colon, and not detectable in the cecum of 
another hind-gut fermenter, the rabbit (343).  Additionally, PepT1 activity has been 
suggested in equine jejunum through increased current flow through equine jejunal 
membrane when incubated with a dipeptide (344). 
For the di-, tri-peptides not transported into the enterocytes by PepT1 and 
oligopeptides, further digestion occurs at the brush border membrane, resulting in free 
amino acids.  Free amino acids are transported into the enterocytes by a variety of apical 
transporters, specific for certain types of AA.  The free amino acids transported into the 
cytosol of the enterocyte cells can be further metabolized by the enterocytes, used for 
enterocyte protein synthesis, or transported across the basolateral membrane and into 
portal vein.  Both apical and basolateral membrane amino acid transporters are specific to 
the amino acids transported, based on the amino acid properties such as size, polarity, and 
charge (345).  The majority of amino acid transporters do not require energy; however, 
sodium dependent transporters require ATP because the co-transport of sodium and 
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amino acid requires the removal of sodium out of the enterocyte via a sodium/potassium-
ATPase (345).  Some amino acid transporters are unique to the apical (system names: 
ASC, B0, B0,+, b0,+, IMINO, X-AG) or basolateral membrane (system names: A, L, y+, y+L) 
while others can be found on both membranes of the enterocyte (system name: T) (345, 
346).  The study of amino acid transporters in the equine gastrointestinal tract has been 
limited.  However, glutamine transport has been demonstrated across the basolateral 
membrane from the bloodstream to the enterocytes where it is proposed to be used as a 
key energy substrate in the equine enterocyte (347).  This study was useful in that it 
examined the amino acid flow, so although Duckworth and colleagues (347) did not 
determine the amino acid transport system, their study indicated that there is a glutamine 
transporter on the basolateral membrane of the enterocyte transporting from the 
bloodstream into the enterocyte.  More recently, Woodward and colleagues (348) have 
examined the distribution of the mRNA of specific amino acid transporters along the 
intestinal tract of mature horses, where the mRNA expression of the apical b0,+ system 
was expressed similarly throughout the jejunum, ileum, cecum and colon.  The mRNA 
expressions of the basolateral y+ and basolateral medium affinity L transport systems 
were higher in the small intestine than in the large intestine, while the low affinity L 
transport system mRNA expression was greater in the cecum than the jejunum (348).  
These results indicate that, at least for the b0,+ system, there may be similar absorption 
throughout the jejunum, ileum, cecum and colon; however, because the basolateral y+ and 
basolateral medium affinity L transport were greater in the small intestine, this indicates 
that the greatest absorption of amino acids that contributes to whole-body protein 
metabolism occurs in the small intestine due to the greater mRNA expression of 
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basolateral amino acid transporters and therefore, a greater ability to transport the 
absorbed amino acids from the enterocytes into circulation.  Because there was 
expression of some transport systems in the cecum and colon, this study (348) also 
indicates that there may be some amino acid absorption in the large intestine; providing a 
mechanism for the absorption of microbial amino acids.  However, additional research is 
needed to characterize the presence and function of amino acid transport systems in the 
cecum and colon. 
Not all of the dietary protein that is consumed is completely digested and then 
absorbed in the small intestine.  The dietary protein that bypasses digestion and/or 
absorption in the small intestine and reaches the cecum and large intestine can be 
metabolized by the residing microbial population.  Although little is known of the 
microbial protein metabolism in the equine hindgut, it has been demonstrated that the 
microbial population of the equine hindgut can degrade and utilize dietary protein, 
partially degraded protein and ammonia and urea that have bypassed small intestine 
absorption (349).  Once absorbed by the microbe, peptides are cleaved into free amino 
acids for microbial protein synthesis or degraded to the carbon skeleton and ammonia.  
The carbon skeleton can be utilized for energy while the ammonia can be used to 
synthesize amino acids or secreted by the microbe (350).  Because microbial digestion 
occurs proximal to digestion and absorption in the ruminant, microbial protein can be 
digested and absorbed similar to dietary protein in nonruminants.  However, microbial 
digestion occurs distal to digestion and absorption in the horse, and therefore microbial 
proteins cannot be absorbed similarly to dietary proteins due to anatomical constraints.  
As a result, researchers have attempted to increase the understanding of the physiological 
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mechanisms contributing to possible amino acid absorption and quantify the microbial 
amino acid contribution to whole-body amino acid metabolism in the horse. 
The use of isotope tracers has led researchers to believe that some microbially 
synthesized amino acids may end up in circulation.  Infusing 15N labeled cecal bacterial 
protein into the cecum of an anaesthetized pony, resulted in 15N labeled amino acids in 
circulation (351).  There was less than 10% labeled amino acid recovery in the tissues of 
ponies fed 15N urea (352).  However, the infusion of 14C labeled bacteria or protein into 
the cecum of ponies showed no 14C labeled amino acids in the circulation (353).  These 
studies show that a small amount of N is being absorbed in the large intestine; however, 
the fact that the carbon backbone of these amino acids was not absorbed may indicate 
that microbial amino acids are not being absorbed, but rather a N compound such as 
ammonia is (352, 354, 355).  Once ammonia is absorbed, it can be used to form 
dispensable amino acids.  However, urea supplementation to horses has not been found to 
be beneficial if the indispensable amino acid requirements are not met (355).  
Even though amino acid transport systems have been found on the apical 
membrane of the large intestine of horses (348), the isotope tracer work (mentioned 
above) and ex vivo studies do not currently support the idea of large amounts of 
indispensable dietary amino acids being absorbed in the large intestine and contributing 
to whole-body protein metabolism.  Minimal amounts of alanine (356), arginine (357), 
histadine (357), leucine (358), and lysine (357) have been demonstrated to cross the 
equine colonic mucosa in ex vivo experiments.  However, a great deal of ammonia is 
transported across the mucosal membrane of the equine colon (357).  As a result, it is 
generally accepted that ammonia that is transported across the apical membrane of the 
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equine large intestine contributes to protein metabolism; however, this is an area where 
additional research is needed. 
1.6.1.3.  Protein digestibility in the horse 
 It was mentioned above (Section 1.6.1.1) that horses actually require amino acids, 
but the current requirements according the NRC (336) are for crude protein and lysine.  
Unfortunately, not all protein is created equal with regards to digestibility and quality.  
Quality refers to the amino acid composition of the protein in relation to the animal’s 
amino acid requirements, whereas digestibility refers to the amount of dietary protein that 
disappears, and is presumably absorbed, along the gastrointestinal tract. 
 Studies in horses examining protein digestibility vary extensively in the method 
of measuring digestibility, age of horse, and feedstuffs examined.  The method of 
measuring digestibility is crucial when comparing these studies, because it accounts for 
how much protein has been digested at which point along the gastrointestinal tract (337).  
The simplest measurement is apparent total tract digestibility and is determined by the 
difference of the N intake (feed) and N output (feces) divided by the N intake (337).  This 
does not correct for endogenous losses such as sloughed cells, microbes and microbial 
protein, and typically underestimates protein absorption.  Correction factors that have 
been determined for endogenous losses range from 0.72 - 0.91 mg endogenous 
nitrogen/kg dry matter consumed, due to differences in total intake and diet composition 
(359-362).  When endogenous losses are accounted for in the calculation of protein 
digestibility, it is no longer coined apparent digestibility, but rather true digestibility 
(337).  Because it is believed that the majority of protein is digested and amino acids are 
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absorbed proximal to the cecum, pre-cecal digestibility has been a tool used by 
researchers in an attempt to more accurately determine protein absorbed as amino acids 
(337).  Again, the endogenous losses must be accounted for, and the correction factors for 
pre-cecal endogenous N losses that have been reported to range from 1.8 - 5.8 mg 
endogenous nitrogen/kg dry matter consumed (359-362). 
 Diet composition and intake affect endogenous losses and protein digestibility.  
The NRC (336) has reported estimates of total tract apparent nitrogen digestibility and 
pre-cecal apparent nitrogen digestibilities of 79 and 51%, respectively.  Concentrates tend 
to have higher pre-cecal digestibility than forages (360-365).  The differences in protein 
digestibility and endogenous losses between diets high in forage or concentrate are 
thought to be a factor of the bulkiness and slow rate of movement through the 
gastrointestinal tract of diets primarily composed of forage, where there are higher 
endogenous losses than diets that have a greater proportion of concentrate.  Specifically, 
pre-cecal apparent digestibilities of concentrates range from 48 - 72% depending on the 
type of concentrate (360, 362) and pre-cecal apparent digestibilities of forages range from 
1.3 - 21% (361).  The pre-cecal true digestibilities of concentrates and forages range 59 - 
62% (364) and 27 - 42% (361), respectively.  Additionally, protein intake also affects 
digestibility and endogenous losses.  As CP intake increases, there is a reduction in 
endogenous N losses relative to intake,  resulting in greater apparent nitrogen digestibility  
(365).  However, increasing CP intake from low to moderate does not alter true CP 
digestibility, but increasing CP intake to high levels reduces true and apparent pre-cecal 
digestibility (360).  Others claim that regardless of dietary N concentration, true total 
tract digestibility ranges between 0.7 - 0.9 (337).  Overall, compared to forage-based 
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diets, endogenous losses and protein digestibility, regardless of type (true or apparent), 
appear to be reduced and elevated, respectively, in diets that are primarily composed of 
concentrates in mature horses. 
 The discussion of protein digestibility has focused on CP digestibility; however, it 
was previously mentioned that horses actually have requirements for amino acids.  It has 
been determined that the majority of amino acids have pre-cecal apparent digestibilities 
that range from 0.3 - 0.6 (366).  Similar to what was seen with increasing CP intake, 
apparent amino acid digestibility is increased with increasing amino acid intake (367).  
True and apparent amino acid  digestibilities range for the individual amino acids from 
52.8 - 86.3% for glycine and leucine, respectively (367).  Additionally, physiological 
state may alter amino acid digestibilities, gestating mares were reported to have higher 
amino acid digestibilities (368) than those reported in foals (367).  This is an area where 
additional research is warranted. 
 The growing horse has received less attention in the area of protein digestibility 
than the mature horse, and it appears that the growing (~6 months old) horse may have a 
decreased capacity to digest and absorb protein than their mature counterparts.  Weaned 
foals (3 - 7 months old)  and yearlings consuming a primarily concentrate diet (<60%) 
had apparent total tract N digestibilities of 35 - 45% (369) and 80% (370), respectively.  
The apparent total tract N digestibility reported in the weaned foals is lower than the 
estimate for mature horses by the NRC (336); however, the apparent total tract N 
digestibility reported in the yearlings was comparable to that of mature horse.  This may 
indicate that there are developmental limitations in protein digestibility; however, it is 
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necessary to elucidate the time course changes in protein digestibility that occur during 
development. 
1.6.1.4.  Protein and amino acid requirements in the horse 
 There are several methods for expressing protein requirements of horses, which 
are used in various locations across the world.  In the United States, protein requirements 
are expressed as amounts of CP and lysine required, and have been detailed in the recent 
NRC (336).  CP and digestible CP are used to express the protein requirements of horses 
in Japan and Germany, respectively.  In France, protein requirements of horses are 
expressed in “horse digestible crude protein” or “Matieres Azotees Digestibles Cheval” 
(MADC).  A detailed examination of all of these systems is beyond the scope of this 
dissertation.  However, this section will provide a brief overview of the US system, 
including a discussion of the research that was used to determine the requirements, and a 
short comparison of the US to the French system. 
1.6.1.4.1.  Protein and amino acid requirements based on physiological status in the 
horse 
 Nutrient requirements are specific to the physiological state of the animal.  The 
NRC (336) separates these physiological states into: Maintenance, Growth, Pregnancy, 
Lactation, and Exercise.  Examples of the protein and lysine requirements of a 600 kg 
mare at various physiological states according to the NRC (336) are provided in Table 
1.1.  The focus of this section will be to discuss the factors affecting protein requirements 
in the various physiological states and some of the research that led to the development of 
those requirements. 
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Maintenance requirements for protein are generally the amount of protein 
consumption needed by the animal in order to support the daily processes of life.  
Although animals at maintenance are making and degrading protein at the same rate and 
for this reason should be able to “recycle” amino acids released from protein degradation 
for use in protein synthesis, this system is not perfectly matched and even at maintenance 
dietary amino acids are needed.  “Losses” of amino acids in animals in the maintenance 
state include endogenous losses in the gastrointestinal tract, cutaneous losses, and amino 
acids from proteins that have been post translationally modified (for example: amino 
acids that are methylated) and can no longer interact with their respective tRNA to be 
used for protein synthesis.  The maintenance requirements have been calculated from 
linear regression and broken line analysis of means from the numerous N balance studies 
that have been conducted in mature horses, receiving a variety of feedstuffs.  The CP 
requirement has been identified based on the N intake where N retention is zero.  
However, the minimum CP requirement was actually set slightly higher than zero 
because the majority of N balance studies do not account for endogenous losses of hair, 
skin and sweat; thus overestimating N retention (336).  As a result, the CP of average 
maintenance has been derived as: BW × 1.26g CP/kg BW/d (336).  The requirements of 
amino acids during maintenance have not been determined due to lack of data; however, 
based on the amino acid content of common feedstuffs fed to horses and the limiting 
amino acids of other nonruminants, mainly swine (371), it is thought that the first three 
limiting amino acids may be lysine, threonine, and methionine.  The lysine requirement 
during maintenance has been calculated as 4.3% of CP requirement (336).  Linear 
regression of N balance studies that reported the diet composition were used to determine 
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the lysine intake required to obtain zero N retention.  Then, broken-line analysis was used 
to determine the lysine intake at which N retention plateaued (336).  Additionally, in 
horses receiving diets supplemented with lysine and threonine, the amino acid 
supplementation resulted in lower plasma urea N concentrations in mature and aged 
horses, compared to horses receiving the unsupplemented diet (372), providing additional 
support that lysine and/or threonine are likely candidates for limiting amino acids in the 
mature horse.  
During growth, the maintenance requirements must initially be met in order to 
sustain the physiological processes and maintain the current weight.  Then, the growing 
horse requires additional amino acids (protein) to support the tissue (for example, 
muscle) accretion that occurs when an animal is growing.  The protein requirements of 
growing horses have been derived from N balance studies (369, 373) and the use of ADG 
measurements (369, 374, 375) with varying protein or amino acids intakes provided by 
the diet.  The latter has been a classical tool to study protein requirements extensively 
used in growing horse.  When the protein or amino acid intake provided by the diet is 
below requirements, increases in intake will result in an increased ADG.  Once the 
required level has been met, ADG will not increase with increasing intake of the amino 
acid or protein.  The means of data collected in these studies were fitted to broken-line 
analysis and then extrapolated to a mature body weight to incorporate the changes in 
body weight with age (336).  This provided a total CP requirement for a certain aged 
horse at a specific weight.  In order to determine the separate requirements of 
maintenance and growth, the maintenance requirements must be subtracted from the total 
requirements (336).  The CP requirement of growing horses has been determined using a 
71 
 
factorial approach and based on the assumption that gain is 20% protein: (BW × 1.44 g 
CP/kg BW) + ((ADG × 0.20)/Efficiency of use of dietary protein)/0.79 (336).  The 
efficiency of use of DP is estimated from 50% in 4-6 month old horses to 30% in 
yearlings and older growing horses (336). 
There have also been some studies examining the effects of amino acid 
supplementation, mainly lysine, on ADG in growing horses (369, 375-378), where it has 
been concluded that lysine is vital for growth.  When lysine is supplemented to poor 
quality protein diets of linseed meal (369) and brewer’s dried grains (376), the ADG was 
equivalent to high protein quality diets of milk and soy bean meal, respectively.  
Additionally, ADG was not altered in horses fed low CP diets that were supplemented 
with lysine compared to higher CP diets (375).  Using linear regression and broken-line 
analysis from the means of the previously mentioned studies, the NRC determined that 
the lysine requirement of growing horses was 4.3% of CP requirements (336).  
Additionally, supplementing low protein diets with lysine and threonine resulted in lower 
plasma urea N concentrations, indicating threonine may be the second limiting amino 
acid in growing horse diets (374). 
There is minimal research regarding protein requirements during gestation in 
horses due to the possible unwanted effects, such as fetal loss or stunted growth of the 
foal, of consuming a protein (or amino acid) deficient diet during pregnancy.  From the 
minimal research in this field, there have been more studies examining protein 
requirements during mid to late compared to early gestation.  Similar to the growing 
animal, the maintenance requirements must be met and there are additional protein 
requirements for increased protein synthesis to support fetal and placental growth, as well 
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as for the production and secretion of placental fluids.  However, because there is not a 
large ADG during early pregnancy, the NRC (336) has concluded that protein 
requirements are only slightly higher than maintenance: BW × 1.26 g CP/kg BW/d.  
Linear regression of fetal weight gain was performed in horses (379) and ponies (380), 
which in addition to cow data, were used in non-linear regression analysis to determine 
fetal growth rates.  The NRC (336) then assumed that fetal composition is equivalent to 
neonatal composition.  From this, the NRC (336), could calculate the amount of CP 
deposited per day in horses and ponies.  Using a factorial approach of protein efficiency 
the CP requirements were determined for gestating mares from 5 months through 
parturition: (BW × 1.26 g CP/kg BW/d) + (fetal gain in kg/0.5)/0.79 (336).  The 0.5 
comes from the estimation of 50% efficiency of use of dietary protein in pregnancy, and 
0.79 is representative of the 79% digestibility of the protein (336).  It is also important to 
note that the calculated CP of fetal gain does not account for protein needs of the uterus 
(336).  Additionally, due to the lack of data on amino acid requirements, the NRC 
suggests that the same estimation of lysine requirements during pregnancy as 
maintenance (336). 
Rather than the ADG studies that were used to estimate protein requirements in 
the growing horse, milk production was used for the determination of protein 
requirements beyond maintenance during lactation.  In addition to the maintenance 
protein requirements, lactating mares require additional dietary protein to support the 
synthesis of milk protein.  Broken-line analysis of the CP content of milk produced 
throughout gestation found that milk protein concentration plateaus at day 22 of gestation 
(336).  This led the NRC (336) to determine the CP requirement during the first month of 
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lactation to be greater than the rest of lactation.  Again, the NRC (336) used a factorial 
approach incorporating 50% efficiency of utilization and 79% protein digestibility to 
determine the lactating mare CP requirement: (BW × 1.44 g CP/kg BW/d) + (milk 
production kg/d ×50 g CP/kg milk).  The amino acid requirements during lactation have 
been suggested by Wickens and colleagues (381) and are based on the amino acid to 
lysine ratio in milk.  The NRC (336) accepts this suggestion (kg milk/d multiplied by 
3.3.g lysine per kg milk), but adds the maintenance requirement for lysine. 
Additionally, if any of these physiological classes (adult maintenance, gestating, 
lactating, or growing) of horses undergo exercise, there will be an additional requirement 
above what has already been discussed.  The NRC (336) has classified exercise 
requirements by intensity (light, moderate, heavy, and very heavy), which have been 
classified based on heart rate and oxygen utilization above rest.  Correction factors have 
been developed from the literature to account for protein synthesis for muscle growth and 
to repair damaged muscle following exercise (336).  Additional correction factors have 
also been determined based on the percentage of body weight lost in sweat at each 
intensity of exercise (336).  Again, the NRC (336) used a factorial approach to determine 
the CP requirement of exercising horses based on the 50% efficiency of utilization and 
79% protein digestibility: (BW × muscle gain) + (((BW × sweat loss × 7.8 
g/kg)/0.50)/0.79) + the maintenance requirement for protein (336).  It is also important to 
note that at very high intensities of exercise, a substantial increase in lean gain may also 
increase the maintenance protein requirements.  The lysine requirement of exercising 
horses has been determined using broken-line analysis of the means of data from N 
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retention studies that reported diet composition and intake and lysine intake and was 
determined as 4.3% CP requirement (336). 
1.6.1.4.2.  Protein requirement systems 
The French system expresses protein requirements in MADC, which has some 
similarities to digestible CP, the method used by the Germans.  MADC is based on the 
assumptions that protein quality in terms of amino acid composition and site of digestion 
(pre- versus post- cecal) affect the availability of the amino acids to the animal.  The 
advantage of this system compared to the US and German systems is that differences in 
small intestinal availability of amino acids in various feeds are accounted for.  
Additionally, this system more accurately estimates forage amino acid availability than 
digestible CP because the physical bulkiness of forages result in a decrease in the amino 
acids available for small intestinal absorption from the forage (382, 383).  From a 
scientific perspective, this system has many advantages to the US system because it more 
accurately assesses the availability of amino acids for absorption; however, the lack of 
knowledge of digestible CP and amino acid availability in many of the common 
feedstuffs fed to horses make it difficult to use this system. 
1.6.1.5.  Summary of protein nutrition in the horse 
 Although there is still a vast amount of research to be performed in the horse, 
regarding protein nutrition (digestion, digestibility, and requirements), the scientific 
knowledge base has improved substantially from the previous (384) to the current (336) 
NRC which were published 18 years apart.  The majority of protein digestion and 
absorption occurs in the small intestine of horses.  The primary contribution of the 
75 
 
hindgut to protein metabolism is through the absorption of ammonia produced by the 
hindgut microbes.  The NRC (336) provides both CP and lysine requirements for horses 
at the various physiological states, which have been derived using linear regression and 
broken-line analysis from the means of the available studies, followed by a factorial 
approach considering efficiency of utilization and protein digestibility.  Ultimately, there 
is still a lot left to elucidate and further research is necessary in all of these areas of 
protein nutrition in order to better feed and manage these animals. 
1.6.2.  Muscle biology and development in the horse 
The horse is an athletic animal with nearly 50% of body mass composed of 
skeletal muscle (1).  Thus, there is a considerable amount of research over the past 
century that has focused on equine skeletal muscle.  The majority of equine skeletal 
muscle research has focused around the characterization and possible treatments of 
disease related states, such as metabolic syndrome (385-387), pituitary pars intermedia 
dysfunction also referred to as Cushing’s disease (388, 388, 389, 389), exertional 
rhabdomyolysis also referred to as tying-up (390-394), hyperkalaemic periodic paralysis 
also referred to as HYPP (395-398), neuromuscular disorders (399-402), polysaccharide 
storage myopathy also referred to as PSM (403-405) and the combination of these 
disorders (406-408).  However, a detailed examination of the alterations of skeletal 
muscle physiology and metabolism during these disease states is beyond the scope of this 
literature review.  Rather, this section will focus on the sizeable body of literature 
examining the characterization of skeletal muscle fiber type, the alterations of skeletal 
muscle physiology and metabolism during development, exercise (409-414), and exercise 
during development (411, 415-419). 
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1.6.2.1.  Characterization of skeletal muscle fiber types 
1.6.2.1.1.   A historical introduction 
 Researchers have been examining skeletal muscle fiber types for well over a 
century.  The characterization of fiber types began in 1865 with the correlation of a 
greater blood supply to red muscle compared to white muscle, and was followed by the 
demonstration that contraction velocity was faster in the white muscle compared to the 
red muscle (420).  With advances in technology in the mid 1880s to the late 1910s, 
researchers began histological studies of skeletal muscle demonstrating a greater number 
of mitochondria in red compared to white muscle fibers (420). 
 The development of a correlation between velocity of muscle shortening to 
ATPase activity when the muscle was with or without load in both vertebrates and 
invertebrates (421) led to the discovery of a link between morphological and 
histochemical characteristics to physiological properties of the fiber.  This link was 
displayed in the motor units of the cat gastrocnemius (422).  Burke and colleagues (422) 
categorized fibers as fast twitch fatigue sensitive (FF), fast twitch fatigue resistant (FR), 
and slow twitch fatigue resistant (S).  Higher glycogen concentrations, lactate 
dehydrogenase activity, and myofibrillar ATPase activity were seen in FF and FR 
compared to S fibers.  This connection opened the door to the current thought of fiber 
types characterized as slow twitch being primarily oxidative, and fast twitch fibers being 
primarily glycolytic.   
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1.6.2.1.2.   Description of the fiber types 
Most mammalian twitch muscles can be divided into two categories: slow (Type 
I) and fast (Type II) twitch.  Fast twitch fibers can be further subdivided into three 
subcategories: fast oxidative-glycolytic (FOG; Type IIA), fast-glycolytic (FG; Type IIB), 
and an intermediate fiber (Type IIX, Type IIC, or Type IID). 
Slow twitch fibers are characterized with a red color, slow contraction speed and 
duration of contraction, and a high oxidative capacity.  Type I fibers are well vascularized 
providing increased blood flow for the delivery of O2 which increases the oxidative 
capacity.  To further aid in their oxidative capacity, slow twitch fibers contain high 
concentrations of mitochondria and myoglobin.  An increased number of mitochondria 
are present to allow for higher capacity to efficiently operate the Krebs cycle and electron 
chain transport to produce ATP for work.  The high concentration of myoglobin provides 
O2 storage for increased production of ATP. Slow twitch fibers also have a decreased 
glycolytic capacity and glycogen content. 
Fast twitch Type IIA fibers are also described as red in color, but are faster in 
contraction speed and duration of contraction than slow twitch fibers.  Type IIA fibers 
have both oxidative and glycolytic capacities.  As a result, these fibers have many of the 
same properties as both slow twitch Type I and fast twitch Type IIB fibers. 
Fast twitch Type IIB fibers are characterized as a white colored muscle fiber with 
the fastest contraction speed.  These fibers utilize glycolytic metabolism for the 
production of energy for work.  As a result, they are poorly vascularized with a decreased 
need for O2 because of their reliance on anaerobic metabolism.  In addition, Type IIB 
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fibers have low concentrations of myoglobin and mitochondria.  Glycolytic metabolism, 
unlike oxidative phosphorylation, takes place in the sarcoplasm not the mitochondria; 
hence a decreased need for mitochondria in Type IIB fibers. 
Fast twitch Type IIX, or occasionally referred to as IIC or IID, fibers are 
considered an intermediate fiber between the fast twitch types IIA and IIB.  Type IIX 
fibers have both glycolytic and oxidative capabilities, but are faster in speed of 
contraction than Type IIA fibers.  As a result, this fiber type has been poorly 
distinguished until the use of myosin heavy chain isoforms as a tool to differentiate 
between the various fiber types. 
1.6.2.1.3.   Fiber Type Differentiation as a Result of Myosin Heavy Chain Isoforms 
Myosin is one of the most prominent proteins in the muscle and comprises the 
majority of the thick filament.  The myosin molecule is composed of six different 
proteins: two heavy chains (myosin heavy chains; MHC) and four light chains (myosin 
light chains; MLC; (423).  Both MHC and MLC components of myosin occur as several 
uniquely distinct isoforms; all of which are coded by different genes (424).  In fact, there 
are eight different MHC isoforms found in skeletal and cardiac mammalian muscle (425).  
It has been shown that slow and fast twitch fibers contain different isoforms of MHC 
(426).  The MHC-I isoform is expressed in slow fibers, and hydrolyzes ATP slowly.  As 
a result, the cross bridge cycle is slow which leads to a slow velocity of contraction.  
Within the last 25 to 30 years, it has been shown that there are three myosin 
isoforms found in Type II fibers:  MHC-IIA, MHC-IIB, and MHC-IIX or -IID.  
Traditionally, it was thought that there were only two fast twitch fiber types (IIA and 
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IIB), and the IIX fibers were being mistakenly categorized as IIB.  The mistaken identity 
of the IIX fiber was a result of the experimental methods of the time.  The use of methods 
such as ATPase histochemical reactions resulted in the distinction between slow and fast 
twitch fibers in the middle gluteus muscle of horses (411).  On the basis of oxidative 
capacity, a reflection of NADH-diaphorase staining (427) equine skeletal muscle fibers 
have been classified as slow twitch (comparable to Type I), fast twitch with high 
oxidative capacity (comparable to Type IIA), and fast twitch with low oxidative capacity 
(comparable to Type IIB) (411).  This disconnect in nomenclature between and among 
species continued until modern day techniques, such as gel electrophoresis and 
immunoblotting became regularly available, which provided a greater distinction in these 
fiber types (428-430).  Definitive evidence that MHC-IIX was a separate protein and not 
a product of post-translational modification of MHC-IIB was realized when the cDNA of 
MHC-IIX mRNA was isolated.  All three Type II MHC isoform cDNAs display different 
restriction endonuclease maps, indicating their derivation from three separate genes.  In 
addition, each isoform contains a unique 3’ untranslated sequence which has been used to 
develop specific probes for the use in in situ hybridization studies (424).   
1.6.2.1.4.   Classical methods of equine fiber typing 
Traditional methods of fiber typing that have been used in rodents and humans 
have been utilized in horses for nearly 50 years (411).  Generally, the study of equine 
skeletal muscle requires muscle biopsies in order to obtain muscle samples, and these are 
most commonly collected from the gluteus medius muscle using the percutaneous needle 
biopsy technique (411).  The gluteus medius muscle is commonly used due to the role of 
this muscle in both locomotion and posture (411).  The use of myofibrillar ATPase, 
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NADH-diaphorase, and periodic acid-Schiff (PAS) as a marker of contraction speed 
correlation, oxidative capacity, and glycogen distribution, respectively, provided a basis 
for the determination of slow twitch, fast twitch high oxidative, and fast twitch slow 
oxidative.  Other traditional determinates are the use of biochemical analyses of 
metabolites in the muscle: glycogen, pyruvate, lactate, ATP, creatine phosphate, glucose 
and glucose-6-phosphate.  Lastly, the use of enzyme activities as a marker of glycolytic 
and oxidative capacities can aid in the determination of fiber type.   These techniques 
have provided the evidence for delineation of equine skeletal muscle into three major 
fiber types (I, IIA, and IIB (431)). 
1.6.2.1.5.   Electrophoretic and immunohistochemical methods for equine fiber typing 
 After the identification of the myosin heavy chain isoforms (I, IIA, IIB, and IIX) 
in rodents and humans, gel electrophoresis was then used to examine equine skeletal 
muscle (413).  The rat costal diaphragm was used as a control because it contains all four 
of the myosin heavy chain isoforms (432).  Gel electrophoresis revealed three MHC 
isoforms; two of which co-migrated with the Type I and IIA isoforms of the rat.  The 
third equine isoform migrated between the IIX and IIB rat isoforms; but showed a 
mobility closer to that of the IIX.  These results provided a new question to be solved: 
were the fast oxidative fibers previously classified as Type IIB in horses actually Type 
IIB or IIX fibers containing MHC-IIB or -IIX with a different molecular weight due to 
post-translational modifications or were they some newly discovered fiber type 
containing a unique MHC isoform?  Further examination of the MHC isoform at the 
protein level revealed that the rat and equine MHC-IIX isoform has identical antigenic 
and mATPase determinants (412).  This evidence suggests that the MHC-IIB protein is 
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not functional at the protein level in horses.  Additional evidence of the absence of the 
MHC-IIB isoform in equine skeletal muscle was provided with the use of PCR and in situ 
hybridization techniques, which allowed researchers to isolate both mRNA and cDNA for 
MHC-I, -IIA, and -IIX isoforms (433).  The mRNA isolation was performed based on the 
conserved sequences of exon 40 in both fast and slow isoforms (424). 
 Additional proof for the absence of the Type IIB fiber Type In horses came with 
nucleotide sequencing of the equine diaphragm, semitendinosus and longissimus thoracis 
muscles (409).  It could be speculated that if there was an expression of a IIB fiber in the 
horse it would be seen in the diaphragm because it has been shown that in rat and mice all 
four MHC isoforms are expressed in the diaphragm (432).  cDNA synthesis and 
sequencing and PCR analysis was done on all of the MHC genes.  The equine MHC 
isoforms were found to contain 5980, 5982, and 5984 base pairs for IIA, IIX, and I, 
respectively.  These identified sequences coded for MHC isoforms that contain 1937, 
1938, and 1935 amino acids for the IIA, IIX, and I proteins, respectively.  The MHC-IIA 
and -IIX isoforms are similar both in the number of amino acids and in the overall 
structure; however, there are differences in the functional regions of the two proteins.  
Within the functional region of the MHC-IIA protein there are two amino acid deletions 
compared to the functional region of the MHC-IIX protein.  Overall, this study 
demonstrated that there are three functional MHC proteins, -I, -IIA, and –IIX. 
During the examination of the equine diaphragm, semitendinosus and longissimus 
thoracis muscles, Chikuni and his colleagues (409) amplified a 596 base pair fragment of 
the MHC 3’ region using MHC-IIB amplification primers.  This fragment contained a 
similar sequence to the other MHC isoforms, but differed in an additional adenine 
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nucleotide.  This additional nucleotide resulted in a frame shift, and thus, a shortened 
translation.  Chikuni and his colleagues (409) referred to this MHC-IIB fragment as the 
equine MHC-IIB pseudogene because the gene exists, but cannot be translated into a 
functional protein.   
1.6.2.1.6.   The large animal theory and the implications of an absent functional MHC-
IIB isoform 
The absence of the MHC-IIB isoform in horses is thought to be due to the large 
animal theory, which explains the absence of a functional MHC-IIB isoform because of 
differences in velocity of shortening, metabolic energy consumption, and the ability of 
bones to resist force in large animals compared to small on the basis of body size.  For 
example, smaller animals must take a larger number of steps in order to cover the same 
distance as larger animals due to their shorter stride length.  An animal’s force-velocity 
curve must be appropriate for the speed at which they move: larger animals having a 
slower velocity of shortening than their smaller counterparts (434).  In addition, with the 
decreased stride length of smaller animals, more energy must be consumed in order to 
meet their increased velocity of shortening in comparison to the large animal (435).   
 The final component of the large animal theory is that with increases in body size, 
there are added stresses on bone due to increased muscle size.  The ability of bones to 
resist force depends on the ratio of bone to muscle cross sectional area, which decreases 
in proportion to animal weight.  In an effort to adjust for this, the limbs of large animals 
vary in size, and are more closely aligned with the ground reaction force in a size-
dependent manner (436). 
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The lack of the MHC-IIB isoform in horses may indicate an evolutionary 
elimination due to components of the large animal theory.  The entire sequence of the 
MHC-I, -IIA, and -IIX isoforms are highly conserved in mammals; therefore, the equine 
MHC isoform sequences showed high identities to the porcine, bovine and human MHC 
isoforms (409).  The fact that horses contain a “gene” for MHC-IIB isoform that lacks 
expression due to an early termination as a result of a frame shift from the additional 
adenine may further indicate the evolution of the species. 
During the course of history, the modern horse has evolved from a small (0.4m) 
4-toed Hyracotherium to the large (1.6m) hooved animal seen today.  This small equine 
ancestor and its progeny (3-toed, 0.6m Mesohippus and 3-toed, 1m Merychippus) may 
have contained the functional MHC-IIB isoform.  These ancestral precursors to the 
modern horse are related to the pig and other ungulates who express the MHC-IIB 
isoform (409).  This would indicate that ancestral animals of the orders Perissodactyla 
and Artiodactyla may have kept all four MHC isoforms, and the horse and cattle (others 
are still to be determined) lost the functionality of the MHC-IIB isoform.  The absence of 
the MHC-IIB isoform in horses may be a result of an evolutionary need to decrease bone 
stress due to velocity of contraction as the animal evolved to have an increased body size. 
1.6.2.2.  Implications of breed and sampling depth on equine skeletal muscle fiber type 
Fiber type distribution in an individual muscle within a horse is extremely 
variable, and is greatly influenced by breed of horse.  The percentage of Type I fibers in 
the middle gluteus muscle is the highest in Warmblood type horses, and decreases in 
ponies, Arabians, Thoroughbreds, and Quarter Horses (414).  Alternatively, 
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Thoroughbreds express the greatest percentage of Type II fibers, followed by Quarter 
Horses, Arabians, ponies, and Warmbood type horses (414).  Of the Type II fibers, 
Thoroughbreds have the greatest percentage of IIA type fibers, followed by Arabians, 
Quarter Horses, ponies and Warmblood type horses (414).  The Quarter Horse possesses 
the greatest percentage of IIX type fibers and the proportion is lower in Arabians, 
Thoroughbreds, ponies and Warmblood type horses.  Although variation exists, these 
differences are narrow with the range of Type I fibers in the above breeds from 7 - 31%, 
Type IIA from 37 - 51%, and Type IIX from 32 - 45% (414).  Additionally, breed related 
differences are detectable as early as the first day of life (437, 438).  It is also important 
to note, that these studies did not use modern methodologies of immunohistochemistry or 
MHC isoform separation through electrophoresis. 
 Regardless of fiber typing method, age and breed of the horse, variation exists 
within a single skeletal muscle.  Because the gluteal muscle is the most commonly 
sampled, the majority of data is from this muscle and has shown to vary with depth.  The 
proportion of Type IIX fibers decreases and Type I fibers increases with depth in mature 
horses (413, 439-442) and foals (439) in the gluteal muscle.  This is merely a function of 
the muscle; the gluteus muscle is used in both locomotion and posture.  The deeper 
portion of the muscle is used more for posture than the shallower portion of the muscle. 
1.6.2.3.  Changes in skeletal muscle physiology during development and aging 
 The proportion of muscle fiber type shifts during development.  During neonatal 
growth in humans and rodents, there are shifts in the relative proportions of MHC-
neonate, MHC-I, MHC-IIA and MHC-IIX in skeletal muscle, with increases in all forms, 
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except MHC-neonate which vanishes with time.  However, the appearance of MHC-II 
isoforms is delayed in comparison to MHC-I (432, 443-445).  Similar shifts occur in 
MHC protein concentration and mRNA expression during the first year of life in Dutch 
Warmbloods (410, 446-448) and Thoroughbreds (449).  The proportions of MHC-I and 
MHC-IIA are increased and MHC-IIX is decreased at 24 months of age, compared to 12 
months of age in Dutch Warmblood horses (448, 450).  Correlation coefficient analysis 
was performed on MHC isoforms throughout the equine lifespan (from birth to 30 years 
of age), where it was determined that MHC-I dramatically decreases, MHC-IIA slightly 
increases, and MHC-IIX remains unchanged (451).  However, further research is 
warranted to determine the specific time course for these shifts in MHC fiber type 
expression. 
Because fiber type is associated with glycolytic and oxidative capacity, alterations 
in fiber type during development and aging also lead to alterations in glycolytic and 
oxidative capacity.  Glycolytic and oxidative capacity are measured through the 
expression and activity of enzymes involved in the anaerobic (glycolysis) and aerobic 
(Kreb’s cycle and oxidative phosphorylation) production of ATP, respectively (448).  
Markers of oxidative capacity are the enzymes succinate dehydrogenase (SDH) and 
citrate synthase (CS) and the mitochondrial complexes involved in oxidative 
phosphorylation.  The enzymes phosphofructokinase (PFK) and lactate dehydrogenase 
(LDH) are involved in the glycolytic production of ATP, which may also result in the 
production of lactic acid.  There is an increase in the activities of several of the oxidative 
enzymes during growth (452-454), with subsequent declines in oxidative capacity with 
old age in humans and rodents (455, 456).  In horses, SDH activity does increase during 
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the first 2 years of life (446, 448, 449); however, the effects of maturation on CS activity 
appears to be dependent on breed (438, 448).  CS activity in Standardbreds and Quarter 
horses ceases to decrease earlier in development (~14 weeks) (438) than Dutch 
Warmbloods (~22 weeks) (448).  Correlation coefficient analysis has been performed on 
the enzymes involved in oxidative capacity throughout the equine lifespan (birth to 30 
years of age), where it was determined that CS decreases (451), while LDH increases 
(438, 451).  This data indicates that shifts in MHC throughout the lifespan coincide with 
shifts in oxidative capacity. 
The gluteal muscle amino acid profile has been examined during the first year of 
life in horses, where it was demonstrated that glutamine was the most abundant free α-
amino acid in the muscle up to 3 months of age (457).  As foals grow from 3 to 12 
months of age, the concentrations of alanine, glutamate and glycine were greater than that 
of glutamine in the skeletal muscle of mature Standardbreds (457).  Additionally, the β-
amino acid, taurine is extremely abundant in equine skeletal muscle (2, 458) and has been 
shown to decrease with from 6 to 12 months of foal development (457).  However, 
mature equine skeletal muscle has taurine concentrations that compare to 6 month old 
foal (2, 458).  In rodents, taurine protects skeletal muscle from reactive oxygen species 
post-exercise (459), and has been demonstrated to increase skeletal muscle force when 
taurine is supplemented to the diet (460).  Glutamate is the most abundant free α amino 
acid in mature skeletal muscle, followed by alanine, glutamine and glycine (2, 458).  
Carnosine, the di-peptide of histidine and β-alanine, is present in extremely high 
quantities in adult equine skeletal muscle (458, 461), where it buffers lactic acid buildup; 
however, it has not been examined in developing equine skeletal muscle.  The amino acid 
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composition of aged equine skeletal muscle is also limited; therefore, further examination 
of the amino acid profile throughout the lifespan is necessary.  The elevated abundance of 
free α-amino acids in the rapidly growing skeletal muscle of the foal compared to the 
mature horse indicates the increased amino acid availability for protein synthesis in order 
to accrete muscle during this rapidly growing life stage. 
1.6.2.4.  Changes in skeletal muscle physiology following exercise 
 Because of the athletic ability of the horse, there is a considerable amount of 
literature regarding the physiological changes to skeletal muscle following a bout of 
exercise (415, 462-464) and exercise training (416-419, 465, 466).  However, these 
studies vary in the age of horses used, and the intensity of exercise and duration of 
training.  This subsection of the literature review will focus on the alterations in MHC 
content, oxidative and glycolytic capacity, and free amino acid content. 
The recruitment pattern of muscle fiber types in mammals has been well 
characterized, with prolonged exercise there is a shift in the fibers used from Type I to 
Type IIX fibers; however this recruitment does not hold true during short high intensity 
exercise bouts common in racehorses.  Following an 800 and 1200 m race, the 
recruitment of Type IIA and IIX fibers were reduced in the equine gluteal muscle based 
on myosin ATPase activity, and glycogen depletion did not occur in Type I fibers (464).  
An exercise bout, regardless of intensity (462, 463) or track slope (462) will recruit all 
MHC fibers to a similar extent if the exercise bout is a minimum of 8 minutes long.  
However, during shorter bouts of exercise (4 minutes), there is a higher recruitment of all 
MHC fibers in moderate (60% VO2max) to high (80% VO2max) intensity workouts than 
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extremely high intensity (100% VO2max) workouts (463).  Glycogen can be stored in all 
fiber types (Section 1.6.2.1.2), and is typically not depleted in Type I fibers during short 
duration high intensity exercise (464).  Glycogen depletion following a bout of exercise is 
affected by intensity (462, 463), but not track slope (462), where the intensity of the 
exercise coincides with the degree of glycogen depletion.  Overall, these results indicate 
that during short duration high intensity workouts similar to that seen in horse racing 
there is a similar recruitment of fiber type which is not what is characteristic of prolonged 
exercise. 
Duration and intensity alters fiber type recruitment during an exercise bout, but 
also alters the MHC protein content following prolonged training.  Duration of exercise, 
regardless of intensity, there is altered MHC protein composition following exercise, 
where MHC-I, -IIA, and –IIX were greatest with 15, 25, and 5 minute exercise bouts, 
respectively, after 22 days of training (418).  Additionally, following 22 days of training 
at moderate (velocity at which blood lactate concentration is 2.5 mmol/L (V2.5)), and high 
(V4) intensities, regardless of the duration of each training bout, MHC-I, -IIA, and –IIX 
content was higher following the V4, V4, and V2.5 intensity bout, respectively (418).  
Overall, 22 days of training, regardless of bout duration or intensity caused MHC-I, -IIA, 
and –IIX content to remain unchanged, increase, and decrease, respectively (418).  Short 
duration high intensity training for 8 months has been reported to have no effect on MHC 
content, which the authors’ attributed to the superficial sampling site of 2 cm within the 
gluteal muscle (417), which was confirmed when the authors’ performed another short 
duration high intensity training for 22 days and alterations in MHC content were detected 
at a sampling depth of 6 cm within the gluteal muscle (418).  Incline training does not 
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appear to alter MHC content or oxidative capacity: 16 weeks of sloped track training 
increased SDH activity and MHC-IIA content to a similar extent as 16 weeks of flat track 
training (415).  Ultimately, with moderate to high intensity short term training protocols, 
there is a shift in the proportion of fast twitch fibers mainly towards MHC-IIA and an 
increase in glycolytic and oxidative capacities compared to pre-training. 
Endurance type racing is another sport that horses commonly participate in.  As a 
result, this type of exercise training has been examined, where following 90 days of 
endurance type training there was a shift in MHC content towards a greater percentage of 
MHC-I fibers at the expense of –IIX fibers (466).  Similar results were seen following 
endurance training by Rivero and colleagues (416) and Serrano and colleagues (419).  
Additionally, capillarity associated with Type I and IIA fibers has been demonstrated to 
increase following endurance type training (416, 419).  Following endurance type 
training, oxidative capacity is increased (CS activity and glycogen storage as markers), 
and glycolytic capacity is decreased (LDH and PFK activities as markers) (419).  
Endurance type training results in increased MHC content of Type I fibers and oxidative 
capacity. 
Breed has been determined to greatly affect MHC content and also plays a role in 
the susceptibility of MHC recruitment to training.  For example, the Arabian, who were 
breed for endurance type exercise, are more predisposed to MHC conversion toward 
MHC-I following endurance type training (416).  However, additional research is needed 
to examine the susceptibility of MHC recruitment of a breed like the Thoroughbred, 
which was bred for high intensity short duration exercise, following endurance type 
exercise training. 
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Intramuscular amino acid concentrations are altered by exercise.  When muscle 
biopsies were collected 30 minutes following a maximal exercise test, alanine, leucine 
and lysine concentrations increased from pre-exercise values; however, glutamate and 
taurine concentrations decreased (458).  Following a submaximal exercise test, alanine 
concentrations increased immediately and returned to pre-exercise levels 18 hours later 
(467).  The authors did not detect differences in any other amino acid due to the high 
degree of variability, which they attributed to the wide age range of 2.5 to 6 years (467).  
The younger horses may have been growing at a slow rate, whereas the older horses were 
probably not still developing.  Additionally, the increases in alanine post-exercise is most 
likely due to the involvement in the Cori cycle (339), and the decrease in taurine indicates 
that the exercise protocol used in this study created reactive oxygen species, which 
through the indirect measurement of taurine concentration implies that taurine was used 
to suppress these reactive oxygen species (459).  Additional research is necessary to 
determine if alterations in intramuscular amino acids following exercise are influenced by 
duration and intensity. 
1.6.2.5.  Changes in skeletal muscle physiology following exercise during development 
and aging 
 The desire to prepare young prospects for show or race has led horse owners to 
place yearlings in training in order to prepare them for the 2 year old races and in hand 
futurity events for show horses.  As previously discussed (Section 1.6.2.3), there are 
many physiological alterations occurring in skeletal muscle of horses during this stage of 
rapid growth and development.  These normal physiological changes can also be 
influenced by exercise.  Developmental alterations during the first year of life (increase in 
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Type I and IIA and decrease in Type IIX) are less substantial in foals that were housed in 
the pasture (receiving ad libitum exercise) compared to those housed in a stall (receiving 
no exercise) (448).  However, there was no effect of the differences in housing induced 
exercise on capillarity CS or SDH activity (448).  Dingboom and colleagues (446) found 
that the developmental change in fiber type was not altered throughout the first year of 
life in foals that were housed in a stall (receiving no exercise), or those housed in a stall 
but forced to exercise.  The differences in these studies may be a factor of the intensity 
and duration of exercise involved.  However, growing horses in a moderate exercise 
training program that included 6 trips over a 3 fence combination 2 days/week from 
weaning to 3 years of age, had a higher percentage of MHC-I and –IIA at 2 and 3 years of 
age compared to non-exercising 2 and 3 year old horses (450).  This coincided with a 
greater developmental increase in CS activity in the training group compared to the non-
exercising control group (450).  However, short duration high intensity exercise training 
for 16 weeks in 2 year old Thoroughbreds did not alter MHC content, SDH or PFK 
activities (468).  These studies indicate that there is an effect of exercise duration, 
intensity and training period on the developmental changes in muscle biology; however, 
further research is needed to examine the effects of exercise training on the alterations in 
MHC content that occur during development. 
The beneficial effects of exercise in the aged have been demonstrated in humans; 
however, there is limited data on the effects of exercise in the aging horse.  Exercise 
training over a period of 10 weeks in aged horses improved VO2max and plasma lactate 
concentrations (469).  This training period also increased MHC-IIA and –IIX content in 
the semimembranosus and triceps muscles, respectively (469).  Additionally, CS activity 
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was increased in the triceps muscle (469).  Implementation of an exercise protocol during 
aging appears to improve oxidative capacity, and potentially strengthen muscles which 
may prevent injury; however additional research is needed. 
1.6.2.6.  mTOR related signaling in equine skeletal muscle 
 Currently there are only two studies in horses to examine mTOR signaling (2) or 
other signaling pathways that may directly influence mTOR signaling (470).  The first 
study examined the effect of exercise on the mitogen activated protein kinase (MAPK) 
family, which has three subdivisions: the ERK1/2, MAPK, and c-Jun NH2 terminal kinase 
(JNK).  The effects of ERK1/2 and MAPK on mTOR signaling have been discussed in 
detail above (Section 1.2.2.4).  JNK is also a stress-activated MAPK cascade that is 
activated during oxidative stress, and by inflammatory cytokines and growth factors.  Ten 
minutes following a submaximal exercise test, the phosphorylation of p38 MAPK was 
elevated in both the vastus lateralis and pectoralis descendens muscles (470).  The 
authors of that study (470) chose the vastus lateralis because of the involvement of this 
hind limb muscle in forward movement and the pectoralis descendens because of the role 
in posture (470).  The phosphorylation of MAP3K, MAPK activated protein kinase 2 (an 
intermediate signaling factor in the MAPK signaling cascade), and JNK were elevated 10 
minutes following a submaximal exercise test in the vastus lateralis (470).  However, the 
phosphorylation of ERK was not affected by exercise in either muscle examined (470).  
Activation of these signaling factors following exercise could potentially lead to 
increased protein synthesis through inhibiting TSC1/2 complex (Section 1.2.2.4).  
Following the consumption 4g/kg of a high protein pelleted feed (90 minutes), there was 
a greater abundance of the phosphorylated forms of both 4EBP1 and rpS6 in the gluteal 
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muscle of mature horses than during the post-absorptive state (2).  However, feeding 
status did not alter the phosphorylation of Akt (2).  This data indicates that following the 
anabolic stimulus of meal consumption muscle protein synthesis may increase. 
1.6.2.7.  Muscle protein turnover 
To date, only a single study has examined skeletal muscle protein synthesis in the 
horse using isotopes.  Skeletal muscle protein synthesis was examined after a single bout 
of high intensity exercise in long 2 year old Thoroughbreds that had been in short 
duration high intensity training once a week for 3 months (3).  Matsui and colleagues (3) 
found that muscle protein synthesis across the hind leg increased to the greatest extent 
following exercise when an amino acid-glucose mixture was infused in the jugular vein 
during the recovery period compared to the recovery period of the individual infusion of 
saline, amino acids, and glucose.  Infusion of amino acids alone also increased muscle 
protein synthesis (3).  However, infusion of glucose alone or saline did not increase 
protein synthesis during the 120 minutes recovery period.  Skeletal muscle protein 
degradation across the hind leg was also measured in this study, were there was an initial 
decrease in muscle degradation rates during the first hour following exercise in the amino 
acid and amino acid-glucose mixture infused horses (3).  During the second hour of 
recovery there was no difference in rates of muscle protein degradation in any of the 
infused groups; however, during hours 3 and 4 of recovery the rate of muscle protein 
degradation in the amino acid-glucose mixture group was elevated (3).  This study was a 
great step forward in understanding muscle protein metabolism in the exercising horse.  
However, the author’s did not examine the effects of pre- to post-exercise on skeletal 
muscle protein synthesis, and the exercise bout that was used during the experimental 
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period was less intense than the weekly training exercise protocol, which was not typical 
of a competition situation.  Further research is necessary to determine the effects of a 
more intense exercise protocol, similar to that seen in the industry. 
1.6.2.8.  Summary of muscle biology and development 
 Because the horse is a highly athletic animal, there is an extensive amount of 
research pertaining to skeletal muscle development and exercise.  The developmental 
changes in MHC content throughout development are similar to other species; however 
the recruitment of fibers during and following exercise differs from other species mainly 
due to the duration and intensity of the exercise bout.  Additional factors that influence 
fiber type recruitment and content include duration and intensity of exercise training and 
breed and age of the horse.  To date a single study has examined the anabolic stimulus of 
exercise on skeletal muscle protein synthesis, and another study that characterized mTOR 
signaling in response to feeding.  This area of research requires further examination, 
which will be addressed in subsequent chapters of this dissertation.   
1.6.3.  Acute and chronic inflammation in the horse 
 Inflammatory signaling in response to diseases and laminitis has been the focus of 
much of the equine work in this area.  Although the studies are limited, this subsection of 
the literature review will focus in the areas of exercise induced inflammation and 
inflamm-aging in the horse. 
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1.6.3.1.  Characterization of the acute inflammatory response to exercise in the horse 
 Exercise induced inflammation was briefly discussed in (Section 1.5.3), but the 
focus of this section will be on the literature in the horse.  There have been reports 
detailing the increased susceptibility of viral infection following exercise (471, 472); 
however, the reports detailing the inflammatory response following a bout of exercise or 
exercise training will be discussed here. 
Reports of exercise induced inflammation in horses vary due to sampling methods 
and times, exercise protocols and assay methods.  Following prolonged acute exercise, 
leukocyte expression of TNF−α and IL−1β are elevated at 23 and 30 days of-high 
intensity exercise training, but IL-2, -4, -6, or -10 mRNA expression was not affected 
(473).  However, immediately following a maximal exercise test, serum concentrations of 
TNF−α and PGF2α were elevated and returned to pre-exercise levels at 2 hours (474).  In 
circulating leukocytes, IL-6 and TNF−α expression was greatest 2 hours following 
maximal exercise test with no alterations in leukocyte IL−1β expression (474).  
Neutrophil counts have also been demonstrated to be elevated in the blood immediately 
following maximal exercise and remain elevated for 6 hours following exercise (475).  
However, 24 hours post-maximal exercise test, the mononuclear cells obtained from 
circulation did not have differences in the mRNA expression of IL-12, -4, and 
IFN−γ (476).  Although sampling times and exercise protocols differ, it is certain that 
there is an acute increase in circulating inflammatory cytokines following exercise. 
 This led to a valuable study to determine the 24 hour time course response of 
inflammatory cytokines in circulation to a maximal exercise test in horses.  This study 
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reported increased mRNA expression of IL-1 from 2 to 6 hours, TNF−α at 6 hours, and 
IFN−γ immediately following the maximal exercise test (244).  However, there were no 
alterations in the circulating mRNA expression of IL-6 over the 24 hour period (244).  
Because samples were only collected prior to, immediately following, 30 minutes, 1, 2, 6, 
and 24 hours following exercise, any alterations in circulating mRNA expression of IL-6 
may have been missed. 
 There has been minimal investigation in the inflammatory response to exercise in 
equine skeletal muscle.  The 24 hour time course inflammatory response has been 
examined following a maximal exercise test, demonstrated an increase in the mRNA 
expression of IFN−γ at 1 hour, IL-6 at 30 minutes, and TNF−α immediately following 
the maximal exercise test (244).  However, the authors did not report any alterations in 
the skeletal muscle mRNA expression of IL-1 during the 24 hour period following the 
maximal exercise test (244).  One implication of this study is that the overall increases in 
skeletal muscle mRNA expression of inflammatory cytokines to maximal exercise test 
appear to occur more rapidly than increases in circulating inflammatory cytokines. 
1.6.3.2.  Characterization of chronic inflammation in the aging horse 
 Throughout the lifespan, horses exhibit changes in circulating inflammatory 
cytokines as a result of growth, obesity and aging.  Serum C-reactive protein, an acute 
inflammatory phase protein, increases from birth to 12 months of age, but then decreases 
when the horses reach maturity, around 4 to 5 years of age (477).  However, research 
examining inflammatory cytokines in circulation of growing horses is limited.  Similar to 
humans (478-480), obesity in horses is characterized by a mild state of chronic 
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inflammation, and elevations in mRNA expression of TNF−α, IL-1, and IL-6 may play a 
role in the development of insulin resistance (481).  Additionally, aging in horses is 
characterized as inflamm-aging, where there is an increase in circulating inflammatory 
cytokines.  The relative expression of IL-6 to IL-10 and TNF−α to IL-10 is elevated in 
peripheral blood mononuclear cells of aged horses compared to adult horses (482).  Not 
only is there an increase in circulating inflammatory cytokines in aging horses (IL−1β, 
IL-15, IL-18, and TNF−α), the number of actively secreting IFN−γ labeled lymphocytes 
and TNF−α labeled lymphocytes are also elevated (483).  There is also an increase in the 
number of circulating CD5 and CD4 T cell subsets in the aged horse (483).  Obesity in 
the aged horse further alters circulating cytokines; however, diet restriction which led to a 
decrease in bodyweight did lower circulating inflammatory cytokines (484).  Overall, it 
appears that there may be an increase in inflammation or inflammatory mediators in 
circulation during development which decreases during the adult phase of life and then 
increases with post-maturity aging.  However, there has not been a specific study aimed 
at examining inflammatory changes throughout the life span in equine skeletal muscle. 
1.6.3.3.  Exercise induced inflammation in aged horses 
 The response of circulating inflammatory cytokines to an acute inflammatory 
stimuli, exercise, during a state of chronic inflammation, aging, has been examined in 
circulation in the horse.  Horohov and colleagues (485) demonstrated that IL-2 stimulated 
peripheral blood mononuclear cells cultured from pre- and post- exercise samples 
collected in young (~8 years old) and aged (~25 years old) horses (485).  However, the 
post-exercise response to IL-2 in the cultured peripheral blood mononuclear cells was 
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greater in the young horses compared to the aged horses (485).  This study indicates that 
following exercise, older horses are less responsive to an infection than young horses, 
which may be due to the increased production of inflammatory cytokines; therefore the 
response is already saturated. However, the acute inflammatory response during low 
grade chronic inflammation in the aged horse requires additional research. 
1.6.3.4.  Summary of inflammation in the horse 
 Horses respond similarly to other mammals to acute and chronic inflammation.  
Although there is still much work to be done, following exercise there is an increase in 
circulating and muscle inflammatory cytokines, which differs if the horses have been in a 
training program or if untrained horses perform a single bout of high intensity exercise.  
Additionally, horses exhibit inflamm-aging which can be exacerbated by obesity.  The 
effects that these inflammatory states may have on skeletal muscle have not been 
examined and will be partially addressed in subsequent chapters of this dissertation.
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1.7. TABLES 
Table 1.1.  Requirements of various physiological classes of an estimated mature 
weight 600 kg mare according to the NRC1 
Physiological 
State 
ADG or Milk 
produced in 
kg/d 
Crude Protein 
Requirement 
Lysine Requirement 
  g g/kg 
BW/d 
g g/kg 
BW/d 
Maintenance  756 1.26 32.5 0.05 
      
Weanling 
Growth  
(4-6 months old) 
0.94 807 1.35 34.7 0.06 
Yearling Growth 
(12-18 months 
old) 
0.44 987 1.65 42.4 0.07 
      
Early Pregnancy 
(≤ 5 months) 
0.09 789 1.32 33.9 0.06 
Mid-Pregnancy 
(6-8 months) 
0.30 877 1.46 37.7 0.06 
Late Pregnancy 
(9-10 months) 
0.63 1012 1.69 43.5 0.07 
      
Early Lactation 
(1 month) 
19.6 1842 3.07 101.7 0.17 
Mid Lactation 
(2-3months) 
18.7 1799 3.00 98.9 0.16 
Late Lactation 
(4-6 months) 
14.7 1597 3.66 85.5 0.14 
      
Light Exercise  839 1.40 36.1 0.06 
Moderate 
Exercise 
 921 1.54 39.6 0.07 
Heavy Exercise  1034 1.72 44.5 0.07 
      
Growth and 
Exercise 
(18 month old in 
light exercise) 
0.34 1023 1.71 44 0.07 
1Adapted from the NRC 2007 (342)  
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1.8.  FIGURES
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Figure 1.1.  Schematic drawing of the mTOR signaling pathway. 
Abbreviations: P; phosphorylated; IRS1, insulin receptor substrate 1; PTP1β, protein 
tyrosine phosphatase 1β; PI3K, phosphoinositide 3-kinase; PtdIns(3,4)P2/PtdIns(3,4,5)P3 
PDK1, PtdIns(3,4)P2 / PtdIns(3,4,5)P3-dependent kinase 1; PTEN, phosphatase and 
tensin homolog deleted on chromosome 10; SGK, serine/threonine protein kinase; Akt, 
protein kinase B; PP2A, protein phosphatase 2A; GLUT4, glucose transporter 4; AMPK, 
adenosine monophosphate kinase; p53, protein 53; GDP, guanosine diphosphate; GTP, 
guanosine triphosphate; MAP3K, mitogen activated protein kinase kinase kinase; MEK, 
mitogen extracellular kinase (sometimes referred to as MAPK); ERK1,2, extracellular 
regulated kinase 1,2; Wnt, Wingless-Type MMTV Integration; GSK3β, glycogen 
synthase kinase 3β; REDD1,2, Regulated in development and DNA damage response 
1,2; TSC1,2, tuberous sclerosis 1,2; 14-3-3, scaffolding protein 14-3-3; VPS34, PI3K 
catalytic subunit type 3; MAP4K3, mitogen activated protein 4 kinase kinase kinase; 
Rheb, Ras homologue enriched in brain; Ras, RAt Sarcoma protein subfamily; 
mTORC1,2, mammalian target of rapamycin complexes 1 and 2; S6K1, 70kDa S6 kinase 
1; rpS6, ribosomal protein S6; eIF, eukaryotic initiation factors (2, 3, 4A, 4B, 4E, 4G, 5); 
SKAR, Aly/REF-like target; CBP80, 80 kDa RNA splicing export factor nuclear cap-
binding protein; 4EBP1, eukaryotic initiation factor 4 eukaryotic binding protein 1; 40S, 
40S ribosomal subunit; 60S, 60S ribosomal subunit; m7GpppN, Cap structure; an arrow 
indicates an activation; and a perpendicular line indicates inhibition. 
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Figure 1.3.  Schematic drawing of an abridged version of the mTOR pathway. 
Abbreviations: IRS1, insulin receptor substrate 1; PI3K, phosphoinositide 3-kinase; 
PDK1, PtdIns(3,4)P2 / PtdIns(3,4,5)P3-dependent kinase 1; Akt, protein kinase B; 
TSC1/2, tuberous sclerosis 1,2; Rheb, Ras homologue enriched in brain; mTORC1,2, 
mammalian target of rapamycin complexes (1,2); S6K1, 70kDa S6 Kinase 1; rpS6, 
ribosomal protein S6; 4EBP1, eukaryotic initiation factor 4 eukaryotic binding 
protein 1; eIF4, eukaryotic initiation factor 4 (E, G). 
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Figure 1.4.  Schematic drawing of whole-body phenylalanine kinetics. 
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Figure 1.5.  Schematic drawing of the inflammatory signaling in circulation and 
skeletal muscle. 
Abbreviations: TGF−β, transforming growth factor−β; IFN−γ, interferon γ; TNF−α, 
tumor necrosis factor−α; IL, interleukins (-1,-6,-8, -10, -12,-18), IκKB, IκB kinase 
complex; NF-κB, Nuclear factor κ B. 
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Chapter II 
Rationale and Objectives 
2.1.  SCOPE OF DISSERTATION 
 The aims of the research presented in this dissertation were to examine the 
regulation of protein synthesis through the mTOR signaling pathway in the horse during 
various physiological states.  The horses used in this dissertation varied in age from 
growing adolescents to aging horses and were studied in the post-absorptive and 
postprandial states and in states of acute and chronic inflammation.  Muscle biopsies 
were collected in all the studies to examine mTOR signaling responses to growth, aging, 
acute and chronic inflammation, as well as in the postprandial and post-absorptive states.  
Additionally, stable isotopes were infused intravenously to study whole-body protein 
metabolism. 
2.2.  RATIONALE 
As athletic animals, horses’ body mass is nearly 50% skeletal muscle (1).  Horses 
rely on skeletal muscle for mechanical and metabolic functions during exercise and as a 
source of stored protein and amino acids during periods of long term fasting.  Although 
measurements have not been made in the horse, in other mammals skeletal muscle 
accounts for ~25% of whole body protein synthesis (198, 199), indicating that it is a 
major site of protein synthesis.  In horses, there is an increase in skeletal muscle mass 
during growth and development, followed by a decrease during post-adulthood aging 
(486).  In other species, these age-related shifts in muscle mass are accompanied by 
alterations in the response of muscle protein fractional synthesis rates (125-127, 149, 151, 
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154) and whole body protein metabolism (185, 202, 487) to anabolic stimuli.  
Furthermore, age-related changes are present in the activity of the cell signaling pathway 
referred to as the mammalian target of rapamycin (mTOR) pathway, which is responsible 
for regulating protein synthesis in response to anabolic stimuli (23, 50, 129, 139, 155-
157).  Despite the age-related examination of whole body and muscle protein synthesis 
and the mTOR signaling pathway in other species, there has not been a single study in the 
horse to quantify these aging-related changes.  
There have been three studies (2, 3, 470) in horses to examine muscle protein 
synthesis, mTOR signaling and another cell signaling pathway that can affect 
downstream mTOR signaling.  However, all of these studies have been performed in the 
mature horse under various physiological states including postprandial, post-absorptive 
and post-exercise.  Because of the limited number of studies in this area, the optimum 
methods for muscle biopsy collection, for example the muscle and depth from which the 
biopsy is collected, and the lag time between biopsies, have not been determined.  
Currently, there is no standardized method, nor do we know how measurements may be 
influenced by differences in any of these parameters.  Despite the fact that mTOR 
signaling in various muscles respond differently to anabolic stimuli, there are currently 
no studies to determine the best sample collection methodology to study mTOR signaling 
in the horse. 
 By determining the optimum methods to study mTOR signaling in the horse, and 
the age-related changes that occur, insight into protein requirements during these life 
stages may be provided, and allow for the development of better dietary and management 
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strategies for these animals in the future.  This will be extremely important in trying to 
optimize growth and delay the loss of muscle mass accompanied with aging. 
2.3.  SPECIFIC HYPOTHESES AND OBJECTIVES 
2.3.1.  Hypothesis 1. 
Hypothesis 1a:  mTOR signaling will not be altered by gluteal muscle biopsy 
collection depth in mature horses in response to feeding.  Hypothesis 1b: The percentage 
of myosin heavy chain isoforms will be altered by gluteal muscle biopsy collection depth 
in mature horses.  Hypothesis 1c:  There will be no variation in the amino acid 
concentrations due to gluteal muscle biopsy collection depth in mature horses in response 
to feeding. 
 The objective of the first study in this dissertation was to determine whether 
biopsy depth related changes in MHC isoforms were associated with differences in the 
feeding-induced activation of mTOR signaling in the gluteal muscle of mature horses.  
Gluteal muscle biopsies were collected 60 minutes following the consumption of 3g/kg of 
a high protein pellet at 6, 8, and 10 cm below the surface of the skin in mature horses.  
The gluteal muscle biopsies were then prepared and analyzed for the following: Western 
blot analysis for mTOR signaling factors (Hypothesis 1a), myosin heavy chain separation 
analysis (Hypothesis 1b), and reverse phase HPLC for muscle free amino acid 
concentrations (Hypothesis 1c). 
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2.3.2.  Hypothesis 2. 
 Hypothesis 2a:  The collection of gluteal muscle biopsy samples every 24 hours 
for 5 consecutive days will reduce mTOR signaling in response to feeding.  Hypothesis 
2b:  Administration of a non steroidal anti-inflammatory drug (NSAID) will blunt the 
effects of gluteal muscle biopsies repeated every 24 hours over the course of 5 days on 
mTOR signaling.  Hypothesis 2c:  The collection of gluteal muscle biopsy samples every 
24 hours for 5 consecutive days will increase mRNA expression of inflammatory 
cytokines (IL−1β, IL-6, IL-10, TNF−α, IFN−γ) in skeletal muscle.  Hypothesis 2d:  
Administration of a NSAID will reduce mRNA expression of inflammatory cytokines in 
skeletal muscle during consecutive gluteal muscle biopsies repeated every 24 hours over 
the course of 5 days. 
 The objective of the second study of this dissertation was to determine the effects 
of collecting gluteal muscle biopsies every 24 hours for 5 consecutive days on muscle 
inflammatory cytokine expression and the activation of mTOR signaling in response to a 
high protein meal.  Gluteal muscle biopsies were collected 60 minutes following 
consumption of 3g/kg of high protein pellet from 12 mature horses.  This process was 
repeated every 24 hours for the following 4 days.  After the initial biopsy was collected 6 
of the mature horses were randomly assigned to begin receiving the NSAID drug 
treatment (1 g of phenylbutazone every 12 hours), and the other 6 horses did not receive 
any NSAID treatment until the end of the day 5 biopsy.  Muscle tissue samples were 
prepared and analyzed using Western blotting analysis for mTOR signaling (Hypothesis 
2a, 2b) and real time PCR analysis to determine the mRNA expression of the 
inflammatory cytokines (Hypothesis 2c, 2d). 
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2.3.3.  Hypothesis 3. 
 Hypothesis 3a:  There will be an increase in mTOR signaling in the postprandial 
state of compared to the post-absorptive state in yearlings, two year olds and mature 
horses.  Hypothesis 3b:  The responsiveness of mTOR signaling to feeding will be 
greatest in the muscle of yearlings, followed by 2 year olds and will be lowest in mature 
horses.  Hypothesis 3c:  There will be no differences in mTOR signaling in the post-
absorptive state between yearlings, two year olds and mature horses. 
The objective of the third study in this dissertation was to determine the effects of 
feeding following an 18 hour period of feed withholding on the activation of mTOR 
signaling factors in yearling, two year old and mature horses.  Following an 18 hour 
period feed withholding in yearlings, two year olds, and mature horses, gluteal muscle 
biopsies were collected 90 minutes following either the consumption of 4g/kg (2g/kg at 
t=0 min and 2g/kg at t=30 min) of a high protein pellet or after 90 minutes of continued 
feed withholding (Hypotheses 3a, 3b and 3c). All muscle biopsies were prepared and 
analyzed for the activation of mTOR signaling using Western blotting procedures. 
2.3.4.  Hypothesis 4. 
Hypothesis 4a:  Aged horses (23.5 ± 2.6 y old) will have lower rates of whole-
body protein synthesis compared to mature horses (11 ± 2.6 y old).  Hypothesis 4b:  
Aged horses will have decreased gluteal muscle mTOR signaling compared to mature 
horses.  Hypothesis 4c:  Aged horses will have increased gluteal muscle mRNA 
expression of inflammatory cytokines compared to mature horses.  Hypothesis 4d:  Aged 
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horses will have higher mRNA expression of inflammatory cytokines in circulation than 
mature horses. 
The objective of the fourth study in this dissertation was to determine the effects 
of old age on mTOR signaling and whole-body protein synthesis in mature and aged 
horses, and to further characterize the inflammatory state of the aged horses.  Mature and 
aged horses were studied using a 2 hour primed (14.4 μmol/kg), constant (12 μmol/kg/h) 
intravenous infusion of [13C] sodium bicarbonate solution to measure total CO2 
production.  Horses then received a 4 hour primed (8.4 μmol/kg), constant (6 μmol/kg/h) 
intravenous infusion of [1-13C]phenylalanine, with blood and breath sampled every 30 
minutes, to measure whole-body phenylalanine kinetics (Hypothesis 4a).  A gluteal 
muscle biopsy was collected at the end of the infusion period to determine mTOR 
signaling (Hypothesis 4b) and the mRNA expression of inflammatory cytokines 
(Hypothesis 4c) in skeletal muscle.  The day before the infusion procedures, a blood 
sample was collected into a PAXgene tube via venopuncture for the determination of 
circulating inflammatory cytokine mRNA expression (Hypothesis 4d).  mTOR signaling 
and mRNA expression of inflammatory cytokines were determined using Western 
blotting and real time PCR techniques, respectively. 
2.3.5.  Hypothesis 5. 
Hypothesis 5a:  Whole-body protein synthesis will increase in aged (23.5 ± 2.6 y 
old) horses following 4 weeks of NSAID administration.  Hypothesis 5b:  Gluteal 
muscle mTOR signaling will increase following 4 weeks of NSAID administration.  
Hypothesis 5c:  Gluteal muscle mRNA expression of inflammatory cytokines will be 
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reduced in aged horses following 4 weeks of NSAID administration.  Hypothesis 5d:  
Circulating inflammatory cytokine mRNA expression will be reduced in aged horses 
following 4 weeks of NSAID administration. 
The objective of the final study in this dissertation was to determine the effects of 
NSAID (phenylbutazone at 2 g/d) administration over 4 weeks on the activation of 
mTOR signaling and whole-body protein synthesis and skeletal muscle and circulating 
inflammatory cytokines in aged horses.  Aged horses were studied prior to and following 
2 and 4 weeks of NSAID administration.  Horses were studied using a 2 hour primed 
(14.4 μmol/kg), constant (12 μmol/kg/h) intravenous infusion of [13C]sodium bicarbonate 
solution in order to determine total CO2 production, followed by a 4 hour primed (8.4 
μmol/kg), constant (6 μmol/kg/h) intravenous infusion of [1-13C]phenylalanine, with 
blood and breath sampled every 30 minutes, to measure whole-body phenylalanine 
kinetics (Hypothesis 5a).  A gluteal muscle biopsy was collected at the end of the 
infusion period to determine the mTOR signaling (Hypothesis 5b) and the mRNA 
expression of inflammatory cytokines (Hypothesis 5c) in skeletal muscle.  On the day 
before infusion procedures, prior to and following 4 weeks of NSAID administration, a 
blood sample was collected via venopunctiure into a PAXgene tube for the determination 
of circulating inflammatory cytokine mRNA expression (Hypothesis 5d).  mTOR 
signaling and mRNA expression of inflammatory cytokines were determined using 
Western blotting and real time PCR techniques, respectively. 
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Chapter III1 
Gluteal muscle sampling depth does not affect mTOR signaling in response to feeding 
in mature Thoroughbred mares. 
1At the time of the defense (November 21, 2011), a version of this chapter is currently 
under review for publication in the Equine Veterinary Journal. 
3.1.  INTRODUCTION 
The collection of percutaneous muscle biopsy samples from the gluteal muscle is 
commonly used to investigate equine skeletal muscle physiology and metabolism (411); 
however, there is no standardized depth from which samples are collected.  Studies have 
demonstrated variation in MHC isoform expression across depth in the gluteal muscle of 
horses (413) and MHC content reflects the metabolic properties of the muscle fiber (425). 
Protein synthesis is regulated through the mammalian target of rapamycin 
(mTOR/mTORC1) signaling pathway.  The regulation of mTOR signaling has been the 
topic of recent review (488).  Our laboratory has examined the activation of factors along 
the mTOR pathway, Akt, rpS6 and 4EBP1, in response to meal consumption in mature 
horses (2), where it was demonstrated that the anabolic stimulus of meal consumption 
activates mTOR signaling in the mature horse.  In rodents, muscle groups with a greater 
proportion of type II versus I fibers have a greater abundance of the phosphorylated form 
of S6K1 in response to resistance exercise (110).  However, the effects of MHC 
proportion on the activation of mTOR signaling factors in response to feeding have not 
yet been determined. 
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The objective of this study was to determine whether biopsy depth related 
changes in MHC isoforms were associated with differences in the feeding-induced 
activation of mTOR signaling in the gluteal muscle of mature horses. 
3.2.  MATERIALS AND METHODS 
3.2.1.  Animals and housing 
All procedures used in this study were approved by the University of Kentucky 
Institutional Animal Care and Use Committee (2009-0442).  Six Thoroughbred mares 
(13.4 ± 3.4yrs; 536 ± 45 kg BW) of moderate body condition (5-7 on a 1-9 scale (489)) 
and clinically healthy were used in this study.  Mares were housed in 3×15 m partially 
covered dry lot pens with crushed limestone footing, with ad libitum access to both water 
and salt.  Horses were adapted to diet and housing procedures for 1 week prior to 
sampling. 
3.2.2.  Experimental procedures 
Individual meals were provided twice daily (at 800 and 1500).  Diets consisted of 
alfalfa hay cubes [mean ±SD; 0.48 ±0.01Mcal/kg DE, 17.0 ±0.2% CP, 35.2 ±0.8% ADF, 
44.9 ±1.3% NDF, 2.3 ±0.1% crude fat, and 9.5 ±0.2% ash] and a ration balancer (mean 
±SD; 0.49 ±0.01Mcal/kg DE, 14.9 ±0.2% CP, 22.5 ±0.8% ADF, 43.2 ±0.4% NDF, 3.6 
±0.1% crude fat, and 12.9 ±0.1% ash), provided at a rate of 1.75% and 0.2% of BW/d, 
respectively. 
On the morning of the muscle biopsy, horses were weighed on an electronic scale 
(TI-500, Transcell Technology Inc., Buffalo Grove, IL) and then fed 3 g/kg BW of a high 
protein pellet (mean ±SD; 0.57 ±0.01Mcal/kg DE, 36.3 ±0.7% CP, 6.8 ±0.3% ADF, 13.8 
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±0.8% NDF, 3.9 ±0.1% crude fat, and 17.2 ±0.3% ash) at t = 0 min.  This high protein 
pellet is a commercially available feed that was used in a previous study examining 
mTOR signaling in the horse where the amino acid concentrations of the feed were 
provided (2).  At t = 60 min, horses were lightly sedated with xylazine hydrochloride 
(0.3mg/kg, intravenous [100 mg/mL]), the biopsy site was aseptically scrubbed and and 
anesthetized with a local anesthetic (12mL of 2% lidocaine).  Muscle biopsies (~500 mg) 
were collected from a single incision in the middle gluteal muscle at depths of 6, 8 and 10 
cm below the surface of the skin, using the percutaneous needle biopsy technique (411).  
Samples were immediately processed for Western blot analysis (~100 mg) and the 
remaining muscle was frozen in liquid nitrogen, and stored at -80ºC until analysis for 
amino acid concentration determination and myofibrillar protein preparation. 
3.2.3.  Sample analysis. 
3.2.3.1.  Amino acids:  Muscle free amino acid concentrations were measured using 
reverse-phase HPLC (3.9 × 300 mm PICO-TAG reverse phase column; Waters, Milford, 
MA) of phenylisothiocyanate derivatives as previously described (2). 
3.2.3.2.  Muscle homogenate preparation for Western blot analysis:  Muscle homogenates 
were prepared as previously described (2).  Briefly, freshly collected muscle (~ 100 mg) 
was weighed and homogenized over ice in 7 µL/mg tissue wet weight of a buffer solution 
(20 mM HEPES, 2 mM EGTA, 50 mM sodium fluoride, 100 mM potassium chloride, 0.2 
mM EDTA and 50 mM β-glycerophosphate; pH 7.4) that contained 20 µL/mL of a 
protease inhibitor (Sigma P8340; Sigma Aldrich, Saint Louis, MO).  Homogenized 
samples were centrifuged at 10,000 x g for 10 min at 4 ºC and the supernatant was 
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aliquoted then stored at -80 ºC until further analysis.  After protein concentrations were 
determined using a Bradford assay kit (Thermo Scientific, Rockford, IL) modified for a 
96 well plate, 50 µL of supernant was added to 25 µL of a 3X Laemmli buffer (125 mM 
Trizma® hydrochloride pH 6.8, 4% (w/v) SDS, 20% (v/v) glycerol, 100 mM 
dithiothreitol, 0.01% (w/v) bromophenol blue).  Then, varying amounts of 1X Laemmli 
buffer were added to each sample/Laemmli buffer mixture to reach a final protein 
concentration of 2 µg/µL.  The sample/Laemmli buffer mixture was boiled for 5 min, and 
immediately placed on ice prior to gel electrophoresis. 
3.2.3.3.  Western blot analysis of muscle:  The abundance and phosphorylation of 4E-
BP1, Akt, S6K1, and rpS6 in the gluteal muscle were determined using Western blot 
analysis similar to those previously described (2).  Proteins in the muscle samples 
processed and stored in Laemmli buffer were separated in polyacylamide gels using 
electrophoresis and then transferred to 0.45 µm PVDF membranes (BioRad, Hercules, 
CA).  Samples were standardized by the amount of protein loaded per well for 
electrophoresis (20 µg protein was loaded for Akt, rpS6, and 4E-BP1; 30 µg protein was 
loaded for S6K1).  The membranes were blocked in a 5% fat-free milk solution and were 
then incubated with the appropriate primary antibodies for either 16 h at 4 ºC 
(phosphorylated and total forms of Akt, S6K1, and rpS6, and phosphorylated form of 4E-
BP1) or 1 h at room temperature (total form of 4E-BP1). 
Individual rabbit polyclonal antibodies (Cell Signaling Technology®, Inc., 
Boston, MA) were used that recognized total, Ser473, and Thr308 Akt (1:2000 dilution for 
each); total and Thr389 S6K1 (1:1000 and 1:500 dilutions, respectively); and Ser235/236, and 
Ser240/244 rpS6 (1:2000 dilutions for each).  Rabbit monoclonal antibodies (Cell Signaling 
117 
 
Technology®, Inc., Boston, MA) specific to total and Thr37/46 4E-BP1 (1:1000 dilution); 
and total rpS6 (1:10,000 dilution) were also used.  Following washing, membranes were 
incubated with a goat anti-rabbit IgG (H+L) with conjugated horseradish peroxidase 
(1:10,000 dilution) (BioRad, Hercules, CA) for 1 h at room temperature.  Membranes 
were developed using a chemiluminescence kit (Amersham ECL Plus Western Blotting 
Detection Reagents; GE healthcare, Piscataway, NJ) and visualized on x-ray film using a 
film processor (Kodak X-OMAT film processor, Kodak Health Imaging Division, 
Rochester, NY).  Band densities were quantified as the mean*pixels in a photo editing 
computer software program (Adobe Photoshop Elements™ Version 8.0; Alpha Innotech, 
San Leandro, CA). 
Gels were run in duplicate, and the average band densities were used to calculate 
the ratio of phosphorylated to total abundance (Section 3.4.4).  In order, to probe for the 
total versus phosphorylated forms using different primary antibodies, the PVDF 
membranes were first blotted for the phosphorylated protein abundance and were then 
stripped for 10 minutes (62.5 mM Trizma® hydrochloride, 2% (w/v) SDS, 0.1 M β-
mercaptoethanol, boiling), re-blocked with 5% fat-free milk solution and re-probed for 
the total protein abundance.  Membrane stripping and re-probing served to minimize the 
inter-assay error that would have resulted if the total and phosphorylated protein 
abundances had been quantified from different membranes. 
Although total Akt and Akt-Ser473, and total and Ser235/236 and Ser240/244 rpS6 have 
been previously evaluated in equine skeletal muscle using the rabbit antibodies (2), to the 
best of the authors’ knowledge, the other antibodies used in this study had not been 
previously validated for horse samples.  Therefore, positive control samples (Cell 
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Signaling Technology®, Inc., Boston, MA) with known reactivity to the antibodies, were 
loaded and run with all gels (Appendix 2).  In addition, prior to performing the western 
blot analysis for the samples in this study, we confirmed that all antibodies were cross-
species specific to these proteins in horses through the use of blocking peptides (Cell 
Signaling Technology®, Inc., Boston, MA).  Primary antibody was mixed with blocking 
peptide in decreasing ratios of 1:4, 1:1, 1:1/4, and 1:1/16 (antibody volume to blocking 
peptide volume) to determine the competition of blocking peptide to equine protein for 
the given antibody.  In all cases, we were able to verify that the primary antibodies were 
reacting with the equine forms of the proteins of interest, because there was a reduced 
chemiluminescent signal for the protein of interest as increased amounts of the blocking 
peptide were added to the reaction mixture. 
3.2.3.4.  Myofibrillar protein preparation:  Flash frozen muscle was removed from the -
80ºC freezer, and allowed to thaw on dry ice.  Tissue was then divided into (~50 mg) 
portions and homogenized with a manual dounce homogenizer over dry ice in 9 µL/mg 
tissue wet weight of a buffer solution (250mM Sucrose, 25mM NaCl, 20mM Tris; pH 
7.4).  Homogenized samples were centrifuged at 20,000 x g for 30 min at 4 ºC and the 
supernatant was removed.  The pellet was then resuspended in homogenizing buffer (250 
µL).  After protein concentrations were determined using a Bradford assay kit (Thermo 
Scientific, Rockford, IL) modified for a 96 well plate, 40 µL of sample was added to 20 
µL of a 3X Laemmli buffer (0.15 M Tris, pH 6.8, 6% (w/v) SDS, 75 mM dithiothreitol, 
0.06% (w/v) bromophenol blue, 40% (w/v) glycerol).  Then, varying amounts of 1X 
Laemmli buffer were added to each sample/Laemmli buffer mixture to reach a final 
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protein concentration of 0.2 µg/µL.  The sample/Laemmli buffer mixture was boiled for 2 
min, and immediately placed on ice prior to gel electrophoresis. 
3.2.3.5.  Separation of MHC Isoforms via electrophoresis:  The percentage of MHC 
isoform in the gluteal muscle was determined using electrophoresis followed by silver 
staining similar to the methods previously described (490).  In short, myofibrillar proteins 
in the muscle samples processed and stored in Laemmli buffer were separated in 
polyacrylamide gels using electrophoresis.  Samples were standardized by the amount of 
protein loaded per well for electrophoresis (2 µg of myofibrillar proteins was loaded), 
and mouse gastrocnemius muscle served as a control on each gel.  The electrophoresis 
ran at 4ºC for 40 hours with constant voltage of 70 V using a BioRad Power PAC3000 
power supply (Hercules, CA).  Membranes were stained using a silver staining kit (Silver 
Stain Plus Kit; BioRad, Hercules, CA) following manufacturer’s directions (Appendix 3).  
Band densities were quantified as the mean*pixels using a photo editing computer 
software program (Adobe Photoshop Elements™ Version 8.0; Alpha Innotech, San 
Leandro, CA). 
3.2.4.  Calculations and statistics. 
Individual band densities were corrected for the band density of the positive 
control (Akt Control Cell Extracts treated with Calyculin A, Cell Signaling Technology 
®, Inc., Boston, MA) run on each gel.  The averages of the corrected band densities from 
duplicate gels were averaged, and then expressed as a ratio of the phosphorylated to total 
forms for each protein.  Protein abundance of the mTOR signaling factors was expressed 
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in arbitrary units, with the ratio of the phosphorylated to total forms of each protein at the 
6 cm depth set to 1.  MHC isoforms are expressed as a percentage of total MHC. 
All data were analyzed using the MIXED procedure of SAS Version 9.2 (SAS 
Institute Inc., Cary, NC), with statistical significance at P < 0.05.  When the fixed effects 
were significant, pre-planned comparisons of least squares means were made using the 
pdiff test.  The dependent variables were analyzed using repeated measures analysis, with 
depth and block as the fixed effects and horse nested in block as the subject.  The 
variance-covariance matrix was chosen for each analysis based on the lowest value for 
Schwarz’s Bayesian Criterion.  Data are presented as means ± pooled standard error. 
3.3.  RESULTS 
There was a significant effect (P < 0.05; Table 3.1) of sampling depth on the 
muscle concentrations of free alanine, aspartate, glutamate, isoleucine, leucine, 
methionine, proline and valine. 
 The phosphorylation of Akt at Ser473 (P = 0.06; Figure 3.1), S6K1 at Thr389 (P = 
0.66; Figure 3.1), rpS6 at Ser235/236 & 240/244 (P = 0.21; Figure 3.1), and 4EBP1 at Thr37/46 
(P = 0.62; Figure 3.1) was not affected by sampling depth within the gluteal muscle of 
mature mares 60 min following the consumption of a high protein pellet. 
 There was a significant effect of sampling depth on the percentage of MHC IIA (P 
= 0.03; Figure 3.2) and IIX (P = 0.02; Figure 3.2) in the gluteal muscle of mature mares; 
however there was no effect (P = 0.42; Figure 3.2) of sampling depth on the percentage 
of MHC I.  The percentage of MHC IIA and IIX increased by 27% and decreased by 
15%, respectively, from 6 to 10 cm. 
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3.4.  DISCUSSION 
This is the first study to examine the effects of gluteal muscle biopsy sampling 
depth on the activation of mTOR signaling in response to feeding.  The results showed no 
effect of sampling depth on the activation of mTOR signaling, despite changes in the 
proportion of MHC isoforms.  Thus, it appears that if percutaneous muscle biopsy 
sampling occurs within a 6 to 10 cm range then mTOR signaling in response to feeding 
can be compared between mature horses. 
The collection of gluteal muscle biopsies at 6, 8, and 10 cm below the surface of 
the skin showed that the proportion of MHC IIA, IIX and I isoforms increased, decreased 
and remained unchanged, respectively.  The changes seen in the proportion of MHC IIA 
and IIX are consistent with previous reports (413), where the percentage of MHC IIA and 
IIX isoforms increase and decrease, respectively, from 2 cm to 8 cm in the gluteus 
muscle (413).  However, in the present study we did not see a change in the percentage of 
MHC I isoforms which has been previously demonstrated to increase with depth (413), 
and may be due to the sampling protocol in the present study: we collected biopsies at 6, 
8 and 10 cm below the surface of the skin rather than a more shallow collection 
beginning at 2 cm (413).  We also did not account for the variation in subcutaneous fat 
which we have demonstrated to be up to 2 cm in some mature horses (Section 8.1).  
Additionally, it is has been previously demonstrated that extensive variation in fiber type 
exists between breeds (414), and the present results in Thoroughbreds are consistent with 
what has been previously measurements of 10-15% of Type I fibers in this breed (414). 
The activation of the mTOR signaling in response to feeding was not affected by 
sampling depth.  Although this is the first study to examine biopsy sampling depth in 
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horses, it is not the first study to look at the association between of MHC isoform content 
of muscle with mTOR signaling response to anabolic stimuli.  In rodents, 
phosphorylation of mTOR (491) and S6K1 (110) was shown to vary across different 
muscles in response to contractile activity and the authors suggested that different fiber 
types (Type II vs. Type I) maybe exhibiting a greater mTOR signaling response. 
However, the variation in the activation of mTOR signaling factors due to MHC isoforms 
remains unclear (104), and fiber type is not associated with different rates of protein 
synthesis in humans (492).  Horses, like humans, possess a single MHC I and 2 MHC II 
isoforms (409), and do not possess a MHC IIB isoform which is present in rodent skeletal 
muscle (409).  It may be that the increased responsiveness to anabolic stimuli is a 
property that is specific to Type IIB fibers seen in rodents; however, this requires 
additional research.  Additionally, the minimal change in MHC isoforms with depth may 
explain the lack of an effect of depth on mTOR signaling in response to feeding. 
Although sampling depth did not affect the activation of mTOR signaling, the 
gluteal muscle concentrations of branched chain amino acids (BCAA), alanine, aspartate, 
glutamate, methionine, and proline were greatest at the 8 cm sampling depth.  With 
elevated concentrations of BCAA, we expected to see greater mTOR signaling (48) at the 
8 cm depth, but this was not the case, and these depth-related differences remain unclear.  
However, from a methodological perspective, these results indicate that when comparing 
gluteal muscle amino acids of mature horses, researchers need to standardize their biopsy 
collection procedures by depth. 
Conducting muscle biopsies at a depth range of 6 to 10 cm below the surface of 
the skin did not affect the activation of mTOR signaling in response to consumption of a 
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high protein pelleted meal, despite differences in the distribution of the MHC isoforms 
present.  Therefore, the activation of mTOR signaling can be compared across this range 
of depths in mature horses.  
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3.5.  TABLES 
Table 3.1: Muscle amino acid concentrations of the gluteus muscle at 6, 8 and 10 cm 
below the skin in mature mares. 
Amino Acid 6 cm 8 cm 10 cm Pooled 
SEM 
p-Value 
Alanine1 697a 944b 744a 102 0.05 
Asparagine 60 60 59 6 0.97 
Aspartate 70a 94b 68a 9 0.02 
Citrulline 41 50 46 6 0.48 
Glutamate 305a 442b 390b 49 0.03 
Glutamine 246 303 257 35 0.46 
Glycine 664 471 664 133 0.50 
Histidine 58 68 53 8 0.24 
Isoleucine 55a 69b 56a 4 0.004 
Leucine 105a 135b 111a 10 0.007 
Lysine 296 189 267 128 0.67 
Methionine 36a 50b 39a 4 0.004 
Ornithine 15 26 17 9 0.59 
Phenylalanine 48 64 104 29 0.39 
Proline 94a 122b 100a 9 0.004 
Serine 144 150 137 12 0.45 
Threonine 170 207 173 34 0.69 
Tryptophan 18 20 18 2 0.56 
Tyrosine 61 104 62 24 0.36 
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Table 3.1 continued: Muscle amino acid concentrations of the gluteus muscle at 6, 8 
and 10 cm below the skin in mature mares. 
Valine 111a 148b 119a 9 0.005 
 
1 Plasma amino acids concentrations are reported as least square means in μmol/g of wet 
muscle. 
abc Differing letters indicate that values are significantly (P < 0.05) different from each 
other. 
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3.6.  FIGURES 
 
Figure 3.1.  Gluteal muscle phosphorylation of Akt at Ser473, S6K1 at Thr389, rpS6 at 
Ser235/236 & 240/244, and 4EBP1 at Thr 37/46 at 6, 8, and 10 cm below the surface of the 
skin within the gluteus medius muscle of mature mares 60 min after consuming 
3g/kg of a high protein pelleted feed.  The phosphorylated forms of the translation 
initiation factors was corrected by the respective total form abundance, with the value for 
mature horses set at 1.0 AU.  Values are least square means ± pooled SE, n=6 per depth.  
Representative images of the immunoblots are shown above. 
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Figure 3.2.  Percentage of MHC isoforms at 6, 8, and 10 cm below the surface of the 
skin within the gluteus medius muscle of mature mares 60 min after consuming 
3g/kg of a high protein pelleted feed.  Values are least square means ± pooled SE, n=6 
per depth. 
abDifferent letters indicate a significant depth effect (P < 0.05). 
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Chapter IV 
Repeated muscle biopsies over a 5 day period increases mTOR signaling in equine 
skeletal muscle 
4.1.  INTRODUCTION 
Repeated percutaneous needle muscle biopsies, over the span of hours or days, are 
a common practice in human and equine studies examining various factors affecting 
muscle metabolism and physiology.  However, the literature examining the effects of 
repeated biopsies on muscle metabolism and physiology is limited.  Inflammatory 
changes in the muscle are induced by aging (493-495), exercise (244, 245, 255), and 
muscle biopsy collection (248).  In many studies, the effects of repeated biopsies on 
muscle inflammation has been confounded by the inclusion of a simultaneous exercise 
treatment (244, 245, 255, 332).  Multiple biopsies have been reported to increase both 
systemic and muscle inflammatory cytokines 30 (245) and 126 minutes (248) following 
an initial biopsy.  However, repeated biopsies over a 24 hour period in equine skeletal 
muscle did not affect systemic or muscle inflammatory cytokines.  This disconnect 
between human and equine skeletal muscle, in addition to the absence of non-exercise 
related studies, necessitated further investigation. 
Protein synthesis is regulated through the mammalian target of rapamycin 
(mTOR) signaling pathway.  There are numerous reviews (21, 488, 496) examining the 
regulation of this pathway by anabolic stimuli.  Briefly, insulin stimulates the mTOR 
signaling pathway through the phosphorylation of Akt (18, 19, 21), which inhibits the 
activation of several mTOR inhibitors (18, 19, 21).  Amino acids also stimulate the 
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mTOR signaling pathway through the activation of a series of signaling proteins which 
subsequently activate mTOR (45, 46, 497).  mTOR activation results in the 
phosphorylation of two downstream signaling proteins, ribosomal S6 Kinase 1 (S6K1) 
and eukaryotic initiation factor 4E-binding protein-1 (4EBP1) (146, 496).  
Phosphorylation of S6K1 activates ribosomal protein S6 (rpS6) (498), a component of the 
40S ribosomal subunit (498).  Phosphorylation of rpS6 and 4EBP1 result in the activation 
of the translational equipment, allowing for protein synthesis to occur (146, 496).  
Numerous studies have shown that the activation of these key proteins in the mTOR 
signaling pathway in rodents (499-501), humans (99, 502, 503), and pigs (504-506) 
correlate with an increase in the fractional muscle protein synthesis rates. 
The use of multiple biopsies to examine protein synthesis rates and the mTOR 
signaling pathway typically coincide with an exercise treatment, making it impossible to 
separate the effects of exercise from repeated biopsy.  These studies typically occurred 
during approximately a 24 hour period where the initial biopsy was collected and then 
subsequent biopsies are obtained following an exercise regimen or during isotope 
infusion techniques over a several hour period.  Protein synthesis rates do not change 
with multiple muscle biopsies collected between 60, 210 and 240 minutes of a 4 hour 
period (507) and during hourly biopsies over a 6 hour period (508).  However, no study 
has examined the effects of repeated muscle biopsies on muscle protein synthesis rates 
after 6 hour, and there has been no study to examine the effects of repeated biopsies on 
the activation of mTOR signaling factors.  It is crucial to study protein synthesis and 
mTOR signaling during a longer period following inflammatory stimuli because in 
humans inflammation has shown to remain elevated up to 72 hours following exercise 
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(509).  Inflammation may impact the responsiveness of the mTOR signaling pathway and 
subsequently protein synthesis rates in response to anabolic stimuli.  In aged rodents with 
systemic inflammation, the administration of a NSAID was able to increase muscle 
protein synthesis (335).  Therefore, it may be possible to mitigate changes in 
inflammation and mTOR signaling due to repeated biopsies using NSAID administration.  
The objective of this study was to determine the effects of multiple biopsies over the 
course of 5 consecutive days on muscle inflammatory cytokine expression and the 
activation of mTOR signaling in response to a high protein meal. 
4.2.  MATERIALS AND METHODS 
4.2.1.  Animals and housing. 
All procedures used in this study were approved by the University of Kentucky 
Institutional Animal Care and Use Committee (2009-0442).  Twelve Thoroughbred 
mares were obtained from the University of Kentucky Animal and Food Sciences’ Maine 
Chance Farm.  All mares were classified as mature (average age 13.4 ± 3.4; range 10-19 
y old), of a moderate body condition (body condition score 5-7, scale 1-9 (489)), and 
clinically healthy.  Mares were on a regular vaccination, anthelmintic, and farrier 
schedule prior to inclusion on this study.  For the duration of the study mares were 
housed in 3×15 m partially covered dry lot pens with crushed limestone footing.  Ad 
libitum access to both water and salt was provided throughout the study.  Horses were 
adapted to diet and housing procedures for 1 week prior to the initiation of study 
procedures. 
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4.4.2.  Feeding procedures. 
Individual meals were provided twice daily (at 800 and 1500).  Diets consisted of 
alfalfa hay cubes and a ration balancer; and were designed to meet the NRC (336) 
requirements for mature horses with an approximate body weight (BW) of 600 kg and 
average maintenance needs.  The alfalfa hay cubes [mean ±SD; 0.48 ±0.01Mcal/kg DE, 
17.0 ±0.2% crude protein (CP), 35.2 ±0.8% acid detergent fiber (ADF), 44.9 ±1.3% 
neutral detergent fiber (NDF), 2.3 ±0.1% crude fat, and 9.5 ±0.2% ash] and ration 
balancer (mean ±SD; 0.49 ±0.01Mcal/kg DE, 14.9 ±0.2% CP, 22.5 ±0.8% ADF, 43.2 
±0.4% NDF, 3.6 ±0.1% crude fat, and 12.9 ±0.1% ash) were provided at a rate of 1.75% 
and 0.2% of BW/d, respectively,  for the duration of the study.  Samples of the alfalfa hay 
cubes, ration balancer, and high protein pellet, which was offered on sampling days, were 
collected and sent to Dairy One Forage Laboratory (Ithaca, NY) for nutrient analysis. 
4.2.3.  Experimental design and procedures. 
The current study was executed as a 2-way factorial design with day (1-5) and 
NSAID administration (+NSAID or -NSAID) as the fixed effects.  The twelve mares 
were divided into two blocks of 6 horses, with 3 horses on each treatment in each block 
to ease sampling procedures. 
On the morning of day 1, following the adaptation period, horses were weighed 
on an electronic scale (TI-500, Transcell Technology Inc., Buffalo Grove, IL) and fed a 
high protein pellet (mean ±SD; 0.57 ±0.01Mcal/kg DE, 36.3 ±0.7% CP, 6.8 ±0.3% ADF, 
13.8 ±0.8% NDF, 3.9 ±0.1% crude fat, and 17.2 ±0.3% ash) at 3g/kg.  This high protein 
pellet is a commercially available feed that was used in a previous study examining 
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mTOR signaling in the horse where the amino acid concentrations of the feed were 
provided (2).  Pre-feeding (t = -15 min) and post-feeding (t = 60 minute after feed was 
offered) jugular vein blood samples were collected via venapuncture into evacuated glass 
tubes (Vacutainer; Becton-Dickinson, Franklin Lakes NJ) containing sodium heparin.  
Blood samples were immediately centrifuged at 1,500 x g for 10 minutes at 4ºC.  
Aliquots of plasma samples were frozen at -20ºC until the time of analysis.  At t = 60 
min, horses were placed in equine stocks (Priefert® Rodeo & Ranch Equipment, Mount 
Pleasant TX), and were lightly sedated with xylazine hydrochloride (0.3mg/kg, 
intravenous [100mg/mL]).  Muscle biopsies (~500 mg) were collected from both the right 
and left gluteal muscles, at a standardized site from a depth of 8cm (Chapter III) in the 
middle gluteal muscle by use of the percutaneous needle biopsy technique (411).  
Biopsies on day 2 – 5 were collected using separate incisions at least 1 cm apart from all 
previous biopsy sites.  Samples were immediately processed for Western blot analysis 
(~100 mg) and quantitative real time (qRT)-PCR (~80 mg), as described below, and the 
remaining muscle was frozen in liquid nitrogen, and stored at -80ºC until analysis.  
Phenylbutazone (NSAID) was administered orally after the initial biopsy at 1 g every 12 
hours for the next consecutive 5 day in the +NSAID group, and was not administered in 
the -NSAID group.  This procedure was repeated every 24 hr for the next 4 d.  At the end 
of the sampling period on day 5, all horses received phenylbutazone (2g/day) for the next 
3 days to alleviate any discomfort or inflammation that may have been associated with 
the procedures.  All mares were then returned to the Department of Animal and Food 
Sciences Maine Chance Farm Research herd at the end of the study procedures. 
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4.2.4.  Sample analysis. 
4.2.4.1.  Plasma glucose and insulin: Plasma glucose concentrations were determined 
enzymatically using a YSI 2300 STAT Plus™ Glucose and Lactate Analyzer (YSI Inc., 
Life Sciences, Yellow Springs OH) (Appendix 4.1).  A Coat-A-Coat RIA® kit (Siemens 
Healthcare Diagnostics Inc., Deerfield IL) was used to determine plasma insulin 
concentrations (Appendix 4.2). 
4.2.4.2.  Amino acids:  Both plasma free amino acid concentrations (Appendix 1.1 – 1.2) 
and total feed amino acid (Appendix 1.4 – 1.5) content were measured using reverse-
phase HPLC (3.9 × 300 mm PICO-TAG reverse phase column; Waters, Milford MA) of 
phenylisothiocyanate derivatives as previously described (2). 
4.2.4.3.  Western blot analysis of muscle samples:  The abundance of the total and 
phosphorylated forms of Akt, S6K1, rpS6, and 4E-BP1 in the gluteal muscle 
homogenates were determined using electrophoresis followed by Western blotting 
techniques (Chapter III) 
4.2.4.4.  RNA isolation and qRT-PCR.  Freshly collected muscle (~ 80 mg) was weighed, 
submerged in RNAlater (Qiagen Inc., Valencia, CA), and stored at -20oC until further 
analysis.  At time of analysis, muscle was homogenized into the RNA-Stat60 solution 
(Tel- Test, Friendswood, TX) using the bead beating technique (510).  Total RNA was 
then isolated and quantified using phenol-chloroform extraction and quantified using 
spectrophotometer (BioPhotometer, Eppendorf, Hamburg, Germany).  Finally, reverse 
transcription reactions were performed as previously described (244, 484), using 0.5 μg 
of each RNA sample and reverse transcription master mix (Promega, Madison, WI).  
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These reactions were incubated at 42oC for 15 minutes and 95oC for 5 minutes.  cDNA 
samples were stored at -20oC until analyzed by qRT-PCR. 
The mRNA expression of pro -inflammatory cytokines, IFN−γ, IL−1β, IL-6 and 
TNF−α, and the anti-inflammatory cytokine IL-10 were measured in cDNA samples 
using equine specific intron-spanning primer/probe sets (244).  A gene expression master 
mix solution containing: 6.25 μL nuclease-free water (Qiagen), 1.25 μL 20 × assay mix 
for primer/probe set of interest (Applied Biosystems, Foster City, CA), and 12.5 μL 
Taqman™ (Applied Biosystems, Foster City, CA) reacted in 384 well plates with 5 μL of 
cDNA.  All reactions were run in duplicate under the following PCR conditions: 95oC for 
10 minute followed by 45 cycles of 95oC for 15s and 60oC for 60s in an Applied 
Biosystems 7500 sequence detection system (Appendix 5).  Differences in RNA isolation 
and cDNA construction between samples were corrected with the use of an internal 
control, β-glucorindase, for each sample (244, 484). 
4.2.5.  Calculations and statistical analysis. 
Protein abundance of the mTOR signaling factors is expressed in arbitrary units, 
which is the ratio of the phosphorylated to total forms for each protein (Chapter III).  The 
ΔΔCT method (484) was used to calculate relative changes in mRNA expression from the 
initial biopsy.  The calibrator for individual cytokines was set as the mean ΔCT averaged 
for all horses at day 1.  These results are expressed as the relative quantity (RQ), which is 
calculated as 2-ΔΔCT. 
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All data were analyzed using the mixed procedure of SAS Version 9.2 (SAS 
Institute Inc., Cary, NC), with statistical significance and trends considered if P < 0.05 
and 0.05 < P < 0.10, respectively.  When the fixed effects were significant, pre-planned 
comparisons of least squares means were made using the pdiff test. 
The dependent variables plasma glucose, insulin, and amino acid concentrations 
were analyzed using repeated measures analysis, with day, NSAID treatment, 
day*NSAID treatment interaction, and block as the fixed effects and horse nested within 
treatment*block as the random subject.  Baseline concentration was also included in the 
model as a covariate because it significantly (P < 0.05) influenced the post-meal sample.  
Biopsy side (left or right) was initially included in the model for each of the mTOR 
signaling proteins, but was not significant (P > 0.05) and was removed from the model.  
Each of the mTOR signaling proteins and the expression of individual inflammatory 
cytokines were analyzed using repeated measures analysis, with day, NSAID treatment, 
day*NSAID treatment interaction, and block as the fixed effects with horse nested within 
treatment*block set as the random subject.  For all repeated measures analysis, the 
variance-covariance matrix was chosen for each analysis based on the lowest value for 
Schwarz’s Bayesian Criterion.  Data are presented as means ± pooled standard error 
unless otherwise noted. 
4.3.  RESULTS 
4.3.1.  Plasma glucose, insulin, and amino acid concentrations 
Plasma glucose concentrations were significantly affected by the interaction of 
NSAID treatment*day (P = 0.05; Table 4.1), where at 60 minutes following the 
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consumption of a high protein pelleted meal the plasma glucose concentrations decreased 
over the course of the 5 day sampling period in the +NSAID treatment group (P < 0.05), 
and did not change in the -NSAID group (P > 0.10).  Plasma insulin concentrations were 
not affected (P > 0.10; Table 4.1) by day, NSAID treatment, or day*NSAID treatment 
interaction. 
There was a significant effect (P < 0.05; Table 4.1) of treatment on plasma 
concentrations of isoleucine, and proline.  There was a statistical trend for an effect of 
treatment on the plasma concentrations of leucine (P = 0.10), and valine (P = 0.10; Table 
4.1).  Day of sampling significantly affected (P < 0.05; Table 4.1) plasma concentrations 
of alanine, and threonine.  There was a significant (P = 0.04; Table 4.1) day*NSAID 
treatment interaction on the plasma concentrations of asparagine.  
4.3.2.  Muscle mTOR signaling factors 
The phosphorylation of Akt at Ser473 decreased significantly with day of biopsy (P 
< 0.0001; Figure 4.1), regardless of treatment; however, the +NSAID group decreased 
from day 1 to 2, and the –NSAID group decreased from day 1 to 3.  Akt P-Ser473 was not 
affected by treatment or treatment*day interaction (P > 0.10).  There was a significant 
treatment*day interaction on the phosphorylation of S6K1 at Thr389 (P = 0.003; Figure 
4.2), where the +NSAID group had a transient increase from day1 during days 2 and 3 
and returned to baseline by day 4, and the –NSAID group had a greater Thr389 S6K1 on 
day 5 than on day 1.  The phosphorylation of S6K1 at Thr389 was significantly affected by 
day of sampling (P = 0.02), but not treatment (P > 0.10).  There was a significant 
interaction of treatment*day on the phosphorylation of rpS6 at Ser235/236 & 240/244 (P < 
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0.001; Figure 4.3) with a transient decrease from day 1 in the +NSAID group on days 4 
and 5, and an increase from day 1 with collection of each subsequent biopsy in the –
NSAID group.  The phosphorylation of rpS6 at Ser235/236 & 240/244 was significantly 
affected by both day of sampling (P = 0.005) and treatment (P = 0.05).  There was a 
time*treatment interaction on 4EBP1 at Thr37/46 (P = 0.02; Figure 4.4) with no change 
due to day in the +NSAID group and a gradual increase at day 5 from day 1 in the –
NSAID group.  There was a trend (P = 0.06) for an effect of sampling day on the 
phosphorylation of 4EBP1 at Thr37/46 by sampling day, and no effect of treatment (P > 
0.10). 
4.3.3.  Muscle inflammatory cytokines 
IL-1β mRNA expression was significantly affected by sampling day (P = 0.01) 
and there was a trend (P = 0.05) for an effect of the treatment*day of sampling interaction 
(Table 4.2).  IL-1β mRNA expression did not change (P > 0.10) in the +NSAID group 
with day, but dramatically increased (P = 0.001) in the –NSAID group on day 5.  IFN−γ 
mRNA expression was significantly affected (P = 0.003; Table 4.2) by day, with no 
change (P > 0.10) in the +NSAID group, and a decrease (P = 0.006) with day in the –
NSAID group.  However, there was no effect of the treatment*day of sampling 
interaction (P > 0.10) on the expression of IFN−γ mRNA, indicating the main effect of 
sampling day was primarily due to changes in the –NSAID group.  There was a trend for 
an effect of day on IL-10 mRNA with a transient increase in the +NSAID group; 
however, there was no effect of treatment, or the interaction of treatment*day of 
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sampling (P > 0.10).  There was no effect (P > 0.05) of day, treatment, or treatment*day 
of sampling interaction for IL-6 (Table 4.2) and TNF−α (Table 4.2). 
4.4.  DISCUSSION 
To the best of our knowledge, this is the first study to examine the effects of 
multiple gluteal muscle biopsies over 5 consecutive days on local inflammation and on 
the activation of mTOR signaling in response to a high protein meal.  The primary 
finding of this research was that repeated biopsies over 5 consecutive days may be 
obtained without eliciting changes in downstream mTOR signaling response to feeding 
due to increases in inflammation when NSAID are administered.  However, when 
NSAID are not administered, 5 days of consecutive biopsies altered muscle IL−1β and 
IFN−γ and elevated the activation of the downstream mTOR signaling proteins in 
response to feeding.  Thus, the administration of NSAID appeared to reduce the local 
inflammation induced by the collection of repeated biopsies and prevented changes in the 
downstream mTOR signaling response to feeding. 
Reports are varied on the effects of repeated biopsies on local inflammation due 
to the frequency and number of biopsies collected, the method of biopsy collection, and 
the site of biopsy.  In the current study, IFN−γ  and IL−1β skeletal muscle mRNA 
expression decreased and increased, respectively, from the initial to the fifth biopsy in the 
–NSAID group.  However, a previous study in horses found no change in the mRNA 
expression of IFN−γ or IL−1β with repeated biopsies over a 24 hour period (244), 
consistent with our results.  In human, there was an initial elevation in the protein 
expression of IL−1β 30 minute following the first biopsy, but this increase did not persist 
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over the next 7 days (245).  The biopsy sites in the present study were more closely 
spaced (1 cm) than the previous study (2 cm) (245); therefore, our finding of elevated 
IL−1β by day 5 may have been due to the closer spatial arrangement to the previous 
biopsy sites.  Although IFNγ mRNA expression was elevated on days 1 and 2, it then 
decreased on day 3, remaining constant until day 5 in the –NSAID group.  IFN−γ 
functions as a key regulator of other pro-inflammatory parameters, causing an up 
regulation of TNF−α (511) and NF−κB (512), and inhibiting IL−1β (513).  Therefore, the 
increase in IL−1β seen on day 5 in the -NSAID group may be regulated by the decrease 
in IFN−γ expression observed in the current study.  The mechanisms surrounding the 
decrease in IFN−γ expression in the –NSAID group requires further elucidation.  
In the current study, TNF−α mRNA expression was not altered with the 
collection of biopsies over 5 consecutive days in the –NSAID group, which is in 
agreement with previous work in horses over a 24 hour period (244) and humans over a 7 
day period (245).  IL-6 mRNA expression has been shown to increase during 7 days of 
repeated biopsies (245) and with acute repeated biopsies through separate incision sites 
(248) in humans, but this was not seen in the present study or in previous studies in 
horses (244).  IL-6 production may be more responsive in human skeletal muscle than 
equine skeletal muscle; however, this requires further investigation.  In the present study, 
the absence of an effect of repeated biopsies on the mRNA expression of IL-6 and 
TNF−α may have been due to the decline in IFN−γ mRNA expression by day 5 because 
IFN−γ plays a crucial role in the stimulation of the production of IL-6 and TNF−α from 
monocytes and macrophages (511, 513). 
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Although other studies have looked at the effectiveness of NSAID at reducing the 
inflammatory response caused by exercise, this is the first study to determine the effects 
of NSAID administration on inflammatory cytokines using repeated biopsies to elicit 
inflammation.  Oral administration of a herbal supplement with NSAID properties in 
rodents reduced muscle IL−1β, IL-6, and TNF−α mRNA expression following exercise 
(332), although in humans only TNF−α mRNA expression is reduced following post-
exercise NSAID infusion (333).  Intravenous NSAID infusion in horses appeared to 
reduce the systemic inflammatory response of lipopolysaccharide (LPS) infusion; 
however, TNF−α was the only inflammatory cytokine examined (514).  Although the 
methods of NSAID administration, cause of inflammatory response, site of inflammation, 
and inflammatory cytokine examined were different between the three studies, the current 
study also showed that NSAID administration ameliorates the effects of repeated biopsies 
over 5 consecutive days on inflammatory cytokines in the gluteal muscle of mature 
horses through the absence of a change in mRNA expression of the interleukins (-6, -1β, 
and -10), TNF−α, and IFN−γ in the skeletal muscle of the +NSAID group during 5 days 
of biopsies. 
 All animals studied were mature, sedentary and consuming the same meal for 5 
consecutive days; therefore, we did not expect a change in the activation of downstream 
effectors or protein synthesis, as long as the repeated biopsies and/or NSAID 
administration were not influencing muscle metabolism.  There were no differences in 
the downstream mTOR signaling factors in the +NSAID group showing that any changes 
in muscle inflammation or metabolism caused by the repeated biopsies were mitigated by 
the NSAID.  However, in the absence of NSAID administration, the daily collection of 
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muscle biopsies for 5 days increased the activation of the downstream mTOR signaling 
proteins, S6K1, rpS6, and 4EBP1, by 22, 73, and 117%, respectively.  The increase in 
mTOR signaling is suggestive of an increase in rates of muscle protein synthesis in the –
NSAID group (500, 502, 505), although isotopic confirmation is necessary. 
  Following a bout of exercise there is an increase in muscle inflammatory cytokine 
gene expression (244, 255, 509) and the activation of mTOR signaling proteins (515) for 
up to 72 hours.  It is thought that the increase in inflammatory cytokines following 
exercise is necessary for muscle repair post-exercise (334) because inflammatory 
cytokines are regulators of satellite cell proliferation (312, 313).  A similar phenomenon 
may have occurred during the current study, where there was an increase in the activation 
of 4EBP1, S6K1, and rpS6 and the pro-inflammatory cytokine, IL−1β, in the –NSAID 
group after 5 days of biopsy collection.  Additionally, when a NSAID was administered 
locally following eccentric exercise there was a reduction in satellite cell proliferation 
(316), but protein synthesis was unaltered (333).  However, when NSAID are 
administered orally there is a reduction in post-exercise protein synthesis (516).  
Therefore, the increase in IL−1β mRNA expression in the –NSAID group in the current 
study which coincided with an increase in all of the downstream mTOR signaling factors 
may be necessary for muscle to repair; however, further research is needed to confirm 
this.  Overall the findings from the –NSAID group may indicate that future experiments 
using repeated biopsies over the course of several days to examine the activation of 
mTOR signaling proteins in response to anabolic stimuli may require a control group or 
NSAID treatment to account for changes in mTOR signaling not related to the 
experimental treatments. 
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Regardless of treatment, the activation of Akt over the course of 5 days of 
repeated biopsies was reduced.  Akt is activated through insulin signaling (18, 19), and 
circulating insulin levels were variable in the present study regardless of treatment group, 
which may indicate that the phenylbutazone dose (1g every 12 hours) was not sufficient 
to elicit treatment differences.  Hepatic activation of NF−κB, an inhibitor of Akt 
phosphorylation (517), has been associated with systemic insulin resistance in mice 
(518).  Although we did not examine NF−κB in the present study, Akt activation may 
have been inhibited through NF−κB due to insufficient inhibition by phenylbutazone 
(519), or through NF−κB altered insulin sensitivity.  Additionally, the reduction in Akt 
activation could indicate a reduction in insulin sensitivity associated with the repeated 
biopsies that could not be mediated by the administration of an NSAID. 
Although there was a reduction in the activation of Akt with repeated biopsies, 
there was an increase in the activation of all of the downstream mTOR signaling factors 
in the –NSAID group.  This may indicate that although Akt was inhibited and perhaps 
insulin signaling, other factors such as amino acids were sufficiently stimulating the 
activation of mTOR and subsequently S6K1, rpS6 and 4EBP1, which is consistent with 
the results of a previous study (2) performed by our lab. 
The reduced activation of NF−κB by phenylbutazone (519) may allow for an 
increase in the activation of downstream effectors.  Administration of ibuprofen during 
low grade chronic inflammation in aging rodents ameliorated the reduction in muscle 
protein synthesis normally associated with the aging population (335), however, there 
was no affect on mTOR signaling factors.  During an acute inflammatory response 
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following exercise, the administration of local (333) and oral (516) NSAID following 
exercise did not alter and reduced protein synthesis, respectively.  In the present study, 
there was no difference in the activation of the downstream signaling factors between day 
1 and day 5 in the +NSAID group and an elevation in the –NSAID group indicating that 
NSAID ameliorated the effect of repeated biopsies.  This is consistent with the response 
following exercise.  Overall, our results indicate that the administration of a NSAID 
during an acute inflammatory response due to the collection of multiple biopsies 
maintained protein synthesis at levels equal to rates prior to the collection of the initial 
biopsy. 
Conducting muscle biopsy procedures every 24 hours for up to 5 days increases 
muscle inflammatory cytokine gene expression, specifically IL−1β, and increases the 
activation of S6K1, rpS6, and 4EBP1 in response to a meal when NSAID are not 
administered.  However, if repeated biopsies are collected over 5 days with oral 
administration of a NSAID, then the increase in inflammatory cytokines is ameliorated 
and the activation of the downstream effectors of the mTOR signaling factors are not 
different over the 5 day period.  Additionally, repeated biopsy collection every 24 hours 
over the course of 5 days resulted in a reduction in the activation of Akt regardless of 
NSAID. Therefore, a control group may be a useful tool when studying animals using 
repeated percutaneous needle muscle biopsies. 
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Table 4.1 continued: Plasma metabolite concentrations 60 minutes after consuming 
a high protein pelleted meal during 5 days of consecutive NSAID administration in 
mature Thoroughbred horses. 
 
*Within a day, values are significantly (P < 0.05) different from the –NSAID group. 
1Glucose values are reported as least square means in mmol/L. 
2Insulin values are reported as least square means in μIU/mL 
3Amino acids values are reported as least square means in μmol/L 
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4.6.  FIGURES 
 
Figure 4.1.  Gluteal muscle phosphorylation of Akt at Ser473 in mature 
Thoroughbred horses either receiving NSAID administration (1g/12 hours; 
+NSAID) or not receiving NSAID administration (-NSAID) for 5 days 60 minutes 
following consumption of a 3g/kg of a high protein pelleted meal.  Muscle biopsies 
were taken at 60 min after t = 0 min.  Akt phosphorylation at Ser473 was corrected by total 
Akt abundance, with the value for the left side at day 1set at 1.0 AU.  Values are pooled 
least square means ± pooled SE of both gluteal muscle sides because side was not 
significant (P > 0.05), n=6 per treatment group.  Representative images of the 
immunoblots are shown above. 
abcdDifferent letters indicate a significant day effect (P < 0.05) within a treatment group. 
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Figure 4.2.  Gluteal muscle phosphorylation of S6K1 at Thr389 Ser473 in mature 
Thoroughbred horses either receiving NSAID administration (1g/12 hours; 
+NSAID) or not receiving NSAID administration (-NSAID) for 5 days 60 minutes 
following consumption of a 3g/kg of a high protein pelleted meal.  Muscle biopsies 
were taken at 60 min after t = 0 min.  S6K1 phosphorylation at Thr389 was corrected by 
total S6K1 abundance, with the value for the left side at day 1set at 1.0 AU.  Values are 
pooled least square means ± pooled SE of both gluteal muscle sides because side was not 
significant (P > 0.05), n=6 per treatment group.  Representative images of the 
immunoblots are shown above. 
*Indicates that, within a day, the value is significantly different (P < 0.05) from the –
NSAID group value. 
abDifferent letters indicate a significant day effect (P < 0.05) within a treatment group. 
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Figure 4.3.  Gluteal muscle phosphorylation of rpS6 at Ser235/236 & 240/244 in mature 
Thoroughbred horses either receiving NSAID administration (1g/12 hours; 
+NSAID) or not receiving NSAID administration (-NSAID) for 5 days 60 minutes 
following consumption of a 3g/kg of a high protein pelleted meal.  Muscle biopsies 
were taken at 60 min after t = 0 min.  rpS6 phosphorylation at Ser235/236 & 240/244 was 
corrected by total rpS6 abundance, with the value for the left side at day 1set at 1.0 AU.  
Values are pooled least square means ± pooled SE of both gluteal muscle sides because 
side was not significant (P > 0.05), n=6 per treatment group.  Representative images of 
the immunoblots are shown above. 
*Indicates that, within a day, the value is significantly different (P < 0.05) from the –
NSAID group value. 
abc Different letters indicate a significant day effect (P < 0.05) within a treatment group. 
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Figure 4.4.  Gluteal muscle phosphorylation of 4EBP1 at Thr36/47 in mature 
Thoroughbred horses either receiving NSAID administration (1g/12 hours; 
+NSAID) or not receiving NSAID administration (-NSAID) for 5 days 60 minutes 
following consumption of a 3g/kg of a high protein pelleted meal.  Muscle biopsies 
were taken at 60 min after t = 0 min.  4EBP1 phosphorylation at Thr36/47 was corrected by 
total rpS6 abundance, with the value for the left side at day 1set at 1.0 AU.  Values are 
pooled least square means ± pooled SE of both gluteal muscle sides because side was not 
significant (P > 0.05), n=6 per treatment group.  Representative images of the 
immunoblots are shown above. 
*Indicates that, within a day, the value is significantly different (P < 0.05) from the –
NSAID group value. 
abc Different letters indicate a significant day effect (P < 0.05) within a treatment group. 
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Chapter V1 
Developmental regulation of the activation of translation initiation factors in response 
to feeding in the skeletal muscle of horses 
1 A version of this chapter has been accepted for publication in the American Journal of 
Veterinary Research at the time of the defense (November 21, 2011). 
5.1.  INTRODUCTION 
The neonatal period is characterized by the highest growth rate during the lifespan 
with skeletal muscle showing the largest increase in mass (125).  Elevated growth rate in 
the neonate is a result of protein synthesis rates being higher than protein degradation 
rates. However, with post-natal maturation, protein synthesis rates gradually decrease 
(125-127) until both synthesis and degradation are equal in non-growing adult muscle.  
To date, the life stage following the neonatal period, but before maturity, which is often 
characterized by slow growth and is often referred to as the adolescent phase in human 
development, has not been investigated with regards to protein synthesis. 
Protein synthesis is limited by both the abundance and efficiency of ribosomes to 
translate mRNA into protein and the availability of amino acids to form a protein (128).  
The skeletal muscle of neonates has been reported to have a higher concentration of 
ribosomes which decreases with age (127, 147); this may also contribute to the elevated 
protein synthetic rates. The efficiency of ribosomes to translate mRNA into a protein is 
modulated by a series of intracellular signaling cascades that are associated with the 
mammalian target of rapamycin (mTOR) pathway.  The mTOR pathway regulates 
translation initiation and has been the subject of numerous recent reviews (21, 146, 488, 
496).  Briefly, insulin and insulin like growth factor 1 bind to their respective receptors 
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activating protein kinase B (PKB or Akt) through the activation of several intermediate 
signaling proteins (16, 18, 19, 21).  Akt activation occurs when both the Thr308 and Ser473 
sites are phosphorylated, and both sites are activated in association with insulin receptor 
signaling (18, 19, 21).  Activation of Akt inactivates the mTOR inhibitor tuberous 
sclerosis complex 2 through phosphorylation (19, 21); thus, allowing activation of mTOR 
through phosphorylation.  Amino acids, specifically Leu, have also been demonstrated to 
phosphorylate mTOR through the activation of several signaling proteins (45, 46, 497).  
mTOR is recognized in skeletal muscle as the key regulator of translation initiation and 
subsequent protein synthesis through the phosphorylation of two downstream signaling 
proteins: ribosomal S6 Kinase 1 (S6K1) and eukaryotic initiation factor 4E-binding 
protein-1 (4EBP1). Phosphorylation of S6K1 results in the activation of ribosomal 
protein S6 (rpS6), a component of the 40S ribosomal subunit (498).  Phosphorylation of 
rpS6 and 4EBP1 result in the activation of the translational equipment; thus, allowing the 
synthesis of a protein (146, 496). 
Examination of protein synthesis in response to anabolic stimuli during the 
neonatal period has been demonstrated using both translation initiation factor activation 
and isotope infusion techniques to measure protein synthesis (125, 126, 520).  Anabolic 
stimuli such as feeding a meal (521), amino acid administration (520, 522), or insulin 
infusion (522) increases the activation of translation initiation factors in the mTOR 
signaling pathway and fractional muscle protein synthesis rates (133, 140).  As with 
protein synthesis, the responsiveness of the activation of translation initiation factors to 
anabolic stimuli is blunted with post-natal age (133, 140), and is lowered in the adult 
(149); however, the adolescent period of slowed growth has yet to be examined.  
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Furthermore, the activation of translation initiation factors and subsequent protein 
synthesis in response to an anabolic stimuli has been demonstrated to decline from the 
mature to aged individual in rodents (133, 140) and humans (149, 155).  The activation of 
translation initiation factors has been examined in equine skeletal muscle tissue in only a 
single study (2), where the response to meal feeding increased the activation of 
translation initiation factors in the mature horse, but age-related effects have not been 
studied. 
The objective of this study was to determine the effects of feeding following an 
18 hour period of feed withholding on the activation of translation initiation factors, 
specifically Akt, S6K1, rpS6, and 4EBP1 in yearling, two year old and mature horses.  
We chose an adolescent age group, consisting of yearlings and two year olds, because to 
the best of our knowledge, there has not yet been a single study in any species to examine 
the activation of translation initiation factors in response to an anabolic stimulus in 
adolescents.  The translation initiation factors studied were chosen as a representation of 
both up- and down-stream factors in the mTOR signaling pathway. 
5.2.  MATERIALS AND METHODS 
5.2.1.  Animals and housing. 
 The University of Kentucky Institutional Animal Care and Use Committee 
approved all procedures used in this study (2009-0442).  Fifteen Thoroughbred mares, 
two Thoroughbred/Quarter Horse cross mares, and one Quarter Horse mare were 
obtained from the University of Kentucky Animal and Food Sciences’ Maine Chance 
Farm.  Of these 18 mares, 6 were yearlings (15.8±0.8 mo old; 395±12 kg BW), 6 were 2 
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years olds (27.4±1.0 mo old; 484±28 kg BW), 6 were mature (13.8±2.9 years old; 
549±59 kg BW) mares.  All horses were of moderate body condition for their age group 
(body condition score: yearlings: 4-5, two year olds and mature horses: 5-7; scale 1-9 
(489)), and clinically healthy.  The group of mature mares were selected from a candidate 
pool of mares which were no longer growing, but had not yet been defined as 
chronologically old (ie. greater than 20 years) (523).  For the duration of the study, horses 
were housed in 3.7×3.7 m stalls bedded with pine shavings overnight, with daily turn out 
into drylots, and  ad libitum access to water and salt at all times.  Horses were adapted to 
diet and housing procedures for 2 weeks prior to any experimental or sampling 
procedures.  During the 18 hour period of feed withholding, and during the sampling 
procedures, horses remained in the stalls bedded with pine shavings. 
5.2.2.  Feeding procedures. 
 All animals were individually fed in stalls two meals daily (at 0800 and 1500).  
Diets were designed to meet the National Research Council (336) requirements for 
mature horses with average maintenance needs and a BW of 600 kg, two year old horses 
with a targeted average daily gain (ADG) of 0.22 kg/d, and yearling horses with a 
targeted ADG of 0.54 kg/d.  The meals consisted of alfalfa cubes, a ration balancer, and a 
protein/mineral supplement.  The alfalfa cubes [mean ±SD; 0.49 ±0.01Mcal/kg digestible 
energy (DE), 16.95 ±0.24% crude protein (CP), 35.2 ±0.82% acid detergent fiber (ADF), 
44.88 ±1.31% neutral detergent fiber (NDF), 2.28 ±0.05% crude fat, and 9.5 ±0.22% ash] 
were fed at a rate of 1.75% of body weight per day to all age groups.  The ration balancer 
pellet (mean ±SD; 0.48 ±0.01Mcal/kg DE, 14.93 ±0.15% CP, 22.53 ±0.81% ADF, 43.2 
±0.36% NDF, 3.57 ±0.06% crude fat, and 12.9 ±0.1% ash) was fed at a rate of 0.15, 0.25, 
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and 0.40% of body weight per day to mature, 2 years old, and yearlings, respectively.  
The protein/mineral supplement (mean ±SD; 0.57 ±0.01Mcal/kg DE, 36.3 ±0.72% CP, 
6.77 ±0.25% ADF, 13.8 ±0.8% NDF, 3.87 ±0.06% crude fat, and 17.2 ±0.3% ash) was 
fed at a rate of 0, 0.15, and 0.20% of body weight per day to mature, 2 year olds, and 
yearlings, respectively.  Samples of the alfalfa cubes, ration balancer pellet, and 
protein/mineral supplement were collected throughout the experimental period and sent 
to Dairy One Forage Laboratory (Ithaca, NY) for nutrient analysis. 
5.2.3.  Experimental design and procedures. 
 This study was conducted as a 3×2-factorial crossover design with age and 
feeding state (post-absorptive versus postprandial) as the fixed effects, with each horse 
being studied in both feeding states.  To facilitate sampling procedures, the eighteen 
horses were divided into three blocks, with 2 horses from each age group in each block.  
Each horse was studied under both feeding states in a randomly determined order, such 
that within each block there were an equal number of horses (n = 3) receiving each 
treatment during each period.  There was a minimum of 1week between the sampling 
periods for each horse. 
The experimental procedures used in this study were similar to those previously 
reported (2).  Briefly, on the day prior to sampling procedures, horses were weighed and 
a jugular vein catheter (14 gauge X 14.0 cm, Abbocath; Abbott Laboratories, North 
Chicago, IL) was placed.  The gluteus medius muscle was ultrasounded to determine 
subcutaneous fat and gluteal muscle depth (524).  This allowed for the accurate 
determination of 50% of gluteal muscle depth, in order to standardize biopsy collection 
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depth between the different ages of horses; which was determined to be 6.0±0.4, 7.4±0.3, 
and 8.1±0.3 cm for yearlings, two year olds, and mature horses, respectively (Appendix 
6).  Horses were then placed into individual stalls and provided a high crude protein 
pelleted feed meal (Table 5.1), at 2 g/kg BW on an as-fed basis.  The purpose of this meal 
was to standardize the duration of feed withholding prior to the sampling procedures for 
all horses.  Horses were kept in stalls overnight (18 hour), with ad libitum access to 
water, but feed and hay were withheld. 
 At t = 0 minute, 18 hours following the previous meal, horses either remained in 
the post-absorptive state for an additional 90 minutes (post-absorptive treatment) or 
received a 2 g/kg BW meal of the aforementioned pelleted feed at t = 0 minute and again 
at t = 30 minutes, for a total targeted intake of 4 g/kg BW of pelleted feed during the 
postprandial period (postprandial treatment).  This feeding regimen has been previously 
shown to result in differences in plasma glucose, insulin and amino acid concentration 
and in the activation of mTOR-related signaling factors in the gluteal muscle in mature 
horses (2).  Feed intake was monitored and any feed refusals were removed at the end of 
the postprandial period and weighed. 
Two baseline blood samples (10 mL), separated by a minimum of 15 minutes, 
were collected prior to t = 0 minute.  Subsequent blood samples were taken every 10 
minutes until t = 80 minutes.  All samples were collected into evacuated tubes containing 
sodium heparin (Vacutainer; Becton-Dickinson, Franklin Lakes, NJ) and were 
immediately centrifuged at 3,000 x g for 10 minutes at 4ºC.  Aliquots of the plasma 
samples were frozen at -20ºC until the time of analysis. 
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 At t = 80 minutes, horses were placed in equine stocks (HS Equine Stocks; 
Priefert® Rodeo & Ranch Equipment, Mount Pleasant, TX), and lightly sedated with 
xylazine hydrochloride (0.3 mg/kg, intravenous [100 mg/mL]).  The area over the middle 
gluteal muscle (~100 cm2) was shaved, aseptically prepared, and desensitized with a local 
anesthetic (12 mL of 2% lidocaine).  At t = 90 minutes, approximately 500 mg of muscle 
biopsy specimen was obtained at a standardized site and depth (50% of gluteal muscle 
depth) in the middle gluteal muscle by use of the percutaneous needle biopsy technique 
(411).  Approximately 400 mg of the sample was flash frozen in liquid nitrogen, and 
stored at -80ºC until analysis.  The remaining 100 mg was processed in preparation for 
Western blot analysis, as described below.  Phenylbutazone was administered after the 
biopsy (1g every 12 hours for 48 hours post-biopsy) to alleviate any potential discomfort 
associated with the procedure. 
During the second treatment period, horses underwent the same experimental 
procedures as during the first period, but received the alternate treatment.  In the second 
treatment period, the jugular vein catheter was inserted into the vein not used for the 
previous period and the muscle biopsy specimen was taken from the contralateral side.  
Following the second muscle biopsy, horses returned to drylots during the day and were 
stalled overnight and were then returned to the Department of Animal and Food 
Sciences’ Maine Chance Farm Research herd. 
5.2.4.  Sample analysis procedures. 
5.2.4.1.  Plasma Glucose and Insulin: Plasma glucose concentrations were assayed 
enzymatically using a glucose analyzer (YSI 2300 STAT Plus™ Glucose and Lactate 
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Analyzer, YSI Inc., Life Sciences, Yellow Springs, OH).  Plasma insulin concentrations 
were determined using a commercially available kit (Coat-A-Coat RIA®kitSiemens, 
Healthcare Diagnostics Inc., Deerfield, IL). 
5.2.4.2.  Amino Acids:  The plasma free amino acid concentrations and feed amino acid 
content were measured using reverse-phase HPLC (3.9 x 300 mm PICO-TAG reverse 
phase column; Waters, Milford, MA) of phenylisothiocyanate derivatives as previously 
described (2). 
5.2.4.3.  Western blot analysis of muscle samples:  Electrophoresis of the gluteal muscle 
homogenates was followed by Western blotting techniques to determine the abundance of 
the total and phosphorylated forms of Akt, S6K1, rpS6, and 4E-BP1 (Chapter III). 
5.2.5.  Statistical analysis. 
 All data were analyzed using the mixed procedure of SAS Version 9.1 (SAS 
Institute Inc., Cary NC), and data were considered statistically significant if P < 0.05, and 
considered a statistical trend if 0.05 < P < 0.10.  When the fixed effects were significant, 
pre-planned comparisons of least squares means were made using the pdiff test. 
The dependent variables plasma glucose, insulin, and amino acid concentrations 
were analyzed using a repeated measures analysis, with age, treatment, time, 
age*treatment, time*treatment, age*time, age*time*treatment interaction as the fixed 
effects and horse nested in treatment and block as the random effects.  The two baseline 
sample values were averaged for each of the dependent variables, and the resulting 
baseline concentration was included in the model as a covariate if its effect was 
determined to be significant (P < 0.05).  Baseline was significant (P < 0.05) for plasma 
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glucose, insulin, and each amino acid and was therefore included in each of the respective 
models.  Each of the translation initiation factors were analyzed using a repeated 
measures analysis, with treatment, age, treatment*age interaction, treatment period, and 
block as the fixed effects and horse nested with in age*block as the subject.  For all 
repeated measures analysis, the variance-covariance matrix was chosen for each analysis 
based on the lowest value for Schwarz’s Bayesian Criterion. Data are presented as means 
± pooled standard error unless otherwise noted. 
5.3.  RESULTS 
All horses remained healthy and maintained normal growth rates according to the 
recommendations of the NRC (336) throughout the course of the experimental period.  
The yearlings and two year olds maintained an ADG of 0.94±0.67 and 0.18±0.38 kg/d, 
respectively.  The mature mares did not gain weight over the course of the experimental 
period with an ADG of 0.00±0.25 kg/d. 
5.3.1.  Plasma Glucose 
There was a significant effect of treatment (P = 0.0002), time (P < 0.0001), and 
treatment*time interaction (P < 0.0001) on plasma glucose concentration (Figure 5.1); 
where, the yearlings had higher (P < 0.05) plasma glucose concentrations at 30 minutes 
following the meal stimulus than the two year old and mature horses.  Regardless of age, 
the horses in the postprandial state had higher glucose concentrations at 60 and 80 
minutes than those in the post-absorptive state.  During the postprandial phase, plasma 
glucose concentration increased from baseline with time in all age groups.  There was 
also a trend for decreased glucose concentrations with age (P = 0.08).  However, there 
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was no effect of treatment*age interaction (P = 0.53), age*time interaction (P = 0.26), or 
treatment*age*time interaction (P = 0.36) on plasma glucose concentration. 
5.3.2.  Plasma Insulin 
Plasma insulin was significantly affected by treatment (P < 0.0001), time (P < 
0.0001), treatment*time (P < 0.0001), treatment*age (P = 0.003), and 
treatment*age*time interaction (P = 0.032; Figure 5.2).  Circulating insulin was higher in 
the postprandial phase (P < 0.05) compared to the post-absorptive phase beginning at 30 
minutes in the mature horses.  However, the yearlings and the two year olds did not show 
differences between the postprandial and post-absorptive phase until 80 minutes when 
insulin was greater in the postprandial phase.  During the postprandial phase, insulin 
concentrations increased with time across all age groups.  At both 0 and 30 minutes 
following a meal stimulus there was no difference (P > 0.05) between the age groups for 
circulating insulin in the postprandial group.  However, at both 60 and 80 minutes post 
consumption of a high protein pelleted meal the mature horses had significantly greater 
(P < 0.05) circulating insulin than either the yearlings or two year olds.  There was no 
effect of age (P = 0.53), but there was an age*time interaction (P = 0.07) on plasma 
insulin concentration. 
5.3.3.  Plasma Amino Acids 
There was a significant effect of treatment, time, and treatment*time interaction 
(P < 0.05; Table 5.2) on all plasma amino acids examined, except glycine, where its 
concentration was only affected by time (P < 0.05).  For the essential amino acids, plasma 
concentrations were increased at t = 80 minutes by an average of 48% in the postprandial 
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phase, while the plasma amino acid concentrations in the post-absorptive phase remained 
unchanged (P < 0.05) compared to the baseline values.  With the exception of glutamate 
and aspartate, there was no effect of age on any plasma amino acid concentrations (P > 
0.05; Table 5.2).  There was no interaction of treatment*time*age (P > 0.05) for any of 
the plasma amino acids examined. 
5.3.4.  Muscle Translation Initiation Factors 
The phosphorylation of Akt at Ser473 was significantly greater in the postprandial 
period (P < 0.0001; Figure 5.3) in all ages of horses; however, there was no effect of age 
(P = 0.24) or the treatment*age interaction (P = 0.51).  The abundance of Akt 
phosphorylation at Thr308 trended to increase in the postprandial period compared to the 
post-absorptive period.  However, there was no effect of age (P = 0.90) or treatment*age 
interaction (P = 0.48) on Akt phosphorylation at Thr308.  There was a significantly greater 
phosphorylation of S6K1 at Thr389 from the post-absorptive to postprandial period (P = 
0.0001; Figure 5).  There was also a significantly higher phosphorylation of S6K1 at 
Thr389 with age (P = 0.0079), and a significant treatment*age interaction (P = 0.0027).  
Postprandial phosphorylation of S6K1 at Thr389 was greater (P < 0.05) in the mature 
horses than the yearlings or two year olds, and the yearlings had a higher (P = 0.008) 
abundance than the two year olds.  The phosphorylation of rpS6 at Ser235/236 was 
significantly greater in the postprandial period compared to the post-absorptive period (P 
< 0.0001; Figure 6), and a significant treatment*age interaction (P= 0.03) was present; 
where, the yearlings (P = 0.009; 3.3±0.3 arbitrary units) and mature horses (P = 0.002; 
3.6±0.3 arbitrary units) were greater in the postprandial phase compared to the two year 
olds (2.0±0.3 arbitrary units).  There was no difference in the postprandial phase between 
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the yearlings and mature horses (P = 0.42).  However, there was a trend for the main 
effect of age (P = 0.07).  There was a significantly higher phosphorylation of rpS6 at 
Ser240/244 rpS6 in the postprandial period (P < 0.0001; Figure 7); however, there was no 
effect of age (P = 0.35) or treatment*age interaction (P = 0.27).  The phosphorylation of 
4EBP1 at Thr37/46 was significantly greater in the postprandial period (P = 0.003; Figure 
8), and a significant treatment*age interaction (P = 0.04) was present.  The yearlings had 
an increase (P = 0.0007) in the postprandial phase compared to the post-absorptive, with 
no effects of feeding seen in the other ages of horses.  There was no effect of age (P = 
0.68) on the phosphorylation of 4EBP1 at Thr36/47. 
5.4.  DISCUSSION 
To the best of our knowledge, this is the first study to examine S6K1 in the 
skeletal muscle of horses of any age, and the first study to examine the activation of 
translation initiation factors in response to anabolic stimuli in the skeletal muscle of 
adolescent animals of any species.  There was a marked increase in the phosphorylation 
of both up and downstream mTOR signaling factors during the postprandial state 
compared to the post-absorptive state in the gluteal muscle of yearling, two year old and 
mature horses, with the higher degree of sensitivity to anabolic stimuli exhibited by the 
yearlings. 
Following mTOR activation, S6K1 and subsequently rpS6 are phosphorylated 
(21).  Previous work in our lab (2) has shown that the protein abundance of the 
phosphorylated form of rpS6 was higher in the postprandial state in mature horses.  This 
is in agreement with the current study, where protein abundance of the phosphorylated 
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forms of S6K1 and rpS6 were elevated in the postprandial state.  There is an absence of 
comparable literature on the adolescent, therefore, we examined previous work in the 
swine neonate (521, 525) to determine if similar developmental trends continued during 
adolescence.  In the present study, we have demonstrated that there is a decrease in the 
activation of translation initiation factors to a meal stimulus with adolescent development 
which is a trend that appears to continue from neonatal development (521, 525).  There 
was a 158, -7, and 109% percent change in the phosphorylation of S6K1 from the post-
absorptive to postprandial states in yearlings, two year olds and mature horses, 
respectively.  Not only was there a difference in the abundance of S6K1 P-Thr389 in the 
postprandial state between the age groups, but there were also differences in the post-
absorptive state where the yearling had a lower expression than either the mature or two 
year olds, allowing for a more pronounced postprandial response in the younger horses.  
Research in developmental changes of skeletal muscle protein abundance of S6K1-Thr389 
during the post-absorptive state in the neonatal pig vary with reports of no difference 
(521, 525) and increases (526) from 7 to 26d of age, respectively.  Although we 
examined adolescent horses, we demonstrated a similar phenomenon as previously 
described in the swine neonate (526), indicating the horse is not unique in the activation 
of translation initiation in skeletal muscle during development.  Additionally, there were 
increases in the protein abundance of rpS6 phosphorylation at Ser235/236 and Ser240/244.  
rpS6 P-Ser235/236 increased 147, 73, and 228% in yearlings, two year olds, and mature 
horses, respectively, from the post-absorptive to postprandial periods.  Increases of 144, 
76, and 167% in the protein abundance of rpS6 P-Ser240/244 from the post-absorptive to 
postprandial state were exhibited in yearlings, two year olds and mature horses, 
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respectively.  Thus, the S6K1 portion of the signaling pathway following mTOR 
phosphorylation was activated in all age groups in the postprandial period indicating a 
potential increase in translation initiation.  Our results of the downstream effectors 
indicate that there is a decrease in the response to a meal-feeding stimuli in the adolescent 
horse from year one to year two of life, which may be continuation of the development 
decline demonstrated in the neonate (521, 522, 525).  However, further research is 
warranted to elucidate this in the equine neonate. 
The other side of the downstream pathway following mTOR activation is the 
phosphorylation of 4EBP1 at Thr37/46.  Our laboratory has previously shown (2) that 
protein abundance of the phosphorylated form of 4EBP1 was higher in the postprandial 
state in mature horses; however, in the current study, the yearlings were the only age 
group that responded to the anabolic stimuli with a higher protein abundance of the 
phosphorylated form of 4EBP1 in the postprandial state.  This discrepancy may be at 
least partially attributable to the differences in the antibodies used during the Western 
blotting procedure.  In the previous study (2), the 4EBP1 antibody was specific for all 
forms of 4EBP1 (α, β and γ) and then expressed as the percentage of γ; however, in this 
study two antibodies were used: one specific for phosphorylated Thr37/46 4EBP1 and the 
other recognized total 4EBP1.  Activation of 4EBP1 during the postprandial state was 50, 
4, and 15% greater in yearlings, two year olds, and mature horses, respectively, than the 
post-absorptive state; with only a significant activation over post-absorptive abundance in 
the yearlings.  This may indicate that the yearlings were more sensitive to the anabolic 
stimuli of a meal than the two year olds or mature horses, which is in agreement with the 
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previous work in the swine neonate (521, 525) demonstrating a decrease in the activation 
of translation initiation factors to a meal stimulus with development. 
Based on previous research we hypothesized that the anabolic stimuli of 
consuming a meal would cause a greater activation of translation initiation factors in the 
yearlings than the two year olds, who we expected to be more responsive than the mature 
horses; however, this was not observed.  In the adolescent age groups examined in the 
current study the downstream effectors were more responsive to a meal stimulus in the 
yearling group of horses in comparison to the two year olds.  This is comparable to the 
results of previous studies performed in the swine neonate which show a decrease in the 
responsiveness of downstream effectors in the 26 compared to the 7 days old pig to a 
meal stimulus (521, 525, 526), amino acid supplementation (520, 522) or insulin infusion 
(522).  However, postprandial protein abundance of the phosphorylated forms of rpS6 
and 4EBP1 were not different between the yearlings and the mature horses, with the 
lowest abundance seen in the two year old horses.  This may be partially attributed to the 
feeding protocol utilized.  In the current study we fed all age groups a total of 4 g/kg of 
feed in the postprandial treatment in an effort to standardize the protein intake between 
the age groups.  This standardization was intended to meet the protein requirements of a 
mature sedentary horse with an average body weight of 600 kg; as a result, this meal did 
not meet the requirements of the adolescent horses.  This meal only supplied 54 and 80% 
of the daily requirements of the yearlings and two year olds, respectively.  The increased 
responsiveness seen in the yearlings, who were consuming only 54% of their daily 
protein intake, indicates that if this study were repeated standardizing the meal by 
meeting 100% of daily protein requirements, would likely be sufficient anabolic stimuli 
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to elucidate a potential step wise decrease in the activation of translation initiation factors 
with age.  
Although we saw increases in the downstream effectors following a meal stimulus 
across the age groups, future research is needed to examine if this indeed lead to 
increased protein synthesis using isotopic techniques.  It is also necessary to determine if 
there are age related differences in the adolescent equine in whole body and muscle 
fractional protein synthetic rates following a meal stimulus.  Accretion of skeletal muscle 
occurs when protein synthesis is greater than protein degradation.  In mature sedentary 
animals, there should be a balance between protein synthesis and degradation resulting in 
maintenance of skeletal muscle, but no accretion.  Similar to the mTOR signaling 
pathway for protein synthesis, there are signaling pathways in skeletal muscle that are 
associated with protein degradation which include the ubiquitin and proteosomal 
pathways.  In the present study, we did not measure any molecular indicators of protein 
breakdown such as muscle-RING-finger protein 1 or forkhead box proteins.  Previous 
research has demonstrated that there is an increase in the abundance of the factors 
associated with protein degradation with aging in other mammals (179, 180, 296) and in 
the post-absorptive versus postprandial state (180).  Although we saw lower activation of 
the downstream mTOR signaling effectors following a meal stimulus in the two year old 
horses in comparison to the mature horses, we expect that the mature horses would also 
have elevated rates of muscle protein breakdown, as is seen in other mature species (179, 
180, 296); therefore, it is likely that the 2 year old horses were accreting more muscle 
protein than the mature horses, despite having a lower activation of the mTOR related 
signaling factors. 
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Exercise, amino acid, and insulin dependent mechanisms can all stimulate mTOR 
phosphorylation (21, 521, 522).  In the current study, mTOR may have been 
phosphorylated in an insulin- and amino acid-dependent manner because both up- and 
down- stream effectors were activated.  Although Akt phosphorylation at Thr308 only 
showed a trend to increase between the post-absorptive and postprandial states, Akt 
phosphorylation at Ser473 was elevated approximately 86% across the age groups with no 
difference seen between the age groups.  It has been shown that although Akt activation 
requires both sites to be phosphorylated, the contribution of each site is not equal (18, 
19).  Akt P-Thr308 can sufficiently stimulate Akt activation without the phosphorylation 
of Ser473; however, the reverse is not true (18, 19).  Our results may indicate that Akt may 
have already been sufficiently phosphorylated at Thr308 in the post-absorptive state 
resulting in a lack of difference at the postprandial state.  In agreement with the present 
study, Akt P-Ser473 in human skeletal muscle is more responsive to postprandial insulin 
concentrations than phosphorylation at the Thr308 site (527); however, further research is 
needed to confirm this in horses using a hyperinsulinemic-euglycemic isoaminoacidemic 
clamp technique.  The use of the hyperinsulinemic-euglycemic isoaminoacidemic clamp 
technique would allow for the determination of the responsiveness of skeletal muscle Akt 
to administered insulin concentrations independent of other changes that occur in 
response to a meal.  The phosphorylation of Ser473 Akt results in the mature horses during 
the postprandial period are in disagreement with previous results from our lab (2), where 
there was no difference from the post-absorptive to postprandial state in the gluteal 
muscle of mature horses.  The same feed and feeding practices were used in mares of a 
similar age in both studies; however, a different population of horses was used.  Despite 
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the similar postprandial insulin concentrations at the time of biopsy in both groups, the 
horses in the previous study (2) may have been more insulin resistant; explaining the 
absent change in Akt P-Ser473 with feeding.  In future studies, all horses should be 
screened for insulin sensitivity prior to being included in the study population. 
The absence of an age effect on Akt may be attributed to differences in insulin 
sensitivity between the three ages of horses studied.  Postprandial insulin concentrations 
were higher in the mature horses than the yearlings or two year olds at the time of biopsy; 
therefore, we expected the phosphorylation of Akt to be greater in the mature horses than 
the yearlings or two year olds, but this was not the case.  This may indicate that the 
younger age groups had higher insulin sensitivity than the mature horses, which 
corresponds with epidemiological studies on the prevalence of obesity and 
hyperinsulinemia (528).  Furthermore, the majority of obese and hyperinsulinemic horses 
are between the ages of 5 and 15 years (528), which is substantially older than a yearling 
or a two year old, and similar to the mature horses used in the current study whose 
average age was 13.8±2.9 years old.  The response of Akt phosphorylation may have also 
been maximized at the lower insulin concentrations in the yearlings and two year olds; 
however, this requires further investigation. 
Insulin alone cannot sufficiently simulate protein synthesis in adults (529, 530); 
and because the downstream effectors were significantly elevated in the postprandial 
state, it is more likely that the increase in translation initiation was the result of a 
combination of increased amino acids and insulin following the high crude protein pellet.  
There was no difference in the majority of the circulating plasma indispensable amino 
acids at the time of biopsy across the ages; however, the mature horses had an elevated 
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S6K1 response compared to the yearlings or two year olds.  This may indicate an increase 
in amino acid sensitivity with age.  However, amino acid sensitivity decreases with 
neonatal development in pigs (531), and has been shown to decline from maturity to old 
age in humans (155).  Therefore, further research is needed using amino acid clamp 
techniques, which would allow for a controlled dosage of amino acids, in the horse to 
determine if the mature horse truly has increased amino acid sensitivity. 
The current study revealed that feeding a high protein diet after an 18 hours 
period of feed withholding resulted in an increase in the activation of translation initiation 
factors, Akt, S6K1, rpS6 and 4EBP1 in mature, two year old, and yearling horses.  This 
would suggest that regardless of age there is a postprandial increase in rates of muscle 
protein synthesis.  The effect of age on the activation of the downstream effectors with a 
greater postprandial increase in the yearlings compared to the two year olds may indicate 
developmental differences in the responsiveness of muscle protein synthesis to insulin 
and amino acids.  The mature horses appeared to have a greater postprandial 
responsiveness to amino acids and were less sensitive to insulin than the yearlings or two 
year old in the activation of translation initiation factors.  This finding warrants further 
investigation, and it may have implications for designing feeding and management 
strategies specific to young adolescent versus mature horses. 
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5.5.  TABLES 
Table 5.1: As-fed nutrient composition of a high crude protein pelleted diet and 
nutrient intake from the pelleted diet during the postprandial period in horses that 
had feed withheld for 18 hours (mean ± SD values). 
 
Nutrient Pellet composition*  Nutrient intake†
(mg/kg of bodyweight) 
Moisture 9.07 ± 0.31%  
  
Crude protein 33.0 ± 0.53% 1,320 ± 21 
Alanine 1.05 ± 0.01% 42 ± 1 
Arginine 1.79 ± 0.06% 71 ± 2 
Aspartate+asparagine 1.76 ± 0.08% 71 ± 3 
Glutamate+glutamine 4.32 ± 0.07% 173 ± 3 
Glycine 0.91 ± 0.01% 37 ± 1 
Histidine 0.58 ± 0.02% 23 ± 1 
Isoleucine 0.90 ± 0.03% 36 ± 2 
Leucine 1.96 ± 0.15% 78 ± 6 
Lysine 1.36 ± 0.01% 54 ± 1 
Methionine 0.32 ± 0.01% 13 ± 1 
Proline 1.93 ± 0.09% 77 ± 4 
Phenylalanine 1.22 ± 0.01% 49 ± 1 
Serine 1.28 ± 0.02% 51 ± 1 
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Table 5.1 continued: As-fed nutrient composition of a high crude protein pelleted 
diet and nutrient intake from the pelleted diet during the postprandial period in 
horses that had feed withheld for 18 hours (mean ± SD values). 
Threonine 0.93 ± 0.04% 37 ± 2 
Tyrosine 0.85 ± 0.10% 34 ± 1 
Valine 0.92 ± 0.01% 37 ± 2 
  
Acid detergent fiber 6.17 ± 0.25% 247 ± 10 
Neutral detergent fiber 12.56 ± 0.75% 503 ± 30 
Non-fiber carbohydrates 26.2 ± 0.36% 1048 ± 14 
Starch 4.67 ± 0.06% 191 ± 2 
Water-soluble carbohydrates 8.43 ± 0.15% 337 ± 6 
   
Crude fat 3.47 ± 0.07% 139 ± 2 
   
Ash 15.6 ± 0.26% 624 ± 11 
Calcium 3.34 ± 0.13% 134 ± 5 
Phosphorus 2.05 ± 0.09% 82 ± 4 
Potassium 1.44 ± 0.01% 58 ± 0.2 
Sodium 0.682 ± 0.01% 27 ± 0.4 
Iron 1263 ± 32 mg/kg 5.05 ± 0.13 
Zinc 548 ± 40 mg/kg 2.19 ± 0.16 
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Table 5.1 continued: As-fed nutrient composition of a high crude protein pelleted 
diet and nutrient intake from the pelleted diet during the postprandial period in 
horses that had feed withheld for 18 hours (mean ± SD values). 
*Values represent the amount of the nutrient present as a portion of the total diet on an as-
fed basis. †During the postprandial period, following an 18-hour feed withholding period, 
horses were given 2 equal meals of the pelleted feed (targeted total intake of 4 g of 
feed/kg of bodyweight), separated by 30 minutes .   
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Table 5.2: The effect of an 18 hour feed withholding period followed by either 
continued feed withholding (post-absorptive) or subsequent re-feeding of a high 
protein pellet (postprandial) on plasma amino acid concentrations at time of biopsy 
(80 minutes) in yearling, two year old and mature horses1 
Amino Acids Post-absorptive Postprandial  
 Yearling Two 
Year 
Old 
Mature Yearling Two 
Year 
Old 
Mature Pooled
SE 
Alanine 157 163 163 245* 259* 236* 12.3 
Arginine 73 70 71 156* 143* 153* 8.3 
Asparagine 47 43 43 80* 70* 73* 5.4 
Aspartate 4.2a 3.8ab 3.6b 5.7a* 5.7a* 4.8b 0.2 
Citrulline 70 65 66 83* 89* 94* 3.8 
Glutamate 22ab 24a 19b 26ab* 28a* 23b* 1.5 
Glutamine 442 443 420 580* 540* 531* 26 
Glycine 579 569 562 610 629 555 23 
Histidine 60 57 56 72* 68* 68* 3.2 
Isoleucine 67 69 61 97* 102* 88* 4.3 
Leucine 120 124 117 161* 170* 152* 6.7 
Lysine 107 108 102 197* 200* 196* 11 
Methionine 27 28 29 34* 40* 37* 2.5 
Ornithine 35 35 33 56* 56* 57* 2.7 
Phenylalanine 56 56 52 71* 72* 62* 2.8 
Proline 74 70 61 121* 112* 102* 5.2 
Serine 186 184 171 245* 234* 231* 11 
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Table 5.2 continued: The effect of an 18 hour feed withholding period followed by 
either continued feed withholding (post-absorptive) or subsequent re-feeding of a 
high protein pellet (postprandial) on plasma amino acid concentrations at time of 
biopsy (80 minutes) in yearling, two year old and mature horses1 
Taurine 34 35 34 48* 46* 39* 2.1 
Threonine 102 102 94 140* 139* 132* 6.7 
Tryptophan 10 9.3 9.1 14* 12 11 1.3 
Tyrosine 56 49 51 90* 78* 77* 4.4 
Valine 205 204 196 258* 259* 251* 8.3 
1 Plasma amino acid concentrations are presented as least squares mean values in μmol/L. 
a,bWithin a treatment, values with different superscript letters are significantly (P < 0.05) 
different. 
*Within an age, value is significantly (P < 0.05) different from the value post-absorptive 
value. 
   
176 
 
5.6.  FIGURES 
 
Figure 5.1.  Plasma glucose concentrations (mmol/L) in yearling, two year old, and 
mature horses that were fed 2g/kg of a high protein pellet at t = 0 and t = 30 minutes 
following an 18 hour period of feed withholding.  Values are least square means ± 
pooled SE, n=6 per age group. 
*Indicates that, within an age group, the value is significantly different (P < 0.05) from 
the baseline value. 
abDifferent letters indicate a significant age effect (P < 0.05) within a time period. 
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Figure 5.2.  Plasma insulin concentrations (mIU/L) in yearling, two year old, and 
mature horses that were fed 2g/kg of a high protein pellet at t = 0 and t = 30 minutes 
following an 18 hour period of feed withholding.  Values are least square means ± 
pooled SE, n=6 per age group. 
*Indicates that, within an age group, the value is significantly different (P < 0.05) from 
the baseline value. 
abDifferent letters indicate a significant age effect (P < 0.05) within a time period. 
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Figure 5.3.  Gluteal muscle phosphorylation of Akt at Ser473 in yearling, two year 
old, and mature horses that were either fed 2g/kg of a high protein pellet at t = 0 and 
t = 30 minutes (postprandial) or had feed withheld for an additional 90 minutes 
(post-absorptive) following an 18 hour period of feed withholding.  Muscle biopsies 
were taken at 90 minutes after t = 0 minutes.  Akt phosphorylation at Ser473 was corrected 
by total Akt abundance, with the value for the post-absorptive mature horse set at 1.0 AU.  
Values are least square means ± pooled SE, n=6 per age group.  Representative images of 
the immunoblots are shown above. 
*Indicates that, within an age group, the value is significantly different (P < 0.05) from 
the postprandial value. 
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Figure 5.4.  Gluteal muscle phosphorylation of Akt at Thr308 in yearling, two year 
old, and mature horses that were either fed 2g/kg of a high protein pellet at t = 0 and 
t = 30 minutes (postprandial) or had feed withheld for an additional 90 minutes 
(post-absorptive) following an 18 hour period of feed withholding.  Muscle biopsies 
were taken at 90 minutes after t = 0 minutes.  Akt phosphorylation at Thr308 was 
corrected by total Akt abundance, with the value for the post-absorptive mature horse set 
at 1.0 AU.  Values are least square means ± pooled SE, n=6 per age group.  
Representative images of the immunoblots are shown above. 
  
180 
 
 
Figure 5.5.  Gluteal muscle phosphorylation of S6K1 at Thr389 in yearling, two year 
old, and mature horses that were either fed 2g/kg of a high protein pellet at t = 0 and 
t = 30 minutes (postprandial) or had feed withheld for an additional 90 minutes 
(post-absorptive) following an 18 hour period of feed withholding.  Muscle biopsies 
were taken at 90 minutes after t = 0 minutes.  S6K1 phosphorylation at Thr389 was 
corrected by total S6K1 abundance, with the value for the post-absorptive mature horse 
set at 1.0 AU.  Values are least square means ± pooled SE, n=6 per age group.  
Representative images of the immunoblots are shown above. 
*Indicates that, within an age group, the value is significantly different (P < 0.05) from 
the postprandial value. 
abcDifferent letters indicate a significant age effect (P < 0.05) within a treatment group. 
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Figure 5.6. Gluteal muscle phosphorylation of rpS6 at Ser235/236 in yearling, two year 
old, and mature horses that were either fed 2g/kg of a high protein pellet at t = 0 and 
t = 30 minutes (postprandial) or had feed withheld for an additional 90 minutes 
(post-absorptive) following an 18 hour period of feed withholding.  Muscle biopsies 
were taken at 90 minutes after t = 0 minutes.  rpS6 phosphorylation at Ser235/236 was 
corrected by total rpS6 abundance, with the value for the post-absorptive mature horse set 
at 1.0 AU.  Values are least square means ± pooled SE, n=6 per age group.  
Representative images of the immunoblots are shown above. 
*Indicates that, within an age group, the value is significantly different (P < 0.05) from 
the postprandial value. 
abcDifferent letters indicate a significant age effect (P < 0.05) within a treatment group. 
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Figure 5.7.  Gluteal muscle phosphorylation of rpS6 at Ser240/244 in yearling, two 
year old, and mature horses that were either fed 2g/kg of a high protein pellet at t = 
0 and t = 30 minutes (postprandial) or had feed withheld for an additional 90 
minutes (post-absorptive) following an 18 hour period of feed withholding.  Muscle 
biopsies were taken at 90 minutes after t = 0 minutes.  rpS6 phosphorylation at Ser240/244 
was corrected by total rpS6 abundance, with the value for the post-absorptive mature 
horse set at 1.0 AU.  Values are least square means ± pooled SE, n=6 per age group.  
Representative images of the immunoblots are shown above. 
*Indicates that, within an age group, the value is significantly different (P < 0.05) from 
the postprandial value. 
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Figure 5.8.  Gluteal muscle phosphorylation of 4EBP1 at Thr36/47 in yearling, two 
year old, and mature horses that were either fed 2g/kg of a high protein pellet at t = 
0 and t = 30 minutes (postprandial) or had feed withheld for an additional 90 
minutes (post-absorptive) following an 18 hour period of feed withholding.  Muscle 
biopsies were taken at 90 minutes after t = 0 minutes.  4EBP1 phosphorylation at Thr36/47 
was corrected by total rpS6 abundance, with the value for the post-absorptive mature 
horse set at 1.0 AU.  Values are least square means ± pooled SE, n=6 per age group.  
Representative images of the immunoblots are shown above. 
*Indicates that, within an age group, the value is significantly different (P < 0.05) from 
the postprandial value. 
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Chapter VI 
Whole body protein metabolism is not different between healthy aging and older 
mature horses 
6.1.  INTRODUCTION 
Sarcopenia is the involuntary loss of muscle mass and strength, and has been 
partially attributed to a multitude of factors which include a decline in physical activity 
and a less than optimal diet in the aging human population (148-150).  Similar to aging 
humans, horses have also shown a decrease in muscle mass (532).  Furthermore, the 
number of horses over the age of 20 years old is approximately 7.6% of the equine 
population and approaches 20% in some areas (523, 533).  Horses over the age of 20 
years old typically exhibit visible signs of aging (533).  Although there is anecdotal 
evidence to suggest that the aging equine population exhibits a decline in physical 
activity similar to what is seen in aging humans, there has been limited research 
regarding protein requirements.  From the few studies that have examined protein 
nutrition in the aging equine population, it appears that old horses may have lower 
protein digestibility than their mature counterparts (534); however, when studies were 
repeated with a different cohort of old horses the results were conflicting (535).  As a 
result, it is necessary to determine if protein metabolism of the aging horse varies from 
the mature counterparts which would be the first step in determining if protein 
requirements differ between these groups of horses. 
Sarcopenia is a result of an imbalance of protein synthesis and breakdown.  The 
increase in muscle protein fractional synthesis rates in response to anabolic stimuli such 
as exercise (149, 151, 152), amino acids (149, 153), insulin (154), or meal consumption 
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(152, 153) is decreased in the aged compared to the younger adult.  Additionally, 
differences in whole-body protein metabolism suggest that a greater protein requirement 
is necessary for the aging human population (487).  Systemic inflammation associated 
with aging has been associated with lowered rates of muscle protein synthesis (493).  
Although the effects of aging on whole-body or muscle protein metabolism have not been 
elucidated in the horse, there has been a single study to determine whole-body protein 
synthesis rates using stable isotope infusion techniques in the mature horses (Urschel et 
al., University of Kentucky, submitted).  The most effective way to measure whole-body 
protein synthesis is through the use of isotope infusion and stochastic analysis to 
calculate parameters of whole-body protein synthesis and breakdown and these methods 
have been extensively used in a variety of physiological states in humans (151, 487, 536).  
The use of these methodologies may be the first step in determining if the aging equine 
has different protein requirements than their mature counterparts. 
Protein synthesis is modulated by a series of intracellular signaling cascades that 
are associated with the mammalian target of rapamycin (mTOR) pathway.  The mTOR 
pathway regulates translation initiation and has been the subject of numerous recent 
reviews (21, 488, 537).  In short, insulin activates Akt (also referred to as PKB) through 
the activation of several intermediate signaling proteins (16, 18, 19, 21).  Akt activation 
occurs when both the Thr308 and Ser473 sites are phosphorylated, and both sites are 
activated in association with insulin receptor signaling (18, 19, 21).  Activation of Akt 
inactivates the mTOR inhibitor tuberous sclerosis complex 2 through phosphorylation 
(19, 21); thus, allowing activation of mTOR through phosphorylation.  Amino acids (45, 
46, 497) and exercise (149, 488, 538) also phosphorylate mTOR through Akt-
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independent mechanisms.  The activation of mTOR allows for the phosphorylation of 
two downstream signaling proteins: ribosomal S6 Kinase 1 (S6K1) and eukaryotic 
initiation factor 4E-binding protein-1 (4EBP1). Phosphorylation of S6K1 results in the 
activation of ribosomal protein S6 (rpS6) (498), a component of the 40S ribosomal 
subunit (498).  The phosphorylation of rpS6 and 4EBP1 result in the activation of the 
translational equipment and subsequently protein synthesis (21, 537).  The activation of 
translation initiation factors in the mTOR signaling pathway in response to anabolic 
stimuli is reduced with aging (155-157).  Although the activation of translation initiation 
factors in response to a meal have been examined in adolescent (Chapter V) and mature 
(2) equine skeletal muscle, this has not been studied in the aging equine population.  The 
objective of this study was to determine the effects of aging on the activation of 
translation initiation factors, specifically Akt, S6K1, rpS6, and 4EBP1, and whole-body 
protein synthesis in mature and aged horses. 
6.2.  MATERIALS AND METHODS 
6.2.1.  Animals and housing 
The University of Kentucky Institutional Animal Care and Use Committee (2009-
0562) approved all procedures used in this study.  Twelve mixed breed horses were 
obtained from the University of Kentucky Veterinary Sciences’ Farm: 6 aged (23.5 ± 2.6 
y old; 3 geldings and 3 mares) and 6 mature (11 ± 2.6 y old; 3 geldings and 3 mares) 
horses.  To facilitate sampling procedures, the twelve horses were divided into three 
blocks, with 2 horses from each age group (1 mare and 1 gelding) in each block.  All 
horses were of a moderate body condition (body condition score 5-7, scale 1-9 (489)), 
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were clinically healthy with all of their teeth and were able to live outdoors in a group 
housing environment, and on a regular farrier, anthelmintic, dental, and vaccination 
regimen.  Additionally, the pool of candidate horses were screened for plasma α-
melanocyte stimulating hormone (α-MSH) concentration, a marker of pituitary pars 
intermedia dysfunction (PPID; Equine Cushing’s Disease) (539).  Selected horses were 
well below the normal cut-off value of < 35 pmol/L (539).  Horses were group housed on 
dry lots with ad libitum acess to salt and water, and grass hay (mean ± SD; 0.91 ± 0.02 
Mcal/kg DE, 8.2 ± 0.8% CP; 48.3 ± 0.3% ADF; 76.5 ± 1.4% NDF; 2.0 ± 0.5% crude 
fat;and 7.0 ± 0.5% ash) was provided to the group at 2% of body weight per day.  Horses 
were brought into 3.7×3.7 m stalls and individually fed the concentrate ration twice daily 
at 0800 and 1500.  The concentrate ration consisted of a 50:50 mixture of a ration 
balancer pelleted feed (Table 6.1) and oats (Table 6.1) at 0.2% of body weight per day.  
Horses were adapted to diet and housing protocols for 2 weeks prior to the initiation of 
experimental procedures.  During the isotope infusion procedures horses were housed in 
3.7×3.7 m stalls bedded with pine shavings with ad libitum access to water and salt. 
6.2.2.  Experimental design and procedures 
Following the 2 week adaptation period, horses were removed from the group 
housed dry lot at 0800 on day 0, weighed on a portable electronic scale (model 700, Tru 
Test Inc., Mineral Wells, TX), put into individual stalls and fed the morning concentrate 
meal of 0.1% of body weight and their individual portion of hay at 2% of body weight 
per day.  Following consumption of the morning concentrate meal, a blood sample was 
collected into PAXgene™ Blood RNA tubes (Quiagen, Inc., Santa Clarita, CA) via 
jugular vein venipuncture to measure circulating inflammatory cytokines gene 
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expression.  At 1500, horses were fed their afternoon concentrate meal.  Horses remained 
in their individual stall during day 1 and were fed in the same manner as on day 0. 
On day 2, following consumption of the morning concentrate meal which was 
given as previously described, and 2 indwelling jugular vein catheters (14 gauge X 14.0 
cm, Abbocath; Abbott Laboratories, North Chicago IL) were placed using aseptic 
techniques as previously described (2): one for isotope infusion and one for blood 
sampling.  Fat thickness on the croup near the site of biopsy was ultrasounded in order to 
calculate percent body fat (481).  After these procedures were completed, horses were 
returned to their stalls and fed their afternoon meal as previously described. 
On day 3, the whole-body phenylalanine kinetics were measured using primed, 
constant stable isotope infusions.  During the course of the whole-body phenylalanine 
kinetic measurements, horses were fed the morning concentrate divided into 24 equal 
portions, with 1 portion fed every 30 minutes for 7.5 h, with the initial portion was 
provided 1.5 h prior to the start of isotope administration.  This feeding regimen was used 
in order to bring all of the horses to a steady state, which is necessary when using steady-
state isotope kinetics.  In order to accurately quantify feed intake during the isotope 
infusions, hay was removed from the stall during these procedures.  Each horse received 
a 14.4 μmol/kg priming dose of [13C] sodium bicarbonate solution (Isotec™, 
Miamisburg, OH), followed by a 2-h constant infusion at 12 μmol/kg/h in order to 
determine total CO2 production(540).  This was followed by a 4-h primed (8.4 μmol/kg), 
constant (6 μmol/kg/h) infusion of [1-13C]phenylalanine solution (Isotec™, Miamisburg, 
OH) to measure whole-body phenylalanine oxidation and flux(541).  The primed to 
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constant ratio for both [13C] sodium bicarbonate (542) and [1-13C]phenylalanine were 
previously determined (Urschel et al., Univerity of Kentucky, submitted).  The [13C] 
sodium bicarbonate and [1-13C]phenylalanine solutions were individually prepared by 
dissolving the isotope into 0.9% sterile saline (Butler Animal Health Supply, Dublin, 
OH) and filtering the solution through 0.22 μm sterile filters (Millipore, Billerica, MA) 
into empty sterile ethylene vinyl acetate bags (Baxter Healthcare Corporation, Deerfield, 
IL).  The isotope filled ethylene vinyl acetate bags were attached to a surcingle and 
connected to the catheter using a primary IV set (Baxter Healthcare Corporation, 
Deerfield, IL).  Isotope was delivered into the catheter using pressure sensitive, cordless 
intravenous infusion pumps (J-1097 VetPro Infusion Pump, Jorgensen Laboratories Inc., 
Loveland, CO) which was also attached to the surcingle on each horse.  This cordless 
pump-surcingle system permitted the horses to remain in individual stalls during the 
infusion period without restraint. 
Two baseline breath samples were collected prior to the [13C] sodium bicarbonate 
infusion (-30 min and 0 min), and subsequent breath samples were collected every 30 
min throughout the infusion procedures of both [13C] sodium bicarbonate and [1-
13C]phenylalanine.  Breath samples were collected using a modified Equine Aeromask® 
(Trudell Medical International, London ON, Canada) enabling the collection of air 
through a 1-way valve into impermeable gas bags (Wagner Analysen Technik Vetriebs 
GmbH, Bremen, Germany). During breath collection, horses wore the Aeromask® for 
approximately 1 minute to allow time for the air in the mask to equilibrate, and then bags 
were attached to the 1-way valve and remained there until full (approximately 1 min).  
Immediately following each sample collection, another 1/24 meal was provided.  Blood 
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sampling commenced at t = 90 min into the [13C] sodium bicarbonate infusion, and 
continued every 30 min until the end of the [1-13C]phenylalanine infusion.  All blood 
samples were collected into evacuated vacutainers (Vacutainer; Becton-Dickinson, 
Franklin Lakes NJ) containing sodium heparin.  The 90 min [13C] sodium bicarbonate 
and 0 min [1-13C]phenylalanine blood samples provided 2 baseline samples to measure 
the background enrichments of [1-13C] phenylalanine in the blood prior to isotope 
infusion. 
At the end of the [1-13C]phenylalanine infusion, the infusion pumps were turned 
off and the horses were led to a set of equine stocks.  Horses were lightly sedated with 
xylazine hydrochloride (0.3mg/kg, IV [100mg/mL]; Butler Animal Health Supply, 
Dublin, OH), and a gluteal muscle biopsy was collected as previously described (2).  
Briefly, the area over the middle gluteal muscle (~100-cm2) was shaved, aseptically 
prepared, and desensitized with a local anesthetic (12 mL of 2% lidocaine; Butler Animal 
Health Supply, Dublin, OH).  Approximately 500 mg of muscle biopsy specimen was 
collected at approximately 50% (~8 cm; Chapter III; ChapterV) depth of the middle 
gluteal muscle using the percutaneous needle biopsy technique(411).  Of this, ~100 mg 
was processed in preparation for Western blot analysis, as described below, and ~ 80 mg 
was stored in RNAlater (Quiagen, Inc., Santa Clarita, CA) for qRT-PCR analysis of 
inflammatory cytokines as described below.  The remainder was flash frozen in liquid 
nitrogen, and stored at -80ºC until analysis.  Catheters were removed following muscle 
biopsy collection. 
At the end of the sampling period, horses were given the remaining portions of 
concentrate and their daily allotment of hay as a single meal, and then returned to the 
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drylot. Samples of the grass hay, ration balancer pellet, and oats were collected 
throughout the experimental period and sent to Dairy One Forage Laboratory (Ithaca, 
NY) for nutrient analysis.  For the next 3 days, 2g/d of phenylbutazone was administered 
to alleviate any discomfort associated with the sampling procedures. 
6.2.3.  Sample analysis procedures 
6.2.3.1.  Blood sample collection and storage:  Blood samples collected for qRT-PCR in 
PAXgene™ Blood RNA tubes (Quiagen, Inc., Santa Clarita, CA) were gradually frozen 
to -80oC per manufacturer instructions and remained at -80oC until analysis.  The 
remaining blood samples were immediately centrifuged at 1,500 x g for 10 minutes at 
4ºC, and aliquots of plasma samples were frozen at -20ºC until the time of analysis.   
6.2.3.2.  Plasma glucose and insulin:  Plasma glucose concentrations were assayed 
enzymatically using a YSI 2700 SELECT™ Biochemistry Analyzer (YSI Inc., Life 
Sciences, Yellow Springs, Ohio).  Plasma insulin concentrations were determined using 
Coat-A-Coat RIA®kit (Siemens Healthcare Diagnostics Inc., Deerfield, IL). 
6.2.3.3.  Amino acids:  The plasma free amino acid concentrations were measured using 
reverse-phase HPLC (3.9 x 300 mm PICO-TAG reverse phase column; Waters, Milford 
MA) of phenylisothiocyanate derivatives as previously described (2).  Total amino acid 
concentrations of the concentrate, oats, and grass hay were also measured using reverse-
phase HPLC (3.9 x 300 mm PICO-TAG reverse phase column; Waters, Milford MA) of 
phenylisothiocyanate derivatives as previously described (2), following 24 hour acid 
hydrolysis in 6N HCl at 110oC. 
192 
 
6.2.3.4.  Plasma phenylalanine enrichment:  The isotopic enrichment of phenylalanine 
(the amount of [1-13C]phenylalanine relative to unlabeled phenylalanine) in the plasma 
samples collected on day 3 was determined by Metabolic Solutions, Inc. (Nashua, NH) 
using a previously described method (543) which was modified by Matthews, Persola 
and Campbell (544).  Briefly, the isotopic enrichment of plasma samples were 
determined by negative chemical ionization GC-MS analysis of a heptafluorobutyric, n-
propyl derivative. 1-13C-phenylalanine enrichment was measured using methane negative 
chemical ionization GC-MS (Agilent 5973 EI/CI MSD with a Agilent 6890 GC). A 
Phenomenex ZB-1MS capillary column was used to separate the derivative of 
phenylalanine. Selected ion chromatograms were obtained by monitoring ions m/z 383 
and 384 for L-phenylalanine and L-[1-13C]phenylalanine, respectively. 
6.2.3.5.  Muscle phenylalanine enrichment:  Approximately 25-30 mg of flash frozen 
muscle tissue was sent to Metabolic Solutions, Inc. (Nashua, NH) for the determination 
of mixed-muscle protein and intracellular 1-13C-phenylalanine enrichment (545).  Muscle 
was homogenized twice in 10% trichloroacetic acid.  The protein-free solution was 
treated as described above for plasma 1-13C-phenylalanine.  The muscle proteins were 
hydrolyzed in 6N HCl for 24 h at 110°C.  Amino acids were isolated using cation-
exchange chromatography (50W-x8 resin, Sigma-Aldrich®, St. Louis, MO).  Amino 
acids were eluted from the resin using 2 ml of 4N NH4OH.  Eluates were evaporated to 
dryness with nitrogen gas.  The heptafluorobutyric, n-propyl derivative of phenylalanine 
was prepared as described above. 
6.2.3.6.  Breath sample analysis:  The ratio of 13CO2:12CO2 in the breath samples 
(Appendix 7) was determined using an isotope selective non-dispersive infrared 
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absorption (NDIR) analyzer (IRIS-2; Wagner Analysen Technik Vetriebs GmbH, 
Bremen, Germany). 
6.2.3.7.  Western blot analysis of muscle samples:  The abundance of the total and 
phosphorylated forms of Akt, S6K1, rpS6, and 4E-BP1 in the gluteal muscle 
homogenates were determined using electrophoresis followed by Western blotting 
techniques (Chapter III) 
6.2.3.8.  RNA isolation:  Total RNA was isolated from PAXgene™ tubes using the 
PAXgene™ RNA Blood Kit (Quiagen, Inc., Santa Clarita, CA).  Muscle samples that had 
been stored in RNAlater (Quiagen, Inc., Santa Clarita, CA) were homogenized using the 
bead beating technique (510) into the RNA-Stat60 solution (Tel- Test, Friendswood, TX). 
Total RNA was then isolated and quantified from both types of samples as previously 
described (Chapter IV).  Reverse transcription reactions were performed as previously 
described (Chapter IV). 
6.2.3.9.  Real time polymerase chain reaction:  The mRNA expressions of pro -
inflammatory cytokines, IFN-γ, IL-1β, IL-6 and TNFα, and the anti-inflammatory 
cytokine IL-10 were measured in cDNA samples using equine specific intron-spanning 
primer/probe sets (Chapter IV).  Differences in RNA isolation and cDNA construction 
between samples were corrected with the use of an internal control β-glucorindase for 
each sample ((244, 484); ChapterIV). 
 
 
194 
 
6.2.4.  Calculations and statistical analysis 
6.2.4.1.  Fat free mass:  Body fat percentage was determined using the following 
equation: 
Fat (%) = [5.4 × ultrasonic fat depth in cm) + 2.47] (546). 
Once determined, body fat percentage was used to calculate fat mass from total body 
mass: 
Fat mass (kg) = Fat (%) × body mass (kg). 
Fat-free mass was determined by difference of body mass and fat mass. 
6.2.4.2.  Plasma phenylalanine enrichment:  Isotope enrichment in mol percent excess 
was calculated from peak area ratios at isotopic steady state and baseline.  The final value 
for all determinations was corrected using an enrichment calibration curve (Appendix 7). 
6.2.4.3.  Breath CO2 enrichment:  The δ enrichment value obtained from the NDIR 
analyzer for each sample was converted to a % enrichment: 
Enrichment (%) = [0.0112372δ/(0.0112372δ + 1000)] × 100% ((547); Urschel et al., 
University of Kentucky, submitted). 
Then, total CO2 production (FCO2) was calculated based on breath CO2 enrichment using 
the following equation: 
FCO2 = i × [(Ei/Eb) – 1] (Appendix 7). 
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Where, i was the rate of isotope administration in μmol/kg/min, Ei was the enrichment of 
the isotope in the solution and Eb was the enrichment of the breath samples at plateau, 
corrected for baseline enrichment ((540, 542, 547); Urschel et al., University of 
Kentucky, submitted) 
6.2.4.4.  Whole-body phenylalanine kinetics:  The average plasma enrichment at isotopic 
steady state (plateau) was used to calculate whole-body phenylalanine kinetics.  This 
plateau in phenylalanine enrichment included at least 3 values and was defined as not 
having a slope statistically different from 0 (P > 0.05), determined single linear 
regression analysis (GraphPad Prism 4; GraphPad Software, La Jolla CA).  These plateau 
enrichment values were then used to calculate the whole-body phenylalanine flux: 
Flux (Q; μmol/kg/h) = i × [(Ei/Ep) – 1 (Appendix 7), 
where I was the rate of isotope infusion (in μmol/kg/h), Ei was the enrichment of infused 
isotope, and Ep was the plateau plasma enrichment.  Flux includes the amount of amino 
acids entering the pool through dietary intake (I), de novo synthesis (N), and protein 
breakdown (B), or leaving the pool through protein synthesis (Z), oxidation (E), or the 
conversion to other metabolites: 
Q = I + N B = Z + E + M. 
In order to account for the ~50% of dietary phenylalanine that is extracted during first-
pass splanchnic metabolism in other monogastric species ((548, 549); Urschel et al., 
Univeristy of Kentucky, submitted), the amount of phenylalanine entering the plasma free 
amino acid pool from dietary intake was estimated by multiplying dietary intake by 0.5.  
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De novo synthesis of phenylalanine does not occur in horses because it is a dietary 
indespensible amino acid; therefore, phenylalanine released into the free amino acid pool 
as a result of protein breakdown can be estimated using the following equation: 
B = Q – I,  
where I is phenylalanine intake corrected for first-pass splanchnic extraction. 
 The rate of [1-13C]phenylalanine oxidation to 13CO2 (F13CO2) was calculated: 
F13CO2 = FCO2 × ECO2 ((550); Urschel et al., University of Kentucky, submitted) 
(Appendix 7), 
where ECO2 was the average enrichment of the breath samples at isotopic steady state 
(minimum of 3 points, with a slope not different from zero), corrected for baseline 
enrichment, during the [1-13C]phenylalanine infusion.  Then, whole-body phenylalanine 
oxidation was calculated using the following equation: 
O = F13CO2 × (1/Ep – 1/Ei) × 100 ((550); Urschel et al., University of Kentucky, 
submitted) (Appendix 7). 
 Non-oxidative phenylalanine metabolism can be calculated through the difference 
between phenylalanine flux and oxidation, and this can be used as an indicator of whole-
body phenylalanine use for protein synthesis.  The major non-CO2 product of 
phenylalanine is tyrosine, and since all horses were consuming the same diet, and 
tyrosine is not generally considered to be a limiting amino acid in any other monogastric 
species, it was assumed that phenylalanine conversion to tyrosine was minimal.  
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Therefore, any change in non-oxidative phenylalanine disposal was assumed to signify 
changes in phenylalanine use for whole-body protein synthesis. 
6.2.4.5.  Relative quantity of inflammatory cytokines:  Changes in mRNA expression 
were calculated using the ΔΔCT method (484), with the mean ΔCT averaged for mature 
horses set as the calibrator for each individual cytokine.  Results are expressed as relative 
quantity (RQ) calculated as 2-ΔΔCT (Chapter IV). 
6.2.4.6.  Statistics:  All data were analyzed using the mixed procedure of SAS Version 
9.2 (SAS Institute Inc., Cary, NC), with statistical significance and trends considered if P 
< 0.05 and 0.05 < P < 0.10, respectively.  When the fixed effects were significant, pre-
planned comparisons of least squares means were made using the pdiff test.  All of the 
dependent variables were analyzed using an ANOVA with the fixed effect of age and 
horse nested in age and block as the random subject.  Data are presented as means ± 
pooled standard error, unless otherwise noted. 
6.3.  RESULTS 
6.3.1.  Equine demographics 
 The two age groups were only statistically different in age.  There was no effect 
of age (P > 0.05) on body weight (mature: 469±30 kg; aged 499±30 kg) or fat free mass 
(mature: 421±26 kg; aged 448±26 kg).  The measurement of fat free mass indicates that 
the mature and aged animals used in this study were moderately lean.  α-MSH 
concentrations were well below (mature:10.1± 1.8 pmol/L; aged: 9.5 ± 1.8 pmol/L) the < 
35 pmol/L cut-off value to exclude potentially PPID horses(539). 
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6.3.2.  Plasma insulin, glucose, and amino acids 
 Plasma insulin, glucose, and amino acid concentrations were measured in the final 
blood sample of the [1-13C] phenylalanine infusion, immediately prior to biopsy.  Plasma 
insulin (P = 0.53; Table 6.2) and glucose (P = 0.43; Table 6.2) concentrations at the time 
of biopsy were not affected by age.  However, there was a significant effect of age on the 
plasma concentrations of isoleucine (P = 0.05; Table 6.2) and lysine (P = 0.04; Table 
6.2), where both were elevated in the aged compared to the mature group.  Additionally, 
there was a trend for elevated plasma concentrations of asparagine (P = 0.08; Table 6.2) 
and phenylalanine (P = 0.08; Table 6.2) in the aged horses.  The remainder of the amino 
acids were not affected by age (P > 0.05; Table 6.2). 
6.3.3.  Inflammatory cytokines 
 Age did not affect mRNA expression of the circulating inflammatory cytokines 
IL-1β (P = 0.92; Table 6.3), IL-6 (P = 0.90; Table 6.3), IL-10 (P = 0.20; Table 6.3), IFNγ 
(P = 0.30; Table 6.3), and TNFα (P = 0.38; Table 6.3).  Additionally, there was no effect 
of age on the mRNA expression of muscle IL-1β (P = 0.53; Table 6.3), IL-10 (P = 0.23; 
Table 6.3), IFNγ (P = 0.49; Table 6.3), and TNFα (P = 0.58; Table 6.3).  There was 
limited detection of muscle IL-6 mRNA expression where expression was detected in 
only 3 mature horses and a single aged animal. 
6.3.4.  Activation of translation initiation factors 
There was no effect of age on the activation of Akt at Ser473 (P = 0.33; Figure 6.1) 
and Thr308 (P = 0.83; Figure 6.1), rpS6 at Ser235/236 & 240/244 (P = 0.48; Figure 6.1), or 
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4EBP1 at Thr37/46 (P = 0.13; Figure 6.1).  However, the activation of S6K1 at Thr389 was 
significantly lower (P = 0.03; Figure 6.1) in the aged compared to the mature horses. 
6.3.5.  Whole-body protein synthesis 
There was no effect of age on whole-body CO2 production (P = 0.51; Table 6.4), 
phenylalanine flux (P = 0.84; Table 6.4), phenylalanine oxidation (P = 0.15; Table 6.4), 
phenylalanine release from protein breakdown (P = 0.99; Table 6.4) or non-oxidative 
phenylalanine disposal (P = 0.48; Table 6.4). 
 
6.3.6.  Muscle phenylalanine enrichments 
There was no effect of age on the free (P = 0.53; mature: 11.1±0.8%; aged: 
10.3±0.8%) or protein bound (P = 0.62; mature: 0.3±0.1%; aged: 0.4±0.1%) enrichment 
of [1-13C] phenylalanine in the gluteal muscle.  Because we only collected a single biopsy 
at the end of the isotope infusion period, we could not calculate the change in the protein 
bound phenylalanine enrichment, which is necessary to calculate muscle protein 
fractional synthesis rates.  However, if we assume that there were no initial differences in 
muscle bound enrichments of [1-13C] phenylalanine between the age groups, the lack of a 
difference between the ages in both free and protein bound muscle enrichment of [1-13C] 
phenylalanine indicates no difference in muscle protein fractional synthesis rates between 
the age groups. 
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6.4.  DISCUSSION 
To the best of the authors’ knowledge this is the first time that whole-body protein 
kinetics and mTOR signaling have been examined in the aging horse.  There were no 
differences in the whole-body protein kinetics of the mature and aged horses; however 
the phosphorylation of the downstream mTOR signaling factor, S6K1, was lower in the 
gluteal muscle of the aged compared to the mature horses following 7.5 hours of steady 
state feeding. 
Numerous studies of the effects of aging in humans have studied aging 
populations with different demographics than the mature population.  Body fat mass and 
weight were elevated in the aging populations of these previous studies (156, 185, 204); 
however, in the present study there were no differences in the aged compared to the 
mature group for any measurement of body mass.  Additionally, all of the aged horses in 
the current study were clinically normal with no signs of PPID, as plasma α-MSH 
concentrations were within the clinically normal reference range (539).  Although aging 
is typically characterized by low grade chronic inflammation, specifically elevations in 
the mRNA expression of circulating IL-1, IL-6, and TNFα (483, 493, 495), there were no 
differences in the mRNA expression of circulating or muscle inflammatory cytokines 
between the mature and aged horses in the current study.  Previous studies (483) in horses 
have demonstrated age related differences in circulating inflammatory cytokine 
expression; however the mature population in the previous study (483) was younger (4.5 
years old) than the mature group in the current study (11 years old).  Furthermore, the 
aged horses were mobile, had all of their teeth, and were thriving in an outdoor group 
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housing environment, indicating that the aging population in the current study was in a 
healthy aging state. 
The similar demographics and health status of the mature and aged groups used in 
the present study may explain the unexpected result of no significant difference in any of 
the markers of whole-body protein kinetics.  It has been previously demonstrated that up 
to 87% of the variance seen in whole-body protein kinetics can be attributed to fat free 
mass(151).  Further, muscle protein fractional synthesis rates in lean young adult (20 
years old) and aged lean men (75 years old) following the co-ingestion of a protein and 
leucine supplement are not different (209).  Leucine oxidation and fractional synthesis 
rates of sarcoplasmic proteins do not differ between middle aged (52 years old) and aged 
(77 years old) humans (200).  The results from previous studies (200, 201) support the 
present findings that the narrow age range, and similar physical characteristics of the 
subjects were likely a cause of no significant difference in phenylalanine kinetics. 
Of all of the translation initiation factors studied, S6K1 appears to be the most 
influenced by aging.  The phosphorylation of S6K1 at Thr389 was reduced by 42% in the 
aged horses compared to the mature horses, which has also been demonstrated in aged 
(30 mo) and very aged (36 mo) male rodent soleus muscle (551).  Additionally, the 
phosphorylation of S6K1 in response to amino acids and insulin does not increase from 
the basal state in aging humans (156), or following a meal in aged rats with and without 
low grade chronic inflammation (493).  The significant reduction in the abundance of 
S6K1 P-Thr389 without an increase in inflammatory cytokines in the aged horse may 
indicate that the effect of aging on S6K1 occurs through some other mechanism; 
however, this requires further elucidation. 
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The effect of aging on S6K1 phosphorylation in the absence of an effect on 
whole-body protein synthesis may indicate that examining protein synthesis at the whole 
body level masked the possible changes occurring in skeletal muscle.  Although skeletal 
muscle comprises approximately 50% of body weight, there is only about a 25% 
contribution to whole-body protein synthesis (198, 199); therefore, without drastic 
changes at the skeletal muscle level there will not be alterations at the whole-body level 
or if another tissue decreases its rate of protein synthesis and the muscle increases its rate 
of protein synthesis then there would be no net effect at the whole-body level.  The 
significant reduction in the abundance of S6K1 P-Thr389, without similar indications of 
change in muscle fractional synthesis rates or whole-body protein synthesis, requires 
further elucidation. 
No age differences were detected in the activation of Akt, rpS6, and 4EBP1.  The 
lack of an effect of age on Akt, rpS6, and 4EBP1 may be attributed to the narrow age 
range between the mature and aged horses in the current study, which has also been 
demonstrated in middle aged and aged rodents (551).  Additionally, the lack of elevated 
circulating and muscle inflammatory cytokines in the aged group compared to the mature 
group may also explain the absence of an age effect on the activation of Akt, rpS6, and 
4EBP1 because inflammatory cytokines stimulate NF-κB activation which inhibits the 
phosphorylation of Akt (517).  Although NF-κB was not examined in this study, the lack 
of an age effect on inflammatory cytokines may explain the absence of an age effect on 
Akt, rpS6, and 4EBP1 activation. 
The experimental protocol used in the current study may have concealed any 
differences in the activation of translation initiation factors and whole-body protein 
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synthesis that were possibly present.  For 7.5 hours prior to biopsy collection, horses 
received half of their daily concentrate allocation (0.1% BW) divided into 1/24 portions 
every 30 minutes.  Because the whole diet was primarily hay based (2% BW), each of 
these small concentrate meals only met 0.5% and 0.37% of the daily CP and digestible 
energy requirement, respectively.  Feeding small meals throughout the isotope infusion 
procedures may at least partially explain the lack of an age effect on the phosphorylation 
of Akt, rpS6, and 4EBP1, or whole-body protein synthesis rates as it may not have been a 
strong enough anabolic stimulus.  In mature horses, the consumption of a larger high 
protein meal (4g/kg) did result in the activation of translation initiation factors in the 
skeletal muscle of mature horses (2) and it is unknown whether the magnitude of this 
activation may have been lower in the old horses of the present study.  This phenomenon 
is seen during development when yearlings and two year olds consumed 4 g/kg of a high 
protein meal the activation of translation initiation factors was greater in the yearling 
horses compared to two year olds (Chapter V).  The plasma glucose (mature: 5.5 ± 0.28 
mmol/L, aged: 5.3 ± 0.28 mmol/L), insulin (mature: 5.8 ± 0.8 μIU/mL; aged: 6.1 ± 0.8 
μIU/mL), and total indispensable amino acid (mature: 543 ± 40 μmol/L; aged: 670 ± 40 
μmol/L) concentrations at the time of biopsy more closely resembled concentrations of 
mature horses in the post-absorptive state (glucose: 5.5 mmol/L; insulin: 5 mU/L; total 
indispensable amino acids: 898 μmol/L) (2) rather than the postprandial state (glucose: 
6.5 mmol/L; insulin: 36 mU/L; total indispensable amino acids: 1245 μmol/L) (2).  
Additionally, non-oxidative disposal, the indirect measure of protein synthesis, was less 
than phenylalanine release from protein breakdown which is characteristic of the post-
absorptive state (185).  Because the horses were in a physiological state more similar to 
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the post-absorptive state, then our results are consistent with previous findings that there 
are no age-related differences in the activation of translation initiation factors or protein 
synthesis during the post-absorptive state (156, 157, 204).  Further research is necessary 
to determine if age related changes in the activation of translation initiation factors or 
whole-body protein synthesis exist in horses during a true postprandial state. 
Although we did not see differences in whole-body protein synthesis or 
breakdown, there may have been differences in the molecular markers of muscle protein 
degradation, which we did not measure.  Muscle loss traditionally associated with aging 
occurs when there is an imbalance in muscle protein synthesis and breakdown, and 
because there was no difference in the activation of translation initiation factors with the 
exception of S6K1, which may be enough to reduce skeletal muscle protein synthesis, 
differences in the molecular markers of muscle protein degradation (muscle-RING-finger 
protein 1 or forkhead box proteins) may also contribute for the loss of muscle seen with 
aging.  Aging rodents have elevated proteasome content and activity and free ubiquitin 
and ubiquitylated protein concentrations in skeletal muscle than mature rodents (179).  
The aged also have higher abundance of forkhead box proteins than the mature 
counterparts (35).  Additionally, ubiquitination rate is greater in the post-absorptive state 
than the postprandial state in the aged rodent whereas the mature rodents are not affected 
by physiological state (180).  Because our horses were in a state more similar to the post-
absorptive state is possible that our aging may have had elevated molecular markers of 
muscle protein breakdown.  The lack of a difference in body composition between the 
mature and aging horses in the current study may indicate that over the course of an 
entire day protein synthesis is equal to protein degradation because our horses were 
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clinically healthy; however, this requires further investigation.  Additionally, further 
investigation is warranted to determine if aging horses have increased skeletal muscle 
proteolysis which may account for reduced muscle mass traditionally seen in this 
population. 
The implications of the current findings are that clinically healthy aging horses 
may not require different management practices than their mature counterparts.  Previous 
research (534) has indicated that aged horses have lowered protein digestibility than 
mature horses.  However, when the same research group repeated the study 12 years 
later, there was no difference in protein digestibility between the two age groups (535).  
The authors attributed the differences in the results to the fact that the aged horses in the 
initial study may have endured intestinal damage during their youth, growing up prior to 
the use of regular anthelmintics.  As a result, the most recent edition of the NRC (336) 
does not indicate differing requirements between mature and aged horses.  Our results 
show that there are no differences in whole-body protein metabolism, which may imply 
that the protein requirements do not differ between healthy aging and mature horses; 
however, further research is needed to specifically determine individual amino acid 
requirements during aging. 
The clinically healthy aging horses in the current study were similar to their 
mature counterparts; however, the growing aging equine population contains horses with 
PPID at a rate of 15 to 30% (552).  PPID horses are typically insulin resistant, 
hyperglycemic, have abnormal fat deposits, are susceptible to laminitis, and have 
elevated cortisol levels and muscle atrophy (552).  To the best of the authors’ knowledge, 
there is currently no literature pertaining to the activation of translation initiation factors 
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or protein synthesis in this population.  Although clinically healthy aging horses did not 
differ from mature horses and thus may not require different management practices, 
symptoms of the aging horse with PPID may affect Akt and mTOR signaling and whole-
body protein metabolism.  Protein metabolism in the less healthy aged horse is an area 
where additional research is warranted. 
Aging appears to affect equine skeletal muscle similar to both humans and rodents 
in that S6K1 activation is lowered, which could impair muscle protein synthesis, although 
there was not evidence of this in the present study.  Additionally, healthy aging horses do 
not have differences in circulating or muscle inflammatory cytokine mRNA expression 
compared to older mature counterparts (~13 years old) which may have resulted in 
similar whole-body protein synthesis rates.  Although additional research is needed to 
determine age-related differences in muscle protein metabolism in response to a larger 
anabolic stimuli, these findings indicate that healthy older horses have similar whole-
body protein metabolism and requirements to the mature horse. 
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6.5.  TABLES 
Table 6.1: As-fed nutrient composition of ration balancer pellet and oat diet fed to 
the horses during the 7.5 hours of steady state feeding prior to muscle biopsy 
collection 
 
Nutrient Ration balancer pellet 
composition,1 
(mean ± SD) 
Oat composition,1
(mean ± SD values) 
Moisturea 9.5 ± 0.2% 11.2 ± 0.3% 
  
Digestible energya 2.76 ± 0.01 Mcal/kg 3.15 ± 0.06 Mcal/kg 
   
Crude proteina 17.0 ± 0.3% 13.4 ± 1.9% 
Alanineb 0.51 ± 0.03% 0.35 ± 0.04% 
Arginineb 0.56 ± 0.03% 0.49 ± 0.07% 
Aspartate+asparagineb 0.81 ± 0.04% 0.58 ± 0.04% 
Glutamate+glutamineb 1.50 ± 0.06% 1.43 ± 0.14% 
Glycineb 0.44 ± 0.02% 0.35 ± 0.05% 
Histidineb 0.24 ± 0.01% 0.16 ± 0.03% 
Isoleucineb 0.37 ± 0.02% 0.25 ± 0.04% 
Leucineb 0.75 ± 0.02% 0.54 ± 0.08% 
Lysineb 0.41 ± 0.02% 0.27 ± 0.04% 
Methionineb 0.09 ± 0.01% 0.09 ± 0.01% 
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Table 6.1 continued: As-fed nutrient composition of ration balancer pellet and oat 
diet fed to the horses during the 7.5 hours of steady state feeding prior to muscle 
biopsy collection 
Prolineb 0.71 ± 0.04% 0.40 ± 0.06% 
Phenylalanineb 0.47 ± 0.02% 0.37 ± 0.06% 
Serineb 0.47 ± 0.01% 0.37 ± 0.05% 
Threonineb 0.35 ± 0.02% 0.23 ± 0.05% 
Tyrosineb 0.29 ± 0.02% 0.21 ± 0.04% 
Valineb 0.47 ± 0.03% 0.32 ± 0.05% 
  
Acid detergent fibera 18.4 ± 1.1% 11.0 ± 0.9% 
Neutral detergent fibera 32.5 ± 2.8% 23.3 ± 2.2% 
Non-fiber carbohydratesa 45.1 ± 2.4% 63.8 ± 2.7% 
Starcha 29.7 ± 3.0% 56.0 ± 3.8% 
Water-soluble carbohydratesa 7.1 ± 0.5% 4.2 ± 0.8% 
   
Crude fata 6.2 ± 0.2% 8.4 ± 0.7% 
   
Asha 9.6 ± 0.1% 3.6 ± 0.9% 
Calciuma 1.15 ± 0.03% 0.24 ± 0.20% 
Phosphorusa 0.64 ± 0.04% 0.32 ± 0.06% 
Potassiuma 1.81 ± 0.01% 0.62 ± 0.06% 
Sodiuma 0.33 ± 0.04% 0.12 ± 0.15% 
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Table 6.1 continued: As-fed nutrient composition of ration balancer pellet and oat 
diet fed to the horses during the 7.5 hours of steady state feeding prior to muscle 
biopsy collection 
Irona 509 ± 13 mg/kg 157 ± 47 mg/kg 
Zinca 62 ± 5 mg/kg 35 ± 5 mg/kg 
1Values represent the amount of the nutrient present as a portion of the total diet on an as-
fed basis.  Horses received 0.1% of body weight/day of the ration balancer pellet and the 
oats, individually, which resulted in a total of 0.2% of body weight/day. 
aProximate analysis of the feed was conducted by Dairy One Forage Laboratory (Ithaca, 
NY). 
bAmino acid content of the feed was determined using high performance liquid 
chromatography analysis following an acid hydrolysis of the feed sample, as described in 
Materials and Methods. 
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Table 6.2: Plasma metabolite concentration at the time of biopsy in mature and aged 
horses 
Metabolite Mature Aged Pooled 
SEM 
Insulin1 5.8 6.1 0.8 
Glucose2 5.5 5.3 0.28 
Alanine3 203 218 24 
Arginine 69 74 5.8 
Asparagine 38 52† 4.9 
Aspartate 19 14 2.4 
Citrulline 83 91 8.3 
Glutamate 54 49 6.3 
Glutamine 273 306 27 
Glycine 352 441 39 
Histidine 58 64 2.8 
Isoleucine 33 46* 3.9 
Leucine 68 87 7.4 
Lysine 69 92* 6.9 
Methionine 26 32 2.8 
Ornithine 34 44 4.8 
Phenylalanine 68 83† 5.4 
Proline 90 97 7.6 
Serine 232 288 23 
Taurine 21 28 3.4 
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Table 6.2 continued: Plasma metabolite concentration at the time of biopsy in 
mature and aged horses 
Threonine 94 112 11 
Tryptophan 4.7 5.3 0.4 
Tyrosine 50 55 5.0 
Valine 121 148 12 
1 Plasma insulin concentrations are reported as least square means in μIU/mL. 
2 Plasma glucose concentrations are reported as least square means in mmol/L. 
3 Plasma amino acids concentrations are reported as least square means in μmol/L. 
*Indicates the aged horse value is significantly (P < 0.05) different from the mature horse 
value. 
†Indicates the values in the aged horses showed a trend (P < 0.10) to be different from the 
mature horse values. 
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Table 6.3:  Relative quantities of circulating and gluteal muscle inflammatory 
cytokines of mature and aged horses1 
 
1Values are least squares means ± SEM. 
  
Inflammatory Cytokine Mature Aged Pooled SEM 
Circulation 
IFNγ 1.23 1.58 0.22 
TNFα 1.11 1.35 0.18 
IL-6 1.63 1.71 0.77 
IL-1β 1.16 1.14 0.13 
IL-10 1.21 0.72 0.22 
Muscle 
IFNγ 1.02 1.5 0.43 
TNFα 0.43 0.64 0.23 
IL-1β 2.61 5.06 2.53 
IL-10 0.24 0.52 0.17 
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Table 6.4: Whole-body phenylalanine kinetics in mature and aged horses1. 
Mature Aged Pooled SEM 
Phenylalanine flux [μmol/(kg·h)] 
 41.5 42.2 2.3 
Carbon dioxide production [μmol/(kg·h)] 
 16977 15080 1410 
Phenylalanine entering the free phenylalanine pool [μmol/(kg·h)]2 
Phenylalanine from dietary intake 4.0 3.9 0.08 
Phenylalanine from protein 
breakdown 
37.5 37.5 2.2 
Phenylalanine leaving the free phenylalanine pool [μmol/(kg·h)]2 
Phenylalanine oxidation 13.2 16.7 1.6 
Non-oxidative phenylalanine 
disposal 
28.3 25.5 2.7 
1Values are least squares means ± SEM. 
2The following stochastic model of phenylalanine kinetics was used: flux = rate of 
phenylalanine entry = rate of phenylalanine leaving; rate of phenylalanine entry = 
phenylalanine intake + phenylalanine release from protein breakdown; rate of 
phenylalanine leaving = phenylalanine oxidation + non-oxidative phenylalanine disposal. 
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6.6.  FIGURES 
 
Figure 6.1.  Gluteal muscle phosphorylation of Akt at Ser473, Akt at Thr308, S6K1 at 
Thr389, rpS6 at Ser235/236 & 240/244, and 4EBP1 at Thr 37/46 in mature and aged horses 
following 7.5-hours of steady state feeding.  The phosphorylated forms of the 
translation initiation factors was corrected by the respective total form abundance, with 
the value for mature horses set at 1.0 AU.  Values are least square means ± pooled SE, 
n=6 per age group.  Representative images of the immunoblots are shown above. 
*Indicates that, within a translation initiation factor, the value is significantly different (P 
< 0.05) from the mature horse value. 
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Chapter VII 
Whole body protein synthesis is improved following non-steroidal anti-inflammatory 
drug administration to aging horses 
7.1.  INTRODUCTION 
Aging has been associated with low grade chronic inflammation in humans (495), 
rodents (493), and horses (483) and is referred to as “inflamm-aging”.  Chronic 
inflammation is characterized by elevated levels of circulating inflammatory cytokines, 
which have been linked with decreased physical performance and increased incidence of 
injury (553, 554), as well as with the development of sarcopenia in the elderly (553) and 
in aged horses (532).  Additionally, the population of aging horses has been estimated at 
7.6% and in some regions over 20% of all horses (523, 533).  Older horses may 
demonstrate visible signs of aging such as loss of muscle mass and are usually horses 
over the age of 20 years old (523).  Sarcopenia is the involuntary loss of muscle mass and 
strength, and has been partially attributed to a multitude of factors which include a 
decline in physical activity and a less than optimal diet (149, 150, 553), and results from 
a shift in the balance between protein synthesis and breakdown.  Sarcopenia has been 
partly attributed to reduced protein synthesis and activation of translation initiation 
factors in response to anabolic stimuli such as amino acid administration (149, 155), 
insulin (165), or exercise (149, 538).  Further, systemic inflammation in the aged has also 
been associated with decreased activation of translation initiation factors in response to 
various anabolic stimuli (155) and with lower rates of muscle protein synthesis (493); 
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however, the effects of aging on muscle protein metabolism have not been fully 
elucidated in the horse. 
Protein synthesis is limited by both the abundance and efficiency of ribosomes to 
translate mRNA into protein and the availability of amino acids to form a protein (128), 
which is regulated by a series of intracellular signaling cascades associated with the 
mammalian target of rapamycin (mTOR) pathway.  Insulin and insulin like growth factor 
phosphorylate Akt through the activation of several intermediate signaling proteins (16, 
18, 19, 21).  Activation of Akt inactivates the mTOR inhibitor tuberous sclerosis complex 
2 through phosphorylation (19, 21), allowing for the phosphorylation of mTOR.  The 
phosphorylation of mTOR can also be stimulated by amino acids (45, 46, 497) and 
exercise (149, 488, 538), through separate Akt-independent mechanisms.  Phosphorylated 
mTOR phosphorylates and activates two downstream signaling proteins: ribosomal S6 
Kinase 1 (S6K1) and eukaryotic initiation factor 4E-binding protein-1 (4EBP1). 
Phosphorylation of S6K1 results in the activation of ribosomal protein S6 (rpS6) (498), a 
component of the 40S ribosomal subunit (498).  Therefore, the phosphorylation of rpS6 
and 4EBP1 result in the activation of the translational equipment, allowing protein 
synthesis (21, 537). 
The decline in the responsiveness of translation initiation factors and subsequent 
protein synthesis to various anabolic stimuli with aging in rodents (538) and humans 
(149, 155) has been associated with elevated systemic inflammation (155, 493).  In aged 
rodents with systemic inflammation, the administration of a NSAID was able to increase 
muscle protein synthesis (335), but to the best of our knowledge, this has not been 
studied at the whole-body level in any species.  We hypothesized that daily NSAID 
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administration would reduce systemic and muscle inflammation in aged horses and 
increase whole-body and muscle protein synthesis.  The objective of this study was to 
determine the effects of NSAID administration over 4 weeks on the activation of mTOR 
signaling and whole-body protein synthesis in aged horses. 
7.2.  MATERIALS AND METHODS 
7.2.1.  Animals, housing, and feeding 
The University of Kentucky Institutional Animal Care and Use Committee (2009-
0562) approved all procedures used in this study.  Six mixed breed aged (23.5 ± 2.6 y 
old; 3 geldings and 3 mares) horses were obtained from the University of Kentucky 
Veterinary Sciences’ Maine Chance Farm.  Prior to selection, the pool of candidate 
horses were screened for plasma α-melanocyte stimulating hormone concentration, a 
marker of pituitary pars intermedia dysfunction (PPID; Equine Cushing’s Disease) (539, 
555), and horses below the normal cut-off value of < 35 pmol/L  were selected (539, 
555).  Selected horses were of a moderate body condition (body condition score 5-7, 
scale 1-9 (489)), were clinically healthy with all of their teeth and the ability to live 
outdoors in a group housing environment, and on a regular farrier, anthelmintic, dental, 
and vaccination regiment.  Horses were group housed on dry lots with ad libitum acess to 
salt and water.  Grass hay (mean ± SD; 0.91 ± 0.02 Mcal/kg DE, 8.2 ± 0.8% CP; 48.3 ± 
0.3% ADF; 76.5 ± 1.4% NDF; 2.0 ± 0.5% crude fat; and 7.0 ± 0.5% ash) was provided to 
the group at 2% of body weight per day and omeprazole (Gastroguard® Merial Limited, 
Duluth, GA) was administered at preventative dose rate of 1.2 mg/horse/d.  Horses were 
brought into 3.7×3.7 m stalls and individually fed the concentrate ration twice daily at 
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0800 and 1500.  The concentrate ration consisted of a 50:50 mixture of a ration balancer 
pelleted feed (Chapter VI) and oats (Chapter VI) at 0.2% of body weight per day.  Horses 
were adapted to diet, omeprazole administration and housing protocols for 2 weeks prior 
to the initiation of experimental procedures.  During the isotope infusion procedures 
horses were housed in 3.7×3.7 m stalls bedded with pine shavings with ad libitum access 
to water and salt. 
7.2.2.  Experimental procedures 
There were 3 sampling periods before NSAID administration commenced (0 
week of NSAID administration), and then following 2 and 4 weeks of NSAID 
administration.  The following sampling procedures which were described in detail 
(Chapter VI) were repeated during each of the sampling periods.  Briefly, at 0800 on day 
0, following the two week adaptation, horses were weighed fed the morning concentrate 
meal at 0.1% of body weight and their individual portion of hay at 2% of body weight per 
day in individual stalls.  Horses remained in stalls throughout the sampling period.  At 
this time a blood sample was collected into PAXgene™ Blood RNA tubes (Quiagen, 
Inc., Santa Clarita, CA) via jugular vein venipuncture to measure circulating 
inflammatory cytokines via qRT-PCR analysis, described below.  Horses were fed their 
afternoon concentrate meal at 1500.  On d1, horses remained in the individual stalls and 
received feed as described above. 
On day 2, horses were individually fed the morning concentrate meal as described 
above.  Following morning meal consumption, two indwelling jugular vein catheters (14 
gauge X 14.0 cm, Abbocath; Abbott Laboratories, North Chicago IL) were placed using 
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aseptic techniques as previously described (2): one for isotope infusion and one for blood 
sampling.  At this time, fat thickness on the croup near the site of biopsy was 
ultrasounded in order to calculate percent body fat (481).  At 1100 all forage, water and 
salt were removed, and 2 hours later a baseline blood sample (10 mL) was collected into 
an evacuated vacutainer (Vacutainer; Becton-Dickinson, Franklin Lakes NJ) containing 
sodium heparin prior to the bolus intravenous administration of deuterium oxide (Sigma-
Aldrich, St. Louis, MO) at 0.15 g/kg BW.  Three hours following deuterium oxide 
infusion a second blood sample was collected, in order to determine changes in total body 
water, as an indicator of body composition alterations, during the 4 weeks of NSAID 
administration.  Deuterium oxide infusion measurements were performed during the 0 
and 4 week sampling period.  Salt, water and forage were returned at 1630 with the 
addition of the evening concentrate meal.  The removal of all feed and water was 
necessary for the measurement of body water using deuterium oxide isotope techniques. 
On day 3, whole-body phenylalanine kinetics were measured using primed, 
constant stable isotope infusions as previously described (Chapter VI).  During the 
whole-body phenylalanine kinetic measurements, horses were fed half of the daily 
concentrate allocation divided into 24 equal portions, with 1 portion fed every 30 minutes 
for 7.5 h, with the initial portion provided 1.5 h prior to the start of isotope 
administration.  Each horse received a 14.4 μmol/kg primed dose of [13C] sodium 
bicarbonate solution (Isotec™, Miamisburg, OH), followed by a 2-h constant infusion at 
12 μmol/kg/h in order to measure total CO2 production (540).  This was followed by a 4-
h primed (8.4 μmol/kg), constant (6 μmol/kg/h) infusion of [1-13C]phenylalanine solution 
(Isotec™, Miamisburg, OH) in order to measure whole-body phenylalanine oxidation and 
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flux (541).  The isotope filled ethylene vinyl acetate bags were attached to a surcingle and 
connected to the catheter using a primary IV set (Baxter Healthcare Corporation, 
Deerfield, IL).  Isotope was delivered into the catheter using a pressure sensitive, cordless 
intravenous infusion pump (J-1097 VetPro Infusion Pump, Jorgensen Laboratories Inc., 
Loveland, CO) which was also attached to the surcingle on each horse. 
Two baseline breath samples were collected prior to the [13C] sodium bicarbonate 
infusion (-30 min and 0 min), and subsequent breath samples were collected every 30 
min throughout the infusion procedures of both [13C] sodium bicarbonate and [1-
13C]phenylalanine for a total of 6.5 h.  Breath samples were collected using a modified 
Equine Aeromask® (Trudell Medical International, London ON, Canada) enabling the 
collection of air through a 1-way valve into gas impermeable bags (Wagner Analysen 
Technik Vetriebs GmbH, Bremen, Germany).  Immediately following each sample 
collection, another 1/24 meal was provided.  Blood sampling commenced at 90 min into 
the [13C]sodium bicarbonate infusion, and continued every 30 min until the end of the [1-
13C]phenylalanine infusion.  All blood samples were collected into evacuated vacutainers 
(Vacutainer; Becton-Dickinson, Franklin Lakes NJ) containing sodium heparin.  The t= 
90 min [13C]sodium bicarbonate and t= 0 min [1-13C]phenylalanine blood samples were 
used to measure the background amounts of [1-13C] phenylalanine in the blood, prior to 
isotope infusion. 
At the end of the [1-13C]phenylalanine infusion, the infusion pumps were turned 
off and the horses were led to a set of equine stocks.  Horses were lightly sedated with 
xylazine hydrochloride (0.3mg/kg, IV [100mg/mL]; Butler Animal Health Supply, 
Dublin, OH), and a gluteal muscle biopsy was collected as previously described (2).  
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Briefly, the area over the middle gluteal muscle (~100-cm2) was shaved, aseptically 
prepared, and desensitized with a local anesthetic (12 mL of 2% lidocaine; Butler Animal 
Health Supply, Dublin, OH).  Approximately 500 mg of muscle biopsy specimen was 
obtained at a depth of approximately 50% (~8 cm; Chapter III; Chapter V) of the depth of 
the middle gluteal muscle, by use of the percutaneous needle biopsy technique (411).  Of 
this, ~100 mg was processed in preparation for Western blot analysis, as described below, 
and ~ 80 mg was stored in RNAlater (Quiagen, Inc., Santa Clarita, CA) for qRT-PCR 
analysis of inflammatory cytokines as described below.  The remainder was flash frozen 
in liquid nitrogen, and stored at -80ºC until analysis.  Catheters were removed and 1 g of 
phenylbutazone was administered following muscle biopsy collection.  At this time, 
horses were given the remaining portions of concentrate and their daily allotment of hay 
as a single meal.  Following consumption of the evening meal, horses were returned to 
the drylot.  For the next 4 weeks, 2g/d of phenylbutazone paste (Butler Animal Health 
Supply, Dublin, OH) was administered to the horses; 1g was given orally prior to each 
meal.  The experimental procedures were repeated following 2 weeks and 4 weeks of 
phenylbutazone administration.  Samples of the grass hay, ration balancer pellet, and oats 
were collected throughout the experimental period and sent to Dairy One Forage 
Laboratory (Ithaca, NY) for nutrient analysis.  
7.2.3.  Sample analysis procedures 
7.2.3.1.  Blood sample collection and storage:  Blood samples collected for qRT-PCR in 
PAXgene™ Blood RNA tubes (Quiagen, Inc., Santa Clarita, CA) were gradually frozen 
to -80oC per manufacturer instructions and remained at -80oC until analysis.  The 
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remaining blood samples were immediately centrifuged at 1,500 x g for 10 minutes at 
4ºC, and aliquots of plasma samples were frozen at -20ºC until the time of analysis.   
7.2.3.2.  Plasma glucose and insulin:  Plasma glucose concentrations were assayed 
enzymatically using a YSI 2700 SELECT™ Biochemistry Analyzer (YSI Inc., Life 
Sciences, Yellow Springs, Ohio).  Plasma insulin concentrations were determined using 
Coat-A-Coat RIA®kit (Siemens Healthcare Diagnostics Inc., Deerfield, IL). 
7.2.3.3.  Amino acids:  Samples of grass hay, pelleted concentrate, and oats were 
hydrolyzed for 24 hours at 110oC in 6N HCl.  Total amino acid concentrations of the 
hydrolysates were then measured using reverse-phase HPLC (3.9 x 300 mm PICO-TAG 
reverse phase column; Waters, Milford MA) of phenylisothiocyanate derivatives as 
previously described (2).  The plasma free amino acid concentrations were also measured 
using reverse-phase HPLC (3.9 x 300 mm PICO-TAG reverse phase column; Waters, 
Milford MA) of phenylisothiocyanate derivatives as previously described (2). 
7.2.3.4.  Plasma phenylalanine enrichment:  The isotopic enrichment of phenylalanine 
(the amount of [1-13C]phenylalanine relative to unlabeled phenylalanine) in the plasma 
samples collected on day 3 was determined by Metabolic Solutions, Inc. (Nashua, NH) 
using a previously described method (543) which was modified by Matthews, Persola 
and Campbell (544) (Chapter VI). 
7.2.3.5.  Muscle phenylalanine enrichment:  Approximately 25-30 mg of flash frozen 
muscle tissue was sent to Metabolic Solutions, Inc. (Nashua, NH) for the determination 
of mixed-muscle protein and intracellular 1-13C-phenylalanine enrichment ((545); 
Chapter VI). 
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7.2.3.6.  Breath sample analysis:  The ratio of 13CO2:12CO2 in the breath samples was 
determined using an isotope selective non-dispersive infrared absorption (NDIR) 
analyzer (IRIS-2; Wagner Analysen Technik Vetriebs GmbH, Bremen, Germany) 
(Chapter VI). 
7.2.3.7.  Western blot analysis of muscle samples:  The abundance of the total and 
phosphorylated forms of Akt, S6K1, rpS6, and 4E-BP1 in the gluteal muscle 
homogenates were determined using electrophoresis followed by Western blotting 
techniques (Chapter III). 
7.2.3.8.  Real time polymerase chain reaction.  Pro -inflammatory cytokines, IFN-γ, IL-
1β, IL-6 and TNFα, and the anti-inflammatory cytokine IL-10 mRNA expressions were 
measured in cDNA samples using equine specific intron-spanning primer/probe sets 
((244, 484); Chapter IV). 
7.2.4.  Calculations and statistical analysis 
7.2.4.1.  Fat free mass.  Fat free mass was calculated from ultrasonic fat depth as 
previously described (Chapter VI). 
7.2.4.2.  Plasma phenylalanine enrichment.  Isotope enrichment in mol % excess was 
calculated from peak area ratios at isotopic steady state and baseline (Chapter VI).  The 
final value for all determinations was corrected using an enrichment calibration curve 
(Chapter VI). 
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7.2.4.3.  Breath CO2 enrichment.  The equation used to convert the δ enrichment value 
obtained from the NDIR analyzer for each sample to a % enrichment was described in 
Chapter VI. 
7.2.4.4.  Whole-body phenylalanine kinetics.  The average plasma enrichment at isotopic 
steady state (plateau) was used to calculate whole-body phenylalanine kinetics, and was 
described in Chapter VI. 
7.2.4.5.  Relative quantity of inflammatory cytokines.  Changes in mRNA expression 
were calculated using the ΔΔCT method ((244, 484); Chapter IV), with the mean ΔCT 
averaged for all horses during the week 0 sampling period set as the calibrator for each 
individual cytokine.  Results are expressed as relative quantity (RQ) calculated as 2-ΔΔCT 
(Chapter IV). 
7.2.4.6.  Statistics.  All data were analyzed using in the PROC MIXED procedure of SAS 
Version 9.2 (SAS Institute Inc., Cary, NC), with statistical significance and trends 
considered if P < 0.05 and 0.05 < P < 0.10, respectively.  When the fixed effect was 
significant, pre-planned comparisons of least squares means were made using the pdiff 
test.  All of the dependent variables were analyzed using repeated measures with the 
fixed effect of time on NSAID and horse nested in block as the random subject.  For all 
repeated measures analysis, the variance-covariance matrix was chosen for each analysis 
based on the lowest value for Schwarz’s Bayesian Criterion.  Data are presented as means 
± pooled standard error unless otherwise noted. 
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7.3.  RESULTS 
7.3.1.  Equine demographics 
 All horses remained healthy and maintained their body weight (P = 0.87; 0 weeks 
on NSAID: 499±35 kg; 4 weeks on NSAID: 500±35 kg) throughout the experimental 
period.  Additionally, there was no change in fat free mass calculated from ultrasounded 
rump fat thickness (481) (P = 0.75; 0 weeks on NSAID: 448±30 kg; 4 weeks on NSAID: 
451±30 kg).  The measurements of fat free mass that these horses maintained 
approximately 10% body fat throughout the study procedures. 
7.3.2.  Plasma metabolites 
There was no effect of time on NSAID on the plasma insulin (P = 0.37; Table 7.1) 
or glucose (P = 0.12; Table 7.1) concentrations at the time of biopsy.  Plasma 
concentrations of Ala, Asp, Glu, Ile, Leu, Lys, and Thr decreased with time on NSAID (P 
< 0.05; Table 7.1) at the time of biopsy.  Arg, Gln, and Gly plasma concentrations at the 
time of biopsy increased with time on NSAID (P < 0.05; Table 7.1).  Plasma 
concentrations of Phe and Trp at the time of biopsy decreased at week 2 of NSAID 
administration, and then returned to baseline concentrations by week 4 of NSAID 
administration (P < 0.05; Table 7.1).  There was no effect of time on NSAID (P > 0.05) at 
the time of biopsy on plasma concentrations of Asn, His, Met, Pro, Ser, Tyr, and Val. 
7.3.3.  Inflammatory cytokines 
 Time on NSAID did not affect mRNA expression of the circulating inflammatory 
cytokines: IL-1β (P = 0.22; Figure 7.1), IL-6 (P = 0.20; Figure 7.1); IL-10 (P = 0.42; 
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Figure 7.1); IFNγ (P = 0.40; Figure 7.1), and TNFα (P = 0.72; Figure 7.1).  The muscle 
mRNA expression of IL-1β decreased with time on NSAID (P = 0.02; Figure 7.2).  
However, there was no effect of time on NSAID on the mRNA expression of muscle IL-
10 (P = 0.86; Figure 7.2), IFNγ (P = 0.15; Figure 7.2), or TNFα (P = 0.15; Figure 7.2).  
There was limited detection of muscle IL-6 mRNA expression; where expression was 
only detected in 1 horse prior to NSAID administration, 2 horses following 2 weeks of 
NSAID administration, and 1 horse following 4 weeks of NSAID administration. 
7.3.4.  Activation of translation initiation factors 
 There was no effect of time on NSAID on the activation of Akt at Ser473 (P = 
0.14; Figure 7.3) and Thr308 (P = 0.52; Figure 7.3), rpS6 at Ser235/236 & 240/244 (P = 0.14; 
Figure 7.3), or 4EBP1 at Thr37/46 (P = 0.53; Figure 7.3).  However, the activation of S6K1 
at Thr389 showed a trend to increase following 2 weeks of NSAID administration and then 
returned to baseline following 4 weeks of NSAID administration (P =0.09; Figure 7.3). 
7.3.5.  Whole-body protein synthesis 
 Although there was no effect of time on NSAID on whole-body CO2 production 
(P = 0.41; Table 7.2), phenylalanine flux (P = 0.55; Table 7.2), phenylalanine oxidation 
(P = 0.28; Table 7.2), or phenylalanine release from protein breakdown (P = 0.53; Table 
7.2), there was an increase in non-oxidative phenylalanine disposal (P = 0.02; Table 7.2).  
An increase in non-oxidative phenylalanine disposal with time on NSAID is indicative of 
an increase in phenylalanine used for whole-body protein synthesis with time on NSAID. 
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7.3.6.  Muscle phenylalanine enrichment 
 There was no effect of time on NSAID on free (P = 0.64; Table 7.3) or protein 
bound (P = 0.18; Table 7.3) enrichment of [1-13C] phenylalanine in the gluteal muscle.  
Because we only collected a single biopsy at the end of the isotope infusion period, we 
could not measure the changes in [1-13C] phenylalanine incorporation into protein over 
time and could not calculate muscle fractional synthesis rates.  However, if the 
assumption is made that there were no initial differences in muscle bound enrichments of 
[1-13C] phenylalanine on each sampling day, then no change with time on NSAID at the 
end of the isotope infusion periods in both free and protein bound fractional muscle 
enrichment of [1-13C] phenylalanine implies no effect of NSAID administration on 
muscle protein fractional synthesis rates. 
7.4.  DISCUSSION 
This is the first time whole-body protein kinetics and mTOR signaling have been 
examined in the aging horse during NSAID administration.  The oral administration of a 
NSAID, phenylbutazone, at a rate of 2g/day reduced the mRNA expression of IL-1β in 
skeletal muscle, increased whole-body protein synthesis, and tended to increase the 
phosphorylation of S6K1 following 7.5 hours of steady state feeding.  The results of the 
present study indicate that NSAID administration in aged horses may ameliorate the 
blunted response of protein synthesis to anabolic stimuli that is seen in aging mammals. 
The horses used in this study were also used in the companion study (Chapter VI), 
and were characterized as healthy aging horses.  We previously (Chapter VI) determined 
this group of aging horses to be similar to mature horses in body fat mass and weight, 
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circulating and muscle inflammatory cytokines, and to be clinically normal with no signs 
of PPID, as plasma α-MSH concentrations were within the clinically normal reference 
range (539, 555). 
 The reduction in the muscle mRNA expression of IL−1β indicates the 
effectiveness of the phenylbutazone administration of 2 g per day at reducing 
inflammation in the current study.  We have previously (Chapter IV) demonstrated that 
this dose of phenylbutazone was effective at preventing the increase in the mRNA 
expression of IL−1β in skeletal muscle following the collection of 5 days of repeated 
biopsies.  Collectively, these studies may indicate that IL−1β mRNA expression in 
skeletal muscle is responsive to phenylbutazone treatment.  However, there was no effect 
of phenylbutazone administration on the mRNA expression of IFNγ, IL-6, TNFα, and IL-
10 in skeletal muscle or IL−1β, IFNγ, IL-6, TNFα, and IL-10 in circulation in the present 
study.  The lack of an effect of NSAID administration on circulating inflammatory 
cytokines may be due to the fact that the aged horses (23.5 ± 2.6 y old) used in the 
present study did not have elevated levels of circulating inflammatory cytokines 
compared to older (11 ± 2.6 y old) mature horses (Chapter VI).  Additionally, this study 
was designed to determine differences in protein metabolism, where a sample size of 6 is 
large enough to detect statistical differences (Urschel et al., University of Kentucky, 
submitted; Chapter VI); however, previous studies used a minimum of 8 horses (484) 
when studying changes in circulating inflammatory cytokines in response to experimental 
treatments.  As a result, there may not have been enough statistical power to detect 
differences in inflammatory cytokine production in response to NSAID treatment.  The 
extended use (5 months) of oral NSAID administration has been shown to reduce 
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circulating inflammatory cytokines (IL−1β, and IL-6),in the aged rodent (335).  The 
reduction in circulating inflammatory cytokines may occur after prolonged NSAID 
administration, which would explain the lack of an effect of a short term (4 weeks) of 
oral NSAID administration on circulating inflammatory cytokines in the present study.  
The studies examining the effect of NSAID administration on muscle inflammatory 
cytokines in the aged are limited; however, there is an abundance of literature examining 
the reduction of post-exercise skeletal muscle inflammation by NSAID, where NSAID 
administration reduced post-exercise inflammatory cytokines (332, 333).  It is important 
to recognize that post-exercise inflammation is an acute inflammatory response, whereas 
aging is characterized as low grade chronic inflammation; therefore, further research is 
needed to examine the effects of oral NSAID administration on skeletal muscle 
inflammatory cytokine production during chronic inflammation.  Although 
phenylbutazone administration has been implicated with the development of gastric 
ulcers in horses (323, 556) we do not believe there were any adverse effects in the horses 
in the present study.  All horses maintained an appetite, body weight and lean mass 
throughout the four week study period, which may be partly attributed to the 
administration of omeprazole for the prevention of gastric ulcers (557).  Ultimately, we 
believe the dose of phenylbutazone in the present study was effective at reducing some of 
the chronic inflammation associated with aging, because of the reduction of muscle 
IL−1β. 
Variations in whole-body protein metabolism between mature and aged humans, 
suggest that the aged population may have a higher protein requirement (202).  Within 
the aged population, presence of low grade inflammation in circulation may be partially 
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responsible for to the reduced muscle protein fractional synthesis rates in the postprandial 
state (493).  However, both whole-body protein synthesis and muscle protein fractional 
synthesis do not vary between these age groups during the post-absorptive state (186, 
493).  In the present study, there was a 77% increase in whole-body non-oxidative 
phenylalanine disposal, which is an indirect measure of protein synthesis, with the 
administration of oral NSAID for 4 weeks.  This is consistent with the results of a 
previous study (335), where oral administration of ibuprofen reduced in circulating levels 
of inflammatory cytokines and increased muscle fractional synthesis rates in aged 
rodents.  Additionally, the present study demonstrated a reduction in the plasma 
concentrations of the indispensable amino acids, Ile, Leu, Lys, Phe, Thr, and Trp with 
time on NSAID, which is suggestive of an increase in the incorporation of these amino 
acids to support the synthesis of new proteins.  Together the decreased plasma amino 
acids and increased whole-body protein synthesis indicates that oral administration of a 
NSAID may reduce inflammation and increase whole-body protein synthesis.  Studying 
whole-body protein metabolism is a useful tool to examine the subject in its entirety; 
however, it does not allow researchers to isolate the tissues that are responsible for the 
alterations seen at the whole-body level.  Because skeletal muscle comprises 
approximately 25% of whole-body protein synthesis (198, 199), it is possible that 
alterations seen at the whole-body level are due to changes in protein metabolism in 
skeletal muscle, although additional research is necessary to identify the specific tissues 
most affected by NSAID administration.  
Our original hypothesis was that protein synthesis in the skeletal muscle would 
increase following NSAID treatment; however, there was only limited evidence that 
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muscle protein metabolism was altered by NSAID treatment.  Of the translation initiation 
factors studied, S6K1 appears to be the most affected by aging (Chapter VI) and NSAID 
administration.  The phosphorylation of S6K1 at Thr389 tended to be elevated 118% 
following 2 weeks of NSAID administration and then returned to baseline following 4 
weeks of NSAID administration.  The increase in the phosphorylation of S6K1 following 
2 weeks of NSAID administration coincided with a 59% reduction in skeletal muscle 
IL−1β mRNA expression which remained reduced by week 4, and no change in whole-
body protein synthesis or breakdown.  Oral administration of ibuprofen for 5 months to 
rodents resulted in a postprandial elevation in muscle protein fractional synthesis rates 
and reduced circulating inflammatory cytokines, but there were no differences in the 
activation of any of the mTOR signaling factors studied (335), which is in agreement 
with the results from the present study.  However, there were no differences in muscle 
protein fractional synthesis rates or mTOR signaling with 5 months of oral administration 
of ibuprofen to aging rodents in the post-absorptive state (335). 
One of the aims of the experimental protocol was to measure whole-body protein 
kinetics, which necessitated keeping all of the horses in a steady state during the infusion 
procedures.  This was achieved through the consumption of small meals every 30 minutes 
which consisted of half of their daily concentrate allocation (0.1% BW) divided into 1/24 
portions.  This feeding protocol placed plasma glucose (0 week: 5.3 ± 0.2 mmol/L; 2 
weeks: 5.5 ± 0.2 mmol/L; 4 weeks: 5.1 ± 0.2 mmol/L), insulin (0 week: 6.1 ± 0.8 
μIU/mL; 2 weeks: 10.1 ± 0.8 μIU/mL; 4 weeks: 7.9  ± 0.8 μIU/mL), and total 
indispensable amino acid (0 week: 670 ± 40 μmol/L; 2 weeks: 607 ± 40 μmol/L; 4 
weeks: 571  ± 40 μmol/L) concentrations of these horses at the time of biopsy in a 
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physiological state that more closely resembled a post-absorptive state (glucose: 5.5 
mmol/L; insulin: 5 mU/L; total indispensable amino acids: 898 μmol/L) (2) rather than 
the postprandial state (glucose: 6.5 mmol/L; insulin: 36 mU/L; total indispensable amino 
acids: 1245 μmol/L) (2).  In addition, the whole-body protein metabolism data indicated 
that these horses were in a post-absorptive state, because the indirect measure of protein 
synthesis, non-oxidative disposal, was less than phenylalanine from protein breakdown 
(185).  Since our horses were in a post-absorptive state, the lack of an effect of NSAID 
administration on mTOR signaling factors is consistent with previous findings (335). 
Because this is the first study to examine the effects of oral administration of a 
NSAID with the aim of reducing inflammation and examining whole-body protein 
metabolism, there is ample room for additional research.  In the present study, horses 
received a short course (4 weeks) of oral NSAID, which proved to reduce muscle 
inflammation and increase whole-body protein synthesis; however, administration of oral 
NSAID over a longer course may be necessary to examine mechanistic changes in 
skeletal muscle.  Additionally, in the present study horses were examined in a post-
absorptive state, and although we saw an increase in whole-body protein synthesis, 
examining horses in the postprandial state during oral NSAID administration will be 
useful in determining if these alterations seen at the whole-body level will translate to 
skeletal muscle. 
The use of daily administration of a NSAID for 4 weeks to horses in the present 
study was a tool to aid in the elucidation of the mechanism behind reductions in protein 
synthesis with aging.  Although the results of the present study show promise, that with 
reduced inflammation there was an increase in whole-body protein synthesis, it would not 
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be practical or acceptable to horse owner to advocate the daily administration of an 
NSAID for an extended period of time to aging horses.  Rather, the objectives of the 
present study were to examine from a mechanistic standpoint whether the reduction in 
chronic inflammation would have beneficial effects on whole-body and muscle protein 
metabolism.  We chose to use phenylbutuzane as our anti-inflammatory agent because of 
its known anti-inflammatory properties (321) and because it is structurally related to 
ibuprofen, which has previously been shown to increase rates of muscle protein synthesis 
in aged rodents (335).  This study provides initial insight the potential impact of chronic 
inflammation on protein metabolism in the aged horse and is the first step towards 
investigating other means of reducing inflammation in the aged population through 
alterations in the diet or by other strategies.  For example, resveratrol supplemented to the 
diet has showed promise in reducing inflammation in horses through inhibiting the 
formation of reactive oxygen species (558).  Ultimately, there is a need to examine the 
diet of the aging equine population and discover practical methods of reducing 
inflammation which will allow for an increase in whole-body, and hopefully muscle, 
protein synthesis. 
NSAID administration affects aging equine skeletal muscle by tending to elevate 
S6K1 activation after 2 weeks, which coincided with a reduction in mRNA expression of 
IL−1β, and was followed by an increase in whole-body protein synthesis.  Although 
additional research is needed to further elucidate the mechanistic effect that inflammation 
has on both whole-body and muscle protein fractional synthesis, these findings indicate 
that management strategies targeted at reducing inflammation result in  elevations in 
whole-body protein synthesis.  
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7.5.  TABLES 
Table 7.1: Plasma metabolite concentrations at the time of biopsy before NSAID 
administration and following 2 and 4 weeks of NSAID administration in aging 
horses. 
Metabolite 0 weeks 
on 
NSAID 
2 weeks 
on 
NSAID 
4 weeks 
on 
NSAID 
Poole
d 
SEM 
p-Value 
Insulin1 6.1 10.1 7.9 2.0 0.37 
Glucose2 5.3 5.5 5.1 0.2 0.12 
Alanine3 218a 170b 185b 12 0.05 
Arginine 74b 90a 88a 4.9 0.007 
Asparagine 52 54 52 5.8 0.83 
Aspartate 15a 11b 6.7c 1.2 0.002 
Glutamate 49a 35b 28c 2.4 0.0001 
Glutamine 306b 358a 349a 9.3 0.004 
Glycine 441b 467b 520a 54 0.02 
Histidine 64 63 65 3.1 0.75 
Isoleucine 46a 45a 39b 2.6 0.05 
Leucine 87a 79ab 70b 4.3 0.01 
Lysine 92a 86a 69b 5.3 0.01 
Methionine 32 30 29 1.8 0.63 
Phenylalanine 83a 75b 80ab 2.2 0.05 
Proline 97 91 86 5.7 0.24 
Serine 288 277 281 8.3 0.66 
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Table 7.1 continued: Plasma metabolite concentration at the time of biopsy before 
NSAID administration and following 2 and 4 weeks of NSAID administration in 
aging horses. 
Threonine 112a 87b 75c 5.3 0.0001 
Tryptophan 5.3ab 4.3b 6.2a 0.4 0.03 
Tyrosine 55 53 53 2.1 0.63 
Valine 148 138 138 7.1 0.16 
1 Plasma insulin concentrations are reported as least square means in μIU/mL. 
2 Plasma glucose concentrations are reported as least square means in mmol/L. 
3 Plasma amino acids concentrations are reported as least square means in μmol/L. 
abc Differing letters indicate that values are significantly (P < 0.05) different from each 
other. 
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Table 7.2: Whole-body phenylalanine kinetics in aged horses over 4 weeks of NSAID 
administration1. 
 0 weeks of 
NSAID 
administration 
2 weeks of 
NSAID 
administration 
4 weeks of 
NSAID 
administration 
Pooled 
SEM 
p-
value 
Phenylalanine flux [μmol/(kg·h)]  
 42.1 47.7 44.0 3.5 0.55 
Carbon dioxide production [μmol/(kg·h)]  
 15080 16658 14164 1387 0.41 
Phenylalanine entering the free phenylalanine pool [μmol/(kg·h)]2  
Phenylalanine 
from dietary 
intake 
3.9 3.9 3.8 0.06 0.53 
Phenylalanine 
from protein 
breakdown 
37.5 43.2 39.4 3.5 0.53 
Phenylalanine leaving the free phenylalanine pool [μmol/(kg·h)]2  
Phenylalanine 
oxidation 
16.7 17.3 9.4 3.9 0.28 
Non-oxidative 
phenylalanine 
disposal 
25.5a 19.6a 34.6b 3.0 0.02 
1Values are least squares means ± SEM. 
2The following stochastic model of phenylalanine kinetics was used: flux = rate of 
phenylalanine entry = rate of phenylalanine leaving; rate of phenylalanine entry = 
phenylalanine intake + phenylalanine release from protein breakdown; rate of 
phenylalanine leaving = phenylalanine oxidation + non-oxidative phenylalanine disposal 
abValues with different superscript letters are significantly (P < 0.05) different. 
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Table 7.3: Muscle phenylalanine enrichments in aged horses over 4 weeks of NSAID 
administration1. 
 0 weeks of 
NSAID 
administration 
2 weeks of 
NSAID 
administration
4 weeks of 
NSAID 
administration 
Pooled 
SEM 
p-value 
Muscle free enrichments (%)   
 10.1 10.4 11.2 0.8 0.64 
Muscle protein bound enrichments (%)   
 0.41 0.56 0.50 0.08 0.18 
1Values are least squares means ± SEM. 
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7.6.  FIGURES 
 
Figure 7.1.  Circulating inflammatory cytokines (RQ) in aged horses following 0 
weeks, 2 weeks, and 4 weeks of NSAID administration.  Values are least square means 
± pooled SE, n=6 per treatment group. 
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Figure 7.2.  Muscle inflammatory cytokines (RQ) in aged horses following 0 weeks, 2 
weeks, and 4 weeks of NSAID administration.  Values are least square means ± pooled 
SE, n=6 per treatment group. 
abDiffering letters indicate, within an inflammatory cytokine, the values are significantly 
different (P < 0.05). 
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Figure 7.3.  Gluteal muscle phosphorylation of Akt at Ser473, Akt at Thr308, S6K1 at 
Thr389, rpS6 at Ser235/236 & 240/244, and 4EBP1 at Thr 37/46 in aged horses following 0 
weeks, 2 weeks, and 4 weeks of NSAID administration after 7.5-hour of steady state 
feeding.  The phosphorylated forms of the translation initiation factors was corrected by 
the respective total form abundance, with the value for mature horses set at 1.0 AU.  
Values are least square means ± pooled SE, n=6 per treatment group.  Representative 
images of the immunoblots are shown above. 
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Chapter VIII 
Summary, General Discussion and Future Directions 
8.1.  OPTIMIZING METHODOLOGICAL PROCEDURES FOR ASSESSING 
mTOR SIGNALING IN THE HORSE 
 One of the primary objectives of this dissertation was to determine the optimum 
methodological procedures for assessing mTOR signaling in the horse.  Because there 
has only been a single previous study examining mTOR signaling in horses (2), the 
optimum methodological procedures have not been assessed.  The first study in this 
dissertation (Chapter III) examined the effect of sampling depth in the gluteus medius 
muscle on the activation of mTOR signaling in response to feeding and showed that there 
was no effect of sampling depth (6, 8 or 10 cm below the surface of the skin) on the 
activation of any of the mTOR signaling factors in response to feeding in mature horses.  
The focus of the second study in this dissertation (Chapter IV) was to determine the 
effects of conducting percutaneous gluteal muscle biopsy procedures every 24 hours for 5 
days on mTOR signaling in response to feeding in mature horses, both with and without 
NSAID administration.  These results showed that in the absence of NSAID 
administration, obtaining gluteal muscle biopsies every 24 hours for 5 days resulted in the 
decreased activation of Akt and increased the activation of the downstream signaling 
factors (S6K1, rpS6, and 4EBP1) in response to feeding.  On the other hand, there was no 
effect of sampling day on the activation of the downstream mTOR signaling factors in the 
presence of NSAID administration.  A secondary objective this study (Chapter IV) was to 
determine whether there would be differences in mTOR signaling in response to feeding 
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in samples collected from the right and left gluteal muscles at the same time.  The results 
showed that there was no difference in mTOR signaling based on the side of gluteal 
muscle sample.  These initial studies in this dissertation were designed to determine 
optimum sampling methods for assessing mTOR signaling in the horse. 
The results of the first two studies in this dissertation suggest that: 
1. The activation of mTOR signaling in response to feeding in mature horses is 
not affected by biopsy sampling depth as long as samples are collected from 6 
to10 cm below the surface of the skin (Chapter III). 
2. NSAID administration was able to prevent changes in the activation of 
downstream mTOR signaling in response to feeding during 5 days of repeated 
biopsy collection.  Therefore, if study design requires repeated biopsy 
procedures over the course of 24 hours to up to 5 days, NSAID administration 
is recommended to prevent sampling-related changes in mTOR activation 
(Chapter IV). 
3. mTOR signaling in response to feeding from biopsies collected at the same 
time from the same site in the right and left side of the gluteal muscle can be 
compared (Chapter IV). 
These studies were only an initial attempt to determine the optimum 
methodological procedures for assessing mTOR signaling in horses and led to 
several further directions for method development.  Although there was no 
alteration in mTOR signaling in response to feeding in mature horses when 
biopsies were collected at depths ranging from 6 to 10 cm below the surface of 
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the skin (Chapter III), there may have been alterations in mTOR signaling if a 
wider range of depths had been examined, for example, if gluteal muscle depth 
ranged from 2 to 12 cm.  The rodent data has shown that the phosphorylation of 
mTOR (491) and S6K1 (559) in response to contractile activity appears greater in 
Type II than Type I fibers.  The proportion of the different fiber types in the 
gluteal muscle in horses changes with muscle depth, and there is an increase in 
Type I fibers with gluteal muscle depth in the horse (560).  However, the greatest 
changes in fiber type proportions seem to occur between 2 and 6 cm depth, with a 
140% increase in Type I fibers, whereas, changes from 6 to 10 cm in depth 
resulted in no change in Type I fibers (Chapter III).  Therefore, there may be a 
greater activation of downstream mTOR signaling in response to anabolic stimuli 
at a shallower depth of 2 cm than at a deeper depth of 12 cm.  Not only does 
mTOR signaling need to be examined at a wider range of depths, but the different 
types of anabolic stimulus used to activate mTOR signaling must also be 
examined.  Because the anabolic stimuli used in the rodent studies (491, 559) was 
contraction as opposed to feeding, there may have been differences in the 
activation of downstream signaling in response to sampling depth if exercise had 
been used as the anabolic stimuli.  Although contraction and feeding both 
stimulate mTOR signaling, these stimuli act through different upstream factors 
(Section 1.2).  Additionally, in all of the studies in this dissertation muscle 
biopsies were collected from the gluteus medius muscle due to the role of this 
muscle in both locomotion and posture and because external landmarks for 
identifying this muscle have been well described (411).  However, differences in 
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the mitogen activated protein kinase (MAPK) family, a pathway  upstream of 
mTOR signaling (Section 1.2), in response to exercise in mature horses were 
determined when biopsies were obtained from the vastus lateralis and pectoralis 
descendens muscles (470).  The authors chose the vastus lateralis because of the 
involvement of this hind limb muscle in forward movement and the pectoralis 
descendens because of the role in posture, and the MAPK family signaling in 
response to exercise was greater in the vastus lateralis then the pectoralic 
descendens (470).  Additionally, the response of mTOR signaling to contraction 
has been reported to vary due to muscle group in rodents, with greatest activity in 
the tibialis anterior followed by the plantaris and then the soleus (491).  The fiber 
type composition of these muscles in the rodent is tibialis anterior: 3% Type I, 
61% Type IIA, 36% Type IIB; plantaris: 7% Type I, 52% Type IIA, 41% Type 
IIB; and soleus:83% Type I, 17% Type IIA, 0% Type IIB (561).  Therefore, it is 
necessary to determine the response of mTOR signaling in various muscle groups 
to both feeding and exercise because the effect of exercise will likely be greater in 
muscle groups used primarily for locomotion rather than for posture.   
Another important factor to consider in optimizing procedures to study mTOR 
signaling is determining the best time following the anabolic stimuli to obtain the muscle 
biopsy samples.  Previous research (562) has demonstrated that in the gastrocnemius and 
soleus of neonatal piglets 60 and 90 minutes following feeding, there was no difference 
in the abundance of the phosphorylated forms of mTOR, 4EBP1, and S6K1.  As a result, 
in the first study to examine mTOR signaling in horses, Urschel and collegues (2) chose 
to collect gluteal muscle biopsies 90 minutes following feeding in horses.  Their study (2) 
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determined that there was no change in plasma amino acids, insulin and glucose 
concentrations from 60 to 80 minutes post-feeding, indicating that any feed induced 
changes in mTOR signaling due to increased plasma metabolites should not differ 
between 60 and 80 minutes.  Thus, muscle biopsy samples were obtained 60 – 90 minutes 
following the consumption of a high protein meal in the research described in this 
dissertation (Chapters III, IV and V).  However, in order to confirm that the muscle 
samples were obtained at the peak of post-stimuli mTOR signaling, it is necessary to 
determine the time course changes in mTOR signaling in response to feeding in horses. 
The second study of this dissertation (Chapter IV) looked at the effects of 
repeated gluteal muscle biopsies, with biopsies collected every 24 hours for 5 days.  This 
study did not characterize the acute time course changes in mTOR signaling for the first 
24 hours following the initial biopsy.  Although muscle protein fractional synthesis rates 
do not change with multiple muscle biopsies collected between 60, 210 and 240 minutes 
of a 4 hour period (507) or during hourly biopsies over a 6 hour period (508), there has 
not been a single study to examine the effects of repeated multiple biopsy collection 
within a 24 hour period on mTOR signaling.  However, others (248, 563) have examined 
the activation of stress related signaling factors including ERK1/2 and MAPK, which 
influence mTOR signaling (Section 1.2), in response to multiple biopsies.  There is an 
increase in ERK1/2 and MAPK with repeated biopsies collected 30 and 60 minutes 
following the initial biopsy from the same incision site (564).  However, there were no 
alterations in MAPK signaling when repeated biopsies were collected within 126 minute 
period from separate incision sites (248).  Unfortunately, there has not been a study to 
examine the time course changes in MAPK signaling following the collection of a muscle 
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biopsy; however the previous studies (248, 565) have demonstrated that repeated biopsies 
if collected within 2 hours of the initial biopsy from separate incision sites do not alter 
stress related MAPK signaling.  Thus, mTOR signaling should not be altered through this 
mechanism; however, additional research is necessary to elucidate this.  Additional 
research is also necessary to examine the collection of repeated biopsies over a 24-72 
hour period, because the results of the Chapter IV show a greater increase in the 
activation of mTOR signaling in response to feeding 24 hours after the collection of the 
initial biopsy.  The first two studies of this dissertation led to many other areas where the 
knowledge base is lacking and the methods may be improved. 
Although the goal of the last three studies (Chapters V – VII) in this dissertation 
was not to further methodological development, there are methodological lessons that are 
learned from every study.  The goal of the third study in this dissertation (Chapter V) was 
to determine to activation of mTOR signaling in response to feeding in yearlings, two 
year olds and mature horses.  Although the first study in this dissertation (Chapter III) 
showed that sampling depth (6 to 10 cm below the surface of the skin) did not alter 
mTOR signaling in response to feeding in mature horses, there was no way to be sure this 
would hold true in yearlings and two years olds.  Therefore, the decision was made to 
ultrasound the rump fat and gluteal muscle to determine their depths, so that muscle 
biopsy collection could be standardized to 50% of the gluteal muscle depth (Chapter V).  
In this study,  we determined that there was considerable variation in subcutaneous fat 
within and across the age groups (mature horses: 2.07 ± 0.30 cm, 1.7-2.7 cm range; two 
year olds: 1.29 ± 0.49 cm, 0.9-2.1 cm range; yearlings: 1.05 ± 0.18 cm, 0.9 – 1.4 cm 
range), which led to 2 additional considerations.  First, in the initial study (Chapter III) 
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biopsies were collected 6, 8, and 10 cm below the surface of the skin; however, if 
subcutaneous fat in mature horses can vary by a cm, then biopsies were actually being 
collected 4-5 cm, 6-7 cm, and 8-9 cm within the gluteal muscle for the 6, 8 and 10 cm 
depths below the surface of the skin, respectively.  So this variation in collection sites 
may have led to the absence of alterations in mTOR related signaling because there is a 
170% increase in Type I fibers from 4 to 8 cm (560).  The second consideration was that 
because there are alterations in fiber type with development in horses (410, 446-450), it is 
unknown whether 50% of the gluteal muscle is optimum depth for collecting muscle 
biopsies for assessment of differences in mTOR signaling across different ages of horses.  
Therefore, it is also necessary to study mTOR signaling in response to various anabolic 
stimuli at a wide range of gluteal muscle biopsy depths throughout development.   
Another methodological consideration in this study (Chapter V), is that regardless 
of age group, all horses were fed 4g/kg of body weight of high protein pelleted feed 
following an 18 hour period of feed withholding in order to standardize protein intake.  
This standardization met the protein requirement of a mature sedentary horse; however, 
the protein requirements of the yearlings and two year olds differ greatly from that of a 
mature sedentary horse (336).  As a result, this meal only supplied 50 and 72% of the 
daily requirements of the yearlings and two year olds, respectively, and so there was a 
different magnitude of anabolic stimuli used in each of the three ages of horses studied.  
This difference in anabolic stimuli may partly explain why we did not see the 
hypothesized decrease in responsiveness to anabolic stimuli between the adolescent and 
mature horses (Chapter V).  Perhaps rather than examining the response of mTOR 
signaling to a particular protein intake, it may be more valuable for comparison purposes 
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to focus on the response of mTOR signaling to a percentage of protein requirements.  
Because the effects of amino acid concentration on the activation of mTOR signaling is 
dose dependent (101), a potentially graded response of mTOR signaling may exist with 
graded protein requirements (50, 75, 100, 150% of protein requirements) and this should 
be examined in the horse.  Overall, from a methodological perspective Chapter V 
suggests that: 
1. When examining mTOR signaling response to feeding across various age 
groups to standardize feeding by a percentage of protein requirements may be 
more appropriate than standardizing by absolute protein intake. 
Because the samples from the studies described in Chapters VI and VII were 
analyzed at the same time, the methodological lessons for the assessment of mTOR 
signaling in the horse are the same for both studies.  In these studies mTOR signaling was 
examined from gluteal muscle biopsies collected following whole-body protein kinetics 
measurements.  In order to maintain study horses at steady state for the measurement of 
whole-body protein metabolism, horses received half of the daily allocation of 
concentrate divided into 1/24 portions served every 30 minutes for 7.5 hours.  Because 
the whole diet was primarily hay based (2% body weight), each of these small 
concentrate meals only met 0.5% and 0.37% of the daily CP and digestible energy 
requirement, respectively.  The feeding protocol used in this study did not result in 
differences between mature and aged horses in the activation of Akt, rpS6, and 4EBP1, 
and it is unknown whether this was because there were no differences in mTOR signaling 
between these ages of horses or because the small meals did not provide sufficient 
anabolic stimuli to elicit a postprandial mTOR signaling response.  This raises an 
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additional question: at what level of intake (or percent of protein requirements) does 
mTOR signaling increase from the post-absorptive level?  Additionally, it is necessary to 
determine if mTOR signaling is altered by the consumption of a large meal to a similar 
extent as same percent of protein requirements offered as small over a period of time in 
the horse, because feeding a large meal activates mTOR signaling to a greater extent than 
the consumption of the same amount of nutrients through small meals over a period of 
time in neonatal pigs (566).  Therefore, if feeding is to be used as the anabolic stimulus 
for activating mTOR signaling then it may be necessary to administer it as a large meal in 
order for it to be a large enough anabolic stimulus to elicit alterations in mTOR signaling. 
Overall, from a methodological perspective Chapters VI and VII suggest that: 
1. When examining mTOR signaling response to feeding, the feeding stimuli 
must be strong enough to elicit changes in mTOR signaling. 
The focus of the studies of this dissertation were to examine mTOR signaling; 
however, in Chapters VI and VII isotopes were infused with the intention of 
characterizing whole-body protein synthesis and the end point of mTOR signaling, 
muscle protein synthesis.  Although muscle samples were collected following the isotope 
infusion procedures in the studies described in Chapter VI and VII, because only a single 
muscle biopsy was obtained, it was not possible to measure how the amount of isotope 
incorporated in the muscle protein changed over time and so we could not calculate the 
fractional synthesis rates of muscle protein in the horses studied.  Future studies will need 
to collect muscle biopsies during and following isotope infusions in order to calculate 
muscle protein fractional synthesis rates. 
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8.1.1.  Summary of the optimum methodological procedures for assessing mTOR 
signaling in the horse 
 The studies in this dissertation have 5 lessons that should be considered by future 
researchers intending to study mTOR signaling in the horse.  In mature horses, mTOR 
signaling in response to feeding from the right or left side of the gluteal muscle biopsies 
from a depth of 6 to 10 cm below the surface of the skin can be compared; however if 
these biopsies are repeated then a NSAID should be administered in order to avoid the 
confounding effect of biopsy.  Additionally, when examining mTOR signaling in 
response to feeding, the meal should be standardized by a percentage of the animal’s 
protein or amino acid requirement and the researcher must ensure that the level of feeding 
provides a strong enough anabolic stimuli to elicit alterations in mTOR signaling 
compared to the post-absorptive state. 
8.2.  ALTERATIONS IN mTOR SIGNALING THROUGHOUT THE LIFESPAN 
IN HORSES 
 The second major objective of this dissertation was to examine the alterations in 
the activation of mTOR signaling throughout the lifespan in the horse.  mTOR signaling 
in response to feeding in various life stages, including the neonatal period, adulthood, and 
post-adulthood aging, has been characterized in other species.  However, there are no 
studies in any species examining mTOR signaling in the slower growing pre- and post-
pubertal adolescent and relatively few studies examining mTOR signaling and protein 
synthesis in healthy aging animals or humans.  Furthermore, the only studies to examine 
mTOR signaling (2) and protein synthesis (3) in response to anabolic stimuli in the horse 
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have been in mature horses.  As a result, the third study in this dissertation (Chapter V) 
examined developmental changes in the activation of mTOR signaling in response to 
feeding, and the fourth and fifth studies (Chapter VI and VII) examined mTOR signaling 
during post-adulthood aging.  The research described in Chapter V showed that there was 
an increase in mTOR signaling during the postprandial state, compared to the post-
absorptive state, in the gluteal muscle of yearling, two year old and mature horses, and 
the yearlings exhibited a higher degree of sensitivity to anabolic stimuli than the other 
two ages of horses studied.  Specifically, the activation of mTOR signaling factors in 
yearlings appeared to be more sensitive to insulin than for the two year olds and mature 
horses, because there was no difference in the activation of Akt between the age groups 
even though there was an increase in insulin in circulation with development.  The results 
of Chapter VI demonstrated that whole-body protein synthesis and the activation of Akt, 
rpS6 and 4EBP1 did not differ between mature (11 ± 2.6 year old) and healthy aging 
(23.5 ± 2.6 year old) horses.  If taken together, the results of Chapters V and VI may 
suggest that post-natal development alters mTOR signaling to a greater extent than aging; 
however, the magnitude of anabolic stimulus was different in the two studies and 
therefore an additional study examining all of these age groups in response to the same 
anabolic stimuli is necessary.  
 The previous literature examining mTOR signaling throughout the lifespan of 
other mammalian species has focused on alterations in mTOR signaling during the 
postprandial state; however, as discussed earlier (Section 8.1), a true postprandial state 
was not obtained in the horses used for Chapter VI, and therefore, comments on the 
postprandial changes in mTOR signaling throughout lifespan cannot be made.  
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Alternatively, the changes in mTOR signaling during the post-absorptive period 
throughout the lifespan can be commented on.  From the results in the post-absorptive 
state, it appears that mTOR signaling is altered to a greater extent by aging than during 
development.  The evidence of this was shown by the lowered abundance of the 
phosphorylated form of S6K1 in the aging horses compared to the mature horses in 
Chapter VI and no difference in the abundance of the phosphorylated form of S6K1 
during the post-absorptive state between yearlings, two year olds and mature horses in 
Chapter V.  Examination of mTOR signaling during the post-absorptive period in the 
neonatal piglet demonstrated no change in mTOR signaling with neonatal development in 
skeletal muscle (129).  Additionally, in humans there is no change in mTOR signaling 
during the post-absorptive period during post-adulthood aging (157).  Muscle protein 
fractional synthesis rates are also not altered by development (157) or aging (157) during 
the post-absorptive state.  Thus, the results of our studies uniquely indicate that aging in 
horses may have a greater influence on mTOR signaling during the post-absorptive 
period than it does during adolescent development.  This requires further examination 
during the post-absorptive state in the equine neonate to determine if mTOR signaling is 
regulated more during aging than during any other life stage in the horse.  Although the 
results of these studies Chapter V and VI indicate the post-absorptive alteration in mTOR 
signaling throughout the lifespan, even more valuable information could be obtained by 
studying the equine neonate, mature and aging horse using similar methodologies to that 
used in Chapter V in order to study all horses in a postprandial state.  Not only is there 
more available literature to compare postprandial results to, but in the literature the 
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postprandial state shows differences in the increase in mTOR signaling and subsequently 
protein synthesis across different ages of research subjects. 
 As mentioned in the (Section 8.1), in order to accurately compare mTOR 
signaling in skeletal muscle in response to feeding in different age groups, the meal 
should meet an equal percentage of protein requirements for these animals (i.e. 100% for 
each animal).  However, during the research described in Chapter V, horses consumed an 
equal protein intake which met 100, 72, and 50% of the daily requirements of the mature 
horses, two year olds and yearlings, respectively.  Regardless of the varied requirements, 
the yearlings, who were consuming only 50% of their daily protein intake, had an 
increase in mTOR signaling.  This indicates that if this study were repeated standardizing 
the meal by meeting 100% of daily protein requirements, the anabolic stimuli may likely 
be strong enough to elucidate a potential step wise decrease in mTOR signaling with age, 
with mTOR signaling being the greatest in the yearlings, followed by the two year olds, 
then the mature horses, and possibly the aged horse.  This pattern has been described in 
neonatal piglets and mature and aging humans (129, 157). 
The possible mechanisms of amino acids on mTOR signaling were discussed in 
detail in Section 1.2.2.3.  Briefly, amino acids cause the phosphorylation of S6K1 
through mechanisms that are both dependent and independent on mTOR activation, 
although in both cases amino acids phosphorylate S6K1 independently of Akt.  Of all of 
the amino acids, leucine has the greatest influence of mTOR signaling.  Because the 
greatest postprandial rise in the phosphorylated form of S6K1 occurred in the yearlings 
compared to the two year olds or the mature horses (Chapter V), the yearlings may have a 
greater sensitivity to amino acids than the two year olds or mature horses.  Therefore, the 
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results of this study may indicate that younger horses are more sensitive to amino acids, 
which could be confirmed through examining the responsiveness of mTOR signaling in 
growing, mature and aging horses to different levels of amino acid, or specifically 
leucine, intake.  
 The research described in Chapters V and VI found no developmental (during the 
postprandial and post-absorptive states) or aging (during the post-absorptive state) effects 
on the activation of Akt, regardless of the fact that postprandial circulating insulin 
concentrations increased with age in Chapter V.  As previously mentioned, the mature 
and aging horses in studied in Chapter VI were in a post-absorptive state, and there were 
no alterations in circulating insulin concentrations due to age during this physiological 
state.  However, insulin sensitivity in regards to carbohydrate metabolism has been 
demonstrated to decrease with the age of the horse (481).  The effects of insulin 
sensitivity on protein metabolism has been examined in humans, where young humans 
had a greater increase in muscle protein fractional synthesis rates at the same dose of 
insulin than older humans (161), and only supraphysiological doses of insulin were able 
to improve muscle protein fractional synthesis rates and the activation of Akt and mTOR 
signaling in the aged (159).  Thus, the lack of an increase in Akt activation with increased 
concentration of insulin in the mature horse in Chapter V may be a result of a greater 
degree of insulin resistance in the mature horses.  Therefore, the equal activation of Akt 
in adolescent horses and mature horses (regardless of physiological state; Chapter V) and 
mature horses and aging horses (in the post-absorptive state; Chapter VI) indicates that 
Akt activation is more responsive to insulin in the adolescent horses, or that the Akt 
activation response is maximized at the lowest plasma concentrations of insulin (yearling 
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horses).  However, the latter is unlikely, because unpublished data by Urschel and 
colleagues found that mature horses subjected to a wide range of insulin infusion rates (0, 
1.2, 3, 6 mU/kg/min), resulting in plasma insulin concentrations ranging from 10 – 1000 
mU/L, had a dose dependent increase in Akt activation.  This requires further 
examination across the lifespan with controlled levels of insulin using a 
hyperinsulinemic-euglycemic isoaminoacidemic clamp technique, which would allow for 
the determination of the responsiveness of skeletal muscle Akt to administered insulin 
concentrations, independent of other changes that occur in response to a meal. 
 In addition to advancing the physiological understanding of how stage of 
development and aging alter mTOR signaling in response to feeding, the research 
described Chapters V and VI of this dissertation also have several implications specific to 
the horse.  Based on the results discussed in Chapter V, the mTOR signaling in the 
muscle of young growing horses was more sensitive to feeding stimuli than 2 year old 
horses, which coincides with the fact that the greatest rate of average daily gain occurs in 
the yearlings compared to the 2 year olds (336).  This also indicates that the muscle of 
this age of horse may be more sensitive to other anabolic stimuli such as exercise, 
although this requires confirmation.  A related implication is that if the skeletal muscle of 
younger growing horses is more responsive than that of older growing horses to anabolic 
stimuli, then if some factor, such as illness or poor nutrition, impairs growth and muscle 
accretion during the more responsive younger stages of development, could have lasting 
effects on muscle mass throughout the rest of the lifespan.  Additionally, prolonged 
periods of inactivity or stall rest may be more deleterious in the mature horse compared 
to the growing horse, because the muscle lost during this period would be more difficult 
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to recover due to decreased responsiveness to anabolic stimuli.   In order to slow the loss 
of muscle mass associated with post-adulthood aging, it may be necessary to gain a better 
understanding of the factors regulating muscle protein metabolism the mature horse first, 
especially in response to exercise.  Reducing both insulin resistance and inflammation 
will improve protein synthesis in response to feeding; this may reduce the loss of muscle 
mass associated with post-adulthood aging.  A related implication is that if the skeletal 
muscle of aging horses is less responsive than that of mature horses to anabolic stimuli, 
then if some factor, such as illness or poor nutrition, increases age associated muscle loss, 
then muscle recovery will be extremely difficult.  Ultimately, more research is needed but 
the results of the studies in this dissertation provide insight to alternatives in management 
practices that may improve skeletal muscle accretion and maintenance throughout the 
lifespan. 
8.2.1.  Summary of the alterations in mTOR signaling throughout the lifespan in horses 
 A substantial amount of work is still required to examine the effects of aging 
throughout the lifespan on mTOR signaling in the skeletal muscle of horses; however, it 
is also imperative to examine the physiological endpoint of the mTOR signaling pathway 
which is protein synthesis in the muscle.  The studies in this dissertation have provided 
the initial insight to the alterations in mTOR signaling throughout the lifespan in horses 
and are the first to examine changes in mTOR signaling during the adolescent phase in 
any species.  These works indicate that in the post-absorptive state, in post-adulthood 
aging may cause the reduction in mTOR signaling, where there were no differences in 
post-absorptive mTOR signaling during growth.  However, during the postprandial state, 
it appears that mTOR signaling is more responsive in the faster growing young animals.  
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These studies open up many possible future directions for additional research, and imply 
that muscle accretion is more responsive to feeding in growing compared to mature 
horses. 
8.3.  THE INFLUENCE OF INFLAMMATION ON mTOR SIGNALING IN 
HORSES 
 The final key objective of this dissertation was to examine the influence of 
inflammation on mTOR signaling horses.  Models of acute (Chapter IV) and chronic 
(Chapter VI and VII) inflammation were studied through the collection of repeated 
muscle biopsies and aging, respectively.  In both series of studies, the administration of a 
NSAID, phenylbutazone, was administered to determine whether the reduction in 
inflammation would result in changes in the responsiveness of mTOR signaling.   Acute 
inflammation reduced the activation of upstream mTOR signaling and increased the 
activation of downstream mTOR signaling in response to meal consumption.  However, 
when a NSAID was administered, inflammation was reduced and the increase in mTOR 
signaling due to acute inflammation was mediated.  However, during chronic 
inflammation in a relatively post-absorptive state, only the activation of S6K1 was 
reduced.  Because both states of inflammation were studied under different physiological 
states they cannot be compared in the sense of which type of inflammation alters mTOR 
signaling to a greater extent, although they can be discussed from a mechanistic 
perspective.  However, future research is warranted to examine the effects of both types 
of inflammation (acute and chronic) on mTOR signaling under equal physiological states 
(both postprandial and post-absorptive).  For example, aging horses with confirmed low 
grade chronic inflammation could be studied in an experimental design similar to that of 
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Chapter IV: this would allow for the examination of the effect of acute inflammatory 
stimuli in a state of chronic inflammation during the postprandial state on mTOR 
signaling. 
 The activation of NF−κΒ by inflammatory cytokines was discussed in the 
inflammatory signaling Section 1.5.1.  Briefly, inflammatory cytokines activate IκKB 
which phosphorylates NF−κΒ.  Once activated, NF−κΒ inhibits the activation of Akt 
(Section 1.3).  Therefore the reduction in the activation of Akt in response to a meal 
during acute inflammation may be a result of the increase in inflammatory cytokines 
stimulating NF−κΒ activation.  However, the administration of NSAID did not 
ameliorate this reduction in Akt activation, even though there was a decrease in the 
mRNA expression of IL−1β.  Because the mRNA expression of TNF−α was not altered 
in skeletal muscle due to NSAID administration and TNF−α has been demonstrated to 
influence IκKB activation to a greater extent than any other inflammatory cytokine, then 
it is possible that NSAID administration did not alter NF−κB activity which would 
explain the absence of an effect of NSAID on Akt activation.  Either the NSAID used 
(phenylbutazone) did not target TNF−α expression or was not a large enough dose (1g 
every 12 hours) to reduce TNF−α mRNA expression in skeletal muscle.  Therefore, the 
activation of IκKB may not have been altered and subsequently neither was NF−κΒ 
phosphorylation.  Unfortunately, the activation of IκKB and NF−κΒ were not examined, 
which is needed in order to have a clearer perspective of this pathway.  However, acute 
inflammation increased the activation of downstream signaling factors in response to 
meal consumption.  In horses, MAPK signaling in skeletal muscle (470) and 
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inflammatory cytokines in circulation and skeletal muscle (244) are increased following 
exercise.  MAPK signaling reduces the phosphorylation of the TSC1/2 complex 
independent of Akt (Section 1.2), and would be expected to increase mTOR signaling in 
cases of acute inflammation.  The MAPK pathways may be an additional mechanism in 
which inflammatory cytokines alter mTOR signaling. 
 During the post-absorptive state, low grade chronic inflammation has not been 
shown to alter mTOR signaling in humans.  However, Chapter VII showed that reducing 
low grade chronic inflammation by administering 2g/day of phenylbutazone increased the 
activation of S6K1.  This may be due to an increase in MAPK signaling as mentioned 
above; however, further research is warranted to fully elucidate this mechanism during 
both the post-absorptive and postprandial states, and during both acute and chronic 
inflammation. 
 The effect of NSAID administration on whole-body protein synthesis during low 
grade chronic inflammation was also examined in Chapter VII.  The results demonstrated 
an increase in non-oxidative phenylalanine disposal, which is an indicator of protein 
synthesis (Section 1.4.1), following 4 weeks of NSAID administration (2g/day of 
phenylbutazone).  The increase in protein synthesis coincided with a decrease in skeletal 
muscle mRNA expression of IL−1β.  The examination of the effects of NSAID in 
reducing low grade chronic inflammation on protein synthesis are limited; however, it 
has been demonstrated that 5 months of ibuprofen administration to aged rodents reduced 
IL-6 and −1β and increased muscle protein fractional synthesis rates during the 
postprandial state, with no change in muscle protein fractional synthesis rates during the 
post-absorptive state (567).  Thus, if age-related sarcopenia is to be controlled, a 
260 
 
reduction in low grade chronic inflammation may be necessary.  It is not practical or 
healthy to recommend the daily administration of an NSAID, such as phenylbutazone, to 
horses because of the possible damage to the gastrointestinal tract (323).  Therefore, 
investigations in reducing low grade chronic inflammation through dietary alterations are 
necessary.  Resveratrol may be a possible alternative because supplementation has 
showed promise in reducing inflammation in horses through inhibiting the formation of 
reactive oxygen species (558).  Ultimately, there is a need to examine the diet of horses 
with low grade chronic inflammation, most commonly the aged, in order to discover 
practical methods of reducing inflammation which may allow for increased whole-body 
and muscle protein synthesis and support the maintenance of muscle mass with 
advancing age. 
 The studies in this dissertation did not examine the effects of altered mTOR 
signaling on satellite cell proliferation during acute and chronic inflammation.  This is an 
area that requires examination because acute inflammation may be beneficial during post- 
exercise or biopsy recovery.  In humans, the reports of the effects of NSAID 
administration during post-exercise recovery on protein synthesis are mixed due to the 
NSAID drug administered, the dose of the drug administered, the method of 
administration, the intensity of the exercise and the time post-exercise that muscle protein 
fractional synthesis rates were examined.  Reports indicate that oral NSAID 
administration inhibits (568) the increase in muscle protein fractional synthesis rates from 
pre- to post exercise, and localized NSAID administration does not alter (333) post-
exercise increase in the NSAID leg compared to the opposite leg.  The increase in 
inflammatory cytokines following exercise may be necessary for muscle repair post-
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exercise (334) because inflammatory cytokines are regulators of satellite cell proliferation 
(312, 313).  However, local NSAID administration reduces satellite cell proliferation 
(316) without altering muscle protein fractional synthesis rates (333) following exercise.  
Therefore, it remains to be determined if a connection between mTOR signaling and 
subsequent protein synthesis and satellite cell proliferation following exercise exists.  
Additionally, low grade chronic inflammation has been demonstrated to increase 
apoptosis of satellite cells (174, 281) which may influence the loss of muscle mass seen 
with aging; however, further research is required to examine this. 
 In addition to advancing the physiological understanding of how acute and 
chronic inflammation alter mTOR signaling in response to feeding, the research 
described in Chapters IV and VII of this dissertation also have several implications 
specific to the horse.  First, the use of NSAID following acute inflammation in the 
muscle may impair tissue regeneration and protein synthesis, and should be avoided in 
cases where muscle growth or regeneration is desired.  For example, horses in active 
training, where the goal is to develop muscle needed for a particular discipline, the 
beneficial effects of the exercise on muscle growth may be counteracted by NSAID 
administration.  The use of NSAID in reducing low grade chronic inflammation in the 
aged showed that from mechanistic standpoint, the reduction of inflammation may have 
beneficial effects on whole-body and muscle protein metabolism in horses.  However, 
daily NSAID administration would not likely be a practical part of a management plan 
for the older horses, rather alternative strategies should be studied in an attempt to 
mitigate the chronic inflammation that occurs in old horses (483, 484) and control muscle 
loss in the aged. 
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8.3.1.  Summary of the influence of inflammation on mTOR signaling in horses 
 Although a substantial amount of work is required to elucidate the mechanisms 
through which inflammatory cytokines alter mTOR signaling, the studies in this 
dissertation provide insight into the effects of both acute and chronic inflammation on 
mTOR signaling.  Acute and chronic inflammation increased and decreased downstream 
mTOR signaling, respectively, under the experimental conditions used in this research.  
The use of phenylbutazone provided a mechanistic tool to reduce acute and chronic 
inflammation and indicated that inflammatory cytokines may alter mTOR signaling 
through Akt dependent and independent mechanisms.  Ultimately, acute inflammation 
may be beneficial for tissue repair, whereas chronic inflammation reduces mTOR 
signaling and subsequent protein synthesis, likely resulting in a loss of skeletal muscle 
mass over time. 
8.4.  CONCLUSION 
 In conclusion, the series of studies described in this dissertation have provided 
initial knowledge in mTOR signaling in the adolescent and during acute inflammation 
resulting from repeated biopsies.  These studies were also the first examination of mTOR 
signaling and whole-body protein synthesis in the aged horse.  Methodologically, the 
examination of mTOR signaling in mature horses can be compared from right and left 
gluteal muscles at a depth of 6 to 10 cm below the surface of the skin, but if biopsies are 
repeated administration of a NSAID is suggested in order to avoid the confounding effect 
of biopsy.  When examining mTOR signaling in response to feeding stimuli in different 
ages of horses, the protein intake should be standardized by a percentage of the animal’s 
protein requirement and the researcher must ensure that this is a strong enough anabolic 
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stimuli to elicit alterations in mTOR signaling.  Aging appeared to have a greater 
influence on mTOR signaling during the post-absorptive state compared to any other life 
stage; however, mTOR signaling during development appeared to be more responsive to 
anabolic stimuli than any other life stage.  Acute and chronic inflammation altered mTOR 
signaling differently, where acute inflammation may be increase to mTOR signaling and 
aid with muscle recovery from the inflammatory challenge.  The results from this 
dissertation are an important contribution to our knowledge of mTOR signaling, 
regardless of the species studied, but particularly in the horse where the current 
knowledge about muscle protein metabolism is extremely limited.  This dissertation also 
revealed the many potential areas for future research with regards to mTOR signaling in 
horses.  
 
 
 
 
 
 
 
 
 
 
 
 
Copyright © Ashley L. Wagner 2011  
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Appendix 
A.1.  HPLC CHROMATOGRAM EXAMPLES 
 
A.1.1.  An example of a physiological free amino acid standard chromatogram.  The 
free amino acid standard was used in the calculations of free plasma amino acid samples 
and free muscle amino acid samples.  The injected standard had a concentration of 0.5 
nmol/μL of each amino acid and 500 pmol of each amino acid was injected onto the 
column.  Since all of the amino acids had the same concentration, the purpose of running 
the standard was to determine amino acid differences in peak area relative to Norleucine 
(the internal standard run with every sample and standard) to correct peak area to correct 
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sample amino acid peak areas.  The interassay C.V. expressed as standard AA relative to 
Norleucine ranged from as low as 0.07 ± 0.08% for Asp and as high as 1.42 ± 0.10% for 
Lys. 
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A.1.2.  An example of a plasma free amino acid chromatogram.  This is an example 
of a horse from Chapter V at the 15 minute sampling period of the post-absorptive state.  
The calculation used for determining free plasma amino acid concentrations is as follows: 
pmol = [(sample AA peak area)/(standard AA peak area/standard internal standard peak 
area)]*(pmol of internal standard injected with sample/peak area of internal standard in 
sample)  
Then pmol must be converted to μmol/L plasma using the following equation: 
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μmol/L plasma = (pmol of AA/ μL of reconstituted sample injected)*( μL of diluents 
used to reconstitute derivatized sample/ μL of ultrafiltrate that was derivatized)*dilution 
of plasma prior to ultrafiltration*((106 μL/L)/(109 pmol/μmol)). 
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A.1.3.  An example of a muscle free amino acid chromatogram.  This is an example of 
a horse from Chapter III at a sampling depth of 6 cm below the surface of the skin.  The 
calculation used for determining free muscle amino acid concentrations is as follows: 
pmol = [(sample AA peak area)/(standard AA peak area/standard internal standard peak 
area)]*(pmol of internal standard injected with sample/peak area of internal standard in 
sample)  
Then pmol must be converted to μmol/g of wet weight muscle using the following 
equation: 
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nmol/g of wet weight muscle = (pmol of AA/ μL of reconstituted sample injected)*( μL 
of diluents used to reconstitute derivatized sample/ μL of ultrafiltrate that was 
derivatized)* (extraction volume/tissue extracted)*(10-9 μmol/pmol). 
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A.1.4.  An example of a total hydralysate amino acid standard chromatogram.  The 
total hydralysate amino acid standard was used in the calculations of total hydralysate 
amino acid samples for example feed samples.  The injected standard had a concentration 
of 6.25 nmol/μL, and 6250 pmol of each amino acid was injected onto the column.  Since 
all of the amino acids had the same concentration, the purpose of running the standard 
was to determine amino acid differences in peak area relative to Norleucine (the internal 
standard run with every sample and standard) to correct peak area to correct sample 
amino acid peak areas.  The interassay C.V. expressed as standard AA relative to 
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Norleucine ranged from as low as 0.86 ± 0.05% for Thr and as high as 1.76 ± 0.08% for 
Lys. 
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A.1.5.  An example of a total hydralysate amino acid chromatogram from a feed 
sample.  This is an example of the total hydralysate amino acid chromatogram from the 
high protein pellet fed in Chapters III – V.  The calculation used for determining total 
hydralysate amino acid concentrations is as follows: 
pmol = pmol of AA in injected from the standard *[AA peak area in sample/(internal 
standard pear area in the sample/internal standard peak area in the standarad)]/AA peak 
area in the standard. 
Then pmol must be converted to pmol/g of feed using the following equation: 
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pmol/g of feed = (pmol of AA in the injected sample/injection volume, μL)*(volume of 
diluent to reconstitute sample, μL/amount of HCl filtrate derivatized, μL) * (amount of 
HCl used, mL/feed sample weight, g) * (10-3). 
Then to convert pmol of AA/g of feed to g of AA/100g of feed: 
g of AA/100g of feed = (pmol of AA/g feed)* (1 mol/1012 pmol) * (MW of AA residue 
in g/mol) *100. 
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contained 0.002 μg of antigen; the “1:1 antibody to antigen mixture” contained 0.2 μg of 
antigen; and the “1:4 antibody to antigen mixture contained 2 μg of antigen.  These 
mixtures were allowed to incubate at room temperature for 30 minutes, which was the 
manufacturer’s suggested time allotment for the reaction between the antibody and 
antigen to occur.  The mixtures were then placed on the membrane and allowed to react 
with the proteins bound to the membrane for 18 hours at 4oC.  Then, all sections of the 
membrane were washed and treated with secondary antibody which was a goat anti-rabbit 
IgG (H+L) with conjugated horseradish peroxidase (1:10,000 dilution in 5% fat-free milk 
solution; BioRad, Hercules, CA) for 1 hour at room temperature.  Membranes were 
developed using a chemiluminescence kit (Amersham ECL Plus Western Blotting 
Detection Reagents; GE Healthcare, Piscataway, NJ) and visualized on x-ray film using a 
film processor (Kodak X-OMAT film processor, Kodak Health Imaging Division, 
Rochester, NY).  In the wells of the above figure: (1) a molecular marker (MagicMark™, 
Invitrogen, Carlsbad, CA) (2) a positive control (Akt Control Cell Extracts from Jurkat 
cells treated with Calyculin A, Cell Signaling Technology ®, Inc., Boston, MA), (3) a 
negative control (Akt Control Cell Extracts from Jurkat cells treated with LY294002, 
Cell Signaling Technology ®, Inc., Boston, MA), (4) mature equine gluteal muscle in the 
postprandial state, (5) mature equine gluteal muscle in the postprandial state, (6) mature 
equine gluteal muscle in the postprandial state, (7) a positive control (Akt Control Cell 
Extracts from Jurkat cells treated with Calyculin A, Cell Signaling Technology ®, Inc., 
Boston, MA), (8) a negative control (Akt Control Cell Extracts from Jurkat cells treated 
with LY294002, Cell Signaling Technology ®, Inc., Boston, MA), (9) mature equine 
gluteal muscle in the postprandial state, (10) mature equine gluteal muscle in the 
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postprandial state, and (11) mature equine gluteal muscle in the postprandial state.  Wells 
1-4 were treated with 100% primary antibody.  Well 5 was treated with 0% primary 
antibody.  Well 6 was treated with a primary antibody to antigen (P-Akt Ser473 Blocking 
Peptide, Cell Signaling Technology ®, Inc., Boston, MA) at a ratio of 1:1/16.  Wells 7-9 
were treated with a primary antibody to antigen ratio of 1:1/4.  Well 10 was treated with a 
primary antibody to antigen ratio of 1:1, and well 11 was treated with a primary antibody 
to antigen ratio of 1:4.  This validated the use of this primary antibody in the horse, 
because when an antigen was applied there was inhibition of the antibody to bind with 
the mature equine gluteal muscle in the postprandial state.  Additionally, the “0% primary 
antibody” validated the use of this secondary antibody, because in the absence of a 
primary antibody there was total inhibition of binding.  
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the manufacturer’s suggested time allotment for the reaction between the antibody and 
antigen to occur.  The mixtures were then placed on the membrane and allowed to react 
with the proteins bound to the membrane for 18 hours at 4oC.  Then, all sections of the 
membrane were washed and treated with secondary antibody which was a goat anti-rabbit 
IgG (H+L) with conjugated horseradish peroxidase (1:10,000 dilution in 5% fat-free milk 
solution; BioRad, Hercules, CA) for 1 hour at room temperature.  Membranes were 
developed using a chemiluminescence kit (Amersham ECL Plus Western Blotting 
Detection Reagents; GE Healthcare, Piscataway, NJ) and visualized on x-ray film using a 
film processor (Kodak X-OMAT film processor, Kodak Health Imaging Division, 
Rochester, NY).  In the wells of the above figure: (1) a molecular marker (MagicMark™, 
Invitrogen, Carlsbad, CA) (2) a positive control (Akt Control Cell Extracts from Jurkat 
cells treated with Calyculin A, Cell Signaling Technology ®, Inc., Boston, MA), (3) a 
negative control (Akt Control Cell Extracts from Jurkat cells treated with LY294002, 
Cell Signaling Technology ®, Inc., Boston, MA), (4) mature equine gluteal muscle in the 
postprandial state, (5) a positive control (Akt Control Cell Extracts from Jurkat cells 
treated with Calyculin A, Cell Signaling Technology ®, Inc., Boston, MA), (6) a negative 
control (Akt Control Cell Extracts from Jurkat cells treated with LY294002, Cell 
Signaling Technology ®, Inc., Boston, MA), (7) mature equine gluteal muscle in the 
postprandial state, (8) mature equine gluteal muscle in the postprandial state, (9) mature 
equine gluteal muscle in the postprandial state, (10) a positive control (Akt Control Cell 
Extracts from Jurkat cells treated with Calyculin A, Cell Signaling Technology ®, Inc., 
Boston, MA), (11) a negative control (Akt Control Cell Extracts from Jurkat cells treated 
with LY294002, Cell Signaling Technology ®, Inc., Boston, MA), and (12) mature 
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equine gluteal muscle in the postprandial state.  Wells 1-4 were treated with 100% 
primary antibody.  Well 5-7 were treated with a primary antibody to antigen (P-Akt 
Thr308 Blocking Peptide, Cell Signaling Technology ®, Inc., Boston, MA) at a ratio of 
1:4.  Well 8 was treated with a primary antibody to antigen ratio of 1:1.  Well 9 was 
treated with a primary antibody to antigen ratio of 1:1/4, and wells 10-12 were treated 
with a primary antibody to antigen ratio of 1:1/16.  This validated the use of this primary 
antibody in the horse, because when an antigen was applied there was inhibition of the 
antibody to bind with the mature equine gluteal muscle in the postprandial state. 
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antigen; and the “1:4 antibody to antigen mixture” contained 5 μg of antigen.  These 
mixtures were allowed to incubate at room temperature for 30 minutes, which was the 
manufacturer’s suggested time allotment for the reaction between the antibody and 
antigen to occur.  The mixtures were then placed on the membrane and allowed to react 
with the proteins bound to the membrane for 18 hours at 4oC.  Then, all sections of the 
membrane were washed and treated with secondary antibody which was a goat anti-rabbit 
IgG (H+L) with conjugated horseradish peroxidase (1:10,000 dilution in 5% fat-free milk 
solution; BioRad, Hercules, CA) for 1 hour at room temperature.  Membranes were 
developed using a chemiluminescence kit (Amersham ECL Plus Western Blotting 
Detection Reagents; GE Healthcare, Piscataway, NJ) and visualized on x-ray film using a 
film processor (Kodak X-OMAT film processor, Kodak Health Imaging Division, 
Rochester, NY).  In the wells of the above figure: (1) a negative control (Akt Control Cell 
Extracts from Jurkat cells treated with LY294002, Cell Signaling Technology ®, Inc., 
Boston, MA), (2) a positive control (Akt Control Cell Extracts from Jurkat cells treated 
with Calyculin ,A Cell Signaling Technology ®, Inc., Boston, MA), (3) mature equine 
gluteal muscle in the postprandial state, (4) mature equine gluteal muscle in the 
postprandial state, (5) mature equine gluteal muscle in the postprandial state, (6) a 
positive control (Akt Control Cell Extracts from Jurkat cells treated with Calyculin A, 
Cell Signaling Technology ®, Inc., Boston, MA), (7) a negative control (Akt Control Cell 
Extracts from Jurkat cells treated with LY294002, Cell Signaling Technology ®, Inc., 
Boston, MA), (8) mature equine gluteal muscle in the postprandial state, (9) mature 
equine gluteal muscle in the postprandial state, and (10) mature equine gluteal muscle in 
the postprandial state.  Wells 1-3 were treated with 100% primary antibody.  Well 4 was 
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treated with 0% primary antibody.  Wells 5-7 were treated with a primary antibody to 
antigen (Akt pan Blocking Peptide, Cell Signaling Technology ®, Inc., Boston, MA) at a 
ratio of 1:4.  Well 8 was treated with a primary antibody to antigen ratio of 1:1.  Well 9 
was treated with a primary antibody to antigen ratio of 1:1/4, and well 10 was treated 
with a primary antibody to antigen ratio of 1:1/16.  This validated the use of this primary 
antibody in the horse, because when an antigen was applied there was inhibition of the 
antibody to bind with the mature equine gluteal muscle in the postprandial state.  
However, it is important to note that the presence of Akt total in the negative control was 
expected.  Because this protein is ubiquitous, the negative controls serve a greater 
purpose in the validation of the phosphorylated forms.  Additionally, the “0% primary 
antibody” validated the use of this secondary antibody, because in the absence of a 
primary antibody there was total inhibition of binding. 
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side.  The abundance of this protein is reported as a ratio of the phosphorylated to total 
form.  The positive control was used to account for interassay variability.  The C.V. of 
the phosphorylated to total ratio of the positive control for P-Akt Ser473 and P-Akt Thr308 
are 0.22 ± 0.13 and 0.12 ± 0.12, respectively.  The right to left side phosphorylated to 
total ratio of for P-Akt Ser473 was 0.16 ± 0.12.  P-Akt Thr308  was not examined in 
Chapter IV.  These were from Chapter IV for P-Akt Ser473 and Chapter V for P-Akt 
Thr308.  In Chapter IV side was tested in the statistical model and found to not be 
significant (P < 0.05). 
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0.002 μg of antigen.  These mixtures were allowed to incubate at room temperature for 
30 minutes, which was the manufacturer’s suggested time allotment for the reaction 
between the antibody and antigen to occur.  The mixtures were then placed on the 
membrane and allowed to react with the proteins bound to the membrane for 18 hours at 
4oC.  Then, all sections of the membrane were washed and treated with secondary 
antibody which was a goat anti-rabbit IgG (H+L) with conjugated horseradish peroxidase 
(1:10,000 dilution in 5% fat-free milk solution; BioRad, Hercules, CA) for 1 hour at 
room temperature.  Membranes were developed using a chemiluminescence kit 
(Amersham ECL Plus Western Blotting Detection Reagents; GE Healthcare, Piscataway, 
NJ) and visualized on x-ray film using a film processor (Kodak X-OMAT film processor, 
Kodak Health Imaging Division, Rochester, NY).  In the wells of the above figure: (1) a 
molecular marker (MagicMark™, Invitrogen, Carlsbad, CA), (2) a positive control (p70 
S6 Kinase Control Cell Extracts from MCF-7 cells treated with insulin, Cell Signaling 
Technology ®, Inc., Boston, MA), (3) a negative control (p70 S6 Kinase Control Cell 
Extracts from MCF-7 cells untreated, Cell Signaling Technology ®, Inc., Boston, MA), 
(4) mature equine gluteal muscle in the postprandial state, (5) a positive control (p70 S6 
Kinase Control Cell Extracts from MCF-7 cells treated with insulin, Cell Signaling 
Technology ®, Inc., Boston, MA), (6) a negative control (p70 S6 Kinase Control Cell 
Extracts from MCF-7 cells untreated, Cell Signaling Technology ®, Inc., Boston, MA), 
(7) mature equine gluteal muscle in the postprandial state, (8) mature equine gluteal 
muscle in the postprandial state, (9) mature equine gluteal muscle in the postprandial 
state, (10) a positive control (p70 S6 Kinase Control Cell Extracts from MCF-7 cells 
treated with insulin, Cell Signaling Technology ®, Inc., Boston, MA), (11) a negative 
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control (p70 S6 Kinase Control Cell Extracts from MCF-7 cells untreated, Cell Signaling 
Technology ®, Inc., Boston, MA), and (12) mature equine gluteal muscle in the 
postprandial state.  Wells 1-4 were treated with 100% primary antibody.  Wells 5-7 were 
treated with a primary antibody to antigen (P-S6K1 Thr389 Blocking Peptide, Cell 
Signaling Technology ®, Inc., Boston, MA) at a ratio of 1:1.  Well 8 was treated with a 
primary antibody to antigen ratio of 1:1/4.  Well 9 was treated with a primary antibody to 
antigen ratio of 1:1/16, and wells 10-12 were treated with a primary antibody to antigen 
ratio of 1:1/32.  This validated the use of this primary antibody in the horse, because 
when an antigen was applied there was inhibition of the antibody to bind with the mature 
equine gluteal muscle in the postprandial state.  However, it is important to note that the 
presence of both the 85 kDa and 70 kDa S6K1 total in the negative and positive controls 
was expected.  The use of the molecular weight marker allowed us to determine the 70 
kDa from the 85 kDa S6K1 bands, our interest was in the 70 kDa S6K1.  Because S6K1 
is phosphorylated following mTORC1 activation, which can be activated by both insulin 
and amino acids, the negative controls were untreated with insulin but remained in a 
media that contained amino acids resulting in a diminished response than the positive 
controls. 
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0.002 μg of antigen.  These mixtures were allowed to incubate at room temperature for 
30 minutes, which was the manufacturer’s suggested time allotment for the reaction 
between the antibody and antigen to occur.  The mixtures were then placed on the 
membrane and allowed to react with the proteins bound to the membrane for 18 hours at 
4oC.  Then, all sections of the membrane were washed and treated with secondary 
antibody which was a goat anti-rabbit IgG (H+L) with conjugated horseradish peroxidase 
(1:10,000 dilution in 5% fat-free milk solution; BioRad, Hercules, CA) for 1 hour at 
room temperature.  Membranes were developed using a chemiluminescence kit 
(Amersham ECL Plus Western Blotting Detection Reagents; GE Healthcare, Piscataway, 
NJ) and visualized on x-ray film using a film processor (Kodak X-OMAT film processor, 
Kodak Health Imaging Division, Rochester, NY).  In the wells of the above figure: (1) a 
molecular marker (MagicMark™, Invitrogen, Carlsbad, CA), (2) a positive control (p70 
S6 Kinase Control Cell Extracts from MCF-7 cells treated with insulin, Cell Signaling 
Technology ®, Inc., Boston, MA), (3) a negative control (p70 S6 Kinase Control Cell 
Extracts from MCF-7 cells untreated, Cell Signaling Technology ®, Inc., Boston, MA), 
(4) mature equine gluteal muscle in the postprandial state, (5) a positive control (p70 S6 
Kinase Control Cell Extracts from MCF-7 cells treated with insulin, Cell Signaling 
Technology ®, Inc., Boston, MA), (6) a negative control (p70 S6 Kinase Control Cell 
Extracts from MCF-7 cells untreated, Cell Signaling Technology ®, Inc., Boston, MA), 
(7) mature equine gluteal muscle in the postprandial state, (8) mature equine gluteal 
muscle in the postprandial state, (9) mature equine gluteal muscle in the postprandial 
state, (10) a positive control (p70 S6 Kinase Control Cell Extracts from MCF-7 cells 
treated with insulin, Cell Signaling Technology ®, Inc., Boston, MA), (11) a negative 
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control (p70 S6 Kinase Control Cell Extracts from MCF-7 cells untreated, Cell Signaling 
Technology ®, Inc., Boston, MA), and (12) mature equine gluteal muscle in the 
postprandial state.  Wells 1-4 were treated with 100% primary antibody.  Wells 5-7 were 
treated with a primary antibody to antigen (S6K1 Blocking Peptide, Cell Signaling 
Technology ®, Inc., Boston, MA) at a ratio of 1:1.  Well 8 was treated with a primary 
antibody to antigen ratio of 1:1/4.  Well 9 was treated with a primary antibody to antigen 
ratio of 1:1/16, and wells 10-12 were treated with a primary antibody to antigen ratio of 
1:1/32.  This validated the use of this primary antibody in the horse, because when an 
antigen was applied there was inhibition of the antibody to bind with the mature equine 
gluteal muscle in the postprandial state.  However, it is important to note that the 
presence of both the 85 kDa and 70 kDa S6K1 total in the negative and positive controls 
swas expected.  The use of the molecular weight marker allowed us to determine the 70 
kDa from the 85 kDa S6K1 bands, our interest was in the 70 kDa S6K1.  Because this 
protein is ubiquitous, the negative controls serve a greater purpose in the validation of the 
phosphorylated forms. 
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ratio of the phosphorylated to total form.  The positive control was used to account for 
interassay variability.  The C.V. of the phosphorylated to total ratio of the positive control 
for P-S6K1 Thr389 was 0.14 ± 0.13.  The right to left side phosphorylated to total ratio of 
for P-S6K1 Thr389 was 0.18 ± 0.16.  These were obtained from Chapter IV.  In Chapter 
IV side was tested in the statistical model and found to not be significant (P < 0.05). 
  
 A
d
d
sa
p
re
w
ac
b
T
an
ro
m
an
M
an
an
m
co
.2.6a.  An e
etermine cro
etermination
mples from
olyacrylami
garding elec
as then stain
id), which s
etween well
he Fast Gree
d the memb
om tempera
ixtures were
tibody that 
A), and pre
tibody to an
tigen mixtu
ixture” cont
ntained 0.0
xample of t
ss-species r
 of the abun
 horses in th
de gels and t
trophoresis
ed with Fas
tains the pro
s 4 and 5, 7 
n Stain was
ranes were 
ture.  Mean
 prepared a
recognized 
pared as a 1
tigen mixtu
re” containe
ained 7.8*1
01 μg of ant
he P-rpS6 S
eactivity of 
dance of the
e postprand
hen were tr
 and transfer
t Green Stai
tein bound 
and 8, 8 and
 removed w
washed and
while, the p
s follows: th
P-rpS6 Ser2
:2,000 diluti
re” containe
d 1.95*10-1
0-15 μg antig
igen.  These
296 
er235/236 An
the primary 
P-rpS6 Ser2
ial state und
ansferred to 
 can be foun
n (1% fast g
to the memb
 9 and 9 and
ith Destain 
 blocked wit
rimary antib
e “100% pr
35/236 (Cell S
on in 5% fa
d 4.88*10-2
8 μg antigen
en; and the 
 mixtures w
tibody Val
and seconda
35/236, poole
erwent elect
a PVDF me
d in Section
reen, 50% m
rane.  Next
 10, and pla
(50% metha
h 5% fat-fre
ody and prim
imary antibo
ignaling Tec
t-free milk s
2 μg antigen
; the “1:1/4 
“1:1 antibod
ere allowed
idation.  In 
ry antibodie
d equine glu
rophoresis o
mbrane (add
 3.4.1.3).  T
ethanol, 1%
 the membra
ced in indiv
nol, 1% glac
e milk solu
ary antibo
dy” was a r
hnology®, 
olution; the
; the “1:1/16
antibody to 
y to antigen
 to incubate
order to 
s used for t
teal muscle
n 
itional deta
he membra
 glacial ace
ne was cut 
idual contai
ial acetic ac
tion for 1 ho
dy and antig
abbit polycl
Inc., Boston
 “1:1/32 
 antibody to
antigen 
 mixture” 
 at room 
 
he 
 
il 
ne 
tic 
ners.  
id), 
ur at 
en 
onal 
, 
 
297 
 
temperature for 30 minutes, which was the manufacturer’s suggested time allotment for 
the reaction between the antibody and antigen to occur.  The mixtures were then placed 
on the membrane and allowed to react with the proteins bound to the membrane for 18 
hours at 4oC.  Then, all sections of the membrane were washed and treated with 
secondary antibody which was a goat anti-rabbit IgG (H+L) with conjugated horseradish 
peroxidase (1:10,000 dilution in 5% fat-free milk solution; BioRad, Hercules, CA) for 1 
hour at room temperature.  Membranes were developed using a chemiluminescence kit 
(Amersham ECL Plus Western Blotting Detection Reagents; GE Healthcare, Piscataway, 
NJ) and visualized on x-ray film using a film processor (Kodak X-OMAT film processor, 
Kodak Health Imaging Division, Rochester, NY).  In the wells of the above figure: (1) a 
molecular marker (MagicMark™, Invitrogen, Carlsbad, CA), (2) a positive control (p70 
S6 Kinase Control Cell Extracts from MCF-7 cells treated with insulin, Cell Signaling 
Technology ®, Inc., Boston, MA), (3) a negative control (p70 S6 Kinase Control Cell 
Extracts from MCF-7 cells untreated, Cell Signaling Technology ®, Inc., Boston, MA), 
(4) mature equine gluteal muscle in the postprandial state, (5) a positive control (p70 S6 
Kinase Control Cell Extracts from MCF-7 cells treated with insulin, Cell Signaling 
Technology ®, Inc., Boston, MA), (6) a negative control (p70 S6 Kinase Control Cell 
Extracts from MCF-7 cells untreated, Cell Signaling Technology ®, Inc., Boston, MA), 
(7) mature equine gluteal muscle in the postprandial state, (8) mature equine gluteal 
muscle in the postprandial state, (9) mature equine gluteal muscle in the postprandial 
state, (10) a positive control (p70 S6 Kinase Control Cell Extracts from MCF-7 cells 
treated with insulin, Cell Signaling Technology ®, Inc., Boston, MA), (11) a negative 
control (p70 S6 Kinase Control Cell Extracts from MCF-7 cells untreated, Cell Signaling 
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Technology ®, Inc., Boston, MA), and (12) mature equine gluteal muscle in the 
postprandial state.  Wells 1-4 were treated with 100% primary antibody.  Wells 5-7 were 
treated with a primary antibody to antigen (P-rpS6 Ser235/236 Blocking Peptide, Cell 
Signaling Technology ®, Inc., Boston, MA) at a ratio of 1:1.  Well 8 was treated with a 
primary antibody to antigen ratio of 1:1/4.  Well 9 was treated with a primary antibody to 
antigen ratio of 1:1/16, and wells 10-12 were treated with a primary antibody to antigen 
ratio of 1:1/32.  This validated the use of this primary antibody in the horse, because 
when an antigen was applied there was inhibition of the antibody to bind with the mature 
equine gluteal muscle in the postprandial state.  However, it is important to note that the 
presence P-rpS6-Ser235/236 in the negative and positive controls was expected, because 
rpS6 is phosphorylated following S6K1 phosphorylation which is activated by the active 
from of mTORC1.  mTORC1 is activated due to both insulin and amino acids, the 
negative controls were untreated with insulin and the positive controls were treated with 
insulin, but both were in media containing amino acids.  As a result, P-rpS6 Ser235/236 is 
present in the negative control, but diminished in comparison to the positive control. 
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temperature for 30 minutes, which was the manufacturer’s suggested time allotment for 
the reaction between the antibody and antigen to occur.  The mixtures were then placed 
on the membrane and allowed to react with the proteins bound to the membrane for 18 
hours at 4oC.  Then, all sections of the membrane were washed and treated with 
secondary antibody which was a goat anti-rabbit IgG (H+L) with conjugated horseradish 
peroxidase (1:10,000 dilution in 5% fat-free milk solution; BioRad, Hercules, CA) for 1 
hour at room temperature.  Membranes were developed using a chemiluminescence kit 
(Amersham ECL Plus Western Blotting Detection Reagents; GE Healthcare, Piscataway, 
NJ) and visualized on x-ray film using a film processor (Kodak X-OMAT film processor, 
Kodak Health Imaging Division, Rochester, NY).  In the wells of the above figure: (1) a 
molecular marker (MagicMark™, Invitrogen, Carlsbad, CA), (2) a positive control (p70 
S6 Kinase Control Cell Extracts from MCF-7 cells treated with insulin, Cell Signaling 
Technology ®, Inc., Boston, MA), (3) a negative control (p70 S6 Kinase Control Cell 
Extracts from MCF-7 cells untreated, Cell Signaling Technology ®, Inc., Boston, MA), 
(4) mature equine gluteal muscle in the postprandial state, (5) a positive control (p70 S6 
Kinase Control Cell Extracts from MCF-7 cells treated with insulin, Cell Signaling 
Technology ®, Inc., Boston, MA), (6) a negative control (p70 S6 Kinase Control Cell 
Extracts from MCF-7 cells untreated, Cell Signaling Technology ®, Inc., Boston, MA), 
(7) mature equine gluteal muscle in the postprandial state, (8) mature equine gluteal 
muscle in the postprandial state, (9) mature equine gluteal muscle in the postprandial 
state, (10) a positive control (p70 S6 Kinase Control Cell Extracts from MCF-7 cells 
treated with insulin, Cell Signaling Technology ®, Inc., Boston, MA), (11) a negative 
control (p70 S6 Kinase Control Cell Extracts from MCF-7 cells untreated, Cell Signaling 
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Technology ®, Inc., Boston, MA), and (12) mature equine gluteal muscle in the 
postprandial state.  Wells 1-4 were treated with 100% primary antibody.  Wells 5-7 were 
treated with a primary antibody to antigen (P-rpS6 Ser240/244 Blocking Peptide, Cell 
Signaling Technology ®, Inc., Boston, MA) at a ratio of 1:1.  Well 8 was treated with a 
primary antibody to antigen ratio of 1:1/4.  Well 9 was treated with a primary antibody to 
antigen ratio of 1:1/16, and wells 10-12 were treated with a primary antibody to antigen 
ratio of 1:1/32.  This validated the use of this primary antibody in the horse, because 
when an antigen was applied there was inhibition of the antibody to bind with the mature 
equine gluteal muscle in the postprandial state.  However, it is important to note that the 
presence P-rpS6-Ser240/244 in the negative and positive controls was expected, because 
rpS6 is phosphorylated following S6K1 phosphorylation which is activated by the active 
from of mTORC1.  mTORC1 is activated due to both insulin and amino acids, the 
negative controls were untreated with insulin and the positive controls were treated with 
insulin, but both were in media containing amino acids.  As a result, P-rpS6 Ser240/244 is 
present in the negative control, but diminished in comparison to the positive control. 
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antigen mixture” contained 6.3*10-12 μg antigen; and the “1:1 antibody to antigen 
mixture” contained 0.0002 μg of antigen.  These mixtures were allowed to incubate at 
room temperature for 30 minutes, which was the manufacturer’s suggested time allotment 
for the reaction between the antibody and antigen to occur.  The mixtures were then 
placed on the membrane and allowed to react with the proteins bound to the membrane 
for 18 hours at 4oC.  Then, all sections of the membrane were washed and treated with 
secondary antibody which was a goat anti-rabbit IgG (H+L) with conjugated horseradish 
peroxidase (1:10,000 dilution in 5% fat-free milk solution; BioRad, Hercules, CA) for 1 
hour at room temperature.  Membranes were developed using a chemiluminescence kit 
(Amersham ECL Plus Western Blotting Detection Reagents; GE Healthcare, Piscataway, 
NJ) and visualized on x-ray film using a film processor (Kodak X-OMAT film processor, 
Kodak Health Imaging Division, Rochester, NY).  In the wells of the above figure: (1) a 
molecular marker (MagicMark™, Invitrogen, Carlsbad, CA), (2) a positive control (p70 
S6 Kinase Control Cell Extracts from MCF-7 cells treated with insulin, Cell Signaling 
Technology ®, Inc., Boston, MA), (3) a negative control (p70 S6 Kinase Control Cell 
Extracts from MCF-7 cells untreated, Cell Signaling Technology ®, Inc., Boston, MA), 
(4) mature equine gluteal muscle in the postprandial state, (5) a positive control (p70 S6 
Kinase Control Cell Extracts from MCF-7 cells treated with insulin, Cell Signaling 
Technology ®, Inc., Boston, MA), (6) a negative control (p70 S6 Kinase Control Cell 
Extracts from MCF-7 cells untreated, Cell Signaling Technology ®, Inc., Boston, MA), 
(7) mature equine gluteal muscle in the postprandial state, (8) mature equine gluteal 
muscle in the postprandial state, (9) mature equine gluteal muscle in the postprandial 
state, (10) a positive control (p70 S6 Kinase Control Cell Extracts from MCF-7 cells 
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treated with insulin, Cell Signaling Technology ®, Inc., Boston, MA), (11) a negative 
control (p70 S6 Kinase Control Cell Extracts from MCF-7 cells untreated, Cell Signaling 
Technology ®, Inc., Boston, MA), and (12) mature equine gluteal muscle in the 
postprandial state.  Wells 1-4 were treated with 100% primary antibody.  Wells 5-7 were 
treated with a primary antibody to antigen (rpS6 Blocking Peptide, Cell Signaling 
Technology ®, Inc., Boston, MA) at a ratio of 1:1.  Well 8 was treated with a primary 
antibody to antigen ratio of 1:1/4.  Well 9 was treated with a primary antibody to antigen 
ratio of 1:1/16, and wells 10-12 were treated with a primary antibody to antigen ratio of 
1:1/32.  This validated the use of this primary antibody in the horse, because when an 
antigen was applied there was inhibition of the antibody to bind with the mature equine 
gluteal muscle in the postprandial state.  However, it is important to note that the 
presence of rpS6 Total in both positive and negative controls was expected.  Because this 
protein is ubiquitous, the negative controls serve a greater purpose in the validation of the 
phosphorylated forms. 
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form.  The positive control was used to account for interassay variability.  The C.V. of 
the phosphorylated to total ratio of the positive control for P-rpS6 Ser235/236 & 240/244 was 
0.14 ± 0.14.  The right to left side phosphorylated to total ratio of for P-rpS6235/236 & 240/244 
was 0.19 ± 0.13.  These were obtained from Chapter IV.  In Chapter IV side was tested in 
the statistical model and found to not be significant (P < 0.05). 
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room temperature for 30 minutes, which was the manufacturer’s suggested time allotment 
for the reaction between the antibody and antigen to occur.  The mixtures were then 
placed on the membrane and allowed to react with the proteins bound to the membrane 
for 18 hours at 4oC.  Then, all sections of the membrane were washed and treated with 
secondary antibody which was a goat anti-rabbit IgG (H+L) with conjugated horseradish 
peroxidase (1:10,000 dilution in 5% fat-free milk solution; BioRad, Hercules, CA) for 1 
hour at room temperature.  Membranes were developed using a chemiluminescence kit 
(Amersham ECL Plus Western Blotting Detection Reagents; GE Healthcare, Piscataway, 
NJ) and visualized on x-ray film using a film processor (Kodak X-OMAT film processor, 
Kodak Health Imaging Division, Rochester, NY).  In the wells of the above figure: (1) a 
molecular marker (MagicMark™, Invitrogen, Carlsbad, CA), (2) a positive control (p70 
S6 Kinase Control Cell Extracts from MCF-7 cells treated with insulin, Cell Signaling 
Technology ®, Inc., Boston, MA), (3) a negative control (p70 S6 Kinase Control Cell 
Extracts from MCF-7 cells untreated, Cell Signaling Technology ®, Inc., Boston, MA), 
(4) mature equine gluteal muscle in the postprandial state, (5) a positive control (p70 S6 
Kinase Control Cell Extracts from MCF-7 cells treated with insulin, Cell Signaling 
Technology ®, Inc., Boston, MA), (6) a negative control (p70 S6 Kinase Control Cell 
Extracts from MCF-7 cells untreated, Cell Signaling Technology ®, Inc., Boston, MA), 
(7) mature equine gluteal muscle in the postprandial state, (8) mature equine gluteal 
muscle in the postprandial state, (9) mature equine gluteal muscle in the postprandial 
state, (10) a positive control (p70 S6 Kinase Control Cell Extracts from MCF-7 cells 
treated with insulin, Cell Signaling Technology ®, Inc., Boston, MA), (11) a negative 
control (p70 S6 Kinase Control Cell Extracts from MCF-7 cells untreated, Cell Signaling 
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Technology ®, Inc., Boston, MA), and (12) mature equine gluteal muscle in the 
postprandial state.  Wells 1-4 were treated with 100% primary antibody.  Wells 5-7 were 
treated with a primary antibody to antigen (P-4EBP1 Thr37/46 Blocking Peptide, Cell 
Signaling Technology ®, Inc., Boston, MA) at a ratio of 1:1.  Well 8 was treated with a 
primary antibody to antigen ratio of 1:1/4.  Well 9 was treated with a primary antibody to 
antigen ratio of 1:1/16, and wells 10-12 were treated with a primary antibody to antigen 
ratio of 1:1/32.  This validated the use of this primary antibody in the horse, because 
when an antigen was applied there was inhibition of the antibody to bind with the mature 
equine gluteal muscle in the postprandial state.  However, it is important to note that the 
presence P-4EBP1 Thr37/46 in the negative and positive controls was expected, because 
4EBP1 is phosphorylated following activation of mTORC1.  mTORC1 is activated due to 
both insulin and amino acids, the negative controls were untreated with insulin and the 
positive controls were treated with insulin, but both were in media containing amino 
acids.  As a result, P-4EBP1 Thr37/46 is present in the negative control, but diminished in 
comparison to the positive control.  Also, 4EBP1 has a large band that represents the 
three isoforms (α, β, and γ).  
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30 minutes, which was the manufacturer’s suggested time allotment for the reaction 
between the antibody and antigen to occur.  The mixtures were then placed on the 
membrane and allowed to react with the proteins bound to the membrane for 1 hour at 
room temperature.  Then, all sections of the membrane were washed and treated with 
secondary antibody which was a goat anti-rabbit IgG (H+L) with conjugated horseradish 
peroxidase (1:10,000 dilution in 5% fat-free milk solution; BioRad, Hercules, CA) for 1 
hour at room temperature.  Membranes were developed using a chemiluminescence kit 
(Amersham ECL Plus Western Blotting Detection Reagents; GE Healthcare, Piscataway, 
NJ) and visualized on x-ray film using a film processor (Kodak X-OMAT film processor, 
Kodak Health Imaging Division, Rochester, NY).  In the wells of the above figure: (1) a 
molecular marker (MagicMark™, Invitrogen, Carlsbad, CA), (2) a positive control (p70 
S6 Kinase Control Cell Extracts from MCF-7 cells treated with insulin, Cell Signaling 
Technology ®, Inc., Boston, MA), (3) a negative control (p70 S6 Kinase Control Cell 
Extracts from MCF-7 cells untreated, Cell Signaling Technology ®, Inc., Boston, MA), 
(4) mature equine gluteal muscle in the postprandial state, (5) a positive control (p70 S6 
Kinase Control Cell Extracts from MCF-7 cells treated with insulin, Cell Signaling 
Technology ®, Inc., Boston, MA), (6) a negative control (p70 S6 Kinase Control Cell 
Extracts from MCF-7 cells untreated, Cell Signaling Technology ®, Inc., Boston, MA), 
(7) mature equine gluteal muscle in the postprandial state, (8) mature equine gluteal 
muscle in the postprandial state, (9) mature equine gluteal muscle in the postprandial 
state, (10) a positive control (p70 S6 Kinase Control Cell Extracts from MCF-7 cells 
treated with insulin, Cell Signaling Technology ®, Inc., Boston, MA), (11) a negative 
control (p70 S6 Kinase Control Cell Extracts from MCF-7 cells untreated, Cell Signaling 
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Technology ®, Inc., Boston, MA), and (12) mature equine gluteal muscle in the 
postprandial state.  Wells 1-4 were treated with 100% primary antibody.  Wells 5-7 were 
treated with a primary antibody to antigen (4EBP1 Total Blocking Peptide, Cell 
Signaling Technology ®, Inc., Boston, MA) at a ratio of 1:1.  Well 8 was treated with a 
primary antibody to antigen ratio of 1:1/4.  Well 9 was treated with a primary antibody to 
antigen ratio of 1:1/16, and wells 10-12 were treated with a primary antibody to antigen 
ratio of 1:1/32.  This validated the use of this primary antibody in the horse, because 
when an antigen was applied there was inhibition of the antibody to bind with the mature 
equine gluteal muscle in the postprandial state.  However, it is important to note that the 
presence P-4EBP1 Thr37/46 in the negative and positive controls was expected, because 
4EBP1 is a ubiquitous protein.  The negative control has a greater role in phosphorylated 
forms.  Also, 4EBP1 has a large band that represents the three isoforms (α, β, and γ). 
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protein is reported as a ratio of the phosphorylated to total form.  The positive control 
was used to account for interassay variability.  The C.V. of the phosphorylated to total 
ratio of the positive control for P-4EBP1 Thr37/46 was 0.10 ± 0.07.  The right to left side 
phosphorylated to total ratio of for P-4EBP1 Thr37/46 was 0.13 ± 0.10.  These were 
obtained from Chapter IV.  In Chapter IV side was tested in the statistical model and 
found to not be significant (P < 0.05). 
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A.4.  STANDARD CURVES 
 
A.4.1.  An example of a glucose standard curve used in the YSI 2700 SELECT™ 
Biochemistry Analyzer.  The YSI 2700 SELECT™ Biochemistry Analyzer determines 
glucose concentration enzymatically.  This is an example of the standard curve of glucose 
from Chapter VI.  The r2 is 0.99 and the standard C.V. is 0.004 ± 0.003.  
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A.4.2.  An example of the standard curve used in the Coat-A-Count RIA® kit.  
Along the y axis is %B: percent of radioactive binding, and along the x axis is the 
concentration of insulin in μIU/mL.  The linear range of this graph is from 6 μIU/mL to 
103 6 μIU/mL with a %B of 80.17 and 31.6%, respectively.   
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A.5.  qRT-PCR AMPLIFICATION PLOTS 
 
A.5.1.  An example of β-glucoronidase amplification plot from a negative control.  
This is an example of an amplification plot of the housekeeping gene, β-glucoronidase, 
from a negative control (RNA free water) in Chapter IV.  As expected, there was a lack 
of amplification. 
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A.5.2.  An example of β-glucoronidase amplification plot from a positive control.  
This is an example of an amplification plot of the housekeeping gene, β-glucoronidase, 
from a postivie control (pooled equine tissues post infection challenge) in Chapter IV.  
The linear portion of the amplification curve begins following 20 cycles and ends at 26 
cycles.  The linear portion has an r2 of no less than 0.95, and the amplification efficiency 
must be between 0.8 and 1. 
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A.5.3.  An example of an IFN−γ amplification plot from a negative control.  This is 
an example of an amplification plot of the pro-inflammatory cytokine, IFN−γ, from a 
negative control (RNA free water) in Chapter IV.  As expected, there was a lack of 
amplification. 
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A.5.4.  An example of an IFN−γ amplification plot from a positive control.  This is an 
example of an amplification plot of the pro-inflammatory cytokine, IFN−γ, from a 
positive control (pooled equine tissues post infection challenge) in Chapter IV.  The 
linear portion of the amplification curve begins following 27 cycles and ends at 33 
cycles.  The linear portion has an r2 of no less than 0.95, and the amplification efficiency 
must be between 0.8 and 1. 
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A.5.5.  An example of a TNF−α amplification plot from a negative control.  This is 
an example of an amplification plot of the pro-inflammatory cytokine, TNF−α, from a 
negative control (RNA free water) in Chapter IV.  As expected, there was a lack of 
amplification. 
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A.5.6.  An example of a TNF−α amplification plot from a positive control.  This is an 
example of an amplification plot of the pro-inflammatory cytokine, TNF−α, from a 
positive control (pooled equine tissues post infection challenge) in Chapter IV.  The 
linear portion of the amplification curve begins following 25 cycles and ends at 29 
cycles.  The linear portion has an r2 of no less than 0.95, and the amplification efficiency 
must be between 0.8 and 1. 
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A.5.7.  An example of an IL−1β amplification plot from a negative control.  This is 
an example of an amplification plot of the pro-inflammatory cytokine, IL−1β, from a 
negative control (RNA free water) in Chapter IV.  As expected, there was a lack of 
amplification. 
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A.5.8.  An example of an IL−1β amplification plot from a positive control.  This is an 
example of an amplification plot of the pro-inflammatory cytokine, IL−1β, from a 
positive control (pooled equine tissues post infection challenge) in Chapter IV.  The 
linear portion of the amplification curve begins following 20 cycles and ends at 26 
cycles.  The linear portion has an r2 of no less than 0.95, and the amplification efficiency 
must be between 0.8 and 1. 
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A.5.9.  An example of an IL−6 amplification plot from a negative control.  This is an 
example of an amplification plot of the pro-inflammatory cytokine, IL−6, from a negative 
control (RNA free water) in Chapter IV.  As expected, there was a lack of amplification. 
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A.5.10.  An example of an IL−6 amplification plot from a positive control.  This is an 
example of an amplification plot of the pro-inflammatory cytokine, IL−6, from a positive 
control (pooled equine tissues post infection challenge) in Chapter IV.  The linear portion 
of the amplification curve begins following 24 cycles and ends at 30 cycles.  The linear 
portion has an r2 of no less than 0.95, and the amplification efficiency must be between 
0.8 and 1. 
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A.5.11.  An example of an IL−10 amplification plot from a negative control.  This is 
an example of an amplification plot of the anti-inflammatory cytokine, IL−10, from a 
negative control (RNA free water) in Chapter IV.  As expected, there was a lack of 
amplification. 
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A.5.12.  An example of an IL−10 amplification plot from a positive control.  This is 
an example of an amplification plot of the anti-inflammatory cytokine, IL−10, from a 
positive control (pooled equine tissues post infection challenge) in Chapter IV.  The 
linear portion of the amplification curve begins following 27 cycles and ends at 32 
cycles.  The linear portion has an r2 of no less than 0.95, and the amplification efficiency 
must be between 0.8 and 1. 
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A.5.13.  The amplification plots for β-gus, IFN−γ, TNF−α, IL−1β, IL-6, and IL-10 in 
various equine gluteal muscle samples collected in Chapter IV.  
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A.6.2.  Gluteal muscle biopsy collection depths from yearlings, two year olds and 
mature horses in Chapter V.  The gluteal muscle biopsy collection depths were 
determined following the performance of ultrasound measurements on gluteal muscle 
depth and subcutaneous fat.  Gluteal muscle biopsy collection depth was determined as 
(50% of the gluteal muscle depth) + subcutaneous fat depth. 
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A.7.  WHOLE-BODY PROTEIN METABOLISM 
 
A.7.1.  An example of the percent isotope enrichment over baseline in the breath 
from a mature horse during the [13C] sodium bicarbonate infusion period in 
Chapter VI.  The ratio of 13CO2:12CO2 in the breath samples was determined using an 
isotope selective non-dispersive infrared absorption (NDIR) analyzer (IRIS-2; Wagner 
Analysen Technik Vetriebs GmbH, Breman, Germany).  This ratio is given in δ units, 
which is the ratio in the sample – the average ratio at baseline.  This δ enrichment value 
can then be converted into a percent enrichment using the following equation: 
Enrichment (%) = [0.0112372δ/(0.0112372δ + 1000)] × 100%.  The red box indicates a 
plateau in the percent enrichment over baseline, which can be used to calculate total CO2 
production.  The average number of points used to determine plateau were 3.2 ± 0.5.  The 
average C.V. of the plateau percent enrichment was 2.4 ± 1.8%.  Total production of CO2 
can be calculated using the following equation: 
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FCO2 = i × [(Ei/Eb) – 1].  Where, i is the rate of isotope administration in μmol/kg/min, Ei 
is the enrichment of the isotope in the solution and Eb is the enrichment of the breath 
samples at plateau, corrected for baseline enrichment (average of the red box points). 
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A.7.2.  An example of the percent isotope enrichment over baseline in the breath 
from an aged horse during the [1-13C] phenylalanine infusion period in Chapter VII.  
The ratio of 13CO2:12CO2 in the breath samples was determined using an isotope selective 
non-dispersive infrared absorption (NDIR) analyzer (IRIS-2; Wagner Analysen Technik 
Vetriebs GmbH, Breman, Germany).  This ratio is given in δ units, which is the ratio in 
the sample – the average ratio at baseline.  This δ enrichment value can then be converted 
into a percent enrichment using the following equation: 
Enrichment (%) = [0.0112372δ/(0.0112372δ + 1000)] × 100%. 
The red box indicates a plateau in the percent enrichment over baseline.  This plateau can 
be used to calculate the rate of [1-13C]phenylalanine oxidation to 13CO2 (F13CO2): F13CO2 
= FCO2 × ECO2, where ECO2 is the average enrichment of the breath samples at isotopic 
steady state (average of the 3 points in the red box), corrected for baseline enrichment, 
during the [1-13C]phenylalanine infusion.  The average number of points used for the 
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plateau were 3.1 ± 0.5.  The average C.V. for the plateau percent enrichments was 1.1 ± 
1.3%. 
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A.7.3.  An example of the percent isotope enrichment in the plasma from an aged 
horse during the [1-13C] phenylalanine infusion period in Chapter VII.  This is the 
percent enrichment corrected for the baseline enrichment.  The red box indicates a 
plateau in the percent enrichment over baseline.  The average number of points used in 
the plateau were 4.8 ± 1, and the average C.V. of the enrichment values used in the 
plateau was 3.7 ±1.3%.  This plateau can be used to calculate whole-body phenylalanine 
flux:  
Flux (Q; μmol/kg/h) = i × [(Ei/Ep) – 1, where I is the rate of isotope infusion (in 
μmol/kg/h), Ei is the enrichment of infused isotope, and Ep is the plateau plasma 
enrichment (average of the red box points).  Flux includes the amount of amino acids 
entering the pool through dietary intake (I), de novo synthesis (N), and protein 
breakdown (B), or leaving the pool through protein synthesis (Z), oxidation (E), or the 
conversion to other metabolites: Q = I + N B = Z + E + M.  Because phenylalanine is a 
dietary indispensable amino acid, N is negligible; thus B = Q – I.  Then, whole-body 
phenylalanine oxidation can be calculated using the following equation: O = F13CO2 × 
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(1/Ep – 1/Ei) × 100, where Ei is the enrichment of infused isotope, and Ep is the plateau 
plasma enrichment (average of 3 points in the red box).  If tyrosine is balanced in the diet 
and is not generally considered to be a limiting amino acid in nonruminant, the 
assumption can be made that phenylalanine conversion to tyrosine is minimal.  As a 
result, non-oxidative phenylalanine metabolism can be calculated through the difference 
of Q – O, which can be used to indicate changes in phenylalanine used for whole-body 
protein synthesis. 
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A.8.  SAS EXAMPLES 
A.8.1.  Repeated measures input example. 
 
data rpS6_Density; 
input horse depth$ block$ PrpS6; 
cards; 
1  6cm  A  1.027141
1  8cm  A  1.048161
1  10cm  A  1.068832
2  6cm  B  1.034807
2  8cm  B  1.172738
2  10cm  B  0.942196
3  6cm  A  . 
3  8cm  A  1.285698
3  10cm  A  1.122919
4  6cm  B  0.938052
4  8cm  B  0.958085
4  10cm  B  1.121907
5  6cm  B  0.520908
5  8cm  B  0.958247
5  10cm  B  0.867442
6  6cm  A  1.479092
6  8cm  A  1.48873
6  10cm  A  1.571769
; 
run; 
PROC mixed data= rpS6_Density; 
class horse depth block; 
model PrpS6 = depth block/ddfm=kr;  
random horse (block); 
repeated depth/type=un r rcorr sub=horse(block); 
lsmeans depth/pdiff; 
run; 
PROC mixed data= rpS6_Density; 
class horse depth block; 
model PrpS6 = depth block/ddfm=kr;  
random horse (block); 
repeated depth/type=ante(1) r rcorr 
sub=horse(block); 
lsmeans depth/pdiff; 
run; 
PROC mixed data= rpS6_Density; 
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class horse depth block; 
model PrpS6 = depth block/ddfm=kr;  
random horse (block); 
repeated depth/type=simple r rcorr 
sub=horse(block); 
lsmeans depth/pdiff; 
run; 
PROC mixed data= rpS6_Density; 
class horse depth block; 
model PrpS6 = depth block/ddfm=kr;  
random horse (block); 
repeated depth/type=toep r rcorr sub=horse(block); 
lsmeans depth/pdiff; 
run; 
PROC mixed data= rpS6_Density; 
class horse depth block; 
model PrpS6 = depth block/ddfm=kr;  
random horse (block); 
repeated depth/type=arh(1) r rcorr 
sub=horse(block); 
lsmeans depth/pdiff; 
run; 
PROC mixed data= rpS6_Density; 
class horse depth block; 
model PrpS6 = depth block/ddfm=kr;  
random horse (block); 
repeated depth/type=ar(1) r rcorr sub=horse(block); 
lsmeans depth/pdiff; 
run; 
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A.8.2.  Repeated measures output example. 
The variance-covariance matrix was chosen for each analysis based on the lowest value 
for Schwarz’s Bayesian Criterion, which is highlighted in this example. 
                                       The Mixed Procedure 
 
                                        Model Information 
 
                      Data Set                     WORK.RPS6_DENSITY 
                      Dependent Variable           PrpS6 
                      Covariance Structures        Variance Components, 
                                                   Unstructured 
                      Subject Effect               horse(block) 
                      Estimation Method            REML 
                      Residual Variance Method     None 
                      Fixed Effects SE Method      Kenward-Roger 
                      Degrees of Freedom Method    Kenward-Roger 
                                         Fit Statistics 
 
                              -2 Res Log Likelihood            -5.6 
                              AIC (smaller is better)           8.4 
                              AICC (smaller is better)         30.8 
                              BIC (smaller is better)           6.9 
 
 
                                  Type 3 Tests of Fixed Effects 
 
                                        Num     Den 
                          Effect         DF      DF    F Value    Pr > F 
 
                          depth           2    3.65       1.19    0.4005 
                          block           1    4.08       1.45    0.2932 
 
                                       The Mixed Procedure 
 
                                        Model Information 
 
                      Data Set                     WORK.RPS6_DENSITY 
                      Dependent Variable           PrpS6 
                      Covariance Structures        Variance Components, 
                                                   Ante-dependence 
                      Subject Effect               horse(block) 
                      Estimation Method            REML 
                      Residual Variance Method     None 
                      Fixed Effects SE Method      Kenward-Roger 
                      Degrees of Freedom Method    Kenward-Roger 
                                         Fit Statistics 
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                              -2 Res Log Likelihood            -5.6 
                              AIC (smaller is better)           6.4 
                              AICC (smaller is better)         20.4 
                              BIC (smaller is better)           5.1 
                                  Type 3 Tests of Fixed Effects 
 
                                        Num     Den 
                          Effect         DF      DF    F Value    Pr > F 
 
                          depth           2    3.65       0.83    0.5035 
                          block           1    4.08       1.49    0.2873 
 
                                       The Mixed Procedure 
 
                                        Model Information 
 
                      Data Set                     WORK.RPS6_DENSITY 
                      Dependent Variable           PrpS6 
                      Covariance Structure         Variance Components 
                      Subject Effect               horse(block) 
                      Estimation Method            REML 
                      Residual Variance Method     Parameter 
                      Fixed Effects SE Method      Kenward-Roger 
                      Degrees of Freedom Method    Kenward-Roger 
                                         Fit Statistics 
 
                              -2 Res Log Likelihood            -4.1 
                              AIC (smaller is better)          -0.1 
                              AICC (smaller is better)          1.1 
                              BIC (smaller is better)          -0.5 
 
 
                                  Type 3 Tests of Fixed Effects 
 
                                        Num     Den 
                          Effect         DF      DF    F Value    Pr > F 
 
                          depth           2    9.13       1.85    0.2117 
                          block           1    4.06       3.29    0.1426 
 
                                       The Mixed Procedure 
 
                                        Model Information 
 
                      Data Set                     WORK.RPS6_DENSITY 
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                      Dependent Variable           PrpS6 
                      Covariance Structures        Variance Components, 
                                                   Toeplitz 
                      Subject Effect               horse(block) 
                      Estimation Method            REML 
                      Residual Variance Method     Profile 
                      Fixed Effects SE Method      Kenward-Roger 
                      Degrees of Freedom Method    Kenward-Roger 
                                         Fit Statistics 
 
                              -2 Res Log Likelihood            -4.1 
                              AIC (smaller is better)           1.9 
                              AICC (smaller is better)          4.6 
                              BIC (smaller is better)           1.3 
                                  Type 3 Tests of Fixed Effects 
 
                                        Num     Den 
                          Effect         DF      DF    F Value    Pr > F 
 
                          depth           2    4.98       1.51    0.3073 
                          block           1    3.93       3.22    0.1485 
 
                                       The Mixed Procedure 
 
                                        Model Information 
 
                      Data Set                     WORK.RPS6_DENSITY 
                      Dependent Variable           PrpS6 
                      Covariance Structures        Variance Components, 
                                                   Heterogeneous 
                                                   Autoregressive 
                      Subject Effect               horse(block) 
                      Estimation Method            REML 
                      Residual Variance Method     None 
                      Fixed Effects SE Method      Kenward-Roger 
                      Degrees of Freedom Method    Kenward-Roger 
                                         Fit Statistics 
 
                              -2 Res Log Likelihood            -5.6 
                              AIC (smaller is better)           4.4 
                              AICC (smaller is better)         13.0 
                              BIC (smaller is better)           3.4 
                                  Type 3 Tests of Fixed Effects 
 
                                        Num     Den 
                          Effect         DF      DF    F Value    Pr > F 
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                          depth           2    5.03       1.09    0.4034 
                          block           1    4.07       1.44    0.2949 
 
                                       The Mixed Procedure 
 
                                        Model Information 
 
                      Data Set                     WORK.RPS6_DENSITY 
                      Dependent Variable           PrpS6 
                      Covariance Structures        Variance Components, 
                                                   Autoregressive 
                      Subject Effect               horse(block) 
                      Estimation Method            REML 
                      Residual Variance Method     Profile 
                      Fixed Effects SE Method      Kenward-Roger 
                      Degrees of Freedom Method    Kenward-Roger 
                                         Fit Statistics 
 
                              -2 Res Log Likelihood            -4.1 
                              AIC (smaller is better)           1.9 
                              AICC (smaller is better)          4.6 
                              BIC (smaller is better)           1.3 
 
 
                                  Type 3 Tests of Fixed Effects 
 
                                        Num     Den 
                          Effect         DF      DF    F Value    Pr > F 
 
                          depth           2    4.98       1.25    0.3625 
                          block           1    3.93       3.46    0.1377 
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A.8.3.  One Way ANOVA input example. 
data Akt_Density; 
input horse age$ block$ PSerAkt; 
cards; 
2  Mature  A  0.808913
4  Mature  A  1.191087
8  Old  A  0.775572
10  Old  A  0.987907
3  Old  B  0.670911
6  Mature  B  1.082008
11  Old  B  0.271198
12  Mature  B  0.917992
1  Mature  C  1.288538
5  Mature  C  0.711462
7  Old  C  1.165816
9  Old  C  1.15654
; 
run; 
PROC mixed data= 
Akt_Density; 
class horse age block; 
model PSerAkt = age block/ddfm=kr;  
random horse (age block); 
lsmeans age/pdiff; 
run; 
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A.8.4.  One Way ANOVA output example. 
                                       The Mixed Procedure 
 
                                        Model Information 
 
                      Data Set                     WORK.AKT_DENSITY 
                      Dependent Variable           PSerAkt 
                      Covariance Structure         Variance Components 
                      Estimation Method            REML 
                      Residual Variance Method     Profile 
                      Fixed Effects SE Method      Kenward-Roger 
                      Degrees of Freedom Method    Kenward-Roger 
                                  Type 3 Tests of Fixed Effects 
 
                                        Num     Den 
                          Effect         DF      DF    F Value    Pr > F 
 
                          age             1       8       1.06    0.3342 
                          block           2       8       1.62    0.2573 
 
 
                                       Least Squares Means 
 
                                             Standard 
             Effect    age       Estimate       Error      DF    t Value    Pr > |t| 
 
             age       Mature      1.0000      0.1115       8       8.97      <.0001 
             age       Old         0.8380      0.1115       8       7.52      <.0001 
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